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cLASSIFIcATION OF INFLUENZA VIRUSES AND SUMMARy OF 
THEIR HOST RANGE
Influenza viruses (family Orthomyxoviridae) may cause respiratory disease in humans 
and animals worldwide. Within the family of Orthomyxoviridae, four genera of influenza 
viruses are recognised based on different antigenic and structural characteristics: A, B, 
C, and D, which also largely determine their respective host ranges.
Influenza A viruses (IAVs) are endemic in a large variety of mammalian and avian 
species. Although in principle all bird species may be infected with IAVs, waterfowl and 
poultry play a special role in their epidemiology. In addition to endemic IAV infections in 
a particular species, IAV sporadically can jump the species barrier into another species, 
causing either individual cases of infection or more or less extensive epidemics. Such 
introduction of a novel strain or subtype of IAV into the human population with variable 
levels of pre-existing immunity can lead to localised epidemics or worldwide pandemics 
with variable infection rates and mortalities. Seasonal influenza viruses circulating in 
the human population cause annual epidemics, which in the temperate climate zones 
occur predominantly in the winter months.
Influenza B viruses (IBVs) can cause similar disease in humans as seasonal IAVs. 
Whilst IBV infections were considered to be restricted to humans, in recent years IBV 
has also been found in seals (1, 2), and in pigs (3). IBVs are classified in lineages and 
strains, with the two currently lineages being B/Yamagata and B/Victoria.
Influenza C virus can cause mild upper respiratory tract (URT) illness in humans, 
and can infect pigs as well (4). Influenza B and C virus are not implicated in causing 
pandemics. Influenza D virus is the most recent recognised genus, detected since 2011 
in pigs and cattle only (5).
GENOME AND cATEGORISATION OF INFLUENZA A VIRUS
The following sections of this introductory chapter are limited to IAVs, as all studies 
in this thesis have focused on this influenza virus genus. IAV is an enveloped virus 
containing a negative-sense single-stranded RNA genome in eight segments (polymerase 
basic 2, PB2; polymerase basic 1, PB1; polymerase acidic, PA; haemagglutinin, HA; 
nucleoprotein, NP; neuraminidase, NA; matrix 1 and 2, M; non-structural 1 and 2, 
NS). These eight gene segments encode for eleven or twelve different viral proteins: 
RNA polymerase complex (PB1, PB2 and PA), N40 protein of unknown function (PB1), 
receptor-binding glycoprotein haemagglutinin (HA), RNA-binding nucleoprotein (NP), 
sialic acid (SA)-destroying enzyme neuraminidase (NA), ribonucleoprotein-interacting 
matrix protein (M1), ion channel protein (M2), nuclear export protein also known as 
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non-structural protein 2 (NS2), interferon (IFN)-antagonising non-structural protein 1 
(NS1). In addition, some viruses express the pro-apoptotic protein PB1-F2 (PB1). The 
viral envelope that encloses the gene segments and carries glycoproteins HA and NA on 
its surface is formed by a lipid bilayer originating from the infected host cell’s membrane 
upon release of a new infectious virus particle.
IAVs are classified in subtypes on basis of antigenic differences of their HA and NA. 
To date, 18 HA subtypes (H1-H18) and 11 NA subtypes (N1-N11) are recognised. Sixteen 
different HA subtypes (H1-H16) and nine different NA subtypes (N1-N9) have been 
detected mostly in wild waterfowl, where they are considered to replicate asympto-
matically in the intestine. In contrast, IAVs of the subtypes H5 and H7 can mutate into 
a highly pathogenic form in poultry, which induces systemic disease and high mortality 
rates. H17N10 and H18N11 are the most recently detected IAV subtypes found in 
a symptomatic New World fruit bats (Sturnira sp. and Artibeus sp.) in 2012 and 2013, 
respectively (6-8). However, there is ongoing scientific debate whether these bat-
derived H17N10 and H18N11 viruses should be classified as influenza A H17/18N10/11-
like viruses because of their relative antigenically distant HA and NA genes compared 
with those of the previously recognised H and N subtypes (9-11).
IAVs subtypes are further classified into different strains, based on host species, 
geographical location, and year of origin (12). All subtypes are given a chronological 
strain number. For example, A/equine/Newmarket/2/1993 (H3N8) denotes strain 2 of 
an H3N8 subtype isolated from a horse in Newmarket in 1993, and A/Perth/16/2009 
(H3N2) denotes strain 16 of an H3N2 subtype isolated from a human in Perth in 2009. 
The host species is not included in the name of the virus strain if it is from humans. 
Usually, for avian IAVs (AIVs), a prefix is given to indicate the virus’ pathogenicity in 
chickens e.g., H5N1 highly pathogenic avian influenza virus (HPAIV) or H7N9 low 
pathogenic avian influenza virus (LPAIV).
HOST RANGE OF INFLUENZA A VIRUSES
The host range of established endemic IAV infections is remarkably broad compared 
to the host ranges of genera B, C, and D, as it includes: humans, wild and domestic 
birds, domestic pigs, horses, domestic dogs, and most recently New World bats. Wild 
waterfowl (mainly geese, ducks, swans, gulls, and waders) are regarded the original 
reservoir of all IAVs, from which mammalian virus strains are derived. Many sporadic 
infections of various IAVs have been detected in carnivores, cetaceans, non-human 
primates, bats, uneven-toed and even-toed ungulates, rodents, lagomorphs, and 
anteaters. Multiple epidemics with considerable mortality rates of avian-origin IAVs 
have occurred in populations of harbour seals (Phoca vitulina) (13-15).
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INFLUENZA IN HUMAN BEINGS
1. Epidemiology of seasonal influenza
Two seasonal IAVs, subtypes H1N1 and H3N2, have circulated (together with IBV) 
globally amongst humans since 1977 and account for up to 500,000 mortalities every 
year (16). In 2009, the seasonal H1N1 virus was replaced by the 2009 pandemic H1N1 
IAV. Such replacement of the previously circulating seasonal subtype commonly 
occurred when a new pandemic IAV was introduced in the population. An exception 
was the reintroduction of H1N1 IAV in 1977 as the ‘’Russian flu’’, which has continued to 
co-circulate with H3N2, as seasonal IAVs. Each year, small antigenic changes (antigenic 
drift) in the HA gene and/or NA gene, resulting from continuous point mutations, provide 
an escape from pre-existing immunity of the human population. The genes of IAV 
have high mutation rates because their RNA polymerase complex has no proofreading 
activity (17). The glycoprotein HA is the major antigenic constituent of IAV. Pre-existing 
neutralising antibodies drive positive selection of these spontaneous escape mutants 
and result annually in new seasonal influenza virus infections and outbreaks. Influenza 
is an acute infectious disease without chronic latent infections and is maintained within 
the population by continuous human-to-human transmission. Infections occur in winter 
months of temperate climate regions when decreased levels in relative air humidity 
stabilise infectious aerosols and are thus considered to favour viral transmission (18, 
19). Seasonality is less prominent in tropical and subtropical regions where these viruses 
circulate throughout the year. The prevalence of disease peaks in school-age children, 
whereas influenza-associated morbidities that require hospitalisations prevail in young 
children < 2 years of age and in the elderly > 65 years of age. Infection rates and severity 
of induced disease depend, besides susceptibility and age of the individual, on the 
levels of pre-existing immunity and on the virulence of the virus. Risk factors associated 
with developing severe disease such as pneumonia are: underlying cardiovascular and 
pulmonary conditions reduced immune status, metabolic and neoplastic diseases, and 
pregnancy. The cumulative interpandemic seasonal mortality rates usually surpass the 
mortalities due to pandemics.
2. Epidemiology of pandemic influenza and avian influenza
When a major change (antigenic shift) in the HA gene and/or NA gene in a human IAV 
occurs, attributed to the introduction of an IAV or one or more of gene segments from 
an animal reservoir a new IAV with pandemic potential may emerge. This may be due to 
direct zoonotic infections, or an intermediate animal species may be involved. The 1918 
and 2009 pandemic H1N1 IAVs involved introductions of a whole virus with all eight 
gene segments into the human population. Prerequisites for such a new IAV gaining 
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pandemic proportions are: (a) efficient human-to-human transmission in (b) a relatively 
immunologically naive human population, permitting high infection rates.
Influenza pandemics are usually designated according to the geographic location 
of first emergence of the new virus. During the last century four influenza pandemics 
originating from antigenic shifts have occurred: the 1918 H1N1 pandemic (‘’Spanish 
flu’’) from introduction of presumed avian IAV, the 1957 H2N2 pandemic (‘’Asian flu’’) 
and the 1968 H3N2 pandemic (‘’Hong Kong flu’’), both from reassortants of human and 
avian IAVs, and the 2009 H1N1 pandemic (‘’Mexican flu’’) from a swine IAV (complex 
reassortant of swine, human, and avian IAVs) (20), all of which caused significant 
morbidity and mortality. Indeed, the Spanish flu was so severe that a quarter of the 
world’s population was affected by illness during the pandemic and an estimated 50 
million people died, plummeting the life expectancy of Americans by 11.8 years from 
1917 to 1918 (21). Highest mortality rates prevailed in previously healthy young adults 
in the age range of 18-34 years, associated with acute respiratory distress syndrome 
(ARDS) and bacterial super-infections (22, 23).
The Mexican influenza virus, mostly designated as ‘’H1N1 pdm09 IAV’’ or ‘’pH1N1 
IAV’’, was first identified in April 2009 in Mexico and caused an estimated 151,700–
575,400 deaths (24) in its first year of global circulation. Mortalities occurred in 0.5% 
of cases with severe respiratory disease (25), which prevailed in infected older children 
and young adults. People > 60 years of age were less infected than these younger 
people, which has been attributed to protective cross-immunity from exposure to pre-
1950 H1N1 strains (26, 27). Although the elderly experienced fewer infections, the case 
fatality rate in this age group was high. Common risk factors associated with developing 
severe disease such as pneumonia were: obesity, underlying respiratory (asthma) and 
cardiovascular conditions, diabetes mellitus, smoking, and pregnancy or immediate 
post-partum period (28-30).
In May of 1997 in China (Hong Kong), H5N1 HPAIV was first shown to have crossed 
the species barrier from chickens to infect humans (31, 32). H5N1 IAVs continue to 
circulate in wild birds and poultry in Asia, Africa, and Europe, and occasionally infect and 
kill humans. This avian virus replicates in the lower respiratory tract (LRT) of humans, 
inducing acute pneumonia, severe respiratory disease and potentially fatal ARDS. To 
date (July 19, 2016), there have been 854 confirmed human infections of which 450 
people died. This corresponds to a current case fatality rate of 53% for H5N1 HPAIV-
infected humans. Highest mortality rates prevailed in previously healthy teenagers. In 
2015, 39 fatal human cases of H5N1 HPAIV were reported in Egypt alone (33). Most 
human cases of H5N1 HPAIV-infections had a history of recent exposure to potentially 
contaminated environments, particularly live poultry markets. Infected humans are 
regarded poorly infectious to other people, as sustained transmission of H5N1 HPAIV 
among people is not apparent. However, there is concern that if this pathogenic virus 
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gains human transmissibility through mutations and/or reassortments, it could evolve 
into a pandemic virus (34-36).
In March of 2013 in China, another avian-origin influenza virus, H7N9 LPAIV, spread 
to humans. Infected people, with a predisposition for middle-aged to older men, suffered 
from severe respiratory disease. To date (July 19, 2016), there have been 793 laboratory-
confirmed human infections of which 319 people died. This corresponds to a current 
case fatality rate of 40% for H7N9 LPAIV-infected humans (37). Common underlying 
medical conditions in hospitalised patients were: coronary heart disease, hypertension, 
diabetes mellitus and chronic obstructive pulmonary disease (COPD) (38). Like H5N1 
HPAIV, most human cases of H7N9 LPAIV had a history of recent exposure to potentially 
contaminated environments, such as live poultry markets. Although limited human-to-
human H7N9 LPAIV transmission could not be entirely excluded in a few clusters of 
cases, no evident sustained human-to-human transmission has been reported for H7N9 
LPAIV (37), but again concern remains that reassortments or mutations may give rise to 
a new pandemic virus (39).
3. The disease
3a.  Uncomplicated influenza: pathogenesis, clinical signs and symptoms, and 
pathological changes
Pathogenesis of uncomplicated influenza
The pathogenesis describes the process of development of disease. Commonly, 
infectious aerosols or droplets expelled into the air by infected people are deposited 
in the URT and LRT of permissive people. Indirect virus transmission via manipulation 
of freshly contaminated object surfaces (fomites) followed by oronasal or conjunctival 
self-inoculation is considered another route of infection (40). The virus particle attaches 
with its surface glycoprotein HA to the host‘s cell surface receptors, the sialic acid (SA) 
terminated glycans. Human adaptation of IAVs such as seasonal IAV entails preferential 
attachment to glycan receptors terminating in SA linked to galactose (Gal) by an α-2,6 
SA-linkage (‘’human type IAV receptors’’). These α-2,6 SA-linked receptors are expressed 
on epithelial cells throughout the human respiratory tract (nasal mucosa, paranasal 
sinuses, pharynx, trachea, bronchi, bronchioles, and alveoli) but their abundance varies 
according to anatomical location (41). In contrast, avian IAVs’ HA preferentially attach 
to α-2,3 SA-linked receptors (‘’avian type IAV receptors’’) expressed on epithelial cells of 
the respiratory and intestinal tract of aquatic birds (42). Confirmed by virus attachment 
studies using seasonal influenza virus-histochemistry (43), epithelial cells targeted by 
seasonal IAVs are localised within the nasal cavities, trachea, bronchi, bronchioles and 
alveoli (type I pneumocytes). The attachment is most abundant to ciliated epithelial 
18
cells of the nose, trachea and bronchi. Following viral attachment, epithelial cells can be 
infected and constrained into actively replicating the virus. Release of newly-synthesised 
infectious virus particles still anchored to the hosts’ cell membrane by their HA occurs 
actively by enzymatic cleavage of the receptors’ sialic acid (SA) by viral neuraminidase 
(NA). Absence of NA activity results in aggregates of virus particles and loss of infectivity.
Viral replication typically peaks around 2 days after infection in the nasopharynx, 
to decline slowly in the following days. Even after the infectious virus can no longer be 
recovered, viral antigen and RNA can be detected in cells and secretions of infected 
individuals for several days (44).
Virus infection and replication commonly result in cell death (or cell lysis; 
‘’cytolytic effect’’) directly by necrosis, or indirectly by cytokine-mediated and/or 
inflammatory cell-induced apoptosis. Viral infection and damage to cells and tissues 
incite inflammatory responses characterised by localised infiltration of inflammatory 
cells (that may exacerbate cell and tissue damage) and localised and systemic release 
of pro-inflammatory cytokines and other acute phase proteins. This process results in 
acute inflammation of the URT; e.g., rhinitis (coryza), sinusitis, pharyngitis, and partially 
of the LRT; e.g., tracheitis and bronchitis, but also results in systemic responses such as 
fever and altered haematological values.
Clinical signs and symptoms of uncomplicated influenza
Seasonal influenza is typically characterised by URT infections (nose, throat) evidenced 
by sudden onset of local signs and symptoms like nasal congestion and a runny nose 
(rhinorrhoea), sore throat, non-productive cough, but also includes more generalised 
signs and symptoms like high fever, muscle ache (myalgia), headache, chills, and general 
malaise. Aerosols and droplets expelled during sneezing and coughing are highly 
infectious. These signs and symptoms are due to viral replication causing mucosal 
inflammation and to systemic release of pro-inflammatory cytokines (45, 46). The 
severity of these acute symptoms can vary but endure usually for a week (47), whereas 
malaise may last longer.
Diagnosis of influenza involves direct demonstration of replication competent 
infectious virus by viral culture, or demonstration of viral antigens or viral genetic 
material by PCR, or indirectly by demonstration of a fourfold increase in titre of specific 
antibodies in paired sera or respiratory secretions (48). Additionally, tissues sampled by 
intravitam biopsies (or during autopsy) may be used to confirm IAV infection by means 
of in situ hybridisation (ISH) or immunohistochemistry (IHC). The aetiological differential 
diagnoses of influenza-like illness (ILI) include: IBVs, ICVs, parainfluenza viruses (PIV), 
respiratory syncytial virus (RSV), human metapneumovirus (HMPV), and Mycoplasma 
pneumoniae. IAVs are isolated in about one-third of patients with ILI during peaks of 
seasonal influenza epidemics (49).
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Pathological changes of uncomplicated influenza
Infections with seasonal IAVs usually induce a form of uncomplicated influenza. 
Uncomplicated influenza entails a mild and transient inflammation of typically the URT, 
potentially involving rhinitis, paranasal sinusitis, pharyngitis, laryngitis, but can extend 
deeper into the LRT, involving tracheitis and bronchitis, that correspond to the pattern 
of seasonal influenza virus attachment (50). From 1 day after onset of symptoms, 
corresponding histological lesions such as epithelial vacuolar degeneration with 
oedema and loss of cilia, epithelial desquamation, hyperaemia, oedema, hemorrhage, 
and lymphohistiocytic infiltration of the lamina propria can be detected. Already from 
2 days after onset of symptoms onward, epithelial regeneration indicative of repair can 
be present (51, 52). Respiratory epithelial repair has shown to be complete in 10 days in 
animal models (53), although it may take 1 month to heal (44).
3b.  Viral pneumonia: pathogenesis, clinical signs and symptoms, and pathological 
changes
Pathogenesis of viral pneumonia
The primary complication of influenza is extension of viral infection and inflammation 
to the lungs, reaching the alveoli (51). In contrast to damage to the conducting airways 
of the URT and LRT, damage to the alveoli directly impairs gas exchange. Like cellular 
damage in uncomplicated influenza, alveolar epithelial cell (AEC) damage is induced by 
direct cytolytic effects of viral infection and by indirect effects of the host immune res-
ponse (54). These alveolar epithelial cells, composed of type I pneumocytes that firmly 
seal the walls of the air-filled alveolar lumina, and of type II pneumocytes that resorb 
fluid from the alveolar lumina, constitute the main stronghold of the barrier between 
air and blood stream, i.e., the alveolar epithelial-endothelial barrier (EEB). Thus, loss of 
pneumocytes allows fluid from the adjacent capillaries to leak into the alveolar lumen, 
which leads to respiratory dysfunction and may initiate ARDS. ARDS is an aspecific 
syndrome that can complicate different acute causes of severe lung damage or shock.
Risk factors predisposing for viral pneumonia include specific or generalised 
compromised immunity, age > 65 years, pre-existing cardiovascular and pulmonary 
disease, diabetes mellitus, and pregnancy (55). People not exposed previously to 
immunity-inducing IAV antigens, from vaccines or from natural priming by cross 
immunity-inducing IAV strains, lack protective specific IgG in serum and alveolar lining 
fluid (56-58). Concentrations of specific immunoglobulins in the alveolar lining fluid 
match those of serum. Long-term immunosuppressive medication in organ transplant 
patients is a cause of reduced generalised immunity. Chronic pre-existing pulmonary 
diseases such as COPD, asthma and interstitial fibrosis may reduce the defense against 
respiratory pathogens. Hypertension associated with cardiovascular disease and 
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pregnancy is believed to increase the risk for pulmonary oedema to develop when the 
alveolar epithelial cells are damaged after infection (59). Many fatal cases of ARDS were 
complicated by bacterial infections (60, 61) that aggravate inflammation of the lung and 
may lead to sepsis.
According to virus attachment studies using virus-histochemistry, pH1N1 IAV 
attaches to ciliated epithelial cells of nasal conchae, trachea, bronchi, bronchioles, and 
to type I pneumocytes (43). In severe pneumonia and fatal cases of pH1N1 IAV infections 
a change in the receptor binding specificity from α-2,6 SA-linked (‘’human type’’) to 
α-2,3 SA-linked glycan receptors (‘’avian type’’) present on ciliated bronchial cells and 
alveolar type II pneumocytes is observed. After natural infection, pH1N1 antigens are 
predominantly expressed in type II pneumocytes, and less in alveolar type I pneumocytes 
and alveolar macrophages, and in airway epithelium (29). The cell tropism of pH1N1 IAV 
for the LRT likely predisposes for development of severe pneumonia, whereas the cell 
tropism for the URT likely predisposes for viral transmission. Comparable with seasonal 
IAV infection, shedding of pH1N1 IAV peaks in the first 2 days of disease and lasts for 5-7 
days after onset of disease, whereas prolonged shedding is observed in infants and the 
elderly, immunocompromised patients and in patients suffering from ARDS (44).
According to virus attachment studies using virus-histochemistry, H5N1 HPAIV 
attaches mainly to non-ciliated epithelial cells of the LRT; the bronchioles and type 
II pneumocytes of alveoli (62). Evidenced by positive IHC and ISH, virus-infected 
type II pneumocytes and tracheal epithelial cells are associated with pathological 
changes in the respiratory tract (63). During H5N1 HPAIV infections, extra-respiratory 
complications may occur, more likely resulting from the interaction of ARDS and 
multi-organ dysfunction syndrome (MODS) (64), rather than from viraemia and viral 
dissemination. The pathogenesis of MODS is attributed to haemodynamic disturbances 
and hypercytokinaemia, and may include liver, kidneys, gastro-intestinal tract, and 
cardiovascular tract. Nonetheless, there is evidence for limited extra-respiratory 
replication of H5N1 virus in people: in some cases, H5N1 virus has been isolated from 
the cerebrospinal fluid and H5N1 antigen has been demonstrated by IHC and/or ISH in 
neurons of the brain, intestinal epithelial and mononuclear cells, lymphocytes of lymph 
node tissue, Kupffer cells of the liver, fetal macrophages and cytotrophoblasts of the 
placenta, and in fetal pneumocytes (63).
The high pathogenicity of H5N1 HPAIV may originate in part from the susceptibility 
of its HA to host proteases, as is valid for infection of chickens. For IAVs to be infectious, 
their HA must be cleaved into two subunits, HA1 and HA2 (55, 65). In contrast to a single 
arginine at the cleavage site of seasonal IAVs’ HA cleavable by trypsin-like proteases of 
the respiratory and gastrointestinal tract, the HA of H5N1 HPAIV possesses multiple 
basic amino acids at its cleavage site and may be cleaved by ubiquitously present 
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furin-type proteases. This may explain H5N1 HPAIV’s ability to cause extra-respiratory 
infection, resulting in increased pathogenicity.
Additional viral virulence factors of H5N1 HPAIV in humans include: the RNA 
polymerase complex and NA protein permitting fast and efficient viral replication, the 
NS1 that antagonises interferon (IFN) production in virus-infected cells, and the PB1-F2 
protein responsible for inducing apoptosis and proinflammatory cytokines, such as 
TNF-α (66). Indeed, elevated serum cytokine concentrations in patients correlated to 
high oropharyngeal H5N1 viral loads and poor prognosis (67).
H7N9 LPAIV can bind to both α-2,3 SA-linked glycan receptors (avian type) and α-2,6 
SA-linked glycan receptors (human type), and attaches to epithelial cells of both URT 
and LRT. According to virus attachment studies using virus-histochemistry, H7N9 LPAIV 
attaches to both type I and type II pneumocytes in the alveolus (68, 69). In acute serum 
samples of H7N9-infected patients, increased levels of proinflammatory cytokines 
and chemokines are detected. High replication of H7N9 LPAIV in vitro is attributed to 
blocking of the induction of antiviral IFN-β by the viral NS1 protein (70).
Clinical signs and symptoms of viral pneumonia
The clinical signs and symptoms of IAV-associated pneumonia and ARDS in general 
include: high fever, general malaise, laboured breathing (dyspnoea) that may aggravate 
over time, cyanosis, and coughing up blood (haemoptysis). Multi-organ failure and death 
(mortality rate up to 60%) may occur as soon as 48 hours after onset of symptoms. Viral 
pneumonia may be complicated by opportunistic bacterial co-infections that aggravate 
the clinical disease.
Similar clinical signs and symtoms were reported for pH1N1 IAV-infected people 
who developed pneumonia during the 2009 pandemic. Fatal cases were associated with 
ARDS, concomitant bacterial infections, and multi-organ failure. The median time from 
onset of symptoms to death varied from 8 - 12 days (28-30).
Other acute signs and symptoms besides those typical for viral pneumonia reported 
by people infected with H5N1 HPAIV included abdominal pain, chest pain, diarrhoea 
and rare neurologic symptoms. The incubation period of H5N1 HPAIV infections ranged 
from 2-5 days, whereas the time from onset of symptoms to death varied from 2 - 9 
days (71, 72).
People with severe viral pneumonia from H7N9 LPAIV infection also showed vomiting 
and diarrhoea. The incubation period after exposure to live poultry was estimated at 5 
days. ARDS was the most common complication with a median time from the onset of 
illness to ARDS development of 7 days (38).
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Pathological changes of viral pneumonia
Gross pathological changes in influenza viral pneumonia are characterised by extensive 
consolidation and swelling of the pulmonary parenchyma and variable degree of 
hemorrhage. The lung surface may show rib imprints upon opening of the thorax. 
The main histological lesion of acute viral pneumonia is diffuse alveolar damage 
(DAD) characterised by necrosis and desquamation of the alveolar epithelial cells, 
flooded alveolar lumina with oedema fluid admixed with variable quantities of fibrin 
strands, neutrophils, macrophages and erythrocytes. The fibrin-rich oedema fluid may 
be inspissated to form characteristic hyaline membranes lining the alveolar septa. 
In general, the alveolar septa are thickened due to hyperemia of alveolar capillaries, 
interstitial oedema, and due to infiltrates of mainly neutrophils, macrophages and 
lymphocytes, and occasional eosinophils. Alveolar septa may be necrotic, possibly due 
to ischaemia-inducing fibrinous thrombo-emboli that may be present in pulmonary 
blood vessels as well.
If patients survive the initial 2 weeks, the histopathology of chronic viral pneumonia 
is characterised by type II pneumocyte hyperplasia indicative of re-epithelisation, 
interstitial fibrosis of the septa infiltrated by mainly lymphocytes and plasma cells. 
Eventually, squamous metaplasia may occur (47). Inflammation of the bronchioles 
is characterised by epithelial necrosis, and infiltration by variable numbers of mainly 
neutrophils and lymphocytes. The often-concurrent bacterial infection causes a 
pyogenic inflammatory reaction, i.e., a suppurative bronchopneumonia, that differs 
morphologically from a typical virus-induced interstitial pneumonia, as it is characterised 
by a prominent infiltration of neutrophils, which commonly congregate and lyse to form 
pus within bronchi, bronchioli and alveoli.
Similar typical histopathological findings of DAD were reported for people infected 
with pH1N1 IAV, H5N1 HPAIV and H7N9 LPAIV. Additionally reported for pH1N1 IAV 
cases was haemophagocytosis in draining lymph nodes, and pulmonary thromboemboli 
(29).
4. Influenza interventions
Intervention options against influenza entail prevention by vaccination or administration 
of antiviral medication prophylactically or therapeutically. Vaccination is among the 
most effective methods of influenza prevention. Immunisation may be induced by 
inactivated or live-attenuated influenza virus vaccines (LAIVs). Inactivated vaccines 
usually contain purified viral HA, and additionally may contain an aspecific immune 
response enhancing adjuvant, whereas LAIVs contain a vaccine virus capable of limited 
replication. Inactivated seasonal influenza vaccines are tri- or quadrivalent, containing 
three or four antigenic types of HA matching the current circulating strains of H1N1 
and H3N2 IAVs, and IBVs. Antibodies against the HA glycoprotein prevent virus binding 
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to the cell receptor and are effective at preventing infection. Vaccinations have 
shown an efficacy of 70-90% in preventing disease in normal healthy young adults, 
with moderately lower efficacy rates in the elderly who exhibit lower serum antibody 
responses (55). The combined effects of relatively rapid decline in antibody titres and of 
antigenic drift of seasonal influenza viruses require yearly updated vaccinations against 
seasonal influenza in people from high risk groups. Candidate vaccines against avian 
influenza in humans, including adjuvanted inactivated and recombinant H5N1 vaccines, 
have been developed and elicit protective immune responses in animal models, and are 
currently in clinical evaluation.
Two classes of antiviral drugs are available for prophylaxis and therapy of influenza 
virus infection. The adamantane class of antivirals (amantadine [Symmetral] and 
rimantadine [Flumadine]) are matrix 2 ion channel blockers and effective against IAVs, 
but their relative toxicity and rapid development of viral resistance limits current 
application, and thus they are not recommended by the Centers for Disease Control 
and Prevention (CDC) for clinical use (73). The class of neuraminidase inhibitors (NAI) 
(zanamivir [Relenza®], oseltamivir [Tamiflu®], peramivir [Rapivab®], and laninamivir 
[Inavir®]) are effective against both IAVs and IBVs. In 2009, oseltamivir resistance and 
even multi-NAI resistance of mutated pH1N1 IAVs were detected in patients receiving 
prolonged antiviral treatment, in particular patients under immunosuppressive therapy 
(74, 75).
A recent development entails antiviral antibody preparations for prophylactic 
and/or therapeutic medication against influenza. The aim is to produce monoclonal 
antibodies directed against epitopes conserved in different subtypes of influenza viruses 
that may allow for a universal efficacy against IAVs regardless of differences in classic 
antigenicities (55).
AIMS AND OUTLINE OF THIS THESIS
Although clinical disease and associated lesions (also necrosis, also haemodynamic 
changes) of the respiratory tract due to IAV infections are well known, the pathoge-
nesis of ARDS is not yet fully understood. ARDS is a fatal complication of influenza virus 
infection, and accounts for many influenza-related mortalities. At the starting point of 
this thesis, the mechanism of pulmonary oedema formation, as one of the hallmarks 
of influenza-induced ARDS, was unknown. Pulmonary oedema as a representative 
lesion of ARDS was of major interest in this thesis as it is an acute lesion that is easily 
detectable in histopathology. The intricate chronic process of scarring fibrosis that may 
develop subsequent to acute alveolar damage is outside the scope of this thesis.
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Several factors (cellular integrity, inflammatory cells, and cytokines) are known to 
influence the homeostasis of the EEB preventing or permitting oedema to develop. 
The obvious question that arose at the start of this thesis was: what is the mechanism 
by which influenza virus induces pulmonary oedema? Therefore the main aim of this 
thesis was unravelling the pathogenesis of influenza-induced ARDS and pulmonary 
oedema formation, to ultimately pinpoint the most significant pathogenic factors. A 
better understanding of the pathogenesis, especially identifying the most important 
causative pathogenic factors is essential in the development of new intervention 
strategies. Improved intervention options will likely reduce the recurrent global burden 
of seasonal influenza epidemics and pandemics.
The ferret (Mustela putorius furo) has shown to be very susceptible to infections 
with human and avian IAVs and associated diseases, and it has been used to study 
human influenza since the 1930s, and is regarded by many as the most suitable animal 
available to mimic human influenza. According to literature reviews summarised in this 
thesis, various mammalian animal species’ susceptibility and sensitivity to IAV infections 
were assessed in comparison to ferrets. Overall, intratracheally inoculated ferrets were 
concluded to be particularly suited to model influenza-induced ARDS. This model of 
experimental intratracheal (IT) IAV inoculation of ferrets is simply referred to as ‘the 
ferret model’ throughout this thesis. Although models merely approximate the truth, 
the benefits of a good animal model are to provide better insights in the vast array of 
intricate host responses to infectious inflammatory diseases. Often there are no in vitro 
alternatives to study such host responses.
Throughout several scientific publications that constitute this thesis’ chapters 2 
to 6, the term ‘necropsy’ is used. Classically, necropsy is the preferred terminology 
in ve terinary medicine designating post-mortem examination. However as recently 
argued by Law and colleagues, it is time to set dogma and tradition aside for the sake 
of better communication in the contexts of comparative pathology and One Health 
initiatives (76). Autopsy (‘’the act of seeing with one’s own eyes, from Greek: aut- + 
opsis’’ (77)) commonly used in human medicine, is currently regarded the preferred 
universal terminology designating post-mortem examination regardless of the species. 
In adherence, ‘autopsy’ will be applied in the remainder of this thesis.
The outline of this thesis according to chapter numbers is as follows: In this chapter 
1, a brief introduction was given on influenza A viruses in general, followed by a 
description of the epidemiology, clinical signs and symptoms, pathogenesis, and the 
main types of influenza-induced lesions in the respiratory tract. In chapter 2, the basic 
development of influenza-induced ARDS, including pulmonary oedema formation, is 
reviewed and analysed mainly from a histological and cellular perspective. This leads 
to the novel interpretation that the alveolar lining epithelium is the main stronghold 
25
Ch
ap
te
r 
1
of the EEB against leakage of plasma fluids into the pulmonary airspace. In chapter 3, 
the susceptibility of various animal species to influenza virus infections and subsequent 
disease is reviewed. This host-specific susceptibility is an important determinant 
for the suitability of a laboratory animal species to model influenza-induced ARDS. 
Variables involved in using experimental animals in influenza research are outlined 
and summarised in a table with pros and cons inherent to the commonly used animal 
models. In chapter 4, the pathogenesis of influenza virus infections in the ferret model 
is evaluated and described, exemplified by inoculations with human IAV isolates: 2009 
pH1N1 IAV and 2013 H7N9 AIV. In chapter 5, a novel approach to quantify alterations 
in aerated lung tissue in pH1N1-IAV-inoculated ferrets is presented. The method of 
repeated computed tomography (CT)-scanning of inoculated and acutely inflamed 
ferret lungs is validated and described as proof of principle and potential additional 
read-out parameter in influenza research. In chapter 6, several practical applications 
of the ferret model to assess the efficacy of human influenza vaccines with novel 
administration routes and adjuvant formulations are outlined, including quantification 
of altered ferret lung aeration by CT-scanning as correlate of protection. In chapter 7, 
the summarising discussion, the findings and conclusions from previous chapters are 
discussed and integrated with existing knowledge culminating in perspectives on future 
research regarding pathogenesis and intervention strategies of influenza-induced 
ARDS. In chapter 8, a thesis summary in Dutch is given. In chapter 9, scientific literature 
references concerning all chapters are listed. A list of abbreviations, Curriculum vitae, 
PhD portfolio, list of publications, and acknowledgements, are provided as addenda to 
this thesis.
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SUMMARy
ARDS is a fatal complication of influenza infection. In this Review we provide an 
integrated model for its pathogenesis. ARDS involves damage to the EEB, fluid leakage 
into the alveolar lumen, and respiratory insufficiency. The most important part of the 
EEB is the alveolar epithelium, strengthened by tight junctions. Influenza virus targets 
these epithelial cells, reducing sodium pump activity, damaging tight junctions, 
and killing infected cells. Infected epithelial cells produce cytokines that attract 
leucocytes—neutrophils and macrophages—and activate adjacent endothelial cells. 
Activated endothelial cells and infiltrated leucocytes stimulate further infiltration, 
and leucocytes induce production of reactive oxygen species (ROS) and nitric oxide 
(NO) that damage the barrier. Activated macrophages also cause direct apoptosis of 
epithelial cells. This model for influenza-induced ARDS differs from the classic model, 
which is centred on endothelial damage, and provides a rationale for therapeutic 
intervention to moderate host response in influenza-induced ARDS.
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INTRODUcTION
Influenza A virus is a respiratory pathogen that substantially affects human health 
worldwide. Seasonal viruses circulating in the human population cause annual 
epidemics with about 500 000 deaths per year (16). A novel strain of influenza A virus 
without pre-existing immunity in the population could cause a global pandemic with 
variable mortality; the 2009 H1N1 pandemic caused 151,700–575,400 deaths in its 
first year of circulation (24), whereas the 1918 H1N1 pandemic caused more than 40 
million deaths (78). There is concern that newly emerging strains of influenza A virus 
from animal re servoirs (e.g., avian-origin H5N1 and H7N9 viruses) could gain efficient 
transmissibility in human beings and cause a severe pandemic (39, 79). To mitigate the 
severity of such a pandemic, the mechanisms by which influenza A causes respiratory 
disease need to be understood.
The main complication of influenza virus infection is viral pneumonia, which often 
occurs together with, or is followed by, bacterial pneumonia (22, 23, 51, 80-82). In this 
Review, we focus on primary viral pneumonia, which can then lead to ARDS (38, 83-86). 
Clinically, the acute phase of ARDS is characterised by cyanosis, hypoxaemia, pulmonary 
oedema, and increasing respiratory failure over time, resulting in multiorgan failure and 
a high mortality rate (up to 60%) (87). In addition to influenza A virus, various other 
disorders—e.g., sepsis, pneumonia, trauma, and aspiration of gastric contents—can 
cause ARDS (88). A major cause of respiratory failure in the acute phase of ARDS is 
damage to the epithelial–endothelial barrier of the pulmonary alveolus, where gas 
exchange takes place (Figure 2.1.1). Damage to this barrier results in flooding of the 
alveolar lumen with proteinaceous oedema fluid containing fibrin, erythrocytes, and 
inflammatory cells. This oedema fluid reduces alveolar gas exchange and can result in 
severe respiratory insufficiency, as noted in patients with ARDS (88).
Much of the understanding of damage to the EEB in the acute phase of ARDS comes 
from studies of bacterial sepsis, in which the first site of damage is the endothelium 
(88-90). This model might not be appropriate for influenza virus, which first infects the 
epithelium. Additionally, although some reviews have focused on different factors of 
influenza-virus-induced lung damage —including viral virulence factors (91), cytokine 
production (92), and pathological changes (47)— no review has brought these features 
together. We review the available literature on the interaction between influenza 
A virus and key cell types present in the pulmonary alveolus in the acute phase of 
ARDS. Specifically, we focus on the roles of pulmonary epithelial and endothelial cells, 
neutrophils, and macrophages in damage to the EEB to develop a new conceptual 
framework for influenza-induced ARDS.
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Figure 2.1.1 Schematic representation of the EEB in the human respiratory tract. (A) In the lower 
respiratory tract, the trachea divides into primary bronchi and several levels of bronchi and bronchioles 
until the terminal bronchioles. (B) Each terminal bronchiole supplies an acinus of about 2000 alveoli. The 
alveolar walls contain a network of pulmonary capillaries, supplied with blood coming from pulmonary 
arterioles and draining into pulmonary venules. (C) Each alveolus contains several alveolar macrophages 
and is lined by flat type 1 pneumocytes and cuboidal type 2 pneumocytes. The pneumocytes lie on a base-
ment membrane, which is directly juxtaposed to or fused with the basement membrane of the pulmonary 
capillaries, which are lined by endothelial cells. (D) Gas exchange between blood in pulmonary capillaries 
and air in alveolar lumina takes place across the EEB, consisting of the alveolar epithelial layer, basement 
membrane or membranes, and pulmonary endothelial layer. (E) Specific staining for pankeratin stains type 
1 pneumocytes (arrowheads) and type 2 pneumocytes (arrows) in a normal human alveolus (reduced by 
13% from ×1000). (F) Specific staining for von Willebrand factor stains capillary endothelial cells (arrow) in a 
serial section of the same tissue shown in part E (reduced by 13% from ×1000). BM=basement membrane. 
TJ=tight junction.
EPITHELIAL cELLS
Among the first cells that influenza virus encounters after entering the alveolus are 
epithelial cells, either type 1 or type 2 pneumocytes. Type 1 pneumocytes are flat cells 
that cover 95% of the alveolar surface and allow easy diffusion of gas between air in the 
alveolar lumen and blood in the capillaries. Type 2 pneumocytes are cuboidal cells that 
secrete lung surfactant, which is important to reduce alveolar surface tension. Tight 
junctions at the sites where adjoining epithelial cells meet reduce the permeability of 
the alveolar epithelial cell layer. Tight junctions are composed of different proteins, 
including claudins and zona occludens 1, 2, and 3 (93). More than 90% of the resistance 
to protein transport across the EEB arises from the alveolar epithelium (94). By limiting 
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protein transport, the epithelium maintains osmotic pressure across the barrier and 
prevents pulmonary oedema (87).
A second mechanism by which the alveolar epithelium keeps the alveolar lumen 
free of fluid is through the action of ion channels and membrane proteins, which 
include the amiloride-sensitive epithelial sodium channels (ENaCs), the cystic fibrosis 
transmembrane conductance regulator, and many different aquaporins. The best 
characterised ion channel in the lung is the ENaC, which is present on the apical surface 
of both type 1 and type 2 pneumocytes (95, 96). This channel is complemented by 
an Na+/K+ ATPase on the basolateral cell surface. Na+ ions entering the channel at the 
apical surface are translocated to the basolateral cell surface, where Na+/K+ ATPase 
pumps them into the underlying interstitium (where present). The presence of Na+ 
in the interstitium creates an osmotic gradient that removes water from the alveolar 
lumen through aquaporins and intracellular pathways in alveolar epithelial cells, thus 
preventing pulmonary oedema (95, 96).
Not only are pneumocytes a crucial component of the EEB, but they are also target 
cells for infection by influenza A virus. Influenza A binds to its target cell by attachment 
of viral haemagglutinin to a sialosaccharide on the cell surface. The expression of 
sialosaccharides differs for different pneumocytes: type 1 pneumocytes express 
predominantly α-2,6-linked sialosaccharides, generally preferred by human influenza 
viruses, whereas type 2 pneumocytes express mainly α-2,3-linked sialosaccharides, 
generally preferred by avian influenza viruses (41, 50, 62). Consistent with the tropism 
of avian influenza viruses for α-2,3-linked sialosaccharides, autopsy findings of patients 
who died from influenza H5N1 showed that H5N1 virus antigens are most prominent 
in type 2 pneumocytes (97-99). By contrast, autopsy findings of fatal cases of infection 
with 2009 pandemic H1N1 virus (which has dual tropism for both α-2,3-linked and 
α-2,6-linked sialosaccharides (100)) showed antigen expression for pandemic H1N1 
virus in both type 1 and type 2 pneumocytes (29). These virus-dependent differences 
in attachment are dependent on specific aminoacid residues in the receptor-binding 
domain of the haemagglutinin globular head. Positions 190 and 225 (influenza A H1 virus) 
and positions 226 and 228 (influenza A H2 and H3 viruses) are the main determinants of 
receptor specificity for pandemic influenza viruses (101). Mutations at these positions 
also define the receptor-binding preference of the influenza A H5N1 virus (102). Thus, 
the type of alveolar epithelial cell targeted might differ between influenza A strains.
Very early after infection, influenza A virus causes fluid accumulation in the alveolar 
lumen by direct inhibition of ENaCs (Figure 2.1.2) (103). In vitro exposure of type 2 
pneumocytes to influenza A/Puerto Rico/8/1934 (H1N1) for 1 h decreased ENaC activity 
while maintaining the integrity of the epithelium (103). This decrease in activity was due 
to activation of protein kinase C and phospholipase by the viral haemagglutinin (103, 
104). The M2 ion channel of influenza virus might also inhibit the activity of ENaCs on 
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epithelial cells by triggering the production of ROS and subsequently activating protein 
kinase C (105). Consistent with these findings, rats infected with influenza virus and 
then intratracheally given saline solution had significantly less fluid clearance from the 
lungs at 2 h after infection than did uninfected rats (103).
Figure 2.1.2 The role of alveolar epithelial and endothelial cells in influenza-induced ARDS. (A) 
In the early stages of ARDS, influenza A virus can inhibit the action of ENaCs (i) on alveolar epi-
thelial cells. Later in infection, influenza virus can trigger the apoptosis or necrosis (ii) of alveolar 
epithelial cells, cytokine production (iii), and disruption of tight junctions (iv). Ultimately, these 
changes lead to the accumulation of proteinaceous fluid in the alveolus (pink). Specific staining 
for influenza A nucleoprotein shows influenza A H5N1 infection (inset) of an alveolar epithelial 
cell (arrowhead) in human lung tissue after 24 h (reduced by 22% from ×400). (B) After influenza 
A virus infection, the capillary endothelial cells enable the extravasation of monocytes (v) and 
neutrophils (vi) into the alveolus via the upregulation of adhesion molecules such as E-selectin 
and P-selectin. The inset shows adhesion of neutrophils (arrowhead) and other leucocytes to the 
endothelium of a pulmonary blood vessel from a ferret, 4 days after in vivo infection with influ-
enza A H5N1 (Haematoxylin and eosin (H&E) stain, reduced by 22% from ×800). The endothelium 
can produce various proinflammatory cytokines (vii) in response to influenza A. In both (A) and 
(B), epithelial cells represent both type 1 and type 2 pneumocytes. ARDS=acute respiratory dis-
tress syndrome. ENaC=amiloride-sensitive epithelial sodium channel. BM=basement membrane. 
RBC=red blood cell. TJ=tight junction. TNF=tumour necrosis factor.
At a later stage of infection, death of epithelial cells induced by influenza A virus plays 
a major part in damage to the EEB by destruction of the physical epithelial layer (106). 
Both types of cell death—apoptosis and necrosis—have been reported in post-mortem 
tissues of patients with ARDS induced by influenza virus (107, 108). The mechanisms by 
which influenza virus induces cell death have been shown in vitro (109-111), although 
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typically for bronchial or bronchiolar epithelial cells rather than alveolar epithelial cells. 
Infection of a human bronchiolar epithelial cell line (NCL-H292) with reassortant influenza 
A/England/939/69 (H3N2) resulted in caspase-8-dependent apoptosis (109). Influenza 
virus can induce epithelial cell apoptosis through various different pathways, including 
the activation of protein kinase R, which subsequently upregulates proapoptotic genes 
(e.g., FAS) (112). Alternatively, viral neuraminidase can activate transforming growth 
factor β to its active form, which then induces apoptosis by interacting with its cognate 
receptors (113). The expression of non-structural protein 1 (NS1), derived from influenza 
A/Hong Kong/483/97 (H5N1), is also sufficient to induce epithelial cell apoptosis in a 
caspase-dependent manner (111). By contrast with influenza-virus-induced apoptosis 
of NCL-H292 cells, infection of primary human bronchial epithelial cells with a mouse-
adapted strain of influenza A/Puerto Rico/8/1934 (H1N1) resulted in necrosis (110). The 
viral polymerase complex (particularly the nucleoprotein) could contribute to influenza-
virus-induced cell death by removal of the cap structures of host-cell mRNA (so-called 
cap snatching), which reduces the amounts of capped host mRNAs that are translated 
into functional proteins (114). Because of the important role of the epithelium in 
minimisation of pulmonary oedema, the loss of epithelial cells as a result of influenza-
virus-induced cell death has a major role in damaging the architecture of the lung.
The effects of epithelial cell death on damage to the EEB could be compounded by 
the ability of influenza virus to damage tight junctions of epithelial cells. Specifically, 
some H5N1 strains might directly disrupt tight junctions through a PDZ-ligand-binding 
motif present in the ESEV consensus sequence in the carboxyl terminus of viral NS1 
(115). This sequence mediates binding of viral NS1 to host proteins such as scribble 
and DLG1, which are important to the formation of tight junctions (115). Accordingly, 
infection of Madin-Darby canine kidney (MDCK) cells with viruses possessing the ESEV 
motif disrupts the formation of tight junctions (115). However, the expression of the 
ESEV motif is limited to a subset of influenza A strains (115). Thus, direct targeting of 
tight junctions by viral NS1 might not occur in all influenza virus infections.
Finally, in influenza virus infection, epithelial cells produce cytokines that can 
subsequently damage the EEB. Post-mortem analysis of a fatal case of influenza virus 
H5N1 pneumonia showed the production of tumour necrosis factor α (TNFα) by alveolar 
epithelial cells (116). Findings from in-vitro studies suggest that influenza-virus-infected 
alveolar epithelial cells produce other cytokines in addition to TNFα (Table 2.1.1) (109, 
110, 117-125). Generally, data from in-vitro studies must be interpreted with caution 
because results can differ dependent on the influenza virus strain and cell type used, and 
because many studies use primary cells or cell lines derived from the trachea, bronchus, 
or bronchiole (rather than from the alveolus). Findings of studies with primary human 
type 2 pneumocytes suggest that the increased production of CXCL10, interleukin 6, and 
CCL5 after infection with H5N1 (compared with infection with a seasonal H1N1 strain) 
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could contribute to increased disease severity (118). However, the mechanism by which 
these or other cytokines damage the EEB is unclear. ENaC activity can be decreased by 
cytokines such as interleukin 1β (126). Tight junctions can also be disrupted by cytokines 
such as TNFα (127). Several cytokines produced by alveolar epithelial cells in response 
to influenza virus infection are also chemotactic, or can upregulate the expression of cell 
adhesion molecules on pulmonary endothelial cells, and thus enable the extravasation 
of leucocytes (128). These cells can then damage the EEB.
ENDOTHELIAL cELLS
Endothelial cells are the most abundant cell type in the lung, constituting 30% of the 
total cell population (129). In the alveolus, endothelial cells line the capillaries that form 
a network in the alveolar walls. On their apical side, endothelial cells are in direct contact 
with circulating blood and form the site of attachment for recruited inflammatory cells. 
After appropriate activation, endothelial cells express cell adhesion molecules, which 
bind to their cognate ligands on leucocytes and mediate leucocyte extravasation (87). 
On their basolateral side, endothelial cells lie on a basement membrane, which is closely 
apposed to (or even fused with) the epithelial basement membrane (129). This intimate 
contact suggests that endothelial cells are strongly affected by signals and virus particles 
released from epithelial cells and inflammatory cells in the alveolar lumen. Activation of 
the endothelium by these signals and virus particles is essential to mediate an effective 
immune response against influenza A. However, activation of the endothelium might 
play a part in damage to the EEB and contribute to pulmonary oedema.
Influenza virus infection can upregulate the expression of endothelial adhesion 
molecules (e.g., E-selectin, P-selectin, ICAM1, and VCAM1), thereby enabling the 
recruitment of leucocytes to the alveolus (Figure 2.1.2) (130, 131). The presence of a 
large number of neutrophils and macrophages could damage the EEB through various 
mechanisms. Infection with influenza A H5N1 virus results in increased expression of 
E-selectin and P-selectin on human endothelial cells compared with infection with 
1918 pandemic H1N1 or a seasonal H1N1 strain (131). This differential activation of 
the endothelium might help to account for the increased leucocyte recruitment that 
occurs in H5N1 influenza virus infection (132) and the consequent increase in alveolar 
damage. Influenza virus infection can also trigger cytokine production by pulmonary 
endothelial cells. Seasonal H3N2 and H1N1 viruses trigger the production of interleukin 
6, CXCL9, and CXCL10 by human umbilical-vein endothelial cells (133, 134), whereas 
infection with H5N1 virus can trigger the production of CXCL10, TNFα, and interleukin 
6 (131). Findings of murine studies have shown that influenza-virus-induced activation 
of the pulmonary endothelium contributes to disease severity in mice infected with 
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2009 pandemic H1N1 or seasonal H1N1 viruses (135). Specifically, the pulmonary 
endothelium produced cytokines such as CCL2, CXCL10, interferon α, interleukin 6, 
TNFα, and interferon γ in response to influenza A virus and recruited leucocytes to 
the lung during infection (135). Accordingly, inhibition of endothelial-induced cytokine 
production and leucocyte recruitment by treatment with a sphingosine-1-phosphate 
agonist significantly improved survival rates after infection with influenza virus (135). 
Unfortunately, the mechanism by which endothelial-derived cytokines could have 
damaged the EEB in influenza virus infection is unknown (135). Nevertheless, these 
findings emphasise the important role that endothelial activation has in influenza-virus-
induced damage of the alveolus.
Influenza A virus might also damage the EEB by directly infecting endothelial cells, 
triggering cell death, and thereby creating sufficient endothelial damage to mediate 
pulmonary oedema (130, 136, 137). In vitro, the presence of a multibasic cleavage site 
in haemagglutinin enables the productive replication of H5N1 viruses in endothelial 
cells (131). In poultry, haemagglutinins with a multibasic cleavage site enable systemic 
virus replication because these haemagglutinins can be cleaved by ubiquitously 
expressed proteases, by contrast with haemagglutinins with monobasic cleavage sites 
that depend on trypsin-like proteases expressed only in the airways and gastrointestinal 
tract (138). However, unlike the epithelial layer, the endothelial layer is not as 
important a barrier to fluid leakage from the capillary lumen to the alveolar lumen. 
Together with the basement membrane, the endothelial layer constitutes only 10% of 
the resistance to protein transport (which maintains osmotic pressure) across the EEB 
(94). Therefore, damage to the endothelial layer alone is not a key cause of pulmonary 
oedema. Exposure of sheep to endotoxin caused moderately severe injury to the lung 
endothelium but no pulmonary oedema, probably because the alveolar epithelium 
remained morphologically and functionally intact (139). Furthermore, although H5N1 
influenza virus and other influenza virus strains infect endothelial cells of human beings 
and laboratory mammals in vitro (130, 131, 133, 136, 140, 141), little evidence suggests 
that influenza virus infection of the endothelium occurs in vivo. Findings of post-
mortem studies of fatal human cases show no infection or rare infection of endothelial 
cells by H5N1 and other influenza virus strains (29, 51, 142). Similarly, findings of many 
detailed pathological studies of H5N1 and other influenza virus strains in laboratory 
mammals also show no evidence for endotheliotropism (143), and extensive infection 
of the endothelium is seen only when H5N1 virus is given to cats through the intestine 
(144). Together, these results suggest that influenza virus infection of endothelial cells is 
absent or rare in human beings and other mammals. Thus, endothelial activation plays 
a more important part than does direct infection of endothelial cells with influenza virus 
in damage to the alveolar EEB.
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NEUTROPHILS
Neutrophils arrive in the pulmonary alveolus within 1 day of influenza virus infection 
(132), where they join residential leucocytes such as alveolar macrophages. Neutrophils 
are short-lived, phagocytic granulocytes that, in response to proinflammatory stimuli, 
extravasate from the blood into the alveolar lumen. Extravasation of neutrophils has 
several steps: rolling along the endothelium, adherence to selectins and adherins on 
endothelial cells, and migration through both the endothelial and the epithelial layer 
into the alveolar lumen (145). This migration can cause temporary damage to the EEB, 
but is not sufficient to cause pulmonary oedema (145-147).
After entering the alveolar lumen, neutrophils become activated in response to locally 
present cytokines and pathogens. Activated neutrophils can phagocytose pathogens. 
The resulting phagosome can fuse with intracytoplasmic primary, secondary, and tertiary 
granules, which contain various toxic compounds to kill phagocytosed pathogens. 
These toxic compounds can be released extracellularly after contact with indigestible 
material (e.g., immune complexes deposited on a basement membrane), phagocytosis 
of membranolytic substances (e.g., urate crystals), or fusion of the granules with the 
phagosome before it is completely closed (87, 148-150). In addition to phagocytosis, 
neutrophils can trap and kill pathogens by forming neutrophil extracellular traps (NETs), 
which consist of extracellular DNA studded with histones, chromatin, and antimicrobial 
compounds (151). The importance of neutrophils in limiting the replication and spread 
of influenza virus is shown by the fact that mice depleted of neutrophils have increased 
virus titres in the lungs and extrapulmonary sites compared with control mice (152).
However, neutrophils might also have an important role in damage to the EEB. In 
human cases of ARDS, neutrophil concentrations in bronchoalveolar lavage (BAL) fluid 
are positively correlated with disease severity (153). Similarly, pulmonary lesions in 
influenza-virus-infected mice are reduced by blocking of neutrophil recruitment to the 
lungs (154). Although several mechanisms have been proposed as to how neutrophils 
might damage the EEB in ARDS, those best characterised for influenza virus infection 
are the ability of neutrophils to produce ROS, cytokines, and NETs (Figure 2.1.3).
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Figure 2.1.3 The role of neutrophils and macrophages in influenza-induced ARDS. (A) Neutrophils can 
damage the EEB in influenza virus infection via the production of ROS (i). In response to influenza virus 
infection, neutrophils also produce cytokines (ii), which can then indirectly damage the EEB. The produc-
tion of NETs (iii) can also damage epithelial and endothelial cells. The inset shows NETs (arrowheads) in 
large blood vessels of a mouse after in-vivo infection with influenza virus (H&E stain). (B) Macrophages 
can damage the EEB directly by influenza-induced expression of TRAIL, which interacts with DR5 (iv) to 
cause epithelial cell apoptosis. TRAIL expression is triggered by interferon β. In response to influenza virus, 
macrophages also produce various cytokines (v) that can indirectly damage the EEB. The inset shows a 
macrophage (arrowhead) interacting with an alveolar epithelial cell in human lung tissue, 24 h after ex-vivo 
infection with influenza A H5N1 virus (H&E stain, reduced by 33% from ×500). Finally, influenza A induces 
macrophages to mediate the production of NO (vi) and the subsequent formation of peroxynitrite, which 
can damage the EEB. In both (A) and (B) epithelial cells represent both type 1 and type 2 pneumocytes. 
Newly recruited macrophages are depicted in dark pink, and resident alveolar macrophages are depicted 
in green. Accumulation of proteinaceous fluid in the alveolus is shown in pink. ARDS=acute respiratory 
distress syndrome. BM=basement membrane. ROS=reactive oxygen species. NET=neutrophil extracellular 
trap. TNF=tumour necrosis factor. NO=nitric oxide. DR5=death receptor 5. TRAIL=tumour-necrosis-factor-
related apoptosis-inducing ligand. Inset of part iii reproduced from Narasaraju and colleagues (155) by 
permission of Elsevier.
Neutrophils can produce ROS (e.g., superoxide) through NADPH oxidase, a 
multicomponent enzyme complex consisting of proteins in the cytosol and cytochrome 
b558 on the membrane of secondary granules. Fusion of secondary granules with 
phagosomes or the plasma membrane results in production of ROS in the phagosome 
or extracellular environment (156). Accordingly, ROS can not only kill pathogens such 
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as influenza virus, but also damage the alveolus (157, 158). Consistent with this notion, 
removal of superoxide (by injection of superoxide dismutase) protected mice from 
lethal influenza virus infection (159). Similarly, influenza virus infection caused less 
tissue damage in NADPH-oxidase-deficient mice than in wild-type mice (160).
Myeloperoxidase is present in primary granules and enables the production of 
hypochlorous acid from hydrogen peroxide and free chloride ions. Myeloperoxidase, 
interacting with the macrophage mannose receptor, can trigger macrophages to release 
ROS and cytokines (161). These effects can not only inactivate influenza virus (162), but 
also damage the EEB (163). Accordingly, influenza virus infection causes less disruption 
of the pulmonary architecture and less pulmonary oedema in myeloperoxidase-deficient 
mice than in wild-type mice (164). Additionally, myeloperoxidase-deficient mice also 
showed increased expression of claudin 9 and claudin 18-1 (164), suggesting that 
myeloperoxidase could damage the EEB by disrupting tight junctions. How important 
myeloperoxidase-induced damage is to influenza-virus-induced mortality is not clear; 
although survival did not differ between wild-type and Mpo−/− mice inoculated with a 
high viral dose, the knockout mice had a trend for prolonged survival at a lower dose 
(164).
Neutrophils might indirectly damage the EEB by producing cytokines. Influenza 
virus infection triggers neutrophils to produce CXCL2 and interleukin 8 (165), both of 
which recruit additional neutrophils to the site of infection. Neutrophils are also the 
key producers of CXCL10 after influenza virus infection (166). Influenza virus infection 
caused less pulmonary injury and mortality in CXCL10-deficient mice than in wild-type 
mice. Neutrophil-derived CXCL10 might act in an autocrine fashion and bind to its 
receptor CXCR3, which is expressed on neutrophils. In doing so, CXCL10 triggers the 
generation of superoxide and enhances chemotaxis towards CXCL2 (166). Accordingly, 
treatment of ferrets with a CXCR3 antagonist reduced the severity of clinical signs after 
H5N1 virus infection (167).
Neutrophils might also damage the EEB through the production of NETs (155). 
Mice infected with influenza A/Puerto Rico/8/1934 developed NETs both in the lumina 
of alveoli and in terminal bronchioles in areas of tissue damage, and attached to the 
endothelium in areas of haemorrhage (155). These results suggest that NETs could 
damage both alveolar epithelial and endothelial cells. The role of influenza virus in 
the production of NETs in vivo was supported in vitro by co-incubation of neutrophils 
and influenza-virus-infected epithelial cells (155). However, the survival rate of mice 
deficient in peptidyl arginine deiminase 4 (an enzyme that is essential for formation 
of NETs did not differ substantially from that of wild-type mice after influenza virus 
infection (168), suggesting that formation of NETs might not be crucial for damage to 
the EEB.
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MAcROPHAGES
Like neutrophils, macrophages are an important component of the innate immune 
response against influenza virus infection. Macrophages ingest pathogens and infected 
or apoptotic cells. Phagocytosed pathogens are then killed through a so-called 
respiratory burst and the production of ROS and NO. Macrophages can also produce 
a broad range of both proinflammatory and anti-inflammatory cytokines. Within the 
alveolus, two types of macrophages need to be distinguished. The first type are the 
alveolar macrophages, which are long-lived resident cells that occur at a density of about 
seven per alveolus (169). They typically express an alternatively activated phenotype 
to minimise pulmonary inflammation in response to innocuous pathogens, while still 
protecting the lung from more virulent pathogens (170). Their importance in control 
of influenza virus infection is shown by the fact that depletion of alveolar macrophages 
before influenza virus infection leads to increased viral replication and disease severity 
(155). In influenza virus infection, alveolar macrophages are soon outnumbered by 
monocytes that are attracted to the alveolus by chemokines (e.g., CCL2, CCL5, and 
CXCL10). These monocytes migrate from the blood to the alveolar lumen, where they 
differentiate into macrophages. This second type of macrophages—recently recruited 
macrophages—typically have a classically activated phenotype. Although blocking of 
monocyte recruitment to the lung leads to increased virus replication (171), recently 
recruited macrophages could also have an important role in damage to the EEB. After 
influenza virus infection, mice deficient in CCR2 (the receptor for CCL2, which mediates 
monocyte chemotaxis) had reductions in both monocyte recruitment to the lungs and 
severity of pulmonary lesions (172). The main mechanisms for damage by recently 
recruited macrophages are related to release of tumour-necrosis-factor-related 
apoptosis-inducing ligand (TRAIL, also known as TNFSF10), production of NO, and 
production of proinflammatory cytokines (Figure 2.1.3).
After infection with influenza A/Puerto Rico/8/1934 recently recruited macrophages 
express TRAIL, which interacts with death receptor 5, a protein that is upregulated on 
alveolar epithelial cells in influenza virus infection; this interaction induces apoptosis 
of these cells. Accordingly, inhibition of TRAIL reduced the rate of epithelial cell 
apoptosis, the amount of pulmonary oedema, and the mortality rate of mice infected 
with influenza A virus (173). TRAIL production is dependent on activation of protein 
kinase R by influenza A virus, and subsequent production of interferon β. Autocrine 
interaction of interferon β with its receptor (interferon α, β, and ω receptor) triggers 
the production of TRAIL in a JAK–STAT-dependent manner (174). In accordance with 
this pathway, blocking of interferon β signalling in mice impaired TRAIL production and 
reduced alveolar epithelial damage after influenza virus infection (174).
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Macrophages—and, to a lesser degree, neutrophils—that are stimulated by 
proinflammatory cytokines express inducible nitric oxide synthase (NOS2), which 
mediates the production of NO (158). NO can combine with superoxide to form 
peroxynitrite, which can both kill pathogens (175) and damage cells (176). Inhibition of 
NOS2 activity reduced the extent of pneumonia and mortality rate after lethal influenza 
virus infection (177). These findings complement the finding that, unlike wild-type mice, 
NOS2-deficient mice do not develop pneumonia after influenza virus infection (178). 
Karupiah and colleagues (178) suggested that NOS2 expression contributes more to 
severity of pneumonia than to cytopathic effects of influenza virus infection, because 
increasing viral titres in NOS2-deficient mice by blocking of interferon γ still did not 
induce mortality. The findings of this study emphasise the importance of pulmonary 
damage induced by NO in influenza virus infection.
The production of cytokines by macrophages is broad (Table 2.1.2) (132, 179-191), 
and depends on both strain of influenza virus and type of macrophage. The importance 
of these cytokines to protect against influenza virus is shown by the fact that viral NS1 
acts at several levels to interfere with interferon production and interferon-mediated 
induction of antiviral proteins (192). For example, the Asp92Glu mutation in NS1 
renders H5N1 IAV relatively insensitive to interferon α, interferon γ, and TNFα (193). 
Typically, however, H5N1 strains induce higher concentrations and a more diverse 
repertoire of cytokines in macrophages than do other influenza A strains (132, 180, 185, 
186), and whereas this induction represents an important component of the antiviral 
response, it could also contribute to the hypercytokinaemia and subsequent pulmonary 
dysfunction reported in some human cases of influenza H5N1 infection (180). Human 
monocyte-derived macrophages—perhaps representative of recently recruited ma-
crophages—produce significantly higher concentrations of proinflammatory cytokines 
than do human alveolar macrophages upon ex-vivo influenza virus infection (186, 191). 
Any macrophage-mediated, cytokine-induced pulmonary damage could therefore 
come mainly from recently recruited macrophages. However, the many different roles 
of cytokines in influenza virus infection, and the redundancy in many cytokine-signalling 
pathways, results in contradictory findings from experimental inoculations of influenza 
virus in mice deficient in specific cytokines (194, 195). Which macrophage-induced 
cytokines are most important in damage to the EEB, whether this damage is direct or 
indirect and the mechanism of this damage are unclear.
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Table 2.1.2 Cytokine production after influenza A virus infection of human monocyte-derived and 
alveolar macrophages
Influenza A strain
Infection of monocyte-derived macrophages
Interleukin 1β(132, 179-181) A/HK/486/97(H5N1),* A/Beijing/353/89(H3N2), A/
PR/8/34(H1N1), A/Vietnam/1203/04(H5N1),* A/
HK/54/98(H1N1),* A/Vietnam/3212/04(H5N1),* A/
Thailand/16/04(H5N1), A/Thailand/SP/83/04(H5N1)
Interleukin 10(180) A/HK/486/97(H5N1)*
Interleukin 12(132, 180) A/HK/486/97(H5N1),* A/HK/483/97(H5N1),* A/
HK/1174/98(H3N2),* A/Thailand/16/04(H5N1), A/Thailand/
SP/83/04(H5N1), A/South Carolina/1/18(H1N1), A/
Texas/36/91(H1N1)
CCL3(180, 182-184) A/HK/486/97(H5N1),* A/HK/483/97(H5N1),* A/
HK/1174/98(H3N2),* A/Beijing/353/89(H3N2), A/
Vietnam/1203/04(H5N1),* A/Vietnam/3212/04(H5N1),* A/
HH/01/09(H1N1), A/California/07/04(H3N2), A/Thailand/1(Kan-
1)/04(H5N1)
CCL4(132, 180) A/HK/486/97(H5N1),* A/HK/483/97(H5N1),* A/
Thailand/16/04(H5N1), A/Thailand/SP/83/04(H5N1)
CCL2(180, 182, 183, 185) A/HK/486/97(H5N1),* A/HK/483/97(H5N1),* A/
Vietnam/HN3028(H5N1),* A/California/04/09(H1N1),* 
A/HK/403946(H1N1),* A/Beijing/353/89(H3N2), A/
Vietnam/1203/04(H5N1),* A/Vietnam/3212/04(H5N1),* A/
Thailand/16/04(H5N1), A/Thailand/SP/83/04(H5N1)
CCL5(180, 182, 183, 186, 187) A/HK/486/97(H5N1),* A/HK/483/97(H5N1),* A/
Beijing/353/89(H3N2), A/Vietnam/1203/04(H5N1), A/
Thailand/1(Kan-1)/04(H5N1),* A/PR/8/34(H1N1)*
Interferon α(179-181, 188, 189) A/HK/486/97(H5N1),* A/Beijing/353/89(H3N2), A/
Finland/553/09(H1N1),* A/PR/8/34(H1N1), A/Thailand/1(Kan-
1)/04(H5N1)*
Interleukin 
6(132, 181, 184, 185, 187)
A/Vietnam/HN3028(H5N1),* A/California/04/09(H1N1),* A/
HK/415742(H1N1),* A/HK/403946(H1N1),* A/PR/8/34(H1N1), 
A/Vietnam/1203/04(H5N1), A/HH/01/09(H1N1), A/
California/07/04(H3N2), A/Thailand/1(Kan-1)/04(H5N1), A/
Thailand/16/04(H5N1), A/Thailand/SP/83/04(H5N1)
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Table 2.1.2 Cytokine production after influenza A virus infection of human monocyte-derived and 
alveolar macrophages (continued)
Influenza A strain
Interferon β(179-182, 188, 189) A/HK/486/97(H5N1),* A/HK/483/97(H5N1),* A/
HK/54/98(H1N1),* A/HK/1174/98(H3N2),* A/
Beijing/353/89(H3N2), A/Finland/553/09(H1N1),* A/
PR/8/34(H1N1), A/Vietnam/1203/04(H5N1),* A/
Vietnam/3212/04(H5N1),* A/Thailand/1(Kan-1)/04(H5N1)*
TNFα(179-182, 185, 186, 188-191) A/HK/486/97(H5N1), A/HK/483/97(H5N1), A/HK/54/98(H1N1), 
A/HK/1174/98(H3N2), A/Beijing/353/89(H3N2), A/
Vietnam/1203/04(H5N1), A/Vietnam/1194/04(H5N1), A/
Thailand/MK2/04(H5N1), A/Vietnam/3046/04(H5N1), A/
Vietnam/HN3028(H5N1),* A/California/04/09(H1N1),* A/
HK/415742(H1N1),* A/PR/8/34(H1N1), A/HK/403946(H1N1),* 
A/Vietnam/3212/04(H5N1),* A/HH/01/09(H1N1), A/
California/07/04(H3N2), A/Thailand/1(Kan-1)/04(H5N1), A/
Thailand/16/04(H5N1), A/Thailand/SP/83/04(H5N1), A/
Finland/553/09(H1N1),* A/PR/8/34(H1N1)*
CSF2(132) A/Thailand/16/04(H5N1), A/Thailand/SP/83/04(H5N1)
CSF3(132) A/Thailand/16/04(H5N1), A/Thailand/SP/83/04(H5N1)
Interleukin 4(180) A/HK/483/97(H5N1)*
Interferon γ(185) A/Vietnam/HN3028(H5N1),* A/California/04/09(H1N1),* A/
HK/403946(H1N1)*
TGFβ(191) A/Netherlands/602/09(H1N1),* A/Vietnam/1194/04(H5N1)*
Interleukin 7(180) A/HK/483/97(H5N1)*
Interleukin 18(179) A/Beijing/353/89(H3N2)
Interferon λ(182, 188) A/Finland/553/09(H1N1),* A/Vietnam/3212/04(H5N1),* A/
HK/483/97(H5N1)*
CXCL10(182-184, 186-188) A/Finland/553/09(H1N1),* A/Vietnam/1203/04(H5N1), 
A/New Caledonia/20/99(H1N1), A/HH/01/09(H1N1), A/
California/07/04(H3N2), A/Thailand/1(Kan-1)/04(H5N1), 
A/HK/483/97(H5N1), A/Beijing/353/89(H3N2), A/
Vietnam/3212/04(H5N1),* A/HK/54/98(H1N1)*
CCL8(189) A/Thailand/1(Kan-1)/04(H5N1),* A/PR/8/34(H1N1)*
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Table 2.1.2 Cytokine production after influenza A virus infection of human monocyte-derived and 
alveolar macrophages (continued)
Influenza A strain
CXCL11(189) A/Thailand/1(Kan-1)/04(H5N1),* A/PR/8/34(H1N1)*
Infection of alveolar macrophages
CXCL10(186) A/HK/483/97(H5N1)
TNFα(186) A/HK/483/97(H5N1)
CCL5(186) A/HK/483/97(H5N1)*
Interferon β(186) A/HK/483/97(H5N1)*
Interleukin 6(186) A/HK/483/97(H5N1)*
CCL2(186) A/HK/483/97(H5N1)*
*Determined by mRNA expression. TNF=tumour necrosis factor. TGF=transforming growth factor.
cONcLUSIONS & PERSPEcTIVES
In this Review, we set out the main cell types and mechanisms involved in influenza 
virus infection of the lung that lead to the following model for influenza-virus-induced 
da mage to the EEB (Figure 2.1.4). Upon entering the alveolus, influenza virus infects 
its main target, epithelial cells, which undergo apoptosis or necrosis, opening the 
epithelial layer. Influenza-virus-infected epithelial cells also produce cytokines (e.g., 
CCL2, CCL5, and CXCL10) that recruit neutrophils and monocytes to the alveolus by 
direct chemotaxis. Activation of endothelial cells in influenza virus infection results in 
the upregulation of adhesion molecules for leucocyte extravasation and the production 
of cytokines such as CCL2, CXCL10, interferon α, interleukin 6, TNFα, and interferon γ. 
Both processes further attract neutrophils and macrophages to the alveolus. Recruited 
neutrophils produce ROS, which can cause tissue damage. Neutrophils also produce 
cytokines in response to influenza virus infection. In particular, the production of 
CXCL10 could damage the EEB by triggering the production of superoxide or enhancing 
neutrophil chemotaxis. Recruited macrophages can damage the EEB in three ways. 
First, they can express TRAIL, which interacts with death receptor 5 on the epithelial 
cell and induces epithelial cell apoptosis. Second, by the activation of NOS2, recruited 
macrophages can increase concentrations of NO and peroxynitrite, which cause tissue 
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damage. Third, they are important producers of proinflammatory cytokines, which 
further exacerbate the inflammatory response and could damage the EEB.
The pathogenesis of influenza-virus-induced ARDS is centred on the alveolar 
epithelium. This framework contrasts with the classic model of ARDS pathogenesis, in 
which lung vascular endothelium is thought to be the main target. An important cause 
of ARDS in the classic model is bacterial sepsis, which differs in two important ways from 
influenza virus infection. First, the typical pathological agent in sepsis, lipopolysaccharide 
(LPS), enters the alveolus through the blood circulation (89), whereas influenza virus 
enters through the airways. Second, the main target of LPS is the endothelial cell (89), 
whereas that of influenza virus is the epithelial cell. Because many in vitro and in vivo 
models used to study the pathogenesis of ARDS make use of LPS that the endothelial 
cell has received such attention is not surprising. However, irrespective of whether 
the cause of ARDS is sepsis, a respiratory virus such as influenza virus, or another 
pathological agent, its pathogenesis is highly dependent on damage to the alveolar 
epithelium, which is mainly responsible for maintaining the osmotic pressure across 
the EEB (94).
This new model for influenza-virus-induced ARDS has implications for pathogenesis 
research, both by identification of topics of particular interest and by exposure of gaps 
in our knowledge. Can this framework, which is based on information from various 
sources, be validated in one experimental system? By which mechanisms does influenza 
virus induce cell death in alveolar epithelial cells? Which factors establish whether 
apoptosis or necrosis occurs? How is this mechanism affected by cell type (ie, type 1 
or type 2 pneumocytes)? By which mechanisms do cytokines produced by epithelial 
cells, endothelial cells, and recently recruited macrophages damage the EEB? Which 
are the most important mechanisms by which endothelial cells are activated; direct 
contact with influenza virus, cytokines produced by influenza-virus-infected epithelial 
cells, or cytokines produced by other cell types? At which stage of damage to the 
EEB are influenza virus particles released into the systemic circulation, and on which 
factors is this release dependent? Does influenza virus infection damage the basement 
membrane? If so, how? What effect does this damage have on re-epithelialisation? 
Which characteristics in influenza-virus-induced damage to the alveolar epithelium are 
crucial to establish whether re-epithelialisation or fibrosis occurs? How do the above 
mechanisms vary between different influenza virus strains? Which host factors define 
whether a patient with influenza goes on to develop ARDS? How is the difference in 
main target (epithelium vs endothelium) between influenza-virus-induced ARDS and 
sepsis-induced ARDS shown in disease progression, response to intervention, or clinical 
outcome? Findings that patients with sepsis-induced ARDS have higher concentrations 
of procalcitonin and interleukin 6 on days 1 and 2 after diagnosis of ARDS, more severe 
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Figure 2.1.4 Pathogenesis model and histopathology of influenza-induced ARDS. 
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disease, and higher mortality than do patients with non-septic ARDS lend support to the 
notion that different causes of ARDS can result in different clinical outcomes (196-198).
The model described in this Review also provides a rationale to choose therapeutic 
targets to minimise the tissue-damaging response against influenza virus infection of 
pulmonary alveoli (199, 200). Potential therapeutic targets for influenza-virus-induced 
ARDS are the alveolar epithelium, infiltrating leucocytes, and the overall proinflammatory 
response. Growth factors such as keratinocyte growth factor (KGF) (199) and 
hepatocyte growth factor (HGF) (201) help to protect and restore alveolar epithelium. 
Inhibitors of the CXCL10–CXCR3 axis reduce infiltration of neutrophils and induction of 
ROS production (166, 167). Apocynin, an inhibitor of NADPH oxidase 2, also reduces 
production of ROS (202, 203). Celecoxib and mesalazine, cyclo-oxygenase-2 inhibitors, 
reduce cytokine dysfunction and prevent apoptosis (204). Gemfibrozil, an agonist of 
peroxisome proliferator-activated receptor α, reduces the release of proinflammatory 
cytokines (204). Mesenchymal stem cells moderate inflammatory response, improve 
alveolar fluid clearance, and maintain integrity of lung epithelium and endothelium in 
pneumonia (200). Lung stem cells have been identified that undergo rapid proliferation 
and radiate to areas of alveolar damage and express markers typical of alveoli after 
sublethal influenza virus infection in mice. Understanding of the signals that trigger 
this cell proliferation and radiation, and apparent regeneration of alveolar structures, 
could be useful to develop new therapies for treatment of influenza-virus-induced 
ARDS. Furthermore, therapies should promote re-epithelialisation in the absence of 
widespread fibrosis (which can result in decreased lung function and increased ventilator 
← Figure 2.1.4 Pathogenesis model and histopathology of influenza-induced ARDS. (A) A schematic 
model of the pathogenesis of influenza-induced ARDS. In a healthy lung, the alveolar lumen is free of fluid 
to ensure optimum gas exchange (upper right quadrant). After infection, influenza A virus induces epithe-
lial cell death, resulting in leakage of proteinaceous fluid into the alveolar lumen (lower right quadrant). In-
fluenza virus also induces cytokine production by epithelial and endothelial cells, and selectin upregulation 
on endothelial cells. Selectin upregulation on endothelial cells enables extravasation of neutrophils, which 
are among the first cells recruited to the lung in influenza virus infection (lower left quadrant). Neutrophils 
damage the EEB via the release of toxic granules and cytokine production, resulting in increased leakage of 
proteinaceous fluid into the alveolar lumen. Selectin upregulation on endothelial cells enables extravasa-
tion of macrophages, which damage the barrier via the production of NO, TRAIL, and cytokines (upper left 
quadrant). In addition to proteinaceous fluid and infiltrating leucocytes, the progressive damage to the 
EEB results in fibrin deposition and haemorrhage into the alveolar lumen. (B) Histopathology panel shows 
representative stages of ARDS in a ferret lung 4 days after infection with influenza A H5N1. The upper right 
quadrant shows normal air-filled alveoli from an uninfected ferret. The lower right quadrant shows alveoli 
abundantly filled with proteinaceous fluid, visible as homogeneous pink material (arrowhead). The lower 
left quadrant shows alveoli filled with proteinaceous fluid mixed with infiltrating leucocytes, mainly neu-
trophils (arrowheads). The upper left quadrant shows alveoli filled with proteinaceous fluid mixed with 
macrophages, erythrocytes, and fibrin strands. Additionally, the alveolar walls are disrupted (H&E stain, 
reduced by 24% from x400). ARDS=acute respiratory distress syndrome. IAV=influenza A virus. NO=nitric 
oxide. TRAIL= tumour-related apoptosis-inducing ligand.
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dependence) (205). However, treatments that limit influenza-virus-induced damage in 
mice might not necessarily produce equivalent effects in human beings. Therefore, 
prevention of damage to the alveolus in influenza virus infection needs an approach 
that combines knowledge obtained with use of experimental infection in laboratory 
animals together with clinical data.
Influenza-virus-induced ARDS has a high case fatality rate, despite intensive 
hospital care, development of lung-protective ventilation strategies, and the use of 
extracorporeal membrane oxygenation (ECMO). Therapies directed against the virus 
are often not adequate to cure the disease because the lung damage remaining after 
the virus infection has been abrogated is too severe to resolve by itself. Only through 
better understanding of the mechanism by which this damage develops and is repaired 
can therapeutic strategies be developed to improve the outcome of this intractable 
complication of influenza.
Search strategy and selection criteria
We identified relevant articles by searching PubMed and Google Scholar with the search 
terms “epithelial cell”, “influenza”, “macrophages”, “neutrophils”, “endothelial cells”, 
“H5N1”, “tight junctions”, “interferon”, “alveolar macrophage”, “sodium channel”, “lung 
damage”, “ENaC”, “cytokines”, “necrosis”, “post-mortem”, “NETs”, “reactive oxygen 
species”, “nitric oxide”, “toxic damage”, “myeloperoxidase”, “NADPH”, “peroxynitrite”, 
“acute lung injury”, “apoptosis”, “ARDS”, and “cytokine storm”. We reviewed relevant 
articles that were found in these searches, articles cited by those found, and articles 
present in our own files. Only English-language articles that were published before July 
2013 were included.
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ABSTRAcT
Influenza A virus infection is an important cause of respiratory disease in humans. 
The original reservoirs of IAV are wild waterfowl and shorebirds, where virus infection 
causes limited, if any, disease. Both in humans and in wild waterbirds, epithelial 
cells are the main target of infection. However, influenza virus can spread from wild 
bird species to terrestrial poultry. Here, the virus can evolve into highly pathogenic 
avian influenza. Part of this evolution involves increased viral tropism for endothelial 
cells. HPAIV infections not only cause severe disease in chickens and other terrestrial 
poultry species but can also spread to humans and back to wild bird populations. 
Here, we review the role of the endothelium in the pathogenesis of influenza virus 
infection in wild birds, terrestrial poultry and humans with a particular focus on 
HPAIVs. We demonstrate that whilst the endothelium is an important target of virus 
infection in terrestrial poultry and some wild bird species, in humans the endothelium 
is more important in controlling the local inflammatory milieu. Thus, the endothelium 
plays an important, but species-specific, role in the pathogenesis of influenza virus 
infection.
Keywords: influenza virus, endothelial cells, highly pathogenic avian influenza, zoonotic 
infection, poultry
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INTRODUcTION
IAV is a negative-sense RNA virus of the Family Orthomyxoviridae. IAVs can be classified 
into different subtypes based on antigenic differences in the two surface glycoproteins 
of the virus, the HA and NA. Each year, antigenic changes (or “drift”) in the HA and NA 
result in a seasonal outbreak of IAV in the human population. However, when there is a 
dramatic change in the HA and/or NA, often originating from the avian reservoir, global 
pandemics can result. In the last 100 years there have been four IAV pandemics in the 
human population: the 1918 H1N1 pandemic, the 1957 H2N2 pandemic, the 1968 H3N2 
pandemic and the 2009 H1N1 pandemic. These pandemics have all caused significant 
morbidity and mortality. Indeed, the 1918 H1N1 virus was so severe that life expectancy 
in the U.S.A. dropped by 11.8 years from 1917 to 1918 (21). The constant threat of a 
future IAV pandemic highlights the need to study and understand IAV pathogenesis not 
only in humans, but also in the virus’ natural avian reservoirs. The original reservoirs 
of IAV are wild waterfowl (order Anseriformes—which includes geese, ducks, and 
swans) and shorebirds (order Charadriiformes—which includes gulls and waders). 
Sixteen different HA subtypes and 9 different NA subtypes of IAV have been recorded 
in wild waterfowl. A subset of these different IAV strains can then spread from wild 
bird populations to terrestrial poultry (order Galliformes). Here, IAV can cause a mild or 
subclinical infection of the respiratory and/or gastrointestinal tract, and is thus referred 
to as a low pathogenic AIV. LPAIVs of the H5 and H7 subtypes can subsequently evolve 
in poultry to become HPAIVs, which typically cause a fatal and systemic infection. LPAI 
and HPAI viruses can cause respiratory infection in humans, with HPAIVs occasionally 
reported in extra-respiratory organs.
The pathogenesis of IAV infection differs markedly between wild waterbirds, 
terrestrial poultry and humans. In all three host groups, endothelial cells play a key role 
in disease pathogenesis—either as the primary cellular target of viral infection or as 
orchestrators of the anti-viral immune response. Here, we review the currently available 
literature on the role of the endothelium in the pathogenesis of IAV (in particular H5N1 
HPAIVs) in terrestrial poultry, wild birds and humans. Specifically, we will compare the 
ability of IAV to infect and/or “activate” the endothelium across these different host 
groups.
TERRESTRIAL POULTRY (ORDER GALLIFORmES)
Typically, terrestrial poultry infected with LPAIVs display limited clinical signs and with 
no evidence of endothelial cell infection (rather the virus preferentially infects epithelial 
cells of the respiratory tract) (206). However, viruses of the H5 and H7 subtype can 
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evolve in terrestrial poultry to become HPAIVs. This evolution typically occurs via the 
addition of a multi-basic cleavage site in the viral HA. This then allows the HA to be 
cleaved (a prerequisite for viral infection) by the ubiquitously present furin family 
of enzymes. In contrast, LPAIVs can only be cleaved by trypsin like enzymes that are 
present within the respiratory and digestive tract. Upon evolution to HPAIV, the cell 
tropism of IAV changes dramatically. Studies on naturally or experimentally infected 
chickens show that HPAIVs can infect the endothelium in a variety of different organs 
including, but not limited to, the lung, heart, brain, and spleen (207-216) (Figure 2.2.1) 
This endothelial cell tropism can be so striking that in chickens infected with H5N1, IAV 
antigen is more prevalent in the endothelial cells of the respiratory and intestinal tract 
than in the epithelial cells of the same tissues (215). Similarly, in Galliformes other than 
chickens viral antigens are predominant in the vascular and capillary endothelial cells of 
various tissues including the lung, liver, brain, skeletal muscle, pancreas, heart, kidney, 
spleen, and bursa (217-221). The endothelial tropism of HPAIVs is determined, at least 
in part, by the presence of the multi-basic cleavage site in the HA, as the removal of 
these basic amino acid residues reduces endothelial tropism (65). The polarity of virus 
budding may also contribute this distinct pattern of viral infection (222).
The endothelial tropism of HPAIVs in chickens and other Galliformes has important 
pathological ramifications. Firstly, IAV infection of chicken endothelial cells is associated 
with the apoptotic death of these cells (209). The loss of endothelial cells is likely to 
contribute to the oedema and hemorrhaging observed in the wattle, comb, lungs and 
legs of chickens infected with HPAIVs (216, 223). A loss of endothelial cells can also 
detrimentally affect blood coagulation (212, 213). Damage to endothelial cells activates 
the extrinsic coagulation cascade and facilitates the microthrombosis. This can then 
lead to disseminated intravascular coagulation (DIC) whereby the coagulation cascade 
become “hyper-activated,” resulting in thrombocytopenia, widespread hemorrhaging 
and ischaemia. Consistent with a role for DIC in the pathogenesis of HPAIVs in chickens, 
Muramoto and colleagues demonstrated that chickens intravenously infected with 
H5N1 display both microthrombosis and thrombocytopenia (212). Similarly, chickens 
infected intranasally with H5N1 display microthrombosis in the lung within 24 h post-
infection. It has also been suggested that the replication of HPAIVs in endothelial cells 
could disrupt the innate immune response, thermoregulation (224) and facilitate the 
systemic spread of the virus to parenchymal cells of the brain, skin, and visceral organs 
(225). Together, these features help account for the rapid and high mortality rates of 
HPAIVs in Galliformes. For example, in chickens death typically occurs within 2 days 
post-infection, often in the absence of visible clinical signs (215). Similarly, during an 
outbreak of a H7N1 HPAIV in Italy, turkeys and guinea fowl (reared on litter) had a 100% 
mortality rate within a mere 48–72 h of becoming symptomatic (226).
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Figure 2.2.1 Endotheliotropism and epitheliotropism of IAVs in chickens. Virus distribution in: (A) en-
dothelial cells of the wattle of a chicken naturally infected with H7N7 HPAIV. Brown-reddish staining anti-
gen indicative of viral replication is present in many endothelial cell nuclei (arrows) and cytoplasm lining 
the small blood vessels. The dermis is expanded by oedema (asterisk). (original magnification 200×, in van 
Riel and colleagues (216)  (B) Epithelial cell nuclei (arrowheads) and in endothelial cells (arrows) of the 
nasal mucosa of a chicken 24 h after experimental intranasal (IN) infection with 105 TCID50 of H5N1 HPAIV 
A/Indonesia/05/2005, illustrating both epitheliotropism and endotheliotropism of the virus (original mag-
nification 200×). (C) Endothelial cell nuclei (arrows) of the lung interstitium 24 h after infection of the same 
chicken as in (B), the alveolar lining epithelial cells nuclei (arrowheads) do not stain positive for viral antigen 
(original magnification 400×). (IHC for IAV-NP with hematoxylin counterstain).
WILD BIRDS (ORDER ANSERIFORmES AND CHARADRIIFORmES)
In wild birds, LPAIVs normally present as a sub-clinical infection with little involvement 
of the endothelium in disease pathogenesis (225, 227). Prior to the emergence of H5N1 
HPAIVs, there was only one recorded incidence of a HPAI strain being detected in wild 
birds (228). It was therefore assumed that HPAI strains were unlikely to transmit back 
to the wild bird population and cause disease following their emergence in poultry. 
However, since 2002 the H5N1 HPAIV strain has caused infection and mortality in a 
variety of wild birds. Unlike LPAIVs, H5N1 viruses in wild birds do not infect intestinal 
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epithelial cells. Instead, the virus predominantly infects cells in the respiratory tract 
and other organs (Tables 2.2.1 and 2.2.2) and infection can be associated with severe 
necrosis and inflammation (215, 229-232). H5N1 viruses display, at most, limited tropism 
for the endothelium in wild birds (Tables 2.2.1 and 2.2.2), and it is therefore unlikely 
that endothelial cell infection plays a major role in disease pathogenesis. However, 
one notable exception to this trend is black swans (233). Upon infection with H5N1 A/
whooper swan/Mongolia/244/05 AIV, 100% (n = 5) of black swans succumbed to disease 
within 2–3 days (as seen during H5N1 infection of chickens, this was often observed in 
the absence of clinical signs of disease) (233). IHC showed that the endothelial cells 
throughout the body were the primary target of IAV infection, and the presence of IAV 
antigen was associated with multiorgan necrosis and mild acute inflammation (233). 
Although a tropism for the endothelium is observed in other species of swans, this 
does not appear to be as pronounced as that seen in the black swan (233-237). For 
example, viral antigen was detected infrequently or not at all in the endothelial cells 
of whooper swans (233, 235) and trumpeter swans (233) following either a natural or 
experimental infection with H5N1. Similarly, whilst endothelial cells of mute swans were 
positive for IAV, and widespread hemorrhage was recorded, this was only detected in 
3 out of 12 birds (236). Thus, although the ability of H5N1 HPAIV to infect endothelial 
cells contributes to the severity of the disease observed in black swans this does not 
necessarily hold true for other species of swans or wild birds.
HUMANS
In humans, the primary cellular targets of IAV are epithelial cells in the respiratory 
tract. Seasonal IAVs, which are adapted to and circulate in the human population, 
typically infect ciliated cells in the upper respiratory tract, trachea and bronchi (43, 
50). In contrast, HPAIVs such as H5N1 preferentially infect the lower respiratory tract, 
specifically club cells and alveolar type II pneumocytes (50, 62). This differential tropism 
reflects, in part, the ability of H5N1 viruses to bind to α-2,3-linked sialosaccharides 
(expressed on type II pneumocytes) whilst seasonal IAVs typically display a preference 
for α-2,6-linked sialic acid (41, 50, 62). Within the lower respiratory tract, alveolar 
epithelial cells are in close proximity to the underlying endothelium. Indeed, in the 
human alveolus there is on average only 0.5 μm separating the airspace from the 
capillary (88). During IAV infection the endothelium is therefore likely to be exposed 
to free virus particles produced by infected and damaged epithelial cells. It is often 
suggested that—like chickens and black swans—IAV infects human endothelial cells, 
and that this contributes to disease pathogenesis (131, 136, 141). For example, in 
vitro studies using primary human lung microvascular endothelial cells demonstrated 
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that endothelial cells can be infected by seasonal H3N2 IAV, with infection ultimately 
resulting in increased endothelial cell permeability (136). Others have suggested that 
IAV infection of the pulmonary endothelium is a unique feature of infection with H5N1 
viruses, as H5N1 strains are able to efficiently infect and replicate in human microvascular 
endothelial cells whereas other IAV strains do not (131, 136, 141). However, in spite of 
these in vitro studies, there is limited evidence suggesting that IAV infection of human 
endothelial cells occurs in vivo. Post mortem analysis of patients who succumbed to 
H5N1 did not demonstrate the presence of virus in pulmonary endothelial cells (142). 
Similarly, endothelial cells were only very infrequently infected in a limited number of 
patients infected with fatal pandemic 2009 H1N1 (29). Whilst one recent study in mice 
recorded endothelial cell infection (245), in most animal models of human infection 
IAV infection of the endothelium is rarely observed (143) (Figure 2.2.2). Together, these 
data suggest that infection of endothelial cells by IAV is unlikely to contribute to disease 
severity in humans.
Although human endothelial cells are not infected by IAV in vivo, endothelial cells 
may still play an important role in the pathogenesis of IAV in humans. During IAV 
infection pulmonary endothelial cells are thought to be the most important source 
of cytokines in the lung (135). Specifically, in a mouse model of influenza, treatment 
with a SIP1 receptor agonist reduced IAV-induced mortality by blocking endothelial cell 
cytokine and chemokine production (135), suggesting a key role for endothelial cells in 
IAV pathogenesis. It has also been shown that the IAV-induced inflammatory response 
(namely the production of TNFα, IL-6 and IL-1β) upregulates trypsin production 
(246). The increased amount of trypsin then damages the tight junction protein 
zona-occludens 1 that is found between endothelial cells and increases endothelial 
permeability (246). However, it is important to note that this is unlikely to account 
for the pulmonary oedema observed during severe IAV infection as it is epithelial, not 
endothelial, cells that play the most important role in ensuring that the alveolus remains 
free of fluid (94). Pro-inflammatory cytokines, derived either from the endothelium or 
other cells in the lung, may also contribute to the development of thrombosis during 
IAV infection (137, 247). For example, treatment of human umbilical vein endothelial 
cells with TNFα significantly increased platelet binding to the cells by promoting the 
interaction between the F11 receptor on platelets and the F11 receptor on endothelial 
cells (247). This observation is supported by epidemiological evidence from the 2009 
H1N1 pandemic, whereby 5.9% of patients hospitalised for influenza virus infection had 
thrombotic vascular events (248).
In addition to mediating cytokine production, endothelial cells may also indirectly 
control the inflammatory response in the lung during IAV infection via the expression of 
adhesion molecules, such as E-selectin, P-selectin, ICAM1, and VCAM1, on their apical 
surface. These adhesion molecules can bind to various leukocytes and mediate their 
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ravasation to the infected lung. The increased expression of E/P-selectin expression on 
human endothelial cells following exposure to H5N1 (132) may therefore account for 
the increased inflammatory response (and lung lesions) associated with this virus. In 
sum, whilst human endothelial cells are not infected with IAV, endothelial cells still play 
an important role in the pathogenesis of IAV in humans.
Figure 2.2.2 Epitheliotropism of IAVs in ferrets. IAV distribution in: (A) Epithelial cell nuclei and apical 
cytoplasm of the nasal respiratory mucosa of a ferret 24 h after experimental intranasal infection with 106 
TCID50 of seasonal influenza H3N2 A/Netherlands/177/2008 (original magnification 800×). (B) Epithelial 
cells of a bronchiole (asterisk) and in few alveolar lining epithelial cell nuclei (arrows) of a ferret lung 24 h 
after experimental intratracheal infection with 106 TCID50 of influenza pH1N1 A/Netherlands/602/2009. The 
blood vessel lumen lining endothelial cell nuclei (arrowhead) do not stain positive for viral antigen (original 
magnification 200×). (C) Alveolar lining epithelial cell nuclei (arrows) of a ferret lung 24 h after experimental 
intratracheal infection with 106 TCID50 of H5N1 HPAIV A/Indonesia/05/2005. The blood vessel lumen lining 
endothelial cell nuclei (arrowhead) do not stain positive for viral antigen (original magnification 400×). 
Brown-reddish staining antigen indicative of viral replication was present only in epithelial cells of ferret 
respiratory tract, not in ferret endothelial cells. (IHC for IAV-NP with hematoxylin counterstain).
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ENDOTHELIAL cELL INFEcTION IN cATS
Upon the initial emergence of H5N1 viruses, mortality in cats was observed in areas 
where the viruses were spreading in wild and domestic birds. This suggested that cats 
were susceptible to infection. This was unusual as cats have long been considered to be 
refractory to IAV infection. H5N1 viruses administered to cats intratracheally resulted in 
productive infection of many organs, including the respiratory tract, with parenchymal 
and epithelial cells as the primary targets for viral replication (249). These studies de-
monstrated that domestic cats could indeed develop clinical disease upon H5N1 HPAIV 
infection. Cats and other carnivores can be exposed to H5N1 viruses by feeding on sick 
or dead birds. In order to mimic this route of infection, Reperant and colleagues (144) 
administered H5N1 HPAIV to the small intestine of cats using enteric-coated capsules 
(the use of which avoided accidently exposing the respiratory tract to the inoculum). 
Three days post-infection H5N1 infected cats became lethargic and began to display 
severe clinical signs. Surprisingly, IHC demonstrated that there was an overwhelming 
infection of endothelial cells in virtually every organ of infected cats, in a pattern 
reminiscent of that observed in chickens. In contrast, parenchymal cells were rarely 
infected. In particular, infection of respiratory epithelial cells was not observed, despite 
massive infection of the pulmonary endothelium. The virus used to infect the cats 
via the intestine had been isolated from the liver of infected chickens, and may have 
accumulated mutations potentially responsible for such difference in tissue tropism. 
However, analyses of the viruses used to infect, and recovered from, cats inoculated 
intra-tracheally and via the intestine, revealed no coding differences associated with the 
difference in tropism. These data suggest that the route of virus exposure may influence 
the role of the endothelium in the pathogenesis of influenza virus in mammals.
cONcLUSIONS AND FUTURE DIREcTIONS
Endothelial cells play important but distinct roles in the pathogenesis of IAV in wild birds, 
poultry and humans. Whilst endothelial cells are infected by HPAIVs in chickens and 
swans, in humans they are more important in driving and controlling the inflammatory 
response in the lung. It is important to note that endothelial cells in both chickens 
and swans may also influence the inflammatory response to IAV. It has already been 
suggested that the overwhelming endothelial tropism of H5N1 viruses in poultry may 
disrupt the innate immune response (224). However, the details of this ‘disruption’ 
have been hard to elucidate due to the limited availability of reagents to study the 
avian immune response. This remains a key research priority for the future. In addition, 
what makes the endothelial cells of chickens and black swans (and not those of other 
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wild bird species and humans) so permissive to H5N1 viruses in vivo remains to be 
determined. It is likely that as research and the availability of reagents for studying avian 
species continues to grow new roles for endothelial cells in pathogenesis of IAV will be 
discovered. However, what is clear at present is that endothelial cells contribute to the 
severity of IAV infections across multiple different species.
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ABSTRAcT
Influenza viruses can infect a wide range of mammals, including carnivores, cetaceans, 
non-human primates, bats, ungulates, rodents, lagomorphs, and anteaters. We here 
provide a comprehensive overview of the sporadic influenza virus infections reported 
in these species. Besides a special section on highly pathogenic avian influenza virus 
subtype H5N1, which has the ability to cause severe disease in multiple mammalian 
species, and an in-depth discussion of the new bat-origin subtypes H10N17 and 
H11N18, we deal with all other influenza virus subtypes known to infect mammals. 
For each host-virus pair, we describe the history, clinical and pathological features, 
epidemiology, molecular virology, public health risk, and control measures. The scale 
of current global changes makes for a dynamic process, in which the sporadic infection 
of today may develop into the endemic situation of tomorrow.
Keywords: Influenza A Virus, H5N1, Carnivores, Marine mammals, Cetaceans, Non-
human primates, Bats, Ungulates, Rodents, Lagomorphs.
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INTRODUcTION
From the original wild bird reservoir, IAVs have crossed the species barrier at some time 
or other in the past and established endemic IAV infections in humans, domestic pigs, 
horses, and, most recently, domestic dogs. However, there seem to be few limits with 
regard to the range of mammalian species that IAVs can infect. This may be in part due 
their use of ubiquitous sialosaccharides as the receptor for virus attachment, and their 
ability to efficiently suppress the host innate immune response. This chapter provides 
an overview of the many mammals for which there is evidence of sporadic infections 
by diverse IAVs, namely carnivores, cetaceans, non-human primates, bats, uneven-toed 
and even-toed ungulates, rodents, lagomorphs, and anteaters.
A game changer in recent years has been the discovery of IAV infection in New World 
bats. Not only do these IAVs appear to be endemic in these bat populations, but also 
they are subtypes that are not represented in the wild bird reservoir. Therefore they 
appear to represent an additional original reservoir of IAVs, and are only included in this 
chapter because of their recent discovery.
The characteristics that are shared by mammalian species in which IAV has become 
endemic are large population numbers and aggregation in enclosed spaces (public 
buildings for human beings, barns for domestic pigs, stables for horses, and kennels for 
domestic dogs). In these species, IAV infection is present in the population continuously, 
and the virus has adapted to its host species. At the other end of the scale are mammalian 
species in which IAV infections are limited to sporadic cases in individual animals due to 
cross-species transfer, exemplified by the spread of pandemic H1N1 IAV from humans 
to their pet cats and ferrets. Intermediate between these two extremes are mammalian 
species in which efficient IAV transmission appears to be possible, but for some reason 
does not result in persistence of the virus in the population. The multiple reports of 
avian IAV epidemics in harbour seals (Phoca vitulina) are a clear example of this.
However, the situation can change rapidly. Who would have thought 20 years ago 
that an avian IAV like H5N1 would have wreaked such havoc among such a wide range 
of mammals, or that domestic dogs would harbour their own canine-adapted IAV? The 
scale of global change in animal populations and the ecosystems that they inhabit, 
together with the plastic nature of IAV, has resulted in a dynamic situation. Therefore 
the information presented in this chapter should be viewed as a snapshot of the current 
situation. Today’s sporadic infection may be tomorrow’s endemic situation.
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H5N1 HPAIV INFEcTIONS IN MIScELLANEOUS MAMMAL SPEcIES
The H5N1 HPAIV that emerged in Asia in 1996 in poultry has shown the capacity to 
infect a wide range of mammalian species, including humans. In these species, the 
virus may spread to multiple organs beyond the respiratory tract, resulting in severe 
disease and death. Natural infections have been reported in multiple species of wild 
and domestic carnivores (250-264) (Tables 3.1.1 and 3.1.2), domestic pigs (265), black-
lipped pikas (Ochotona curzoniae) (266), and donkeys (267) (Table 3.1.3). Serological 
evidence of natural infection or exposure to H5N1 HPAIV has been recorded in brown 
rats (Rattus norvegicus) (268, 269), raccoons (Procyon lotor) (270), and horses (268). 
Furthermore, experimental H5N1 HPAIV infections (not extensively discussed here) 
have been performed in laboratory mice, laboratory rats, laboratory hamsters (271-
275), ferrets (Mustela putorius furo) (273, 276, 277), cynomolgus macaques (Macaca 
fascicularis) (278-280), red foxes (Vulpes vulpes) (281), cattle (Bos taurus) (282), and 
laboratory rabbits (266).
Two concerns about the many sporadic cases of mammalian H5N1 HPAIV infection 
are that they form a source of infection for humans, and they provide the opportunity for 
the virus to adapt to allow efficient mammal-to-mammal transmission. Until now there 
has been no concrete evidence of H5N1 HPAIV spreading from infected wild or domestic 
mammals to humans. With regard to efficient mammal-to-mammal transmission, the 
only strong evidence has been the probable tiger-to-tiger spread of H5N1 HPAIV at a zoo 
in Sri Racha, Thailand, in 2004 (262). Therefore the main source of H5N1 HPAIV infection 
for humans continues to be poultry, in which the virus continues to circulate in eastern 
Asia and northern Africa (33). The first indication that H5N1 HPAIV could spread from 
birds to mammals other than humans was in December 2003, when fatal H5N1 HPAIV 
infection was reported in two tigers (Panthera tigris) and two leopards (Panthera pardus) 
from a zoo in Suphanburi, Thailand (251). This was followed by a second outbreak in 
October 2004 in Sri Racha, Thailand, which involved the death or euthanasia of 147 tigers 
(262). Affected felids had high fever, respiratory distress, and (in some cases) nervous 
signs, and died with serosanguinous nasal discharge 3 days after the onset of clinical 
signs (Figure 3.1.1). Autopsy revealed severely congested and hemorrhagic lungs, which 
corresponded microscopically with bronchointerstitial pneumonia and co-localisation of 
influenza virus antigen expression in pneumocytes. Extra-respiratory spread of the virus 
was demonstrated by meningoencephalitis and hepatitis, co-localised with influenza 
virus antigen expression in neurons and hepatocytes, respectively (251, 262). The felids 
were initially infected as a result of feeding on fresh poultry carcasses – the H5N1 HPAIV 
isolates from felids at both zoos were very similar to H5N1 HPAIV strains circulating 
in poultry at the time (283). It is likely that tiger-to-tiger transmission of H5N1 HPAIV 
also occurred at Sri Racha, because the outbreak continued after the feeding of fresh 
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poultry carcasses had been stopped. There was limited evidence of H5N1 HPAIV spread 
to humans. Five zookeepers at Sri Racha were placed under surveillance after showing 
influenza-like signs (284). However, only 2 of 58 zookeepers and veterinarians, neither 
of whom had shown clinical signs, had anti-H5N1 HPAIV antibodies in their serum 6 
weeks after the outbreak (262).
H5N1 HPAIV infections were reported not only in Thailand, but also in Cambodia and 
China. In December 2003 there was an outbreak of H5N1 HPAIV in 26 species of birds, 
including birds of prey, in Phnom Tamao Wildlife Rescue Centre, Cambodia. During 
this outbreak, two lions (Panthera leo), two tigers, two Asiatic golden cats (Catopuma 
temminckii), three leopards, and one clouded leopard (Neofelis nebulosa) exhibited 
anorexia and lethargy for 5–7 days, but neither respiratory illness nor mortality. Serum 
samples were collected from one tiger, one leopard, one Asiatic golden cat, and one 
clouded leopard, and had neutralising antibody titers of 10–40 against H5N1 HPAIV. The 
H5N1 HPAIV isolates from the zoo birds were phylogenetically highly similar to those 
from poultry in Cambodia, and it was assumed that infected poultry carcasses used as 
a food source both for birds of prey and for felids were the source of infection (250). 
In 2005, a tiger at a zoo in Shanghai, China, died with similar clinical and pathological 
findings to those in tigers from Thailand. The H5N1 HPAIV isolate from the tiger’s lung 
belonged to clade 2.2, and was phylogenetically almost identical to that isolated in the 
same year from a migratory duck at Poyang Lake, China. However, it was not reported 
whether the tiger had consumed chickens or wild birds (256).
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Figure 3.1.1 Natural infection of tigers with H5N1 highly pathogenic avian influenza virus in Sri Racha, 
Thailand, in 2004. Affected animals had high fever, respiratory distress, and—in some cases—nervous signs, 
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Starting in 2004, there were several reports from all around the world of domestic cats 
with natural H5N1 HPAIV infection – from Thailand in 2004 (260, 327), Germany and 
Austria in 2006 (253, 255, 335), Iraq in 2006 (263), Indonesia in 2006 (328), and Israel 
in 2012 (326). Most of these reports indicated that contact with or feeding on infected 
birds was the route of infection, and described severe clinical disease or death in the 
cats. Five days after eating a pigeon, a cat in Thailand developed high fever, dyspnea, 
and depression, and it died 2 days later (260). Several cats on the German island of 
Rügen were infected by an H5N1 HPAIV that belonged to clade 2.2 (336) and was 
genetically very similar to an isolate from a dead whooper swan (Cygnus cygnus) from 
the same area (253, 335). Several cats in Israel showed respiratory signs, weakness, 
and subsequently died after feed- ing on turkey carcasses. The H5N1 HPAIV found in 
the cats was similar to that from the turkeys (326). In contrast, no overt clinical disease 
was observed in several cats that had pharyngeal swabs positive for H5N1 HPAIV by PCR 
after contact with infected birds at an animal shelter in Austria (255).
Experimental H5N1 HPAIV infection, either by intratracheal inoculation or by feeding 
on infected chicks, showed that cats were susceptible to both severe respiratory disease 
and widespread extra-respiratory complications. Cats developed not only a severe 
bronchointerstitial pneumonia, but also severe necrosis and inflammation in the brain, 
← Figure 3.1.1 Natural infection of tigers with H5N1 highly pathogenic avian influenza virus in Sri 
Racha, Thailand, in 2004. Affected animals had high fever, respiratory distress, and—in some cases—ner-
vous signs, and died with serosanguinous nasal discharge. Photograph courtesy of Dr Roongroje Thana-
wongnuwech, Chulalongkorn University, Thailand.
← Figure 3.1.2 Systemic histological lesions in domestic cats after experimental H5N1 HPAIV infec-
tion. Necrotising inflammatory foci are present in multiple tissues stained with H&E in the left column. 
Influenza virus antigen (red-brown staining) is present in serial sections of the same tissues, stained for nu-
cleoprotein by IHC in the right column. Reprinted from: The American journal of Pathology, January 2006, 
Vol. 168, No. 1, p. 176-83, Rimmelzwaan GF, van Riel D, Baars M, Bestebroer TM, van Amerongen G, Fouchier 
RA, Osterhaus, AD, Kuiken, T. Influenza A virus (H5N1) infection in cats causes systemic disease with poten-
tial novel routes of virus spread within and between hosts, with permission from Elsevier.
← Figure 3.1.3 Low pathogenic avian influenza A virus (H7N7), human seasonal influenza A virus 
(H3N2), and human influenza B virus show different degrees of attachment to the trachea and bron-
chiole of a harbor seal (Phoca vitulina). Red staining indicates virus attachment to the epithelial cell sur-
face. Reprinted from: Ramis AJ, van Riel D, van de Bildt MWG, Osterhaus A, Kuiken T. Influenza A and B virus 
attachment to respiratory tract in marine mammals. Emerg Infect Dis [serial on the Internet]. 2012 May 
[date cited]. Available from http://dx.doi.org/10.3201/eid1805.111828
← Figure 3.1.4 Phylogenetic trees displaying the hemagglutinin (HA) and neuraminidase (NA) genes 
of bat-derived H17N10 and H18N11 influenza viruses (with stars) compared to the relative distance 
of HAs and NAs of all previously known influenza A virus subtypes. Reprinted from: Trends in Micro-
biology, April 2014, Vol. 22, No. 4, p. 183-91, Wu Y, Wu Y, Tefsen B, Shi Y, Gao GF. Bat-derived influenza-like 
viruses H17N10 and H18N11, with permission from Elsevier.
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heart, liver, kidney, spleen, adrenal glands, and intestine, co-localised with influenza 
virus antigen expression in epithelial and mesenchymal cells of these tissues (Figure 
3.1.2) (249, 337, 338). In addition, hemorrhagic pancreatitis was observed in naturally 
infected cats (263).
Serological evidence that cats are exposed to or infected with H5N1 HPAIV depends 
on the situation in poultry. In geographical regions where H5N1 HPAIV was endemic in 
poultry, the following proportions of cats were found to be seropositive: 8 of 111 (7%) in 
central Thailand (348), 100 of 500 (20%) on Java and Sumatra (349), and 9 of 25 (36%) in 
endemic areas of Egypt (268). In contrast, no cats were found to be seropositive in areas 
of Europe where H5N1 HPAIV had occurred in birds as an epidemic (350, 351).
Guidelines for prevention and management of H5N1 HPAIV infections in pet cats 
were published by Kuiken and colleagues (352) and by the European Advisory Board 
on Cat Diseases (353). In areas where H5N1 HPAIV has been detected in poultry or 
wild birds, cat owners should avoid feeding uncooked poultry meats, and keep cats 
indoors to prevent contact between their pets and infected birds or their droppings. In 
suspected cases of H5N1 HPAIV infection in cats, veterinarians and cat own- ers should 
maintain stringent hygienic measures with regard to animal handling, and quarantine 
and test the affected cat(s). An inactivated, adjuvanted heterologous H5N6 AIV vaccine 
has been shown to protect cats against fatal disease from H5N1 HPAIV infection (338).
H5N1 HPAIV infection has also been reported in domestic dogs, but the associated 
disease appears to be milder than in cats. There is only one case report of natural H5N1 
HPAIV infection in a dog (261). Like cats, feeding on infected birds probably infected the 
dog. It developed high fever, dyspnea, and lethargy 5 days later, and died the following 
day. Autopsy revealed severe pulmonary congestion and oedema, which correlated 
histologically with interstitial pneumonia and influenza virus antigen expression 
in pulmonary alveolar cells. Extra-respiratory spread of virus was demonstrated 
histologically by multifocal hepatic necrosis and tubulonephritis, which co-localised with 
influenza virus antigen expression in hepatocytes and epithelial cells of the glomeruli 
and renal tubules, respectively. The H5N1 HPAIV isolated from lung, liver, kidneys, and 
urine was genetically similar to that recovered earlier from a tiger in Thailand (261). In 
experimental H5N1 HPAIV infections in dogs, clinical signs ranged from transient fever 
and conjunctivitis (354) to anorexia, fever, conjunctivitis, laboured breathing, cough, 
and death in one of six dogs (355). In contrast to the fatal case reported by Songserm 
and colleagues (261), virus replication and associated lesions in experimentally infected 
dogs were restricted to the respiratory tract. The high percentage of dogs with specific 
antibodies to H5N1 influenza virus suggests that dogs are commonly infected with or 
exposed to the H5N1 HPAIV in areas where the virus is endemic in poultry (160 of 629 
dogs (25%) in central Thailand (348), and 4 of 25 dogs (16%) in endemic areas of Egypt 
(268).
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There is one report of H5N1 HPAIV infection associated with die-off in raccoon dogs 
(Nyctereutes procyonoides), which belong to the family Canidae (356). About 100 of 
a total of 1000 raccoon dogs from a fur farm in China died with respiratory disease, 
diarrhea, or both in 2005. Genetic and molecular characterisation identified the viruses, 
which were isolated from the lungs of two of the dead raccoon dogs, as H5N1 HPAIV. 
It was assumed that chicken carcasses fed to the raccoon dogs were the source of 
infection (356). None (0%) of 102 free-living raccoon dogs sampled in South Korea in 
2011 had antibodies against IAVs (357).
Red foxes (Vulpes vulpes), which belong to the family Canidae, are an important 
predator on and scavenger of wild and domestic birds, and may potentially be exposed 
to H5N1 HPAIV by this route. An H5N1 HPAIV (A/fox/Azerbaijan/1413/2006) was 
isolated from a fox in Azerbaijan in 2006 (298). Experimental infections show that 
red foxes excrete virus from the throat for up to 7 days after inoculation. Ingestion of 
infected chicks causes subclinical infection or mild pneumonia, whereas intratracheal 
inoculation causes severe pneumonia, myocarditis, and encephalitis. Together these 
results demonstrate that red foxes might play a role in virus dispersal (281). There is 
one report of fatal H5N1 HPAIV infection in Owston’s palm civets (Chrotogale owstoni), 
a globally threatened species belonging to the family Viverridae. It involved three 
Owston’s palm civets that were kept together in captivity at a national park in Vietnam 
in 2005. They showed anorexia and neurological signs, including hind limb paralysis, 
for 1 or 2 days before death. Pathological examination revealed interstitial pneumonia, 
meningitis, cerebral oedema, and multifocal hepatic necrosis. H5N1 HPAIV was 
detected by virus isolation, RT-PCR, and IHC in all of these tissues, as well as in kidney 
and intestine, demonstrating systemic viral infection. Although the H5N1 HPAIV from 
the Owston’s palm civets was similar to that in poultry, and undiagnosed poultry deaths 
were reported in the surroundings of the park, the civets were not fed on bird carcasses, 
so the source of infection remains unknown (259, 358).
There are reports of single cases of H5N1 HPAIV infection in a stone marten (Martes 
foina) (254) and an American mink (Mustela vison) (257), both of which belong to 
the family Mustelidae. The stone marten was from the Isle of Rügen, north Germany, 
and the American mink was from south Sweden. Both animals were free-living, had 
neurological signs, and were identified in 2006. They were probably infected as a result 
of feeding on infected wild birds. Histopathological examination of the stone marten 
revealed encephalitis and pancreatic necrosis, co-localised with influenza virus antigen 
expression in neurons and pancreatic acinar cells, respectively (254). Surprisingly, 
neither pneumonia nor influenza viral antigen were observed in the lungs, which 
contrasts with the pneumotropism of H5N1 HPAIV in most other mammals. Molecular 
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characterisation of the Swedish mink isolate (A/Sweden/mink/V907/2006) revealed no 
specific adaptation to mammals (252, 264).
There is only serological evidence of H5N1 HPAIV infection in raccoons (Procyon 
lotor), which belong to the family Procyonidae. In total, 10 (0.9%) of 1088 healthy 
free-living raccoons that were sampled in Japan between 2005 and 2009 had virus-
neutralizing antibodies to H5N1 IAV, but not to viruses of other hemagglutinin (HA) 
subtypes, including H1, H3, H7, and H9. During that period, Japan experienced two 
outbreaks of H5N1 HPAIV on poultry farms and one in free-living swans. Therefore 
it is likely that the raccoons became infected or exposed by feeding on infected bird 
carcasses (270).
There is also only serological evidence of H5N1 HPAIV infection in brown rats (Rattus 
norvegicus), belonging to the family Muridae. Hemagglutination-inhibiting antibodies 
to H5N1 IAV were found in some brown rats sampled at live poultry markets in Hong 
Kong during the 1997 H5N1 HPAIV outbreak (269), and in 1 (1.4%) of 72 brown rats 
sampled in Cairo, Egypt, and the surrounding area after H5N1 HPAIV became endemic in 
poultry there in 2006 (268). Experimentally, not only laboratory rats, but also laboratory 
mice (Mus musculus), of the family Muridae, and hamsters (Mesocricetus auratus), of 
the family Cricetidae, develop both a productive infection and associated lesions upon 
H5N1 HPAIV inoculation (273-275).
There is one report of H5N1 HPAIV infection in free-living black-lipped pikas 
(Ochotona curzoniae), of the family Ochotonidae, which together with rabbits and hares 
belong to the order Lagomorpha. Evidence of H5N1 HPAIV infection was found in black-
lipped pikas sampled between August 2006 and December 2007 in their natural habitat 
around Qinghai Lake, China (266), where there had been a large-scale outbreak of H5N1 
HPAIV infection in migratory birds (240, 359, 360). Initially, hemagglutination-inhibiting 
antibodies to H5N1 IAV were detected in 11 (13%) of 82 pikas. Subsequently, H5N1 HPAIV 
was isolated from brain, lung, and rectum samples from 5 (3%) of 147 newly caught 
pikas. Phylogenetically, these isolates could be divided into a mixed/Vietnam H5N1 
lineage and a wild bird Qinghai-like H5N1 lineage. Presumably the black-lipped pikas 
contracted these viruses from wild birds at common weed-foraging sites. Experimental 
infection of rabbits (Oryctolagus cuniculus), of the family Leporidae, resulted in a 
productive infection and interstitial pneumonia, with influenza virus antigen expression 
in epithelial cells of nasal turbinates, trachea, and lungs (266). Recently, the host range 
of H5N1 HPAIV has been extended to include donkeys (Equus africanus asinus), which 
together with horses (Equus ferus caballus) belong to the family Equidae. In an Egyptian 
village in 2009, H5N1 HPAIV was isolated from pooled nasal swabs from three donkeys 
with mild respiratory disease. These donkeys showed coughing, fever, and serous nasal 
discharge for 72 hours. Onset of these respiratory signs was 1 week after an outbreak 
of H5N1 HPAIV infection in poultry in the same village. Phylogenetic analysis of the 
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isolate from the donkeys showed close homology to the lineage of Egyptian H5N1 
HPAIV viruses circulating in poultry and humans. Subsequently, antibodies against 
H5N1 IAV were found in 27 (26%) of 105 donkeys from areas where H5N1 HPAIV was 
endemic in poultry. Possible routes of infection included aerosol exposure to bird 
faeces, feed or water contaminated with bird faeces, or direct contact with infected 
birds. Concerns were raised that donkeys commonly housed with poultry might spread 
a mammal-adapted H5N1 HPAIV to humans (267). In a later serological survey, El-Sayed 
and colleagues (268) found antibodies against H5N1 not only in donkeys but also in 
horses from H5N1-endemic areas in and around Cairo.
Although cattle (Bos taurus), of the family Bovidae, may be naturally infected 
with IAV (340, 341), there are no reports of natural H5N1 HPAIV infection in cattle. 
Experimentally, four calves that were inoculated intranasally with H5N1 HPAIV from 
a naturally infected cat had a subclinical infection with low virus excretion from the 
nose. There was no firm evidence of calf-to-calf transmission; although one of two 
sentinel calves housed together with the inoculated calves seroconverted, the nasal 
swabs of both sentinel calves remained negative for H5N1 HPAIV RNA throughout the 
experiment (282).
OTHER INFLUENZA A VIRUSES IN MIScELLANEOUS MAMMAL 
SPEcIES
Influenza A viruses in the order Carnivora, suborder Caniformia
Various species belonging to the order Carnivora, suborder Caniformia, have been 
infected with IAV (Table 3.1.1), and are described in detail in the following sections.
Influenza A viruses in the family Canidae
Sustained circulation of canine-adapted IAVs is a recent phenomenon. In 2002, an H3N8 
IAV originating from horses caused an outbreak of respiratory disease in a pack of 92 
English foxhounds in the UK. Although the route of transmission is not known, the 
dogs were housed adjacent to horse stables, and had recently been fed the meat of 
two euthanised horses (361). Two years later, another horse-origin H3N8 IAV caused 
an outbreak of respiratory disease in greyhound dogs in Florida, USA (362). Starting in 
2007, an H3N2 low-pathogenicity avian influenza virus originating from birds caused 
respiratory disease outbreaks in dogs in South Korea (363), China (364), and Thailand 
(365). These H3N8 and H3N2 viruses have now adapted to their new hosts, are able 
to spread efficiently in domestic dog populations, and are the recognised etiological 
agents of this new disease – canine influenza.
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In contrast to these dog-adapted IAVs, it has been recognised for years that 
human-origin IAVs may sporadically jump the species barrier and infect domestic 
dogs. Experimentally, the susceptibility of dogs to human H1N1 IAV infection was 
demonstrated as early as 1959 (366), and natural infection was first demonstrated in 
1975, when human H3N2 IAV was isolated from affected dogs (285, 286). Studies showing 
serological responses in dogs to human H3N2 IAV (285, 367, 368) also suggested that 
there was transmission of virus from humans to dogs. Both natural and experimental 
human H3N2 IAV infections in dogs are usually subclinical (286-288, 368-370), although 
they may cause transient fever (287). Human H3N2 IAV was transmitted to sentinel dogs 
housed together with experimentally inoculated dogs (287). When the most recent 
influenza pandemic, caused by pandemic H1N1 IAV (pH1N1), occurred in humans, 
it was also reported in domestic dogs in China (290) and the USA (291). The pH1N1-
positive dog from the USA had clinical evidence of pneumonia, with fever, coughing, 
and anorexia. pH1N1 IAV had been confirmed in the dog’s owner 1 week previously. 
Experimental inoculation of the canine isolate from China into dogs resulted in mild 
clinical signs and inefficient dog-to-dog transmission (292). In contrast, inoculation of a 
human isolate of pH1N1 into dogs did not cause infection (371).
Recently, two reassortants of pH1N1 and H3N2 canine influenza virus (CIV) have been 
isolated in South Korea from nasal swabs from domestic dogs with respiratory signs. The 
first reassortant, H3N1, had the HA gene segment of H3N2 CIV and the remaining seven 
gene segments of pH1N1. Experimental inoculation into dogs resulted in a subclinical 
infection with virus shedding from the nose. At autopsy, the severity of pneumonia was 
intermediate between the mild lesions of pH1N1 IAV infection and the marked lesions 
of H3N2 CIV infection (289). The second reassortant, H3N2, had the M gene segment 
of pH1N1 and the remaining seven gene segments of H3N2 CIV. Experimental infection 
of dogs resulted in similar virus shedding, dog-to-dog transmission, and severity of 
pneumonia as classic H3N2 CIV infection (297).
In 2009, an H5N2 LPAIV was isolated in China from nasal swabs from domestic dogs 
with respiratory signs (293, 294). Experimentally infected dogs shed virus, had transient 
fever, and developed mild respiratory signs (294). The virus was transmitted from 
infected dogs both to sentinel dogs (294) and to a cat and chickens (295).
An H9N2 LPAIV was detected by culture and PCR in 13 (2.2%) of 588 juvenile to young 
adult domestic dogs with clinical signs (coughing, vomiting, fever) in Guangxi, China, in 
2010 and 2011. Serologically, up to 45% of dogs tested positive. The virus, known as 
A/canine/Guangxi/1/2011 (H9N2), showed more than 98.5% genetic homology with 
Eurasian-lineage H9N2 LPAIV (296). Dogs could be infected by intranasal inoculation 
(372), but not by feeding on infected chickens (373). Although virus was recovered from 
nasal turbinates, trachea, and lung in association with a mild pneumonia, infection was 
subclinical and no virus was shed from the URT. In contrast, intranasally inoculated 
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dogs in another experiment (373) had mild respiratory signs, shed virus from the nose, 
and infected sentinel dogs. Concerns were raised that dogs may contribute to further 
spread, and adaptation to mammals, of this widely circulating Eurasian LPAIV.
Control of influenza in domestic dogs should include routine hygiene measures, such 
as isolation of infected dogs to prevent virus spread to other animals (374). Because 
dogs are susceptible to avian IAV infection, live in close proximity to humans, and may 
have access to poultry at live animal markets, especially in South-East Asia, they are 
potential intermediate hosts for virus spread to humans. Furthermore, because dogs 
are susceptible to both human and avian IAVs, they have the potential to serve as a 
“mixing vessel” in which new reassortants may arise, as has been seen recently for 
reassortant H3N1 and H3N2 IAVs (289, 297).
Influenza A viruses in the family Ursidae
Bears are long-lived, wide-ranging, opportunistic animals that one would expect to 
be easily exposed to infectious agents from a wide range of animals and humans. 
However, reports of exposure to IAVs in bears are rare. There is one report of weak 
positive IAV (and influenza B virus) serum antibody titers in a juvenile captive Eurasian 
brown bear (Ursus arctos arctos) from Croatia, suggesting exposure to infected humans 
(375). More compelling evidence of infection with IAVs was found in giant pandas 
(Ailuropoda melanoleuca) by Li and colleagues (299). In 2009, during the human H1N1 
pandemic, three captive giant pandas from a conservation center in Sichuan Province, 
China, showed clinical signs of respiratory disease. A nasal swab taken from one animal 
tested positive by PCR for the HA gene of pH1N1, and by culture for IAV. Phylogenetic 
analysis of the virus isolate suggested human-to-panda transmission without significant 
adaptation. All three pandas received 75 mg of oseltamivir twice daily for 5–6 days, 
recovered, and seroconverted to pH1N1 (299).
Influenza A viruses in the family Ailuridae
There is a report of weak positive IAV-nucleoprotein antibody titers by agar gel 
immunodiffusion in one of 73 captive red pandas (Ailurus fulgens) from China (356). 
The source or type of influenza virus was not specified.
Influenza A viruses in the family Mustelidae
The American mink (Mustela vison) is a mustelid species that is kept in captivity in large 
numbers for its fur. Recently this species has been placed in a separate genus (Neovison 
vison or Vison vison) from the domestic ferret (Mustela putorius furo) and the European 
mink (Mustela lutreola), based on molecular phylogeny (376). The susceptibility of 
American mink to IAV infection has been recognised for several decades. In the late 
1970s and early 1980s, antibodies against human H3N2 and H1N1 IAVs were detected 
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in farmed mink from Japan (377, 378). Inoculation of mink with human H3N2 IAV 
resulted in a productive infection with respiratory signs, and transmission to contact 
mink. Productive infection of mink also resulted from inoculation of human H1N1, swine 
H1N1, equine H1N2, and avian H3N2 and H4N1 IAVs (379). In similar experiments (380, 
381), inoculation of different avian (H3N8, H5N3, H7N2, H7N7, H8N4, and H11N4) or 
mammalian (human and swine H1N1, and equine H2N2) IAVs also resulted in productive 
infection, with transmission to contact mink.
In 1984, H10N4 IAV, probably of avian origin, caused an outbreak of severe respiratory 
disease with 100% morbidity and 3% mortality in 100,000 mink on neighbouring farms 
in Sweden (302). Clinical signs included anorexia, sneezing, coughing, and nasal and 
ocular discharge. Pathological examination of fatal cases showed an acute interstitial 
pneumonia. Experimental infection in mink induced similar clinical signs and pathological 
changes, with transmission to sentinel mink separated by a wire fence. The presumed 
origin of the virus was wild birds (corvids, gulls, and ducks) that were attracted to the 
tops of the open wire cages by offal fed to the mink (302). Interestingly, comparative 
infections of mink with either H10N4 IAV (A/mink/Sweden/3900/1984) or H10N7 
IAV (A/chicken/Germany/N/1949) revealed that only H10N4 IAV was transmitted to 
sentinels, and that it caused more severe pneumonia than H10N7 IAV (382, 383). Recent 
full-genome analysis of the viruses showed that the NS gene of H10N4 IAV may have 
contributed to its virulence for mink by helping the virus to evade the innate immune 
response (384).
In 2006 and 2007, swine H3N2 IAV was associated with increased respiratory 
disease and mortality in mink farmed in Nova Scotia, Canada. Clinical signs included dry 
cough, and pathological examination of fatal cases revealed interstitial pneumonia and 
bronchiolitis. The virus isolated from affected mink was related to a triple reassortant 
swine IAV that had emerged in 2005. The presumed route of transmission was the 
feeding of uncooked meat by-products, including ground swine lung from parts of 
Canada where swine H3N2 IAV was known to occur (303).
In 2009 and 2010, a human/swine reassortant H3N2 IAV caused an outbreak of 
respiratory disease in mink on 18 farms in Denmark. Clinical signs included sneezing, 
coughing, and hemorrhaging from the nose, and the average mortality rate was 1.2%. 
The HA and NA genes of the isolated virus were homologous with human H3N2 IAV, 
and the six remaining genes were homologous with a circulating swine H1N2 IAV. These 
findings suggest that mink are susceptible to infection by both swine and human IAVs, 
and may act as a “mixing vessel” (304). The probable source of infection was feeding of 
raw offal, including swine tracheas and lungs. All of the affected mink farms received 
this offal from the same slaughterhouse. The outbreak, which lasted for 10 weeks, may 
have been sustained by continued feeding of infected offal, by horizontal transmission, 
or both (305).
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In 2010 and 2011, human pH1N1 IAV caused respiratory disease outbreaks on 
several mink farms in Denmark, Norway, and the Netherlands (305, 307, 308). Clinical 
signs included nasal discharge, coughing, and sneezing in vixens, and dyspnea in 
kits. Mortality rates in kits ranged from 14% in Norway to 30% in the Netherlands. 
Pathological examination of dead kits showed severe acute interstitial pneumonia. 
Phylogenetic analysis revealed that the virus isolated from Norwegian mink closely 
resembled human pH1N1 IAV from 2009 that circulated among people in Norway 
during the winter of 2010–2011. However, respiratory symptoms were not reported 
for the Norwegian mink farmers at the time of the outbreaks, and feeding of pig offal 
was considered the most likely source of infection. Dutch mink farmers were suffering 
from an influenza-like illness at the time of the outbreaks. It was not reported whether 
mink on Dutch farms were directly exposed to swine or fed on raw swine offal (307, 
308). In 2010, avian/swine reassortant H1N2 IAV caused respiratory disease on a farm 
in the Mid- western USA that had 15 000 mink. Clinical signs included persistent severe 
respiratory distress, and hemorrhaging from the nasal and oral orifices, and mortality 
rates were approximately 3%. Pathological examination of fatal cases revealed a 
hemorrhagic broncho-interstitial pneumonia associated with H3N2 IAV and hemolytic 
Escherichia coli. Phylogenetic analysis revealed that the virus had a matrix gene and a 
nucleoprotein gene that showed genetic relatedness to the swine lineage of IAV. The 
source of the infection appeared to be feeding of raw turkey meat; no swine offal was 
fed, and there were no swine herds nearby (306).
Conclusions from the above reports are that American mink are highly susceptible 
not only to infection, but also to severe disease caused by human, avian, and swine 
IAVs, and that efficient mink-to-mink transmission is possible. Thus mink may serve 
as “mixing vessels” that facilitate the reassortment of IAVs from different host species 
(304). In addition, commonly recurring sources of infection include open housing, 
allowing contact with wild birds, and feeding of raw products from IAV-infected animals, 
such as swine and poultry. Consequently, the use of housing that prevents contact with 
wild birds, and the cooking of animal products prior to feeding (306) are important 
measures for prevention of influenza in American mink.
The domestic ferret (Mustela putorius furo) originates from the European polecat 
(Mustela putorius), and has been used since the 1930s in animal models for IAV 
infection in humans. In part this can be explained by the similarity in the pattern of 
IAV attachment to different parts of the ferret and human respiratory tracts (62). 
The ferret proved highly susceptible to infection with both human (385) and swine 
IAVs (386). Furthermore, human IAV infection in ferrets induced similar clinical signs 
to those observed in humans, namely fever, lethargy, anorexia, and nasal catarrh. In 
contrast, swine IAVs induced more severe disease, and death. In 1934, Shope provided 
detailed, accurate, and well-illustrated descriptions of the associated lesions in affected 
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ferrets, both grossly and microscopically (386). IAV transmission was demonstrated 
from ferrets to humans (387), and among ferrets, both by direct contact (388) and by 
air (389). Numerous studies on vaccine efficacy, antiviral products, pathogenesis and 
transmission, and virus reassortment, all relating to IAVs, have been performed in 
ferrets (390-400). In these studies, inoculation of many human and avian IAVs resulted 
in productive infection and disease.
Based on the above information, one would therefore expect natural IAV epidemics 
in ferrets to be common. However, even individual cases of natural IAV infection in 
ferrets, let alone epidemics, are rarely reported. Fisher and Scott reported natural IAV 
infection in ferrets in 1944 (309). Subsequently, Bell and Dudgeon reported an outbreak 
of IAV infection in two ferret colonies in Sussex, in the UK, in February 1947 (310). 
The affected ferrets exhibited nasal and ocular discharge, blepharosynechia, sneezing, 
lethargy, and fever for about 7 days, and eight ferrets died. Remarkably, none of these 
animals exhibited gross lung lesions at autopsy, although their nasopharynges were 
congested. The animal attendants had influenza-like symptoms immediately before and 
during the outbreak, and were assumed to be the source of infection. The widespread 
seroconversion against IAV in these group-housed ferrets suggested that there was 
efficient ferret-to-ferret transmission of IAV (310).
There were multiple cases of pH1N1 IAV in pet ferrets in the USA in 2009. The affected 
ferrets displayed mild to severe respiratory disease, and some died. Clinical signs 
included fever, lethargy, sneezing, and coughing. In all cases, humans in the household 
were suffering from influenza, and were the probable source of infection (312-315). 
Ferrets that were infected experimentally with pH1N1 IAV showed similar clinical signs, 
and at autopsy exhibited multifocal necrotising bronchointerstitial pneumonia (316, 
399).
Natural infection of ferrets with swine IAVs was not reported until 2009, when 
there was an outbreak of contemporary reassortant swine H1N1 IAV in a ferret 
colony in the USA (311). Ferrets showed typical respiratory signs, and at autopsy 
exhibited bronchointerstitial pneumonia with necrotising bronchiolitis. The genetic 
characterisation of the isolated virus suggested that swine was the source of infection.
In October and November 2009, pH1N1 IAV infection occurred in an American 
badger (Taxidea taxus) and a black-footed ferret (Mustela nigripes) that were housed 
separately in a zoo in California, USA. Clinical signs included lethargy, inappetence, 
dyspnea, nasal discharge, and coughing. The American badger was euthanised due to 
the severity of disease, and at autopsy exhibited bronchopneumonia with IAV antigen 
expression. pH1N1 IAV was identified in lung samples from the American badger and 
swabs from the black-footed ferret by PCR and sequencing. Humans were assumed to 
be the source of infection (301).
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Serological evidence of pH1N1 IAV infection was found in free-ranging northern sea 
otters (Enhydra lutris kenyoni), with an estimated age range of 2–19 years, captured off 
the coast of Washington, USA, in August 2011. ELISA revealed that 21 (70%) of 30 sea 
otters had detectable IgG (>200 mg/dL) for rHA of pH1N1 (A/Texas/05/2009); 22 (73%) 
of these 30 animals had HI antibody titers of ≥ 40 against pH1N1 virus (401). The source 
of infection remains unknown, although potential contact between pH1N1-IAV-infected 
northern elephant seals (Mirounga angustirostris) (325) and sea otters was considered 
to be one possibility, as their feeding ranges and breeding areas along the North-East 
Pacific coast overlap (401).
Influenza A viruses in the family Procyonidae
There is serological evidence of natural avian IAV infection in raccoons (Procyon lotor). 
Of 730 free-living raccoons sampled between 2004 and 2006 in several states of the USA 
(California, Texas, Louisiana, Maryland, Wyoming, and Colorado), 2.4% had antibody to 
avian IAVs of the subtypes H10N7, H4N6, H4N2, H3, and H1 (402). Presumably they 
were infected by direct or indirect contact with infected wild waterbirds. Intranasal 
inoculation of avian H4N8 IAV (A/chicken/Alabama/1975) into raccoons resulted 
in subclinical infection with nasal shedding up to 14 days post infection (dpi), and 
transmission to sentinel raccoons (402). In another experiment, exposure of raccoons 
to avian H4N6 IAV via drinking and washing water only led to a productive infection 
at a high dose, and exposure via infected eggs and waterfowl carcasses did not lead 
to infection (403). These results, together with the peridomestic nature of raccoons, 
suggest that this species is capable of infecting poultry and swine (402).
Influenza A viruses in the family Mephetidae
Between December 2009 and January 2010, eight striped skunks (Mephitis mephitis) 
died on a mink farm near Vancouver, Canada. Autopsy of two of these animals showed 
splenomegaly and pneumonia on gross examination. Histopathological findings 
included rhinitis, bronchopneumonia with intralesional bacteria, multifocal interstitial 
pneumonia, and plasmacytosis of lymph nodes and spleen. Both pH1N1 IAV and Aleutian 
disease virus were identified in organ samples by PCR and sequencing. The cause of 
death was determined as primary influenza viral pneumonia with secondary bacterial 
infection. The presumed source of both viruses was the population of co-habiting 
farmed American mink, some of which had nasal discharge. However, the possibility 
of direct IAV transmission from humans to striped skunks could not be excluded (300).
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Influenza A viruses in the families Phocidae, Odobenidae, and Otariidae
Reports of natural IAV infection are more frequent in pinnipeds – a mammalian clade 
of the order of carnivores that includes the Odobenidae (walruses), the Phocidae (true 
seals), and the Otariidae (fur seals and sea lions).
There have been repeated avian IAV outbreaks in harbour seals (Phoca vitulina), 
with efficient seal-to-seal transmission and high mortality. The first recorded outbreak, 
involving H7N7 AIV, occurred on Cape Cod Peninsula, New England, USA, in the winter 
of 1979–1980 (13, 317, 318). Clinical signs included dyspnea, lethargy, emphysema of 
the neck, and frothy white to red discharge from the nose and mouth. More than 400 
harbour seals, mostly juveniles, died, with an estimated mortality rate of 20% (13). 
This high number suggests efficient seal-to-seal transmission, yet apparently the virus 
was not able to persist in the harbour seal population. Autopsy showed pneumonia 
characterised by necrotising bronchitis and bronchiolitis, and hemorrhagic alveolitis 
(13). H7N7 AIV was isolated at high titers from the lung and at lower titers from the 
brain of diseased harbour seals. Experimentally infected harbour seals also developed 
pneumonia, but this was less severe than in natural cases (318). Antibodies against this 
virus were found in sera of gray seals (Halichoerus grypus) from Nova Scotia, Canada, 
more than 500 miles from Cape Cod, but no mortality of gray seals was reported (13). 
Although avian in origin, the virus replicated more efficiently in mammals (ferret, cat, 
and pig) than in birds (chicken and turkey), thus suggesting adaptation to mammals. 
This included accidental human infection during a seal autopsy, which resulted in 
conjunctivitis, but no human-to-human transmission (319). Experimental conjunctival 
inoculation in squirrel monkeys also induced conjunctivitis, along with respiratory 
disease and systemic viral spread (404). The source of the virus was not determined, 
but was suggested to be waterbirds such as terns (Sterna species), as they were known 
to harbour IAVs and to associate with harbour seals in water and on land. Possible 
factors contributing to the outbreak were abnormally high population densities and 
unseasonably high temperatures, which led harbour seals ashore (13).
In the winter of 1982–1983, there was an out- break of avian-origin H4N5 IAV infection 
in harbour seals from the New England coast, USA. Approximately 60 harbour seals 
died, and the mortality rate was estimated to be 2–4%. Histopathological examination 
revealed a necrotising bronchopneumonia, and H4N5 IAV was isolated from lungs, hilar 
lymph nodes, and brains of affected harbour seals. Interestingly, this virus did replicate 
in duck intestines upon intranasal inoculation, in contrast to earlier avian-origin IAV 
isolates from mammals (320).
In January 1991 and January 1992 there were outbreaks of avian-origin IAV 
infection of the subtypes H4N6 and H3N3, respectively, in harbour seals from Cape Cod, 
Massachusetts, USA. Autopsy showed subcutaneous emphysema and acute interstitial 
pneumonia, acute hemorrhagic pneumonia, or both (14).
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From September to December 2011, there was an outbreak of avian-origin H3N8 
IAV in harbour seals from New England, USA. A total of 162 harbour seals were found 
dead, and autopsy showed acute pneumonia. Based on genetic analysis, the virus 
isolated from the lungs was closely related to H3N8 IAV circulating in waterfowl (15). 
Interestingly, an avian-origin H3N8 IAV had been detected by PCR in a harp seal (Phoca 
groenlandica) caught in coastal waters of the North-West Atlantic Ocean several years 
previously (324). It was not reported whether this seal had respiratory disease. The 
harbour seal H3N8 IAV had a D701N amino acid substitution in the PB2 protein. This 
substitution was also found in H5N1 HPAIV infecting humans (405, 406), and indicates 
adaptation to virus replication in mammals. Based on agglutination assays, this virus had 
an affinity not only for avian-type sialic acid α2,3-galactose (SAα2,3)-linked receptors, 
but also to human-type sialic acid α-2,6 galactose (SAα-2,6)-linked receptors. These 
mammalian adaptations pose an increased risk of human infection (15).
More recently, between March and October 2014, an outbreak of avian-origin H10N7 
IAV infection in harbour seals spread southward along the North-Western European 
coasts of Sweden, Denmark, Germany, and the Netherlands (321-323). Unusually high 
numbers of dead stranded seals (around 2000 in total) were found. Similar pulmonary 
lesions of acute bronchointerstitial pneumonia with emphysema to those reported 
earlier in the North American outbreaks were found. The virus was detected in the lungs 
(321-323) and spleen (323). The HA and NA genes of this seal virus were genetically 
closely related to those of H10N7 IAVs recently found in migratory ducks from Georgia, 
Egypt, and the Netherlands (322).
In April 2010, human-origin pH1N1 IAV infection was detected in northern elephant 
seals (Mirounga angustirostris) from California, USA. The virus was isolated from nasal 
swabs from 2 of 42 apparently healthy adult females, which had just come ashore after 
months at sea. Genetic sequencing of the seal isolate revealed more than 99% homology 
with pH1N1 IAV that had emerged in humans in 2009. Humans were the most likely 
source of infection, although human exposure at sea was limited to shipping vessels. 
Possible adaptation of this isolate to elephant seals was assumed, as replication was 
normal in MDCK cell cultures, but inefficient in human tracheobronchial epithelial cells 
compared with human pH1N1 IAV reference strains. Specific antibodies to pH1N1 IAV 
were detected in sera collected from elephant seals after April, whereas sera collected 
earlier were all negative (325). All of the above-mentioned pinniped species belong to 
the family Phocidae. In addition to virological evidence of IAV infection, there are many 
articles reporting the presence of antibody against IAV in sera of pinnipeds (Table 3.1.4). 
This serological evidence has been found not only in pinniped species belonging to the 
family Phocidae, but also in Pacific walruses (Odobenus rosmarus divergens), belonging 
to the family Odobenidae, and South American fur seals (Arctocephalus australis), 
belonging to the family Otariidae. These serological data indicate that the susceptibility 
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of pinnipeds to IAV infection of both human and avian origin involves more species than 
those in which IAV infection has actually been detected.
The ability of avian IAVs to transmit efficiently among harbour seals and cause high 
mortality is unusual. To investigate this, Ramis and colleagues determined the pattern 
of IAV attachment to the respiratory tract of the harbour seal (Figure 3.1.3). They found 
abundant attachment of avian IAVs to tracheal and bronchial epithelial cells, which is 
consistent with efficient seal-to-seal transmission. In the same study, they also found 
scarce attachment of avian IAVs to bronchiolar and alveolar epithelial cells of harbour 
seals (417). This was paralleled by rare expression of SAα-2,3 receptors in harbour seal 
lungs (15). These findings do not fit with the reports of high mortality of harbour seals 
(13, 317), although they are consistent with the low pathogenicity seen in experimental 
infections with AIV H7N7 in harbour seals (13). One possible explanation is that the 
natural avian IAV epidemics in seals were aggravated by co-infecting agents, such as 
Mycoplasma species (13).
Influenza A viruses in the order Carnivora, suborder Feliformia
Various species of the order Carnivora, suborder Feliformia have been infected with IAV 
(Table 3.1.2), and are described in detail in the following sections.
Influenza A viruses in the family Felidae
Unlike canine influenza in dogs, there is no evidence of sustained transmission of a cat-
adapted IAV among domestic cats. Historically, cats were not even considered susceptible 
to disease from IAV infection (393, 418). However, like dogs, pet cats live in very close 
contact with humans. Indeed, following the human 1968 H3N2 IAV pandemic, naturally 
exposed cats had HI titers of > 40 against human H3N2 IAV, suggesting susceptibility 
to infection. Experimentally, cats were shown to develop a subclinical infection after 
inoculation not only with human H3N2 IAV, but also with avian H7N3, swine H1N1, and 
seal H7N7 IAVs, and with human influenza B virus (285, 393, 419).
The idea that IAV infection does not cause disease in cats was proved to be incorrect 
with the emergence of H5N1 HPAIV in cats (see above). In addition to the pathogenicity 
of this avian virus infection for cats, human-origin pH1N1 IAV was also reported to 
cause severe respiratory disease in cats, both in the USA (329, 330, 420-424) and in 
France (425). In most of these cases, the cat owners or their family members had been 
diagnosed with pH1N1 IAV and were considered to be the source of infection for the 
cats. Some cats died from the infection. At autopsy, they were found to have severe 
necrotising bronchointerstitial pneumonia associated with pH1N1 IAV (329, 330).
Experimentally inoculated cats showed similar lesions, and transmitted the virus to 
in-contact sentinel cats (426). Although most cases involved single animals, there was 
one outbreak in Italy in which 25 of 90 cats in a colony died. The lungs of two cats that 
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died of severe respiratory disease showed necrotising bronchointerstitial pneumonia 
associated with pH1N1 IAV. Of the surviving cats, 21 animals had serum antibodies to 
pH1N1 IAV, and two had PCR-positive nasal swabs. Taken together, these findings were 
strongly indicative of cat-to-cat transmission of pH1N1 IAV (331).
Serological screening of cats for antibodies to pH1N1 IAV yielded variable results. Of 
sera collected from pet cats during the 2009–2010 influenza season, 22.5% from Ohio, 
USA (n = 400) (427) and 21.8% from the southern and Midwestern states of the USA (n 
= 78) (428) had hemagglutination-inhibiting (HI) antibodies to pH1N1 IAV, suggesting 
that cats are highly susceptible to pH1N1 IAV infection. In contrast, only 1.2% of sera 
collected from cats (n = 1080) during the same period in southern China had antibodies 
to pH1N1 IAV by NP-specific ELISA (429), and only 1.93% of sera collected from cats (n 
= 1150) in Germany in 2010–2011 had anti- bodies to pH1N1 IAV by virus neutralisation 
assay (430). Feral cats appeared to be less likely to become infected with pH1N1 IAV 
than pet cats.
Only 0.43% of sera collected from feral cats (n = 200) in Florida between November 
2008 and July 2010 had antibodies to pH1N1 IAV by ELISA (431), and in a survey of cats 
(n = 1140) in north-east China, only 11% of sera from feral cats had antibodies to pH1N1 
IAV, compared with 30.6% of sera from pet cats (432).
Similar short-lived influenza epidemics in cats, but now from H3N2 CIV, occurred in 
South Korea in 2010 in two large animal shelters. These shelters housed dogs as well 
as cats, and both epidemics coincided with or were preceded by H3N2 CIV infections in 
dogs. It is likely that there was virus transmission from dogs to cats, followed by rapid 
cat-to-cat transmission. In one shelter, which had 60 cats, there was 47% morbidity 
and 22% mortality; in the other shelter, which had 50 cats, there was 100% morbidity 
and 44% mortality. Clinical signs in cats included high fever, lethargy, dyspnea, and 
coughing. At autopsy, the lungs showed severe bronchopneumonia, and the isolated 
virus was nearly identical to H3N2 CIV based on sequencing of all eight gene segments 
(332, 333). Experimental H3N2 CIV infection of cats resulted in similar clinical signs and 
severe necrosuppurative bronchointerstitial pneumonia, co-localised with abundant 
influenza virus antigen in bronchial epithelial cells (332). Both for pH1N1 IAV and for 
H3N2 CIV, housing many cats together appeared to be a risk factor for efficient cat-to-
cat transmission of virus.
There is concern that cats, like dogs, might act as an intermediate host for AIV and 
either facilitate its adaptation to mammals or transmit the virus to humans (337, 428). 
Given the recent reports of IAV transmission from birds, dogs, and humans to cats, 
and the potential for efficient cat-to-cat trans- mission of such viruses, cats need to be 
included in influenza monitoring programs to protect public health (418).
Infection with pH1N1 IAV occurred in four captive cheetahs (Acinonyx jubatus) in 
an animal park in California, USA, in November 2009. Clinical signs included ptyalism, 
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anorexia, and lethargy. An IAV isolated from swabs taken from one animal had 100% 
homology by sequence analysis with human isolates of pH1N1 IAV. The animals’ keeper 
had an influenza-like illness and was considered likely to be the source of infection (334).
Serological evidence of infection with an unspecified IAV was detected in one of 
16 wild Pallas’s cats (Felis [Otocolobus] manul) on the Daurian Steppe of Russia in 
2010–2011. The exact source of IAV exposure for these cats was not known, although 
they may have had contact with horses, dogs, cats, and house mice in remote human 
settlements. Furthermore, the Pallas’s cats occupied fox burrows and preyed upon 
Daurian pikas (Ochotona daurica) and voles (Microtus species) (433). Interestingly, both 
red foxes (Vulpes vulpes) (281) and black-lipped pikas (Ochotona curzoniae) (266) were 
found to be susceptible to H5N1 IAV infections.
Influenza A viruses in the family Viverridae
In autumn 2009, severe respiratory disease occurred in a Bornean binturong (Arctictis 
binturong penicillatus) in a zoo in California, USA. Clinical signs included lethargy, 
inappetence, dyspnea, nasal discharge, and coughing. The animal was euthanised 
because it had severe disease, and autopsy showed interstitial pneumonia. By PCR 
and sequencing, pH1N1 IAV was identified in lung samples from an American badger 
(Taxidea taxus) and in swabs from a black-footed ferret (Mustela nigripes) that were 
housed separately at the same zoo and were suffering from respiratory disease during 
the same time period. It was assumed that humans were the source of infection (301).
Influenza A viruses in non-swine species in the order Artiodactyla
Despite the fact that the order Artiodactyla (even-toed ungulates) contains about 220 
species, many of which are important domestic or hunted animals, IAV infection has 
been reported only sporadically in a few species other than domestic and wild pigs 
(Sus scrofa) belonging to the family Suidae. Evidence of infection with or exposure to 
IAVs has been reported in cattle (Bos taurus), sheep (Ovis aries), goats (Capra aegagrus 
hircus), yak (Bos grunniens), and water buffalo (Bubalus bubalis), which belong to the 
family Bovidae, in alpaca (Lama pacos), which belongs to the family Giraffidae, and 
in reindeer (Rangifer tarandus), fallow deer (Dama dama), and European roe deer 
(Capreolus capreolus), which belong to the family Cervidae (Table 3.1.3) (339, 340, 367, 
434-438). The only epidemics of severe respiratory disease caused by IAV infection in 
non-swine artiodactyls were reported in Bactrian camels (Camelus bactrianus), which 
belong to the family Camelidae (342). Influenza in domestic and wild pigs is not treated 
extensively in this chapter.
Possibly the first IAV to be isolated from ruminants was from a sheep in Hungary in 1960 
(339, 340), followed by several H3N2 IAV isolations from cattle in Russia from the early 
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1970s to the 1980s (340). These viruses were isolated during outbreaks of respiratory 
disease in sheep and cattle that coincided with pandemics and circulation of H2N2 IAV 
Asia/1957 and H3N2 Hong Kong/1968 in humans.
Romvary and colleagues reported the isolation of Asian H2N2 IAV (A/
Borzsony/111/1960) from an adult sheep and her mature fetus suffering from 
respiratory disease in Hungary in 1960 (339). This coincided with the H2N2 IAV 
Asia/1957 pandemic in humans. Respiratory disease was observed in several flocks of 
sheep. To confirm the susceptibility of sheep to human IAVs, lambs were intratracheally 
inoculated with egg-adapted strains of H2N2 and PR8 H1N1 IAVs. This resulted in fever, 
anorexia, coughing, dyspnea, and lassitude. Autopsy at 7 dpi revealed viral pneumonia 
both macroscopically and histologically, as well as marked immune responses to the 
inoculated strains (339). However, it was not reported whether IAV was re-isolated 
from inoculated sheep. Reisolation was attempted by McQueen and Davenport in 1963, 
when they infected several 3- to 10-week-old lambs intratracheally with the Hungarian 
sheep isolate H2N2 IAV (A/Borzsony/111/1960) and PR/8/1934 H1N1 IAV. The lambs 
showed febrile responses but no respiratory signs, and no virus could be re-isolated 
from nasal swabs taken at 2 and 3 dpi, or from lungs and tracheas at autopsy 3 dpi. 
Homologous antibody titers were detected in the sera from all inoculated lambs (439). 
During a major H2N2 influenza epidemic in humans in Ireland in January 1961 (440), 
cattle sera taken between early 1960 and summer 1961 were screened for antibodies 
against H2N2 IAV. No compelling evidence of spread to cattle was found, as all of the 
sera were negative (441).
Naturally occurring antibodies against H3N2 IAV were detected in 16 of 28 cattle, 5 
of 12 goats, two water buffalo, and one yak–zebu cross in Nepal and India, which were 
sampled between 1972 and 1973 (436). This coincided with the circulation of H3N2 
IAV (A/England/42/1972, closely related to A/Hong Kong/1/1968) among humans in 
India and Nepal (442). The animals were not reported to exhibit any signs of disease. 
Experimental inoculation of H3N2 IAV into yak induced mild signs of respiratory disease, 
including coughing and malaise, for 6 dpi (436). A more severe influenza-like illness was 
observed in 3- to 4-week-old calves that were experimentally inoculated with cattle 
strain H3N2 IAV (A/calf/Duschanbe/55/1971) isolated from a calf in Russia. For 4 dpi 
the calves had nasal discharge and coughed. The virus was shed from the nose for 7 
dpi. Similar infections of calves with human H3N2 IAV isolates did not induce signs of 
respiratory disease (341). IAV infections in cattle were reported to be associated with 
cases of acute reduction in milk production, known as “milk drop syndrome” (443-446). 
A case–control study of a dairy herd in Devon, UK, showed that rising antibody titers 
against human H1N1 IAV (A/England/333/1980) and H3N2 IAV (A/England/427/1988) 
were associated with sudden milk drop, signs of respiratory disease, and higher rectal 
temperatures compared with controls (444).
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In contrast to sporadic reports of IAV in other ruminants, many outbreaks of 
severe respiratory disease associated with human H1N1 IAV infection were recorded 
in Bactrian camels on farms throughout Mongolia between 1978 and 1988. During a 
severe epidemic in the winter of 1979–1980, 4000 camels showed signs that included 
fever, coughing, bronchitis, and nasal and ocular discharge. Clinical signs typically lasted 
for 5–7 days. Some camels aborted, and the mortality rate was 9.1%. Isolates of H1N1 
IAV from nasopharyngeal swabs from affected animals induced respiratory disease in 
experimentally inoculated serologically naive camels. Genetic sequence anal- ysis of the 
isolates revealed that the PB1, HA, and NA genes were almost identical to a human 
H1N1 IAV isolate from 1977 that was closely related to a UV-light-inactivated reassortant 
(USSR/77 × PR/8/34) H1N1 vaccine strain used in Mongolian people in Leningrad, 
whereas the remaining genes originated from the H1N1 PR/8 laboratory strain. It was 
speculated that humans were the source of infection in camels, because the epidemic 
in camels coincided with a mild influenza H1N1 epidemic among vaccinated Mongolian 
children (342). During that same time period and in the same region as the outbreaks 
in Mongolian camels in 1985, an H1N1 IAV was isolated from a child with respiratory 
disease. This isolate was genetically almost identical to the camel H1N1 IAV (447) 
suggesting that this H1N1 IAV reassortant was capable of crossing the species barrier.
Following the surge of the 2009 H1N1 pandemic, concerns were raised that 
pilgrims gathering at the Hajj might infect dromedary camels (Camelus dromedarius, 
belonging to the family Camelidae) in Saudi Arabia, and that returning pilgrims might 
infect dromedary camels in their countries of origin (448). However, there were no 
subsequent reports that substantiated these concerns. Although parainfluenza-3 virus 
has been associated with respiratory disease in dromedary camels (449), antibodies 
against IAVs have not been reported to date in sera of dromedary camels.
Very recently, an H3N8 IAV was isolated from one of 460 nasal swabs collected 
from healthy Bactrian camels from Mongolia between January 2012 and January 2013. 
Phylogenetic analysis of the isolate indicated that it was a relatively recent horse-to-
camel transmission of an IAV closely related to equine H3N8. In Mongolia, recurring 
equine H3N8 IAV epidemics arise in areas occupied by many free-ranging horses and 
Bactrian camels. Camel-to-camel transmission has not been reported to date (343).
Serological screening has been performed on other members of the family Camelidae. 
Antibodies against IAV were detected in more than 100 Peruvian alpacas (Lama pacos), 
with a prevalence of 4% (438). More recent serological screenings for antibodies against 
IAV, including human H1N1 and equine H3N8, in wild vicuñas (Vicugna vicugna) and 
llamas (Lama glama) from Argentina were negative (450, 451).
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Influenza A viruses in the order Cetacea
Reports of natural exposure to IAVs are rare in cetaceans, the mammalian order that 
includes whales, dolphins, and porpoises (Table 3.1.3). Avian-origin H1N3 IAV was 
isolated from several lungs and one liver collected from live-caught minke whales 
(Balaenoptera acutorostrata) on a whaler in the South Pacific during 1975–1976. The 
virus was identified by electron microscopy and was cultured in eggs. The NA protein 
was antigenically most close to AIV. No associated signs of disease were reported (344, 
345).
H13N2 and H13N9 AIVs were isolated from a long-finned pilot whale (Globicephala 
melaena, currently G. melas) in association with two mass stranding events along the 
coast of Cape Cod peninsula, USA, in 1984 (346). One of the diseased and disorientated 
pilot whales was caught alive, euthanised, and examined. It was extremely emaciated 
and had sloughed skin. Gross autopsy revealed enlargement of the hilar lymph node, 
hemorrhagic lungs, and a small friable liver. Although AIVs of H13N2 and H13N9 
subtypes were isolated from the hilar lymph node and lungs, there was no evidence 
that AIV infection had caused these lesions. Genetic and antigenic properties of the 
pilot whale AIV isolates suggested that they originated from gulls (346). Indeed, 28 
years after the original isolation, the gull origin of the pilot whale H13N2 AIV isolate 
was confirmed by genomic analysis (347). In contrast to other duck-enterotropic H13 
gull isolates, these viruses were apparently sensitive to low pH, as they did not replicate 
or induce disease in orally inoculated ducks. They did replicate in the lower intestine of 
ducks when rectally inoculated, thereby avoiding the acidic milieu of the proventriculus. 
The two isolates also replicated in the nose of intranasally inoculated ferrets. Fecal–
oral transmission from shedding gulls to feeding whales was proposed as a possible 
route of transmission (346). Such transmission may be facilitated by gulls and whales 
feeding concurrently on the same fish species during so-called “multi-species feeding 
frenzies.” Accidental ingestion as a route of transmission is also a possibility, since it is 
not unusual for whole birds to be caught in the mouth of a baleen whale during such 
feeding frenzies, and case reports of birds being ingested by baleen whales have been 
published (452, 453).
Serological evidence of IAV infection in cetaceans has been reported for minke 
whales, Dall’s porpoises (Phocoenoides dalli), and belugas (Delphinapterus leucas) 
(Table 3.1.4). Interestingly, the five positive beluga sera originated from a relatively small 
sample of 34 belugas from one population from the same area (Baffin Island, Nunavut, 
Canada), sampled between 1991 and 1992. No antibodies against IAV were detected in 
76 narwhals (Monodon monoceros) or four bowhead whales (Balaena mysticetus) from 
the same survey (412).
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Influenza A viruses in non-human primates
Only three published articles present virological evidence of natural IAV infection in 
non-human primates (NHPs) (Table 3.1.5). First, in 1971 Johnsen and colleagues (454) 
reported an H3N2 IAV (A/Hong Kong/1968) epidemic in a colony of white-handed 
gibbons (Hylobates lar) from Thailand. The virus was initially introduced into the colony 
by experimental inoculation of a few selected animals, but after 2–3 weeks it developed 
into an epidemic in the colony. The gibbons suffered from mild to fatal respiratory 
disease. Clinical signs consisted of fever, serous to purulent rhinitis, coughing, anorexia, 
depression, and gastrointestinal disturbances. Autopsy of the four fatal cases revealed 
dark red, oedematous lungs, which corresponded to necrohemorrhagic pneumonia 
demonstrated by histological examination (454). Second, in 1975, Malherbe and 
colleagues isolated an unspecified influenza-like virus from the throats of 3 of 20 healthy 
yellow baboons (Papio cynocephalus) that had been imported into the USA from Kenya 
(455). Third, one of 48 oral swabs from pet and free-ranging urban macaques (Macaca 
fascicularis and M. nemestrina) from Cambodia was found to be PCR-positive for IAV 
(456).
Serological evidence of IAV infection in NHPs has been reported in several articles 
(Table 3.1.6). These data suggest that NHPs are commonly exposed to and infected 
with IAV, but are relatively resistant to development of disease. Possible sources of IAV 
for both captive and free-living NHPs are humans, with whom NHPs often have close 
contact. However, other sources of IAV (e.g., birds) cannot be excluded.
Experimental inoculation of IAV has shown that multiple NHP species are susceptible 
to both IAV infection and associated disease. In the 1920s and 1930s, chimpanzees 
(Pan troglodytes) developed signs of influenza-like illness after inoculation with nasal 
washings from human patients with influenza (459, 460). In 1969, Kalter and colleagues 
inoculated H3N2 IAV into baboons (Papio species), which transmitted the virus to 
sentinel baboons but did not develop overt respiratory disease (461). Several other NHP 
species have been found to be susceptible to experimental IAV infection and to develop 
respiratory disease. The most commonly studied species are squirrel monkeys (Saimiri 
sciureus) (462-468) and cynomolgus, rhesus, pigtailed, and bonnet macaques (Macaca 
species) (288, 395, 469-478).
Influenza A viruses in the order Chiroptera
Traditionally, the original reservoir of all IAVs was considered to be wild waterbirds (479). 
This dogma was recently overturned by the discovery of IAVs with new HA (H17 and H18) 
and NA (N10 and N11) subtypes in frugivorous bats from Central and South America (6, 
7) (Table 3.1.5). This was very surprising, because previously there had only been a 
single published report of IAV infection in bats (which belong to the order Chiroptera), 
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when an H3N2 IAV was cultured and isolated from the lungs of insectivorous common 
noctule bats (Nyctalus noctula) from Kazakhstan (457).
The first IAV of previously unknown subtype, H17N10, was detected in little yellow-
shouldered bats (Sturnira lilium) from Guatemala by next- generation sequencing of 
rectal swabs and internal organs, including lungs, liver, intestines, and kidneys. The 
second IAV of previously unknown subtype, H18N11, was detected in a flat-faced fruit 
bat (Artibeus planirostris) from Peru by next-generation sequencing of rectal swabs 
and intestines (liver and spleen were negative). The consistent detection of virus in 
intestinal and rectal swabs suggested that these new bat-origin IAVs replicated in the 
intestine. The viruses could not be propagated in cell cultures or eggs. No clinical signs 
were reported in these bats, which were caught alive (6, 7).
Serological analysis of several Peruvian bat species, including Artibeus species, 
yielded a high percentage (50%, 55 of 110) of sera that contained specific antibodies 
against recombinant H18 and N11 proteins by ELISA. Likewise, specific antibodies 
against recombinant H17 protein were detected by ELISA in 38% (n=86) of 228 sera from 
eight bat species from Guatemala collected during 2009–2010 (7). Tong and colleagues 
interpreted these high seroprevalences of identical bat IAV infections in multiple 
species from distant geographic locations spanning several years as being indicative of 
widespread endemic infections with sustained bat-to-bat transmission in New World 
bats (7). However, no virological evidence was found for such new IAVs from a large 
survey of 26 species of bats from Central Europe, in the Old World (484). These bat 
IAVs contain newly discovered gene segments that encode the major surface envelope 
proteins HA (H17 and H18) and NA (N10 and N11). They differ in form and function from 
all previously known HAs (H1–H16) and NAs (N1–N9). The bat H17 showed on average 
45% amino-acid-sequence similarity to HAs from known IAV subtypes. Sequence motifs 
of the sialic acid (SA) receptor-binding site were identified in bat H17 IAV, although 
position changes in specificity for galactose–SA linkage indicated a ligand preference 
other than SA receptors (6). Zhu and colleagues indeed showed that the presumed 
receptor-binding site of HA H17 was highly acidic, making it unfavourable for binding of 
the negatively charged SA receptors (9). Unlike the HA gene and internal genes, the bat 
N10 was extraordinarily divergent from known NAs. It showed only 24% amino-acid-
sequence similarity to other IAV NA subtypes. Interestingly, this sequence similarity 
was even lower than the similarities between NAs from IAV and influenza B virus (6). 
Otherwise, the crystal structure of N10 resembled other IAV NA structures (e.g., the 
highly conserved N-glycosylation site N146 shared in all IAV NAs). However, enzymatic 
MUNANA assays showed a lack of typical neuraminidase activity (485).
Bat H18 showed 49.1% amino-acid-sequence similarity with other HA subtypes, and 
only 60.2% sequence similarity with H17. The bat N11 NA (more accurately referred to 
as “NA-like protein” or NAL) had only 29.6% identity with all other NAs (7). Furthermore, 
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the HAs H17 and H18 showed no specific binding to sialosides evaluated by sialoside 
microarray and glycan ELISA (7, 9), and it was also found that N10 and N11 NA-like 
proteins did not bind or cleave SAs (7, 485). In contrast to non-bat IAVs, these results 
indicate that bat H18N11 and H17N10 IAVs do not mediate host cell attachment and 
release via SA receptors. The receptors or mechanisms that these bat IAVs use for host 
cell attachment, fusion, entry, and release have yet to be identified (6, 7, 486).
The amino acid sequences of the remaining internal genes of H17N10 and 
H18N11 IAVs showed most of the known functional sequence motifs of other IAVs. 
The polymerase complex proteins (PB2, PB1, PA, and NP) of both showed functional 
viral transcription by means of reporter minigenomes in human and primate cells. 
This transcription was abrogated when PB1 was removed from the minigenome (6, 7). 
Furthermore, it was determined that the N-terminal domain of PA (PAn) from H17N10 
has manganese or magnesium ion-dependent endonuclease activity producing small 
RNA primers essential for initiation of viral gene transcription like any other IAVs (487).
Phylogenetic analysis of the primary genetic sequences of the HA molecules of bat H17 
and H18 indicated that they belong to group 1 HAs (together with H1, H2, H5, H6, H8, H9, 
H11, H12, H13, and H16), and not to group 2 HAs (H3, H4, H7, H10, H14, and H15). The 
more divergent NA-like molecules N10 and N11 did not belong to either of the existing NA 
groups 1 and 2, but were categorised as a separate influenza A-like group 3 (Figure 3.1.4) 
(8). Although their internal genes were almost the same as known IAVs, Wu and colleagues 
proposed that on the basis of the different NA and HA genes these viruses should be 
renamed as “influenza-like viruses” (8). The origins of the NALs are not known, but they 
might be derived from an unknown influenza type other than influenza A, B, or C, either 
extinct or yet to be identified (485). The positions of the six internal genes of bat H17N10 
in the phylogenetic tree were between the IAV and influenza B virus split. However, they 
were more closely related to IAV-type genes (6). Tong and colleagues concluded from 
their findings that these newly discovered IAVs needed to have evolved in bats for a long 
period of time (7). Briefly, these findings included higher viral genetic diversity than was 
previously known to exist, divergence into multiple HA and NA subtypes with a presumed 
SA-independent alternative mechanism or receptor for host cell entry and release, and a 
widespread geographic distribution of these two monophyletic bat IAVs.
The two major surface proteins, HA and NA, of bat H17N10 and H18N11 IAVs lacked 
typical cell attachment and cleavage functions. However, their more conserved internal 
genes responsible for viral transcription were shown to be functional in vitro. These 
genes are considered to be potentially inter- changeable with known IAVs that contain 
classical functional HAs and NAs. This raised serious scientific and public health questions 
about whether such genomic reassortments could occur, thereby possible generating an 
infectious influenza virus capable of causing disease in species other than the bat species 
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in which they were detected (6-8). Furthermore, bats are known to harbour many viruses 
with considerable zoonotic disease potential (488, 489), and are sometimes regarded 
as a “treasure trove” hosting many unknown viruses (488). Indeed discoveries of new 
viruses in bats are ongoing (490, 491). In general, bats possess specific characteristics 
that could favor the evolution and spread of novel viruses, including IAV. Belonging to the 
taxonomic order Chiroptera that contains approximately 1150 species worldwide, bats 
are long-lived globally abundant mammals, which migrate and inhabit urban, rural, and 
natural environments, with possible contacts with humans, livestock, and other wildlife. 
Furthermore, they exhibit clustered roosting in extremely high densities in multi-species 
colonies, practically guaranteeing bat-to-bat transmission of viruses (488). Bats have to 
be considered as a novel potentially important mammalian reservoir of influenza viruses.
Influenza A viruses in the orders Rodentia and Lagomorpha
Although there are about 2300 species in the order Rodentia and around 80 species 
in the order Lagomorpha (492), natural IAV infection has very rarely been reported in 
species belonging to these two orders (268, 275, 367, 493). Specific antibodies against IAV 
indicating infection with human IAV were detected unequivocally by HI and complement 
fixation tests in one domestic rabbit (Oryctolagus cuniculus) and one chipmunk (Tamias 
striatus). This was part of a serological screening study for antibodies against H3N2 
IAV (A/Hong Kong/1/1968) in 6 wild chipmunks, 25 groundhogs (Marmota monax), 13 
cottontail rabbits (Sylvilagus species), 42 snowshoe hares (Lepus americanus), and 106 
pet rabbits from the Ottawa area, Canada, sampled between 1966 and 1970 (367).
Six of six wild house mice (Mus musculus) caught on a gamebird farm in Idaho, USA, 
during an H5N8 LPAIV outbreak in 2008 were found to be positive for antibodies against 
IAV by indirect NP-ELISA (493). Six brown rats (Rattus norvegicus), one harvest mouse 
(Reithrodontomys megalotis), and one deer mouse (Peromyscus maniculatus) that were 
caught and tested in the same study were all seronegative. Subsequent experimental 
intranasal inoculation of newly caught serologically naive house mice with AIV isolates 
from wild birds (H3N6, H3N8, and H4N6) or chickens (H6N2 and H4N8) resulted in virus 
replication in the nasal turbinate, trachea, and lungs. The virus isolates from the wild 
birds replicated to higher titers in the mouse tissues than did the chicken isolates. The 
results indicated that house mice might be a risk factor for transmission of IAV to poultry 
and gamebird farms (493).
Influenza A viruses in other species
An outbreak of human seasonal H1N1 IAV infection occurred in giant anteaters 
(Myrmecophaga tridactyla, belonging to the family Myrmecophagidae, in the order 
Pilosa) in Nashville Zoo, USA, in February 2007. All 11 animals in the group exhibited 
clinical signs of severe nasal discharge and congestion, inappetence, and lethargy. The 
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isolated virus was identified as IAV and showed more than 99% nucleotide identity with 
a human seasonal IAV isolate Tennessee/UR06-0119/2007 (H1N1). The anteaters had 
no contacts except with their keepers, who were suffering from respiratory disease, and 
presumably were the source of infection (494).
The reports, albeit rare, of IAV infection in reptiles and amphibians emphasise the 
broad host range of this virus. In 2006, IAV was detected by PCR for IAV-matrix gene 
in blood samples from 4 of 37 captive crocodilians in Florida, USA, namely a Chinese 
alligator (Alligator sinensis), a Schneider’s dwarf caiman (Paleosuchus trigonatus), a 
Nile crocodile (Crocodylus niloticus), and a broad-snouted caiman (Caiman latirostris). 
Antibodies to IAV were detected by agar gel immunodiffusion testing in sera of all 
these animals except for the broad-snouted caiman. These crocodilians were kept in 
open pens with exposure to wild birds, some of which were eaten, and it is likely that 
these were the source of infection. This is supported by sequence analysis of the non-
structural protein 1 (NS1) gene of the PCR products, which revealed more than 99.7% 
homology with the NS1 gene from duck isolates (495). One other study, by Mancini 
and colleagues (496), suggested that there was susceptibility to IAV (and influenza B 
virus) infection in poikilothermic animals. Antibodies against human H1N1 and H3N2 
IAVs and equine H7N7 and H3N8 IAVs were detected by HI assay in sera collected from 
captive and free-ranging snakes and amphibians from Brazil, namely pit vipers (Bothrops 
jararaca and B. jararacussu), Cascavel rattlesnakes (Crotalus durissus terrificus), Rococo 
toads (Bufo paracnemis), and American bullfrogs (Lithobates catesbeianus, formerly 
Rana catesbeiana) (496).
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ABSTRAcT
Five well-established animal models in influenza research are discussed in a schematic 
fashion. Although there are clear parallels between these models, like viruses 
used, housing and handling conditions under biosafety conditions, routes of virus 
inoculation, sampling strategies, and autopsy techniques, each of these models 
involves specific differences in practical applicability that need thorough assessment 
depending on the scientific question raised. In other words, there is no universal 
animal model for influenza and depending on the actual question to be answered the 
model and the experimental conditions should be carefully selected.
Keywords: Influenza, Animal model, Mouse, Ferret, Guinea pig, Macaque, Chicken, 
Duck, Methods.
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INTRODUcTION
Several animal models for human and animal influenza have been established to answer 
questions related to the pathogenesis of influenza and to the development and testing of 
intervention strategies like the use of vaccines and antiviral drugs. The most commonly 
used mammal species are the laboratory mouse (Mus musculus; predominantly 
BALB/c-strain (497-499) and C57BL/6J-strain (“black/6 strain”) (500-504), the ferret 
(Mustela putorius furo) (505-509), and the cynomolgus macaque (Macaca fascicularis) 
(278, 279, 510-513), which all exhibit respiratory tract lesions to a lesser or greater 
extent comparable to those commonly observed in humans and animals with influenza. 
Several of these models can also be used to study questions related to transmission of 
influenza viruses. Especially ferrets and, more recently, also guinea pigs (Cavia porcellus) 
(514-521) are used in influenza transmission studies. Other mammalian species used in 
influenza models include the cotton rat (Sigmodon hispidus) (522), the domestic pig 
(Sus scrofa domesticus) (395, 523-525), the golden hamster (Mesocricetus auratus) 
(526) (34), and the domestic cat (Felis catus) (249, 337). Frequently used avian species 
are the White Leghorn chicken (Gallus gallus domesticus) for pathogenicity studies 
(337, 527) and vaccine studies (528), and various species of ducks (Anseriformes) for 
studies on the geographical spread of influenza (529, 530). In addition, several of these 
animal models are used to answer basic scientific and practical questions. Each animal 
model has its advantages and disadvantages and limitations that must be considered in 
relation to the research question concerned.
MATERIALS & METHODS APPLIED IN ANIMALS MODELS
Animals
All animal experiments are to be approved by an independent expert governmental 
and/or institutional animal ethics and welfare committee. Laboratory animals need 
access to fresh species-specific commercial food pellets, with or without supplements, 
which meet their individual nutritional requirements, and fresh water ad libitum. If 
animal experiments (including housing, sample handling, and laboratory work) deal 
with biosafety level 3 (BSL3) classified pathogens, they are performed under BSL3-
conditions. The animals are housed accordingly in negatively pressurised and high 
efficiency particulate air (HEPA)-filtered biocontainment isolation units (usually glove 
boxes).
General anesthesia is applied for performing virus challenges (intranasal, 
intratracheal, intra-esophageal, intragastric, intrachoanal), taking nose/throat/rectal/
cloacal swabs, blood samplings, nasal washes, subcutaneous or intraperitoneal 
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implantation of telemetric transponders, and euthanasia (514). Monitoring for 
clinical signs, such as reduced activity, labored breathing, diarrhea, and body weight 
loss is performed at predefined regular intervals as indicators of disease. The body 
temperature may be recorded at regular intervals, ranging from every 5–15 min, using 
a temperature-logging device implanted in the peritoneal cavity or subcutis (514) 14 
days prior to the start of the experiment. Changes in body temperature can individually 
be calculated by subtracting the mean day and night temperatures measured on 4 
successive days during the period before the challenge from the mean day and night 
temperatures measured after infection (510).
Laboratory mouse strains commonly used are C57BL/6J and BALB/c with a specified 
pathogens-free (SPF) status, mostly females 6–8 weeks of age. They are group-housed 
in age-matched study groups in standard filter-top cages or in isolator units.
General anesthesia is induced by means of inhalation of 3% isoflurane in O2, and is 
applied also when mice are immunised intramuscularly. Vaccines or other appropriate 
treatments are administered intramuscularly in the hind legs (maximum injection 
volume used is 100 µl i.m. equally divided over both hind legs). Blood sampling is 
performed from the tail vein.
Monitoring for clinical signs and body weight loss is performed at predefined regular 
intervals as indicators of disease. According to protocol laboratory mice are to be 
euthanised if they show a postinfection weight loss exceeding 20% (504).
Virus challenge is performed by intranasally instilling a volume of 50 µl phosphate-
buffered saline (PBS) that contains generally 102–104 median tissue culture infective 
dose (TCID50) of mouse-adapted H1N1 strains (e.g., influenza virus A/PR/8/34), or 
non-mouse-adapted H5N1 HPAIV (e.g., A/Vietnam/1194/04), amongst other IAVs, 
dosed generally at 103 TCID50 in 50 µl PBS. Sham challenged control animals are similarly 
treated with the matching volume of PBS. Virus shedding is monitored post infection in 
daily serial nose washings and at autopsy.
Euthanasia of laboratory mice is performed under general anesthesia by means 
of exsanguination from orbital puncture or by cervical dislocation at predefined time 
points, or according to predefined clinical criteria.
Studies with ferrets are carried out with outbred males and/or females, approximately 
8 months of age, with body weights ranging from 0.8 to 1.5 kg. The ferrets are housed 
in study groups of 6–10 animals. For transmission experiments, naïve ferrets are placed 
in a transmission enclosure adjacent to an inoculated ferret at 1 day postinfection. The 
animals in these cages are separated by two relatively closely spaced stainless steel grids 
with low walls on each side that allow unidirectional airflow from the inoculated ferret 
to the naïve ferret, but prevent direct contact and fomite (e.g., cage bedding material) 
transmission. Nose and throat swabs are taken from the inoculated and exposed ferrets 
at predefined daily time points to assess potential horizontal virus transmission.
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General anesthesia is induced by intramuscular injection in a hind leg with a mixture 
of ketamine 12.5 mg/kg body weight and medetomidine–HCl 7.5 mg/kg body weight 
(which can be antagonised by atipamezole–HCl 0.5 mg/kg body weight). Intramuscular 
injection of ketamine 25 mg/kg body weight is used for blood sampling, euthanasia, and 
swabbing throat, nose, and rectum. Anesthesia of ferrets can be induced alternatively 
by means of inhalation of 5% isoflurane in O2 (531).
The jugular vein is used for blood sampling and i.v. administration of drugs.
Vaccines or other appropriate treatments are administered intramuscularly in the 
hind legs (maximum injection volume used is 1 ml equally divided over both hind legs). 
When a vaccine based on a live-attenuated virus is applied that needs limited replication 
within the nasal epithelium to induce an adequate protective immunity, this is typically 
instilled intranasally (0.5 ml equally divided over both nostrils).
Since ferrets in influenza research with a SPF status are not readily available, 
previous field infections with circulating influenza viruses may have occurred which may 
interfere with vaccine efficacy and virus challenge studies because of possibly induced 
cross-immunity against the vaccine or challenge virus. Similarly, infection with Aleutian 
disease virus (ADV; a parvovirus) can cause interference by means of an altered immune 
competent status (532). Therefore only animals seronegative for these viruses are used; 
a limited SPF status.
Virus challenge is performed by intratracheal instillation of influenza virus (dosage 
in the range of 105–107 TCID50 depending on the virus used) suspended in 3 ml PBS. 
The challenge virus can also be administered by intranasal instillation of influenza virus 
(dosage in the range of 105–107 TCID50 depending on the virus used) suspended in 
0.3–0.5 ml PBS (equally divided over both nostrils).
Euthanasia of ferrets is performed under general anesthesia usually by means of 
exsanguination from cardiac puncture.
Cynomolgus macaques, male and/or female, adolescent to young adults 
(approximately 3 years), colony bred in captivity, body weight ranging from 3.5 to 4.5 kg 
are most frequently used in influenza infection experiments. The macaques are group 
housed in study cohorts, either in harem groups (one dominant male with several 
females) and/or in male groups (peer group of young adults). Commercial macaque 
food is supplemented with fresh fruit.
General anesthesia is induced by intramuscular injection in one of the legs of a 
mixture of ketamine 1.0 mg/kg body weight and medetomidine–HCl 0.1 mg/kg body 
weight (which can be antagonised by atipamezole–HCl 0.25 mg/kg; i.m.).
The inguinal vein usually is used for blood sampling and intravenous drug 
administration.
Vaccines or other appropriate treatments are administered intramuscularly in the 
legs (maximum injection volume used is 1.0 ml equally divided over both legs). Live-
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attenuated virus vaccines that need limited replication within the nasal epithelium are 
typically instilled intranasally (volume usually used is 1.0 ml equally divided over both 
nostrils).
Virus challenge is performed by intratracheal instillation of influenza virus suspended 
in 3–4 ml PBS (dosage in the range of 104–107 TCID50 depending on the virus used) 
propagated in monkey kidney (MK) cells or MDCK cells. Virus challenge can also be 
performed by intranasal instillation of influenza virus (dosage in the range of 104–107 
TCID50 depending on the virus used) suspended in 1.0 ml PBS (equally divided over both 
nostrils). Intranasal or intratracheal inoculation can be combined with application of 
the virus suspension on the tonsils and conjunctivae (278). Euthanasia of macaques is 
performed under general anesthesia usually by means of exsanguination from cardiac 
puncture.
Female guinea pigs of the outbred Hartley strain, approximately 8 weeks of age 
with body weights of 300–350 g, are used predominantly (514-521) in influenza virus 
transmission models. Guinea pigs in transmission settings are housed each in a standard 
rat cage (Ancare R20 series) with an open wire top, and are usually kept on a 12 h light/
dark cycle. Two cages, one containing the infected animal and the other containing the 
exposed sentinel animal, are placed with the wire grids facing each other at variable 
distances without possible physical contact in an environmental chamber (Caron model 
6030) with supporting unidirectional airflow. During such transmission experiments, 
strict measures are to be implemented to prevent aberrant cross contamination 
between cages. This includes handling of sentinel animals before inoculated animals, 
changing gloves and sanitizing work surfaces between animal handlings (514, 517, 521). 
Guinea pigs can be housed also in HEPA-filtered isolation units under BSL3 conditions 
when infected with, e.g., an H5N1 HPAIV (515).
General anesthesia is induced by a mixture of ketamine (30 mg/kg body weight) 
and xylazine (2 mg/kg body weight) administered intramuscularly in the gluteal muscles 
(514).
Blood sampling is performed from the metatarsal vein. Vaccines are administered 
intramuscularly in the hind legs (gluteal muscles, maximum injection volume used is 
0.5 ml, equally divided over both sites). Live-attenuated virus vaccines are inoculated 
intranasally at 106 plague forming units (PFU) in 300 µl solvent (equally divided over 
both nostrils) (518).
Virus challenge is performed by intranasal instillation of a virus stock that was diluted 
in PBS to a volume of 300 µl (equally divided over both nostrils) (514). Inoculation doses 
reported are 106 (median egg infective dose) EID50 for H1N1 IAV and H5N1 HPAIV (519) 
and 103 PFU for H3N2 IAV and H1N1 (517). Intragastric inoculation of H5N1 HPAI has 
been performed by means of gavage catheter, 106 EID50 in 2 ml PBS (515).
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Human IAV isolates replicate in both upper and lower respiratory tracts of guinea 
pigs without further adaptation. The animals shed high levels of virus in nasal secretions 
that can be transmitted via direct contact and/or droplets and aerosols, to sentinel 
guinea pigs (514). Inoculation of unadapted A/Panama/2007/99 H3N2 IAV into Hartley 
guinea pigs did not result in clinical signs. However, this was dependent on the guinea 
pig strain (514), as similar infection of inbred strain13 guinea pigs resulted in severe 
disease, including weight loss, lethargy, hair loss, and hypothermia.
Other viruses such as a human isolate of highly pathogenic avian influenza H5N1 
did cause slight temporary lethargy in Hartley strain guinea pigs (515). Also, the dose 
of virus used proved important, as intranasal challenge with high dose of influenza A 
virus H3N2 in juvenile Hartley guinea pigs resulted in ruffled fur and reduced activity 
(516). However, since guinea pigs generally do not exhibit clinical signs when challenged 
with influenza A viruses (514), clinical observations are not always performed routinely. 
Since infected guinea pigs do not produce burst expulsions like cough or sneeze, the 
extrapolation of guinea pig transmission data to human transmission does not seem 
straightforward (517).
Euthanasia of sedated guinea pigs is performed by means of intraperitoneal injection 
of sodium pentobarbital (514), or by intracardiac injection with Beuthanasia-D solution 
1 ml/kg (519) (26), or by exposure to CO2 gas (520).
SPF White leghorn chickens are used in influenza research. In general they are not 
used to model human influenza. Instead 1-day-old chicks can serve as route of IAV 
inoculation as infected prey animals in infection experiments in carnivores (e.g., in 
cats). Alternatively, 6-week-old SPF White Leghorn chickens may be used to determine 
the intravenous pathogenicity index (IVPI) of influenza viruses. This is performed by 
intravenous injection in the ulnar vein of 0.1 ml of 106 TCID50 virus. Clinical signs are 
monitored for 10 consecutive days, and the animals are considered diseased when 
displaying one of the following clinical signs: depression, cyanosis of the comb or wattles, 
respiratory involvement, diarrhoea, oedema of the face/head, and nervous signs. They 
are considered severely affected if they displayed two or more of these signs. The index 
is calculated as the mean score per bird per observation (522). Several duck species, 
including the mallard (Anas platyrhynchos) (530), males and females, usually between 
8 and 11 months of age, are used in infection and transmission experiments. There is a 
preference for use of Pekin ducks, a breed of domestic duck, that are preferably captive 
bred and housed indoors since hatching to avoid the risk for inadvertent avian influenza 
virus infection. Chickens and ducks are usually group-housed in study groups of 4–8 
animals. In these bird species, general anesthesia is induced by means of inhalation of 
5% isoflurane in O2, and blood sampling is performed from the jugular or ulnar veins.
Vaccines or other appropriate treatments are administered subcutaneously or 
intramuscularly (pectoral muscle), with volumes correlated to body weight. Injection 
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volumes (of vaccines) per body weights are: <1.4 kg: 0.25 ml, 1.4–7 kg: 0.5 ml, >7–12 kg: 
0.75 ml, >12–44 kg: 1.25 ml, >44 kg: 2.5 ml (533).
Virus challenge is performed by intratracheal instillation of e.g., 2.5 × 104 TCID50 
H5N1 HPAIV in 1-day-old chicks, and euthanised 1 dpi for experimental transmission 
to carnivores. In pathogenicity studies 8 weeks old chickens are inoculated intranasally 
or intrachoanally with, e.g., 104 EID50 H5N1 HPAIV in 0.3 ml PBS (534). Ducks in 
pathogenicity and excretion studies are inoculated with, e.g., 104 TCID50 H5N1 HPAIV 
in PBS, 1.5 ml intratracheally and 1.5 ml intraoesophageally (530) but intranasal is the 
most common inoculation route.
Euthanasia of these avian species is performed under general anesthesia usually by 
means of exsanguination from cardiac puncture.
Serology
Animal studies on influenza are performed in animals seronegative for circulating 
seasonal influenza viruses and other relevant influenza virus strains. Serum samples 
are collected at predefined time points and tested (after treatment with cholera 
filtrate and heat inactivation at 56°C) for the presence of anti-HA antibodies via the 
hemagglutination inhibition (HI) assay and for virus-neutralizing antibodies using the 
(micro-) virus neutralisation (VN) assay. Additionally, ferrets are screened before use 
for the presence of serum antibodies against Aleutian disease virus. Only seronegative 
animals are used. Additional confirmation of the absence of virus-specific antibodies 
can be performed by immunofluorescence assay using MDCK cells infected with 
influenza A or B viruses (535), or by means of commercially available IAV ELISA kit for 
detection of antibodies against NP. If animals are screened just prior to inoculation by 
nasal, oropharyngeal, or cloacal swabs, they need to be RT-PCR negative as well.
Virology
Challenge virus stocks can be either propagated in the allantoic cavity of 10- or 11-day-
old embryonating chicken eggs or propagated in MDCK or MK cell cultures. Allantoic fluid 
is harvested 3 days after inoculation and infectious virus titers are determined in MDCK 
cell cultures. In cell cultures following development of cytopathic changes, supernatants 
are collected and cleared by low-speed centrifugation, and infectious titers are similarly 
determined in MDCK cell cultures. To determine the TCID50, 100 ml of tenfold serially 
diluted culture supernatants are inoculated in quadruplicate or quintuplicate on MDCK 
cells grown confluently in 96-well microtiter plates (105 cells per well) in culture medium 
[minimal essential medium (MEM) supplemented with 10% fetal calf serum (FCS), 100 
IU/ml penicillin, and 100 mg/ml streptomycin]. Before infection, the cells are washed 
twice with PBS. After 1 h at 37°C, cells are washed twice with infection medium [MEM 
supplemented with 4% bovine serum albumin (BSA) fraction V, 100 IU/ml penicillin, 100 
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mg/ml streptomycin, and 4 mg/ml trypsin] in a humid 5% CO2 atmosphere at 37°C for 
6–7 days. To determine the hemagglutination activity, 50 µl volumes of these culture 
supernatants are serially diluted twofold in PBS in round bottom plates. Subsequently, 
25 µl PBS and 25 µl of a 1% suspension of turkey erythrocytes are added. After 1 h 
incubation at 4°C the haemagglutination patterns are read. HA activity is used as an 
indicator for infection of the cells in individual wells (535). Infectious virus titers are 
calculated according to the method of Spearman–Karber (536) or Reed–Muench (537) 
and expressed as log TCID50 per ml. Infectious virus titers can alternatively be assessed 
using 10-day-old embryonating chicken eggs reported as log median egg infective dose 
(EID50) per ml, calculated according to the method of Reed–Muench (515, 537). The 
virus stock is diluted with PBS to obtain the final dose needed for inoculation. Usually a 
large animal experiment is preceded by a dose finding study that includes fewer animals 
in total than the definitive experiment to determine the optimal challenge dose of a 
particular virus, e.g., three to four different challenge groups of six animals each (538). 
Control animals are sham challenged in the same way with the matching volume of PBS, 
or PBS-diluted sterile allantoic fluid or cell culture supernatant.
Virus shedding from inoculated animals and/or sentinel animals in transmission 
experiments can be monitored in vivo by collection of serial swabs from oropharynx, 
nose, rectum, and cloaca, in transport medium daily or at other predefined time points 
post challenge until euthanasia or death. Virus shedding from the respiratory tract of 
macaques also can be assessed by collecting lung lavage fluids (LLF). Swabs collected 
for virus shedding can be stored at −80°C until further analysis. Individual swabs are 
resuspended by vortexing in 3 ml transport medium for virus isolation. The samples 
are analyzed for the presence of virus by inoculating MDCK cells with serial tenfold 
dilutions as stated above. Viral titers are determined according to standard procedures 
and expressed as log TCID50 per ml of swab medium. Additionally, viral RNA can be 
isolated from 200 µl supernatant of swab medium using the MagNA Pure LC system and 
detected by a TaqMan assay.
Alternatively, especially in guinea pigs, nasal washes can be taken to determine 
viral titers. This is performed by instilling 1 ml PBS into the nostrils and collecting liquid 
runoff in a sterile petri dish before aliquots in tubes are centrifuged for 5 min at 2,000 × 
g and 4°C. The supernatants can be stored at −80°C pending analysis (514).
Virus titers also can be determined in tissues collected at autopsy. Tissue samples 
from the respiratory tract (e.g., lung, bronchus, trachea, nasal turbinate), and extra-
respiratory organs are collected at autopsy and can be processed directly or can be 
snap-frozen (tissues enclosed in ampules on dry ice containing ethanol, and stored 
at −70°C/−80°C) pending further processing. During processing, tissue samples are 
weighed and subsequently homogenised in 1 ml of medium (tissue homogenate 
medium or MDCK infection medium) by means of the FastPrep system with two ¼ 
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in. (»6.4 mm) diameter ceramic balls or four 3.0 mm diameter steel balls and then 
resuspended by adding an extra 2 ml medium. Alternatively, a Polytron PT2100 can 
be used to homogenize tissues in 3 ml of medium. The suspension is then clarified by 
centrifugation (10 min at 500 × g). The titers of clarified supernatants of homogenised 
tissues are determined by standard procedures in MDCK cells and expressed as log 
TCID50 per gram of tissue.
A microarray assay to assess differences in mRNA expression profiles can be performed 
using tissue samples collected at autopsy and immediately stored in RNAlater solution. 
Several small fresh tissue samples are collected at autopsy; non-lesional samples versus 
lesional samples, and/or samples of vaccinated/treated animals versus samples of 
sham-vaccinated/placebo-treated control animals. After storage in RNAlater, total RNA 
is isolated, purified, labeled, and hybridised on GeneChip Arrays. GeneChip Arrays are 
readily available for laboratory mice but not yet for ferrets. However, amplified RNA can 
be hybridised to Affymetrix GeneChip Canine Genome 2.0 Array (531). Arrays are also 
readily available for the rhesus macaque (Macaca mulatta) that bears a close genetic 
resemblance to the cynomolgus macaque and can be used successfully (473). Among 
others, differences in gene expression levels of inflammatory mediators like interferons 
and other cytokines and chemokines can be assessed.
Immunology
To avoid hypersensitivity reactions during virus challenge, vaccine preparations should 
be free of BSA. This may occur after repeated exposure to this antigen (518).
In ferrets, peripheral blood mononuclear cells (PBMCs) can be collected and isolated 
from blood samples, and a T-cell proliferation assay can be performed to assess vaccine-
induced T-cell responses. PBMCs are isolated from blood samples, collected 4 weeks 
after vaccination in EDTA tubes by density gradient centrifugation using lymphoprep 
(can be cryopreserved at −135°C), labeled with 0.3 mM carboxyfluorescein diacetate 
succinimidyl ester (CFSE) in PBS for 5 min at 37°C, washed twice and resuspended in 
RPMI medium 1640. 105 cells per well are seeded into a 96-well plate with or without 
the immunogenic compound (200 ng HA content) or phytohemagglutinin (PHA) (1 
mg/ml) and incubated at 37°C/5% CO2 for 6 days. After 2 days, 100 µl supernatant of 
Concanavalin A-stimulated ferret lymph node cells is added per well. After 4 days cells 
are washed and stained with a monoclonal antibody against human CD8 (OKT-8)-Pacific 
Blue. Cells are stained with LIVE/DEAD Aqua Fixable Dead Cell Stain to exclude dead 
cells. Next, cells are fixed and permeabilised with Cytofix and Cytoperm, and stained 
with an Alexa Fluor 647-labeled mAb specific for human CD3 (PC3/188A). These CD3- 
and CD8-specific mAb cross-react with ferret CD3 and CD8. Data are acquired using a 
FACSCanto-II and analyzed with FACS Diva software. The proliferation of CD3 + CD8− 
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(and CD3 + CD8+) cells is calculated by subtracting the control CD3 + CD8-(+) CFSElow 
cells from the HA-stimulated CD3 + CD8-(+)CFSElow cells (505) (9).
Especially in mice, spleens can be harvested for the detection of virus-specific CD8+ 
cytotoxic T lymphocytes (CTL) by tetramer-staining to assess vaccine-induced T-cell 
responses. The erythrocytes are removed from single-cell splenocyte suspensions 
(obtained by using 100 mm cell strainers) with ery-lysis buffer. The cells are washed 
with 0.5% BSA or 2% FCS in PBS and stained for flow cytometry with antibodies such 
as CD3e-PerCP, CD8b.2-FITC, ToPro 3-APC, and APC or PE-labeled H-2Db-PE tetramer 
with the NP366-374epitope ASNENMETH. Cells are analyzed on FACSCalibur with a high 
throughput sampler in combination with PlateManager and CellQuest Pro software 
(504).
Pathology
During autopsy, a thorough macroscopic examination is performed. This includes 
weighing the intact animal and selected organs, and assessment of gross lesions. 
Preferably the trachea is clamped before opening the thorax to prevent lung collapse to 
allow for accurate in situ examination of the non-collapsed lung. The lungs are inspected, 
weighed, and the lung (partially or in toto) is collected during autopsy, gently instilled 
with and immersed in 10% neutral-buffered formalin for a minimum of 2 days to allow 
for adequate tissue fixation and virus inactivation. Lungs and other organs collected 
at autopsy are placed in 10% neutral-buffered formalin with an approximate ratio of 1 
parts tissue to 9 parts formalin. Avian specific tissues collected at autopsy may include 
the caudal thoracic or abdominal airsac, proventriculus, and bursa of Fabricius.
At autopsy, fresh samples can be collected for determination of viral loads. These 
samples may include nose washes with PBS, respiratory tissues ranging from nose to 
lungs, and additional tissues such as tonsils, tracheobronchial lymph nodes, brain, 
spleen, liver, kidney, pancreas, intestines, and plasma. Typically, lung virus titers are 
determined in homogenised pools of lung samples, that are collected in a standardised 
way (e.g., one sample per lung lobe), not guided by the presence of gross lesions, and 
weighed (each sample ≈ 0.1 g, so total averaged weight of sampled lung tissue ≈ 0.4–0.5 
g per animal). Furthermore fresh spleens can be harvested for the detection of virus-
specific CD8+ T cells.
Trimming of formalin-fixed organs and lungs for histopathology is done in a 
standardised way not guided by the presence of gross lesions. The tissue sections are 
routinely processed and paraffin embedded and sectioned at 3–4 µm, deparaffinised 
with xylene and rehydrated with alcohol and stained with haematoxylin and eosin 
(H&E) for histopathological examination by light microscopy. Additionally, IHC can be 
applied to visualise viral protein synthesis. For IHC, consecutive slides are cut at 3–4 
µm and stained using an immunoperoxidase method with a monoclonal antibody 
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directed against the NP of IAV. A horseradish peroxidase-labeled goat anti-mouse (e.g., 
anti-IgG2a) is used as secondary antibody. Endogenous cellular peroxidase is blocked 
with 3% hydrogen peroxide. The peroxidase is revealed using 2,3-diaminobenzidine 
(DAB) as a substrate, resulting in a dark brown granular staining in the cytoplasm and 
especially in the nuclei of influenza virus infected cells, followed by counterstaining with 
haematoxylin. The peroxidase activity can be revealed alternatively by incubating slides 
with 3-amino-9-ethylcarbazole (AEC) for 10 min resulting in deep red nuclear staining 
of infected cells. Lung sections from domestic cats intratracheally inoculated with H5N1 
HPAIV are simultaneously stained and serve as positive controls. Negative controls are 
performed in absence of the primary antibody, substitution of primary antibody by an 
irrelevant monoclonal antibody of the same isotype (279), and preferably include a 
negative tissue control comprised of the same tissue of a non-infected animal stained 
for NP.
materials; media and Biochemical Substances
- Tissue Homogenate Medium (storage condition: +4°C, for maximum of 2 weeks): 
Hank’s balanced salt solution containing 0.5% lactalbumin, 10% glycerol, 200 U/ml 
penicillin, 200 mg/ml streptomycin, 100 U/ml nystatin.
- MDCK Infection Medium (storage condition: +4°C, for maximum of 2 weeks): 500 
ml Eagle’s minimal essential medium, 10 ml Hepes buffer (1 M), 5.7 ml Sodium 
bicarbonate solution (7.5%), 5.0 ml l-Glutamine (200 mM), 5.0 ml Penicillin (10,000 
IU/ml) and Streptomycin (10,000 mg/ml) solution, 350 ml Trypsin 2.5% (10×), 4.3 ml 
BSA fraction V (35%), 5.0 ml Amphotericin B (0.25 mg/ml).
- RNAlater, storage conditions: stable at +4°C for 4 weeks, or long term at −20 to 
−80°C.
- Transport Medium for virology samples (storage conditions: +4°C for 2 weeks, 
and −20°C for 52 weeks): 430 ml General Virus Transport Medium [500 ml Eagle’s 
minimal essential medium, 10 ml Hepes buffer (1 M), 5.7 ml Sodium bicarbonate 
solution (7.5%), 5.0 ml l-Glutamine (200 mM), 5.0 ml Penicillin (10,000 IU/ml) 
and Streptomycin (10,000 mg/ml) solution, 4.3 ml BSA fraction V (35%), 5.0 ml 
Amphotericin B (0.25 mg/ml)], 50 ml Penicillin (10,000 IU/ml) and Streptomycin 
(10,000 mg/ml) solution, 8.6 ml BSA fraction V (35%), 20 ml Amphotericin B (0.25 
mg/ml).
- Transport medium for virology samples: Hank’s balanced salt solution containing 
10% glycerol, 200 U/ml penicillin, 200 mg/ml streptomycin, 100 U/ml polymyxin B 
sulfate, 250 mg/ml gentamicin.
- Viral inoculum, PBS-BA-PS: Viral stock diluted in PBS containing 100 units/ml 
penicillin, 100 mg/ml streptomycin, and 0.3% BSA.
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Suppliers: -standard laboratory reagents: Lonza The Netherlands (NL), Sigma-Aldrich 
NL, ICN NL; -RNAlater: Ambion USA; -veterinary anesthetics: Eurovet NL, Orion Pharma 
Finland, Pfizer NL; -temperature loggers: StarrOddi Iceland; -MagNA Pure LC system: 
Roche diagnostics NL; -IAV antibody ELISA kit: EVL NL; -GeneChips: Affymetrix USA; 
-RPMI medium: Cambrex USA; -Lymphoprep: Axis-Shield Norway; -cytofix, cytoperm, 
cell strainers and Facs software: BD pharmingen NL; -human monoclonal CD8 antibody: 
eBiosciences USA; -labeled human monoclonal CD3 antibody: Santa Cruz Biotechnology 
USA; -Fastprep system: MP biomedicals Europe; -Polytron PT2100: Kinematica AG 
Switzerland.
cONcLUDING REMARKS & SUMMARy TABLE
In influenza research, a variety of animal species can be used in animal models for 
influenza in humans. They show species-specific differences in susceptibility to influenza 
virus infection or subsequent disease. Thorough knowledge and experience of these 
animals are necessary to obtain reliable data for extrapolation to humans. In table 3.2.1 
a summary is given of important advantages and disadvantages of the foremost animal 
species used in influenza research.
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cHAPTER 4
Pathogenesis studies on influenza 
induced ARDS in ferrets

 4.1
Low pathogenic avian infl uenza 
A(H7N9) virus causes high 
mortality in ferrets upon 
intratracheal challenge: A model to 
study interventi on strategies
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ABSTRAcT
Infections with H7N9 LPAIVs have caused more than 100 hospitalised human cases of 
severe influenza in China since February 2013 with a case fatality rate exceeding 25%. 
most of these human infections presented with severe viral pneumonia, while limited 
information is available currently on the occurrence of mild and subclinical cases. In 
the present study, a ferret model for this virus infection in humans is presented to 
evaluate the pathogenesis of the infection in a mammalian host, as ferrets have been 
shown to mimic the pathogenesis of human infection with influenza viruses most 
closely. Ferrets were inoculated intratracheally with increasing doses (>105 TcID50) of 
H7N9 influenza virus A/Anhui/1/2013 and were monitored for clinical and virological 
parameters up to four days post infection. Virus replication was detected in the upper 
and lower respiratory tracts while animals developed fatal viral pneumonia. This 
study illustrates the high pathogenicity of H7N9 LPAIV for mammals. Furthermore, 
the intratracheal inoculation route in ferrets proofs to offer a solid model for H7N9 
LPAIV induced pneumonia in humans. This model will facilitate the development and 
assessment of clinical intervention strategies for H7N9 LPAIV infection in humans, 
such as preventive vaccination and the use of antivirals.
Keywords: H7N9; Avian influenza A; Intervention strategies
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INTRODUcTION
Avian influenza viruses have crossed the species barrier on several occasions and with 
varying impact on human health. From February 2013 onward several human cases with 
severe respiratory illness were reported from South-East China. The causative agents 
were rapidly characterised and subtyped as H7N9 LPAIVs that most likely were the 
result of multiple reassortment events of at least two avian influenza viruses (38, 542). 
Although the exact source of the human infections with this apparently avian influenza 
virus remains to be elucidated, sequence analysis has indicated that the viruses have 
been circulating for a longer period before they recently surfaced (543, 544). Since the 
first reported human cases, the virus has infected at least 131 humans of which 32 
succumbed to the infection with a predilection for older male individuals (545-548). 
It is the largest outbreak of avian influenza in humans since the introduction of H5N1 
HPAIVs in the human population that thus far has resulted in over 600 reported cases 
with a hospitalised case fatality rate of approximately 60%. The majority of the humans 
infected with H7N9 LPAIV have presented with severe viral pneumonia and became 
critically ill (38). The virus has been classified as being low pathogenic based on the 
genotype (the hemagglutinin does not contain a multi-basic cleavage site) and based 
on the results of intravenous pathogenicity index (IVPI) testing in chickens and data 
from poultry and wild birds. However, the clinical manifestation of H7N9 LPAIV infection 
in humans shows a higher pathogenic phenotype. To further explore this discrepancy 
and elucidate the pathogenesis of the infection in mammals, we established a model 
for H7N9 LPAIV induced pneumonia in ferrets (Mustela Putorius furo). The ferret model 
has been used to elucidate the severity of lower respiratory tract infections with 
various influenza A virus subtypes (506). Preliminary data on intranasal inoculation of 
ferrets with H7N9 AIV indicates that the virus causes only mild disease (unpublished 
data) in these animals. However, we have demonstrated in the past that the choice of 
inoculation route has a major impact on the outcome and severity of influenza virus 
infection in ferrets (549). Since the vast majority of currently recorded human cases of 
H7N9 LPAIV infection have been characterised by severe viral pneumonia, replication 
in the lower respiratory route seems to be the major cause of at least severe human 
disease. Therefore intratrachael administration of the virus to ferrets would be the route 
of choice to study the pathogenesis of severe H7N9 LPAIV infection in this mammalian 
model.
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MATERIALS & METHODS
Virus
Influenza virus A/Anhui/1/2013 (H7N9) isolated from a fatal human case in China was 
kindly provided by the Pandemic Influenza Preparedness (PIP) Framework. The virus 
had been isolated and passaged three times in embryonated chicken eggs and was 
subsequently passaged once in MDCK cells. The infectious virus titer was determined as 
described previously and expressed in tissue culture infectious dose 50% (TCID50) (535).
Animals
Healthy outbred female ferrets (Mustela Putorius furo), of around 12 months of age 
and seronegative for antibodies against aleutian disease virus and seasonal influenza 
viruses were used. About two months prior to the start of the experiment, the animals 
were anesthetised using a cocktail of ketamine (Alfasan, Woerden, The Netherlands) 
and domitor (Orion Pharma, Espoo, Finland), and a temperature logger (DST milli-T 
logger; Star-Oddi, Reykjavik, Iceland) was placed in their peritoneal cavity to record the 
body temperature every 10 min. The animals were maintained in standard housing, 
and provided with commercial food pellets and water ad libitum and were placed in 
BSL-3 isolator units just before inoculation. Ferrets were inoculated intratracheally with 
influenza virus A/Anhui/1/2013 (H7N9) at a dose of 105 (n = 2), 106 (n = 3), 107 (n = 
2) or 108 (n = 2) TCID50 in a volume of 3 ml. An independent animal ethics committee 
approved the experimental protocol before the start of the experiments.
Virus replication in the Upper and Lower Respiratory Tract
Nasal and pharyngeal swabs were taken daily during the infection period. After 
spontaneous death or euthanasia three or four days after inoculation, samples of 
all lobes of the right lung and the accessory lobe, nasal turbinates, tonsils, trachea, 
bronchus, tracheobronchial lymph nodes and lungs were collected and snap frozen 
using a dry ice/ethanol bath and stored at −70 °C until further processing. Tissue 
samples were weighed and subsequently homogenised with the FastPrep-24 (MP 
Biomedicals, Eindhoven, The Netherlands) in Hank’s balanced salt solution containing 
0.5% lactalbumin, 10% glycerol, 200 U/ml penicillin, 200 μg/ml streptomycin, 100 U/ml 
polymyxin B sulfate, 250 μg/ml gentamycin, and 50 U/ml nystatin (ICN Pharmaceuticals, 
Zoetermeer, The Netherlands) and centrifuged briefly before dilution. Quadruplicate 
10-fold serial dilutions of lung and swab supernatants were used to determine the 
presence of viral RNA by Taqman and infectious virus titers in confluent layers of MDCK 
cells as described previously (535).
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Histopathological examination and immunohistochemistry
At autopsy all ferrets (n = 9) and their organs were grossly examined by opening the 
thoracic, abdominal, and cranial cavities. The extent of pulmonary consolidation was 
assessed based on visual estimation of the percentage of affected lung tissue. The 
relative lung weight was calculated as proportion of the body weight (lung weight/
body weight × 100). The left lung was routinely collected for histological examination, 
by means of cutting 4 standard sections per animal (one cross section and one sagittal 
section from the cranial lobe, and one cross section and one sagittal section from the 
caudal lobe). Besides the lungs other organs that were sampled for histology included: 
nasal turbinates, brains including olfactory bulb, tonsil, trachea, tracheobronchial 
lymphnodes, heart, liver, stomach, small and large intestines, pancreas, spleen, 
adrenal, kidney, urinary bladder, ovaries, uterus, skeletal muscle (quadriceps), femoral 
bone marrow. All tissues were immersed in 10% neutral-buffered formalin for fixation, 
routinely processed, paraffin embedded, cut to 4 μm on glass slides and stained with 
H&E for histopathological evaluation. Serial sections of the respiratory tract and brains 
were stained for IAV NP by IHC as described previously (550).
RESULTS
clinical signs
All infected animals developed fever with a mean peak body temperature of 41.2 °C (SD 
= 0.53) within 24–48 h post infection. From 2 dpi onwards the animals developed signs 
of respiratory distress (presented as heavy breathing/dyspnoe) and eventually hunched 
posture. During the course of infection the animals’ food and water intake decreased, 
resulting in mild emaciation and dehydration. On day 3 post infection the two animals 
inoculated with 108 TCID50 and animals inoculated with 107 (n = 1) and 106 (n = 1) TCID50 
succumbed. At day 3 post infection the surviving animals were lethargic and by day 4 
one additional animal (106 TCID50) had succumbed whereas one animal (107 TCID50) was 
moribund. Autopsies were performed on all the deceased animals and the surviving 
animals after euthanasia.
138
Table 4.1.1 Clinical parameters
Nr Virus dose 
(TCID50)
Day of 
death
Weight loss 
(%)
Body temperature
Peak (°C) Time post 
inoculation (h)
1 105 4a 11.2 40.8 33
2 4a 10.9 41.3 31
3 106 4b 12.4 41.7 24
4 3b 10.3 41.0 24
5 4a 14.4 41.3 24
6 107 3b 9.8 40.1 21
7 4c 14.0 41.8 23
8 108 3b 7.4 41.2 24
9 3b 8.8 41.8 16
a Sacrificed end experiment
b Found dead
c Euthananised moribund
Virus replication in the respiratory tract
Pharyngeal swabs from all animals tested positive for virus with the highest virus titers 3 
dpi in those obtained from ferrets inoculated with 107 or 108 TCID50: 104.4 TCID50/ml (SD 
= 100.1–101.3). Virus replication in the ferrets inoculated with 105 or 106 TCID50 reached 
peak values 4 dpi (Figure 4.1.1A). These data confirmed the detection of viral RNA in the 
throat by real tie PCR. In seven out of nine animals viral RNA was detected in the nose 
and this again was confirmed by virus isolation with the peak of virus replication on day 
3 post infection: 103.6 TCID50/ml (SD = 100.4) in the ferrets inoculated with 108 TCID50 
(Figure 4.4.1B). On day 4 rectal swabs were taken from the remaining animals and in 
40% of the animals viral RNA was detected but no infectious virus could be detected.
All animals tested positive for virus replication in nasal turbinates, tonsils, trachea, 
bronchus, bronchial lymph nodes and lungs (Figure 4.1.1c). In the bronchial lymph 
nodes and lungs the mean virus titers were highest (105.7–106.8 and 105.0–105.8 TCID50/g, 
respectively). Only in the trachea the virus titers were higher for ferrets inoculated with 
108 TCID50: 106.6 TCID50/g (SD = 101.3). Apart from the bronchial lymph nodes and lungs, 
virus titers were highest in the samples of the ferrets inoculated with 107 and 108 TCID50, 
illustrating a dose dependency of the H7N9 LPAIV infection.
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Histopathological changes and immunohistochemistry
In all the nine animals the foremost macroscopic post-mortem lesions concerned the 
lungs. The lung lesions ranged from extensive multifocal (Figure 4.1.2A) to almost 
diffuse dark red pulmonary consolidation (Figure 4.1.2D) with oedematous frothy 
fluid oozing from the primary bronchi upon section. The most severely affected lungs 
additionally displayed a pale mottled aspect, likely due to trapped air. The extent of 
pulmonary consolidation was assessed based on visual estimation of the percentage of 
affected lung area from the pleural aspect. All animals were found to have practically 
empty gastrointestinal tracts combined with a subtle pale reticular pattern of the li-
vers, indicative of hepatic lipidosis due to inappetence. Except for the two lowest dosed 
animals, all other spleens were slight to moderately swollen and hyperemic. No further 
macroscopic lesions were encountered (Table 4.1.1).
Figure 4.1.1 Virus replication in the respiratory tract. After inoculation with avian influenza A(H7N9) vi-
rus, pharyngeal (A) and nasal (B) swabs were taken daily to monitor virus replication at these sites over time. 
Upon autopsy, samples were taken from the different locations of the respiratory tract for the detection of 
replication competent virus. To calculate the mean virus titers of the respiratory tract samples (C) the data 
were combined from the two (105, 107, 108 TCID50) or three (106 TCID50) animals per group.
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Figure 4.1.2 Representative (histo)pathological changes of the lungs. From left to right, ven-
tral viewed gross lung lesions (A and D), corresponding microscopic lesions serially stained with 
H&E (B and E) and IHC (C and F) for IAV NP, respectively. The top panel depicts animal#1 which 
was intratracheally inoculated with 105 TCID50 Avian influenza A(H7N9) virus, that was grossly af-
fected for approximately 50%. The photomicrographs depict on the right an inflamed bronchiole 
containing an intraluminal plug of neutrophils and cellular debris, the adjoining inflamed alveoli 
contain neutrophils and macrophages and some proteinaceous material. The bottom panel de-
picts animal#8 inoculated similarly with 108 TCID50, which was grossly affected for approximately 
90%, with photomicrographs likewise depicting a bronchiole on the right and adjoining alveoli, 
but more severely inflamed with necrosis and flooding by intense eosinophilic oedema fluid. The 
corresponding IHC stains show the influenza virus infected epithelial cells by dark reddish-brown 
stained nuclei. (Original microscopic magnifications of 400×).
On histopathological examination, the nasal turbinates of the ferrets inoculated with 
the two highest dosages (n = 4: 107 and 108 TCID50) were moderately inflamed. These 
rhinitides were characterised by moderate numbers of mainly neutrophils infiltrated 
within the nasal respiratory epithelium and underlying Lamina propria. These lesions co-
localised with epithelial cells positive for IAV NP by IHC. The nasal olfactory epithelium 
was typically not or very mildly affected. None of the other ferrets displayed rhinitis, 
and the nasal turbinates were negative for influenza A virus NP by IHC (Table 4.1.2). 
The severity of inflammatory lesions in the tracheas was relatively mild, with lesions 
composed of few neutrophils and lesser lymphocytes within the Lamina propria. These 
occurred in three animals inoculated with the three highest virus doses. These relatively 
mild lesions co-localised with tracheal epithelial cells positive for IAV NP by IHC, 
however several tracheas were positive for NP without showing cellular inflammatory 
reaction. In the bronchi of all animals mild to moderate lesions were present that were 
mainly limited to epithelial necrosis of the submucosal glands, mostly without affecting 
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the luminal lining epithelium. The severity and extent of this necrotising bronchial 
submucosal adenitis was associated and co-localised with the number of glandular cells 
positive for IAV NP by IHC. The most severe cases of bronchial submucosal adenitis were 
found in the ferrets inoculated with the two highest virus concentrations. All animals 
showed inflammatory bronchiolar lesions. These marked to severe bronchiolitides were 
characterised by intraepithelial infiltrates of neutrophils mainly, with in the most severe 
cases plugging of bronchioli by sloughed necrotic epithelial cells admixed with mucus 
containing degenerated neutrophils. In the most severely affected animals nearly all 
bronchioles were completely denuded. Rather the extent, than the severity of affected 
bronchioles was associated with virus concentrations inoculated. The necrotising 
bronchiolitis co-localised with the number of epithelial cells strongly positive for IAV NP 
by IHC. However, many severely affected bronchioles were completely denuded of their 
epithelium with only exfoliated cellular debris positive for NP.
Table 4.1.2 Lung parameters & Immunohistochemistry
Nr Virus dose 
(TCID50)
Relative lung 
weighta
Affected 
lung (%)
Immunohistochemistry of respiratory tract 
epitheliumb
Nasal 
cavity
Tra-
chea
Bronchi Bron-
chioles
Alveoli
Glands Lining
1 105 2.08 50 − + + + + ++
2 1.21 30 − + + + ++ ++
3 106 2.52 50 − + ++ + + ++
4 1.74 90 − ++ + + + ++
5 1.70 50 − − + + ++ ++
6 107 3.94 90 + + + + ++ ++
7 3.87 90 + − + + + ++
8 108 2.99 90 ++ + ++ + + ++
9 2.28 90 ++ − ++ + ++ ++
a Relative lung weight = (lung weight/body weight) × 100%.
b Semiquantative parameter for number of influenza A virus NP positive cells in IHC: − = none, + 
= some, ++ = many.
The pattern of inflammation and/or alveolar damage was comparable between all 
animals, whereas the severity and extent varied in relation to virus doses inoculated. 
All animals suffered from an acute necrotising (broncho)interstitial pneumonia whilst 
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the severity combined with the extent ranged from moderate (Figure 4.1.2B and c) 
to severe (Figure 4.1.2E and F). Affected alveoli were centered more or less around 
inflamed bronchioles in the moderate cases, and were coalescing into extensive affected 
areas in the more severe cases. Within the affected alveoli the septa were only slightly 
thickened with some oedema fluid and infiltrated neutrophils, and lesser macrophages 
and lymphocytes, without noticeable type II pneumocyte hyperplasia. The lining 
pneumocytes were mostly necrotic and exfoliated in the affected alveolar areas. In the 
moderate cases the outlines of the affected alveolar septa were present, whereas in the 
most severe cases the alveolar septa were completely necrotic and their outlines poorly 
discernable or sometimes even collapsed. The alveolar lumina were markedly flooded 
by protein rich oedema fluid containing neutrophils, macrophages, erythrocytes, 
degenerated exfoliated cells or cellular debris, and many fibrin strands. These lesions 
within the alveoli co-localised with lining and exfoliated pneumocytes strongly positive 
for IAV NP by IHC. All of the animals’ brains including olfactory bulbs were negative for 
IAV NP by IHC, and histopathology confirmed the slight hepatic lipidosis in all animals. 
The animals displayed some estrous activity but no bone marrow depression as a result 
of that and no further abnormalities were observed.
DIScUSSION
Despite the low pathogenic classification of H7N9 LPAIV for poultry, it does cause high 
morbidity and mortality in ferrets experimentally infected by the intratracheal route. All 
animals developed clinical signs of severe disease caused by severe viral pneumonia. 
A higher infectious dose correlated with earlier onset of disease and a more severe 
outcome and ultimately death within the time frame of the study.
Virus replication was detected both in the upper and lower respiratory tract of 
all animals in this study, which can be explained by the receptor specificity of the H7 
hemagglutinin. The receptor binding pocket mutation Q226L that is found in this virus is 
associated with a shift in receptor preference of the virus from α2,3 to α2,6-linked sialic 
acids (38). The exact receptor specificity of the avian influenza A(H7N9) virus has to be 
determined but it seems that the virus can bind to both α2,3 to α2,6-linked sialic acids. 
The latter are predominant in the upper respiratory tract, thus correlating with the 
rhinitis found in the animals inoculated with 107 and 108 TCID50 (n = 4). Most likely, due 
to the high viral load in these animals, the virus was able to spread more easily from the 
pharynx to the nasal cavity and was able to replicate there, resulting in inflammation of 
the nasal turbinates.
Besides replication in the upper respiratory tract the virus was also detected in 
the lower respiratory tract, most likely associated with the α2,3-linked sialic acids 
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that are found primarily deep In the lung, thus explaining the severe viral pneumonia 
observed here. Conclusively the H7N9 LPAIV can infect cells both in the upper and lower 
respiratory tract, similar to pH1N1 influenza virus (506). H5N1 HPAIVs on the contrary 
primarily replicate in the lower respiratory tract and are able to spread to the central 
nervous system (CNS) and other solid organs. In the current study the H7N9 LPAIV did 
not spread outside the context of the respiratory tract. However the fact that within 
the respiratory tract the virus could spread to the upper region has implications for 
the risk assessment of the virus. The receptor distribution and binding of human and 
avian influenza viruses in the respiratory tract of the ferret is similar to that of humans. 
And since the virus is capable of spreading upwards through the respiratory tract this 
increases the risk of virus excretion, which could lead to transmission (43, 50, 551).
In the N9 neuraminidase of the H7N9 LPAIV a deletion was detected. The lack of these 
five specific amino acids has been associated with enhanced virus replication and alteration 
of the virus tropism (38). Apart from receptor specificity, the avian influenza A(H7N9) 
virus has additional pathogenicity markers. The L89V and especially the E627K mutation, 
associated with enhanced polymerase activity and enhanced virulence in the context of 
avian influenza A(H5N1) virus, are present in the polymerase protein PB2 of the influenza 
virus A/Anhui/1/2013 (38). The presence of these markers may account for the severe viral 
pneumonia that the virus causes in humans and in the ferret model described here.
This study illustrates the potential of the ‘low pathogenic’ H7N9 LPAIV to infect the 
lower respiratory tract of mammals and cause severe viral pneumonia in a manner that 
is comparable to H5N1 HPAIV. This raises questions about whether the pathogenicity 
classification of avian influenza viruses should not also take into account the pathogenicity 
phenotype of the virus in mammals. Taken together the data presented in this paper 
illustrate that intratracheal H7N9 LPAIV infection of ferrets, like other infections with 
different influenza virus subtypes, can be used to investigate the pathogenesis of this 
infection in mammals, as well as urgently needed intervention strategies like vaccination 
and the use of antivirals.
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ABSTRAcT
Only two classes of antiviral drugs, neuraminidase inhibitors and adamantanes, 
are approved for prophylaxis and therapy against influenza virus infections. A 
major concern is that influenza virus becomes resistant to these antiviral drugs and 
spreads in the human population. The 2009 pandemic A/H1N1 influenza virus is 
naturally resistant to adamantanes. Recently a novel neuraminidase I223R mutation 
was identified in an A/H1N1 virus showing cross-resistance to the neuraminidase 
inhibitors oseltamivir, zanamivir and peramivir. However, the ability of this virus 
to cause disease and spread in the human population is unknown. Therefore, this 
clinical isolate (NL/2631-R223) was compared with a well-characterised reference 
virus (NL/602). In vitro experiments showed that NL/2631-I223R replicated as well 
as NL/602 in mDCK cells. In a ferret pathogenesis model, body weight loss was 
similar in animals inoculated with NL/2631-R223 or NL/602. In addition, pulmonary 
lesions were similar at day 4 post inoculation. However, at day 7 post inoculation, 
NL/2631-R223 caused milder pulmonary lesions and degree of alveolitis than NL/602. 
This indicated that the mutant virus was less pathogenic. Both NL/ 2631-R223 and a 
recombinant virus with a single I223R change (recNL/602-I223R), transmitted among 
ferrets by aerosols, despite observed attenuation of recNL/602-I223R in vitro. In 
conclusion, the I223R mutated virus isolate has comparable replicative ability and 
transmissibility, but lower pathogenicity than the reference virus based on these in 
vivo studies. This implies that the 2009 pandemic influenza A/H1N1 virus subtype 
with an isoleucine to arginine change at position 223 in the neuraminidase has the 
potential to spread in the human population. It is important to be vigilant for this 
mutation in influenza surveillance and to continue efforts to increase the arsenal of 
antiviral drugs to combat influenza.
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AUTHOR SUMMARy
Recently, a 2009 pandemic A/H1N1 influenza virus was isolated from an immune 
compromised patient, with antiviral resistance to the neuraminidase inhibitor class 
of drugs. This virus had an amino acid change in the viral neuraminidase enzyme; an 
isoleucine at position 223 was substituted for an arginine (I223R). Patients infected with 
a pandemic virus that is resistant to all neuraminidase inhibitors, would leave physicians 
without antiviral treatment options, since these viruses are naturally resistant to the 
other class of antivirals, the adamantanes. To date, it is unknown if this I223R mutant 
virus is affected in its ability to cause severe disease and to transmit to other humans. 
Therefore, we have addressed this question by comparing the I223R mutant virus with 
a wild type reference virus in a ferret pathogenicity and transmission model. We found 
that the I223R mutant virus was not severely affected in its pathogenicity, although fewer 
lung lesions and alveolitis scores were found for the I223R mutant virus. In addition, we 
demonstrated that this virus transmitted efficiently to naive ferrets. Consequently, we 
conclude that this I223R mutant virus has the potential to cause disease and may spread 
among humans. Therefore, influenza surveillance for this resistance pattern is advised.
INTRODUcTION
Two classes of antiviral drugs are approved for prophylaxis and therapy of influenza virus 
infected patients (552). Antiviral therapy against the new (swine-origin) 2009 pandemic 
A/H1N1 influenza virus relies on the neuraminidase inhibitor (NAI) class of antiviral 
drugs only, because this subtype is resistant to the adamantane class (amantadine 
and rimantadine) of drugs (553). In 2009 pandemic influenza viruses, this resistance 
pattern is mainly caused by an asparagine at amino acid position 31 (N31) in the viral 
M2 membrane protein. Fortunately, NAI treatment, both as prophylaxis and therapy, 
has been shown to be effective against most 2009 pandemic H1N1 virus infections so 
far (554, 555).
To date, the incidence of NAI resistant 2009 pandemic A/ H1N1 viruses is very 
low. Nevertheless, 565 cases of patients infected with an (H275Y, N1 numbering) 
oseltamivir (OS) resistant virus have been reported to the World Health Organisation 
(556). In most of these cases, OS resistance was found in patients receiving prolonged 
antiviral therapy, in particular patients under immunosuppressive therapy (74). The 
H275Y mutant viruses are cross-resistant to peramivir (PER), but remain susceptible 
to zanamivir (ZA). Successful clearance of a H275Y mutant virus from a patient treated 
with ZA was reported previously (557).
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Within the first years after approval of the NAIs in 1999, antiviral resistance in 
influenza viruses at a population level was rare (0.4%). In clinical trials, the incidence 
of resistant viruses was higher, varying from 0.4 to 1% in adults and up to 18% in 
young children (558, 559). However, a dramatic increase, up to 100%, of de novo 
circulating oseltamivir-resistant A/H1N1 viruses characterised the epidemic seasons 
of 2007-2008 and 2008-2009 (560, 561). This resistance phenotype was also caused 
by a H275Y mutation. Remarkably, earlier studies on H275Y mutant H1N1 viruses had 
characterised these viruses as attenuated and not of clinical importance (562-564). The 
resistant viruses from 2007-2008 did not seem to be affected in replication capacity, 
transmissibility and their ability to cause severe disease in humans (565-567). A 
compensatory role was assigned to the NA amino acid changes V234M, R222Q and 
D344N (568, 569). These substitutions may have restored the initial loss of NA activity 
due to the NAI resistance mutation and facilitated the appearance of the H275Y change 
in the epidemic influenza A/H1N1 viruses that circulated before the 2009 outbreak of 
the new pandemic virus. Recently, several research groups have studied the fitness 
of H275Y mutant pandemic influenza A/H1N1 viruses using both in vitro and in vivo 
experiments (570-574). Overall, these data indicate that pandemic viruses with the NA 
H275Y substitution were comparable to their oseltamivir susceptible counterparts in 
pathogenicity and transmissibility in animal models.
Recently, the identification of a novel multidrug resistant 2009 pandemic A/
H1N1 virus was reported, isolated from an immune compromised child with reduced 
susceptibility to all NAIs (75). An isoleucine to arginine substitution at position 223 in NA 
(I223R, N1 numbering) was detected in the patient after antiviral therapy with OS had 
failed due to the emergence of the H275Y mutation and therapy was switched to ZA. 
This I223R containing isolate, in which the H275Y mutation had disappeared, showed 
reduced susceptibility to OS (45-fold), PER (7-fold) and ZA (10-fold). In vitro analysis 
showed that reversion of the arginine to isoleucine fully restored NAI susceptibility. 
In another case, an I223R/H275Y double mutant virus was isolated that showed high 
resistance to the NAIs (575). In combination with the natural resistance of pandemic 
A/H1N1 viruses to adamantanes, an infection of such a multi-drug resistant virus 
leaves physicians without antiviral treatment options. The emergence of this pandemic 
2009 A/ H1N1 virus prompted us to investigate the properties of this clinical isolate by 
evaluating its in vitro replication kinetics and its pathogenicity and transmissibility in the 
ferret model. We here show that this 2009 pandemic influenza A/H1N1 clinical isolate, 
harboring a neuraminidase I223R substitution retains its virulence and transmissibility, 
but is less pathogenic than a virus prototype without this mutation. In addition, 
recombinant NL/602/09 with a single I223R amino acid substitution transmitted as well 
as its recombinant parental virus, suggesting that no additional mutations are needed 
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to compensate for the presence of this I223R mutation in the 2009 pandemic A/H1N1 
virus backbone.
MATERIALS & METHODS
Ethics statement
Animals were housed and experiments were conducted in strict compliance with 
European guidelines (EU directive on animal testing 86/609/EEC) and Dutch legislation 
(Experiments on Animals Act, 1997). All animal experiments were approved by the 
independent animal experimentation ethical review committee ‘stichting DEC consult’ 
(Erasmus MC permit number EUR1821) and were performed under animal BSL3 
conditions. Animal welfare was observed on a daily basis, and all animal handling 
was performed under light anesthesia using ketamine to minimize animal suffering. 
Influenza virus seronegative 6-month-old female ferrets (Mustella putorius furo), 
weighing 800–1000 g., were obtained from a commercial breeder.
Cells and viruses
MDCK cells were obtained from American Type Culture Collection. MDCK-SIAT1 cells, 
constitutively expressing the human 2,6-sialyltransferase (SIAT1), were kindly provided 
by Professor H.D. Klenk, Philipps University Marburg (576). Both cell lines were 
cultured in Eagle’s minimal essential medium (EMEM) (Lonza, Breda, The Netherlands) 
supplemented with 10% FCS, 100 IU/ml penicillin, 100 mg/ml streptomycin, 2mM 
glutamine, 1.5mg/ml sodium bicarbonate (Cambrex), 10 mM HEPES (Lonza) and non-
essential amino acids (MP Biomedicals Europe, Illkirch, France). In addition, MDCK-SIAT1 
cells were cultured in the presence of 1 mg of antibiotic G418/ml. Influenza virus A/
Netherlands/2631_1202/2010 (NL/2631-R223) was isolated from a 5-year-old immune 
compromised child (75). Clonal virus of this isolate was obtained by passaging this 
virus 3 times under limiting diluting conditions in MDCK cells. Full genome sequencing 
after the last MDCK passage confirmed the absence of mutations. Influenza A/ 
Netherlands/602/2009 (NL/602) was characterised previously (508). All eight segments 
of this virus were cloned in a bidirectional reverse genetics plasmid pHW2000 and used 
to generate recombinant viruses by reverse genetics as described previously (538). 
The I223R mutation was introduced in the NA gene of NL/602 using QuickChange 
multi site-directed mutagenesis kit (Stratagene, Leusden, The Netherlands) resulting in 
recombinant viruses recNL/602-I223R. The presence of this mutation was confirmed by 
sequencing.
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Virus titrations
Virus titers in nasal and throat swabs, homogenised tissue samples, or samples for 
replication curves were determined by endpoint titration in MDCK cells. MDCK cells were 
inoculated with 10-fold serial dilutions of each sample, washed 1 hour after inoculation 
with PBS, and grown in 200 ml of infection medium, consisting of EMEM supplemented 
with 100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM glutamine, 1.5 mg/ml sodium 
bicarbonate, 10 mM HEPES, nonessential amino acids, and 20 mg/ml trypsin (Lonza). 
Three days after inoculation, the supernatants of inoculated cell cultures were tested 
for agglutinating activity using turkey erythrocytes as an indicator of virus replication 
in the cells. Infectious-virus titers were calculated from 4 replicates by the method of 
Spearman-Kaerber (536).
Replication curves
Multi-cycle replication curves were generated by inoculating MDCK or MDCK-SIAT1 cells 
at a multiplicity of infection (MOI) of 0.001 TCID50 per cell. One hour after inoculation, 
at time point 0, the cells were washed once with PBS, and fresh infection medium was 
added. The supernatants were sampled at 6, 12, 24, and 48 h post infection and the 
virus titers in these supernatants were determined by means of endpoint titration in 
MDCK cells.
Animal experiments
The pathogenesis experiment was done as described previously with some minor 
changes in the protocol (506). On day 0, the ferrets were inoculated intratracheally with 
106 TCID50 of NL/602 or NL/2631-R223. Throat and nose swabs were collected daily 
to determine virus excretion from the upper respiratory tract. Animals were weighted 
daily as indicator of disease and observed for clinical signs. Three animals from each 
group were euthanised and autopsied at days 4 and 7, and trachea and lung samples 
were collected to study virus distribution.
Autopsy was done by opening the thoracic and abdominal cavities and examining 
all major organs. Whilst inflated, all lung lobes (left cranial lobe, left caudal lobe, right 
cranial-, middle- and caudal lobes and accessory lobe) were evaluated. The extent of 
consolidation was estimated by visual assessment. The lungs were weighed after the 
trachea was removed at its bifurcation. The relative lung weights were calculated as 
proportion of the body weight on day of death (lung weight/body weight x 100). Tissues 
(~0.4 g) from the right lung were collected for determination of lung virus titers at 4 
and 7 dpi. The left lung and trachea were collected for histological examination, and 
immersed for fixation in 10% neutral-buffered formalin. All samples were sectioned 
in a standardised way (a total of 4 lung sections per animal; 1 cross section and 1 
longitudinal section from both the left cranial and left caudal lobe, and 1 central 
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tracheal cross section) and routinely processed, paraffin embedded and cut to 4 μm 
H&E stained slides. The samples were histologically examined for the character and 
severity of influenza virus–associated lesions without knowledge of the identity of the 
animals. The extent of alveolitis/ alveolar damage (0=0%, 1≤25%, 2=25-50%, 3=≥50% of 
a section) and the severity of alveolitis, bronchi(oli)tis (including bronchial submucosal 
glands) and tracheitis (0 = none, 1 = few, 2 = moderate number, 3 = many inflammatory 
cells) were scored per slide. The overall histology score for alveolitis is the sum of the 
scores for the extent and severity of the alveolitis (score 0 to 6).
The transmission experiments were done as described previously (508). The 
transmission cages were specifically designed to allow transmission experiments to be 
conducted in negatively pressurised isolator cages (1.6m x 1m x 1m). On day 0, 4 or 2 
female ferrets were housed individually in transmission cages (30cm x 30cm x 55cm, W 
x H x L) and inoculated intranasally with 106 TCID50 of NL/602, NL/2631-R223, recNL/602 
or recNL/602-I223R respectively, divided over both nostrils (2 x 250 μl). On day 1, 4 or 
2 naive female ferrets were individually placed in a transmission cage adjacent to an 
inoculated ferret, separated by two stainless steel grids. Negative pressure within the 
isolator cage is used to direct a modest (~0.1 m/sec) flow of HEPA filtered air from the 
inoculated to the naive ferret. This experimental setup was designed to prevent direct 
contact or fomite transmission, but to allow airflow, thereby permitting transmission via 
aerosol or respiratory droplets. Nasal and throat swabs were collected on 0, 1, 2, 3, 5 
and 7 dpi from the inoculated ferrets and on 0, 1, 2, 3, 5 and 7 days post exposure (dpe) 
from the naive ferrets. Inoculated ferrets were euthanised at 7 dpi and naive ferrets 
that were found positive by reverse transcription polymerase chain reaction at 7 dpe 
were also euthanized (577). Naive animals that remained negative for virus excretion 
throughout the experiment were euthanised at 15 dpe, and a blood sample was 
collected for serology. Virus titers in the collected swabs were determined by means of 
endpoint titration in MDCK cells.
Statistical analysis
For the pathogenesis experiment, statistical analysis was done for each time point, until 
4 dpi (when there were still 6 animals present in each group). The Mann-Whitney-U test 
was used to compare weight losses and virus shedding of the six animals in both groups. 
P-values less than 0.05 were considered significant.
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RESULTS
Sequence comparison of virus isolates
A pandemic 2009 influenza virus with reduced susceptibility to all NAIs that was isolated 
from a Dutch immune compromised child was studied here. Full genome sequencing of 
this clinical isolate A/NL/2631_1202/2010 (NL/2631-R223, GenBank accession numbers 
JF906180-906187) harboring an I223R mutation in the neuraminidase was performed. 
Since no drug susceptible virus had been isolated from this patient before start of 
antiviral therapy, the well-characterised NAI-susceptible virus isolate A/ NL/602/2009 
(NL/602, GenBank accession numbers CY046940- 046945 and CY039527-039528) was 
used as a reference virus in all experiments. This reference virus is a representative of 
pandemic H1N1 viruses that circulated in 2009, with only amino acid changes I108V 
and V407I (N1 numbering) in NA being unusual among the deposited sequences in the 
Influenza Research Database (508, 578). Pair-wise comparison revealed, in addition to 
the amino acid change I223R, 5 amino acid differences in NA (V106I, V108I, N248D, 
N386D and I407V) and 1 in HA (S203T). The NA and HA amino acid positions are given 
according to the N1 and H1 numbering. Eleven additional amino acid differences 
were found in gene segments PB2 (3), PB1 (2), PA (2), NP (3) and NS (1) compared 
to NL/602. None of these mutations have previously been identified as a virulence 
marker or as a compensatory mutation involved in restoration of NA activity loss, as 
a result of the presence of resistance mutations. By studying these isolates, a direct 
comparison could be made between a NAI susceptible and a novel I223R resistant virus, 
but such comparison does not address the impact of the single I223R mutation directly. 
Therefore, we introduced the I223R mutation in the recNL/602 backbone, resulting in 
the drug-resistant recNL602-I223R, to evaluate the impact of the single I223R mutation 
on virus replication, virus shedding from the upper respiratory tract and transmissibility 
in the ferret model.
I223R Harbouring isolate is not attenuated in vitro
Virus replication was studied in vitro by multi-cycle replication kinetics of the viruses 
of interest. For this purpose, MDCK or MDCK-SIAT1 cell cultures were inoculated at a 
multiplicity of infection of 0.001 TCID50 per cell and at fixed time points supernatants 
were harvested to determine viral titers (Figure 4.2.1). Overall, the initial virus 
replication rates and end point titers were similar for the clinical isolate NL/2631-R223 
and recNL/602. A recombinant derivative of NL/602 with the I223R mutation in 
NA (recNL/602-I223R) replicated to lower peak titers in both cell lines compared to 
recNL/602 and NL/2631-R223. In addition, initial virus replication of recNL/602-I223R 
was delayed by 6 to 12 hours in MDCK-SIAT1 cells.
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Figure 4.2.1 Replication kinetics in MDCK or MDCK-SIAT1 cells. MDCK (panel A) or MDCK-SIAT1 (panel 
B) cells were inoculated with 0.001 TCID50 virus per cell of recNL/602 (black circles), isolate NL/2631-R223 
(black triangles) and recNL/602-I223R (open circles). Supernatants were harvested after 6, 12, 24, and 48 
hours post infections and were titrated in MDCK cells. Geometric mean titers and standard deviations were 
calculated from two independent experiments. The lower limit of detection is indicated by the dotted line.
No marked differences in virus replication in the respiratory tract of ferrets
The pathogenicity of clinical isolate NL/2631-R223 was compared with NL/602 in the 
ferret model that was previously established to study the ability of influenza viruses to 
cause pneumonia (506). Two groups of 6 ferrets were inoculated intratracheally with 
106 TCID50 of virus. The animals were weighed daily as an indicator of disease. Over the 
7-day period, no significant differences were observed in weight loss between the two 
groups inoculated with either virus. At 4 dpi, when there were still 6 animals present in 
each group, the mean percentage of weight loss was 8.2±2.4% and 7.6±6.7% for NL/602 
and NL/2631-R223-inoculated animals respectively, not statistically significant (Figure 
4.2.2A and B). In addition, no marked differences were observed for other clinical 
parameters, such as lethargy, sneezing and interest in food.
Nose and throat swabs were collected daily from the inoculated animals and virus 
titers were determined by end-point titration in MDCK cells. Infectious virus shedding 
from the throat was detected from 1 dpi onwards in all ferrets, with similar patterns of 
virus shedding from the throat of the animals in the two groups (Figure 4.2.2c). At 4 dpi, 
5 and 4 animals were shedding virus from the nose in the NL/602 and NL/2631-R223 
inoculated group respectively (Figure 4.2.2D). Sequence analysis confirmed the 
presence of the I223R mutation in the respiratory samples collected at 7 dpi from the 
NL/2631-R223 inoculated ferrets.
At 4 and 7 dpi, three animals of each group were euthanised and lungs were 
collected for virological and pathological examination. At 4 dpi, no marked differences 
were found between the virus titers for both groups of ferrets (Figure 4.2.3A). At 7 dpi, 
no virus was detected in the lungs of ferrets inoculated with either virus.
154
Figure 4.2.2 Ferret relative weight loss and virus shedding from the ferret upper respiratory tract. 
Ferrets were inoculated intratracheally with 1×106 TCID50 of NL/602 or NL/2631-R223. Body weights for 
NL/602 (Panel A) and NL/2631-R223 (Panel B) inoculated animals are depicted as percentage of body 
weight relative to the time of inoculation. Data are shown for individual animals until the animals were 
euthanised at 4 or 7 dpi. Virus detection in throat (panel C) and nose swabs (panel D) is indicated for NL/602 
(white bars), and NL/2631-R223 (black bars). Geometric mean titers from 6 (day 1 to 4) or 3 animals (day 5 to 
7) are displayed and the error bars indicate the standard deviations. The number of influenza virus positive 
animals per day is depicted in each bar. The lower limit of detection is indicated by the dotted line.
moderate pathogenicity of I223R harbouring isolate
Gross pathology of the lungs of all animals revealed pulmonary lesions at 4 and 7 dpi 
(Figure 4.2.3B). At 4 dpi, no marked difference was observed between the groups, 
but at 7 dpi, the percentage of affected lung tissue was higher in the group inoculated 
with NL/602. The mean relative lung weight increased from day 4 to day 7, with no 
difference between the animals inoculated with NL/602 or NL/2631-R223 (Figure 
4.2.3c). Histopathological examination of the lungs showed multifocal to coalescing 
alveolar damage in both groups characterised by the presence of macrophages and 
neutrophils within the lumina and thickened alveolar walls. At 4 dpi, the severity of 
alveolitis did not differ between the two groups (Figure 4.2.4D). However, in agreement 
with the increased percentage of affected lung tissue at 7 dpi (Figure 4.2.3B), also higher 
alveolitis scores were determined for the NL/602 inoculated animals at 7 dpi. (Figure 
4.2.4D). The bronchial and bronchiolar epithelium from ferrets in both groups showed 
slight multifocal necrosis with moderate intra-epithelial infiltrates of neutrophils and 
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multifocal peribronchiolar infiltration of macrophages, lymphocytes, neutrophils and 
plasma cells. The lumina contained moderate amounts of mucus mixed with cellular 
debris and few neutrophils. The tracheal epithelium in both groups showed mild 
neutrophilic infiltrates. The severity of both bronchiolitis and tracheitis increased from 
4 to 7 dpi in ferrets infected with both viruses, but the differences in scores between 
groups were minimal (Figure 4.2.4E and F).
Figure 4.2.3 Semi-quantitative lung scores and histological examination of the infected ferret re-
spiratory tract. Lung virus titers (panel A), percentage of affected lung tissue (panel B) and relative lung 
weights (panel C) were determined for lungs of ferrets inoculated with NL/2631-R223 (triangles) or NL/602 
(circles) that were euthanised at 4 or 7 dpi. Semi-quantitative assessment of the extent and severity of 
the tracheitis (panel D), bronchiolitis (panel E) and alveolitis (panel F) are shown. Individual values are dis-
played. In panel A, the lower limit of detection is indicated by a dotted line.
I223R Harbouring isolate is transmissible via aerosols or respiratory droplets
Individually housed ferrets were inoculated with virus isolate NL/2631-R223 or NL/602 
and naive animals were placed in a cage adjacent to each inoculated ferret at 1 dpi to 
allow aerosol or respiratory droplet transmission. All inoculated ferrets started to shed 
virus at 1 dpi with virus titers up to 106 TCID50/ml in throat and nose swabs (Figure 
4.2.4A and c).
The naive ferrets became infected, because of aerosol or respiratory droplet 
transmission, 1, 2 or 3 dpe. In the naive animals, virus was detected in 4 (NL/602), 
or 3 (NL/2631-R223) out of 4 animals (Figure 4.2.4B and D). The exposed animal in 
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the NL/2631-R223 transmission experiment, from which no virus could be isolated, did 
not seroconvert in the course of the experiment. At 5 dpe, the presence of the I223R 
mutation was confirmed by sequencing the NA gene of virus isolated from the throat 
swabs of the positive animals.
Figure 4.2.4 Transmission of NL/602 and NL/2631-R223 by aerosol or respiratory droplets in ferrets. 
Virus titers in throat (black bars) and nose swabs (grey bars) are displayed for inoculated (panel A and C) 
and exposed ferrets (panel B and D). The geometric mean titers of positive samples are displayed and the 
error bars indicate the standard deviations. The number of positive exposed animals per day is depicted. 
The lower limit of detection is indicated by the dotted line.
I223R mutant transmits as well as parenteral reference virus
When the multi-cycle replication kinetics were studied of viruses with or without the 
I223R substitution in MDCK cells, it was noticed that the recombinant virus in which 
the I223R mutation was introduced, recNL/602-I223R, replicated to lower titers than 
its parental virus recNL/602 (Figure 4.2.1). To address if this difference in in vitro 
replication capacity could be extrapolated to reduced replication in vivo, the ability 
of recNL/602-I223R to transmit in the ferret model was studied. It was expected that 
reduced replication in ferrets would impede the virus to transmit to na ̈ıve animals, 
thereby suggesting that compensatory mutations are needed to balance the fitness 
loss induced by the I223R mutation. In contrast to the results obtained in MDCK cells, 
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recNL/602-I223R replicated and transmitted as well as recNL/ 602 when evaluated 
in the ferret transmission model. Inoculated animals started to shed virus from the 
upper respiratory tract from 1 dpi onwards and transmission was detected in 4 out of 4 
(recNL/602), or 2 out of 2 (recNL/602-I223R) naive animals from day 2 onwards (Figure 
4.2.5). The presence of the I223R mutation in the recNL/602 backbone was confirmed 
in throat samples obtained from these animals at 5 dpe.
Figure 4.2.5 Transmission of recNL/602 and recNL/602-I223R by aerosol or respiratory droplets in 
ferrets. Virus titers in throat (black bars) and nose swabs (grey bars) are displayed for inoculated (panel A 
and C) and exposed ferrets (panel B and D). The geometric mean titers of positive samples are displayed 
and the error bars indicate the standard deviations. The number of positive exposed animals per day is 
depicted. The lower limit of detection is indicated by the dotted line.
DIScUSSION
Here, a 2009 pandemic influenza A/H1N1 virus isolate, harboring an I223R multidrug 
resistance mutation, was characterised by studying its replication capacity in MDCK 
cells and its pathogenicity and transmissibility in the ferret model. This I223R mutant 
virus is not attenuated for replication in the ferret respiratory tract and transmitted 
as well as NAI susceptible reference virus NL/602. Furthermore, it was demonstrated 
here that compensatory mutations for the I223R mutation are not required, since 
158
recombinant NL/602 with a single I223R change transmitted as efficiently as its parental 
virus in ferrets.
To date, 2009 pandemic viruses with an amino acid substitution at position 223 
have only sporadically been isolated from patients. A I223V/H275Y double mutant was 
detected in two closely residing patients who were treated with OS (579). Besides the 
I223R single mutant virus studied here, an I223R/H275Y double mutant was detected in 
an immune suppressed patient treated with OS and ZA (575). The combination of these 
mutations resulted in an increased NAI resistance pattern, as compared to the resistance 
induced by the single mutations. This emphasizes that neuraminidase position 223 is an 
important marker for antiviral resistance and may be a key residue in the emergence 
of influenza viruses with resistance to all NAIs, especially in combination with other 
resistance-associated mutations. So far, the incidence of 2009 pandemic viruses with a 
223 change is very low. Notably, 2009 pandemic viruses were reported with a serine to 
asparagine change at position 247 (580). In combination with the H275Y change, these 
viruses demonstrated resistance patterns similar to the I223R/H275Y mutant.
In a pathogenesis experiment, no statistical significant differences were found when 
weight loss was compared of ferrets inoculated with clinical isolates NL/2631-R223 or 
NL/602 (Figure 4.2.2A and B). In agreement with high viral loads found in respiratory 
specimens collected from the patient who was infected with NL/2631-R223, high viral 
loads were detected in the throat of animals inoculated with the same virus. Overall, 
identical patterns of virus shedding were observed during the course of the experiment 
in the throats of animals inoculated with either virus. However, virus shedding from 
the nose could not be detected in all inoculated animals. Although virus shedding from 
the nose of NL/ 2631-R223-inoculated animals seem somewhat delayed in comparison 
with NL/602-inoculated animals, these differences were not significant due to the large 
variations within groups and small group size after 4 dpi (Figure 4.2.2c and D).
Both macroscopic and microscopic evaluation of the lungs of the ferrets at 4 dpi 
revealed no major differences in the percentage of affected lung tissue and relative 
lung weights between NL/2631-R223 and NL/602 (Figure 4.2.3B and c). However, at 
7 dpi the lungs of ferrets inoculated with NL/2631-R223 had not further deteriorated, 
whereas the percentage of affected lung tissue had increased to 50% in the NL/602 
inoculated animals (Figure 4.2.3B). This higher score for affected lung tissue in the 
NL/602-inoculated animals was also reflected by the higher score for the degree of 
alveolitis at 7 dpi compared to 4 dpi, whereas the alveolitis scores in the NL/2631-R223-
inoculated animals at 4 and 7 dpi were similar. To recapitulate, both viruses replicated 
to the same extent in the respiratory tract of ferrets, but the NL/2631-R223 seemed less 
pathogenic compared to the NL/602 virus.
Despite the moderate pathogenicity of NL/2631-R223, this virus transmitted to 3 
out of 4 exposed animals via aerosols or respiratory droplets (Figure 4.2.4B). This result 
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is comparable to the data obtained from NL/602, in which 4 out of 4 exposed animals 
got infected (Figure 4.2.4D) (508). This ferret transmission model was designed as a 
qualitative model for transmission and with the limited number of animals, quantitative 
information on virus transmission could not be obtained. Therefore, from these 
experiments it was concluded that both NL/2631-R223 and NL/602 transmitted via 
aerosols or respiratory droplets, although a delay in virus shedding by approximately 1 
day was observed in the naive animals exposed to NL/2631-R223 (Figure 4.2.4B and D).
When the impact of the single I223R mutation in the recombinant NL/602 backbone 
on in vitro replication kinetics was evaluated, a reduction in virus replication in MDCK 
cells was noticed (Figure 4.2.1). In addition, the initial virus replication of NL/ 602-I223R 
on MDCK-SIAT1 cells started 6 to 12 hours later as compared to its parental virus (Figure 
4.2.1B).
These results suggested that compensatory mutations may be required to 
accommodate the isoleucine to arginine substitution at position 223 in NA and 
emphasizes the importance of the viral backbone used to study resistance-associated 
mutations. However, when recNL/602-I223R was tested in the ferret transmission 
model, the virus transmitted to 2 out of 2 exposed animals (Figure 4.2.5B). When these 
results were compared with transmission data of recNL/602 (Figure 4.2.5D) (497), no 
differences were found in the onset of virus shedding and virus titers that were detected 
in the collected throat and nose swabs from the exposed animals. This observation 
demonstrates that the transmissibility of recNL/602-I223R is not significantly diminished 
or can at least not be studied using a ferret transmission model.
Although these results suggest that introduction of the I223R does not attenuate 
the virus, it cannot be ruled out that other mutations than 223R in NL/2631-R223 may 
have compensated for the initial loss of fitness due to the I223R mutation. Sequence 
comparison revealed 5 amino acid differences between NL/2631-R223 and NL/602. The 
only amino acid substitution that is located near the active site of the neuraminidase 
is at position 248, where NL/602 harbors an aspartic acid and NL/2631-R223 an 
asparagine. Interestingly, neighboring residue 247 has been linked to NAI resistance 
in combination with the H275Y mutation (580). Further research is needed to study 
the I223R resistance mechanism in competitive mixture experiments and potential 
co-mutations on a molecular level (581). To note, small differences between NL/602 
and recNL/602 could be observed in replication capacity and transmission patterns in 
ferrets (Figure 4.2.4 and 4.2.5). Previously, differences were also found in pathogenesis 
experiments, where the wild type NL/ 602 was detected more abundantly in the lower 
airways of ferrets than recNL/602 (582). These observed differences may be a result 
of the use of a virus isolate rather than a virus generated by reverse genetics and to a 
different batch of ferrets used in the different studies. A direct comparison between 
virus isolates and recombinant viruses can, therefore, not be made.
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The different inoculation routes and inoculation doses used for influenza research 
is subject of debate. The intratracheal route of inoculation is often used to study 
pathogenicity or to study the efficacy of vaccines to prevent lower respiratory tract 
infection. In contrast, the intranasal route of inoculation is used when transmissibility is 
studied. Unfortunately, these inoculation routes and inoculation doses do not accurately 
mimic the natural way of infection and may mask the fitness differences between the 
drug- resistant and drug sensitive viruses.
However, the recipient animals in the transmission experiment are infected via 
the natural route; aerosols or respiratory droplets shed by the donor ferret. The virus 
secretion pattern, which is the combination of the amount of virus secreted and the 
duration of virus shedding from the upper respiratory tract, of animals exposed to 
recNL/602 and rec/NL602-I223R are similar. This suggests that no marked differences in 
viral fitness are introduced by the single I223R mutation.
The present study demonstrates for the first time that a 2009 pandemic A/H1N1 
clinical isolate containing a resistance mutation at position 223 in the NA is not 
attenuated in its replication capacity and transmissibility in a ferret model. Although the 
pathogenicity of this virus seems less severe compared to a relevant reference virus in 
the ferret model, it is unclear whether this moderate pathogenicity has implications for 
infections with multidrug-resistant viruses in humans. Continuous surveillance is needed 
to monitor the emergence of (novel) influenza viruses with reduced susceptibility to the 
NAIs or mutations that may facilitate the emergence of circulating multi drug resistant 
influenza viruses.
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ABSTRAcT
We investigated the development of pulmonary lesions in ferrets by means of 
computed tomography (CT) following infection with the 2009 pandemic A/H1N1 
influenza virus and compared the scans with gross pathology, histopathology and 
IHC. Ground-glass opacities (GGOs) observed by CT-scanning in all infected lungs 
corresponded to areas of alveolar oedema at autopsy. These areas were most 
pronounced on day 3 and gradually decreased from days 4 to 7 post-infection. This 
pilot study shows that the non-invasive imaging procedure allows quantification and 
characterisation of influenza-induced pulmonary lesions in living animals under BSL3 
conditions and can thus be used in pre-clinical pharmaceutical efficacy studies.
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INTRODUcTION
The ongoing emergence of novel pathogens (583, 584) calls for the concomitant 
development of animal models that address their pathogenesis and assess the potential 
of preventive and therapeutic intervention strategies. For example, the emergence 
of the 2009 pandemic A/H1N1 influenza virus (pH1N1) highlighted the need for the 
rapid development of animal models that closely mimic the human infection (395, 
506, 584). Studies on the pathogenesis of the disease and the timely assessment of 
the efficacy and safety of the rapidly developed vaccine candidates, antiviral drugs, 
antibody preparations and immune modulators, largely depend on newly developed 
animal models (395, 506, 507, 585, 586). However, in these models the assessment 
of virus-induced lesions is largely based on findings from an arbitrarily chosen time 
point after experimental infection. When evaluating infections with a peracute onset, 
significant early findings may be overlooked unless large numbers of animals are 
sacrificed at consecutive time points. Especially when dealing with outbred animals, 
like ferrets, evaluation and integration of consecutive findings from different animals 
may be speculative. In addition, working with highly pathogenic viruses like the pH1N1 
virus when it emerged or with the highly pathogenic avian H5N1 influenza viruses, is 
limited to BSL3 laboratory settings. The complexity of working under these stringent 
restrictions also limits the possibilities to work with large numbers of animals sacrificed 
at consecutive time points. To overcome these limitations we performed repeated CT-
scans of ferrets under BSL-3 conditions before and during infection with the pandemic 
H1N1 influenza (2009) virus. The pattern of influenza virus attachment and replication 
in the ferret respiratory tract is largely similar to that in humans (50, 508), making 
influenza virus infection of the ferret the model of choice to study human influenza.
METHODOLGy & RESULTS
The ferrets (Mustela putorius furo) used were approximately 8 months of age, females, 
all seronegative for antibodies against circulating influenza viruses and for antibodies 
against Aleutian disease virus. They were routinely housed and handled under BSL-
3+ conditions in negatively pressurised and HEPA-filtered biocontainment isolator 
units, approved by an independent institutional laboratory animal ethics and welfare 
committee. Animal handling and scans were performed under general injection 
anaesthesia (ketamine 12.5 mg kg−1 and medetomidine-HCl 7.5 µg body weight kg−1). 
Eight ferrets were inoculated intratracheally with 106 TCID50 of pandemic influenza virus 
A/Netherlands/602/2009 (pH1N1) as described previously (506, 585). The virus was 
propagated in MDCK cell cultures and the infectious dose was determined as described 
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previously (508), and titres calculated according to the method of Spearman–Karber 
(536). Virus shedding was monitored daily by collecting nasal and oropharyngeal swabs 
that were analysed for determination of viral loads by standard procedures (506), 
and expressed as log TCID50. All animals had detectable levels of virus in their upper 
respiratory tract (Figure 5.1).
Figure 5.1 Graph depicting the mean virus loads of oropharyngeal swabs (OS) and nose swabs (NS) 
collected daily from all ferrets after intratracheal infection with 106 TCID50 pH1N1 A/Netherlands/602/2009 
until autopsy on days 4 and 7. Note the oropharyngeal virus peak of 104.06 TCID50 at 3 dpi, which indicates 
highest virus shedding from the respiratory tract at 3 dpi. The error bars designate the SD.
The CT-scanner used is a dual-source ultrafast system (Somatom Definition Flash; 
Siemens Healthcare) with a temporal resolution of 0.075 s and table speed of 458 mm/s, 
the spatial resolution is 0.33 mm. This CT-scanner requires short acquisition times (≈ 0.22 
s) for data recording of an entire ferret thorax. Such a high temporal resolution enables 
accurate scanning of living ferrets without the necessity of breath holding, respiratory 
gating or electrocardiogram (ECG) triggering to generate sharp images. During in vivo 
scanning the anaesthetised ferrets were positioned in dorsal recumbency in a perspex 
biosafety container of approximately 8.3 litre capacity that was purposely designed and 
built (Tecnilab-BMI) (Figure 5.2). The oxygen concentration in the container did not 
drop below 14 % as measured by oxymetry. All animals had been scanned 3 days prior 
to virus inoculation to define the uninfected baseline status of the respiratory system. 
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Four ferrets (#3, #4, #5 and #7) were scanned twice (on days −3 and days 3 or 4), two 
ferrets (#2 and #8) were scanned three times (on days −3, 4 and 7) and two ferrets (#1 
and #6) were scanned four times (on days −3, 3, 4 and 7; Table 5.1).
Figure 5.2 An anaesthetised and influenza virus (pandemic H1N1)-infected ferret is monitored for 
pneumonic (lung) changes by means of CT-scanning, while placed in a perspex biosafety container. 
The scanner requires very short acquisition times to scan the entire thorax (≈ 0.22 s) that disqualify the need 
for electrocardiogram (ECG)-triggered or respiratory-gated recordings.
Table 5.1 Scanning and autopsy schedule of the ferrets (n=8) before and after influenza virus inocu-
lation
Ferret
Day
-3 -2 -1 0* 1 2 3 4 5 6 7
1 CT CT CT CT+MR, autopsy
2 CT CT CT+MR, autopsy
3 CT CT+MR, autopsy
4 CT CT, autopsy
5 CT CT+MR, autopsy
6 CT CT CT CT+MR, autopsy
7 CT CT+MR, autopsy
8 CT CT CT+MR, autopsy
* Intratracheal inoculation with 106 TCID50 pH1N1 A/Netherlands/602/2009.
CT, CT-scanning; MR, magnetic resonance imaging (MRI)-scanning.
In humans, CT-images have been described previously (587-591) for pulmonary 
alterations caused by pandemic (2009) H1N1 influenza virus infection and the 
histopathological nature of these alterations in humans has been evaluated only to 
limited extent (587, 591). We found consistent bilateral ground-glass opacities in the 
lungs on all time points of scanning. They were most severe on 3 and 4 dpi and showed 
a reduction on day 7 (Figure 5.3). The post-infectious reductions in aerated pulmonary 
volumes were measured from 3D CT-reconstructs using lower and upper thresholds 
168
in substance densities of −870 to −430 Hounsfield units (HU). The mean decrease in 
aerated lung volumes (ALVs) was most pronounced on 3 (26 cm3) and 4 (24 cm3) dpi 
compared with day 3 before infection. On day 7 the mean ALV returned to, and equalled, 
baseline values (31 cm3) from day 3 before infection (Table 5.2).
Figure 5.3 Two rows of four consecutive 3D lung CT-images of ferrets #1 and #6. They were recorded in 
vivo under BSL-3+ conditions, compared with their appearance at autopsy on the far right. At day 3 before 
infection, the lungs showed the clear aerated baseline condition, at 3 dpi with the 2009 pandemic H1N1 
influenza virus marked almost diffuse ground-glass opacities are present that show a gradual reduction 
towards 7 dpi. The two photographs taken at autopsy on 7 dpi depict the ventral aspect of the lungs, within 
the centre the hearts still attached to the pulmonary hilus. Both lungs show multifocal reddish consoli-
dated areas of acute inflammation that essentially match with the opacities on the CT-images taken just 
before autopsy; non-affected aerated lung tissue is light pink in colour.
In addition to CT-scanning, we also performed magnetic resonance imaging (MRI) 
scanning of the ferrets. The MRI scanner used is a High Definition 3 Tesla clinical scanner 
(General Electric Healthcare) that requires data acquisition times to such a degree that 
motionless imaging, without the application of respiratory gating and/or ECG triggering, 
is only possible post-mortem. Because of this limitation and the lower spatial resolution 
compared with CT-scanning, the MRI scan proved impractical for use in this animal 
model and set-up. Accordingly, the MRI results are not presented. However, MRI 
scanning under BSL-3 conditions could be of value to image other organ systems in vivo 
that are not hampered by heartbeat or respiratory motion.
Within 1 h after euthanasia by exsanguination from cardiac puncture (time needed 
for post-mortem MRI scanning) the ferrets were submitted for a full autopsy to compare 
(histo)pathological data with those that were CT-scanned. Animal #4 succumbed 
spontaneously on 3 dpi and had to be autopsied without prior MRI scanning. The entire 
intact lungs were instilled with, and submerged in 10 % neutral buffered formalin for 
fixation and disinfection. The lungs were transversely cut just caudal (approximately 
10 mm) of the tracheal bifurcation and matched to the same transversal CT-image. 
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Additionally from each animal, four similarly cut left lung sections were made not guided 
by gross lesions. The lung sections were routinely processed, paraffin embedded and 4 
µm thin micro-sections were stained with H&E for histopathology. All entire slides were 
evaluated and scored for the extent of alveolar damage/alveolitis and for the extent 
of alveolar oedema (0, 0 %; 1, <25 %; 2, 25–50 %; and 3, >50 %). For the detection of 
influenza A virus-infected cells, additionally serial cut micro-sections were stained for 
influenza A virus nucleoprotein (NP) as described previously (50).
The pulmonary ground-glass opacities corresponded on histology to extensive 
alveolar oedema admixed with variable proportions of alveolar macrophages, 
neutrophils, erythrocytes, fibrin and cellular debris. IIHC staining for viral NP showed 
infected pneumocytes lining the inflamed and flooded alveoli (Figure 5.4). Additionally, 
there was a moderate necrotising bronchiolitis and similar but milder bronchitis. Despite 
the return to baseline values in mean ALV on 7 dpi there were still histological lesions 
mainly in the form of mixed inflammatory cellular infiltrates and type II pneumocyte 
hyperplasia. Although not statistically significant, the median histopathology scores for 
the extent of alveolar damage/alveolitis did show a slight decrease from 3 (range 2–3) 
on day 4 to 2 (range 2–3) on 7 dpi Additionally, matching the improvement in lung 
aeration is a significant (P = 0.031) decrease in the median extent of alveolar oedema 
from 3 (range 2–3) on day 4 to 1.5 (range 1–3) on 7 dpi (Table 5.2).
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5Figure 5.4 Matching CT-scan to histopathology of influenza pH1N1-infected ferret #7 on 4 dpi. (a) 
Axial CT-image recorded 10 mm caudally of the tracheal bifurcation depicts bilateral pulmonary ground-
glass opacities with peribronchovascular predominance. The rounded white heart shadow (H) is visible in 
the centre enclosed by the darker lung lobes. During scanning the ferret is placed in dorsal recumbency 
on a V-shaped tray. The red frame indicates the approximate location of micrograph (c). (b) Subgross his-
tological image matching the location of the axial CT-scan. The red frame indicates the exact location of 
micrograph (c) (H&E-staining; bar, 10 mm). (c) Low magnification micrograph depicting the histological 
lesions of the right lung corresponding to consolidated ground-glass opacities, they are composed of ex-
tensively flooded alveoli and thickened alveolar septa adjacent to a bronchus containing a plug of mucus 
with few neutrophils and desquamated epithelial cell remnants (arrow). On top right and middle to bot-
tom left, white non-staining still aerated alveoli are present. The blue frame indicates the exact location of 
micrograph (d) (H&E-staining; bar, 1 mm). (d) Micrograph depicting the damaged alveoli characterised by 
infiltrated thickened septa and luminal flooding with protein-rich oedema (pink areas) admixed with vari-
able proportions of macrophages, neutrophils, fibrin, erythrocytes and cellular debris (H&E-staining; bar, 
200 µm). Insert on top right: high magnification of serially cut IHC-slide from the same area of micrograph 
(d), depicting thickened alveolar septa infiltrated by neutrophils (arrows) and adjacent dark-brown staining 
nuclei of influenza virus-infected pneumocytes lining the flooded alveolus (immunoperoxidase-staining 
for NP of influenza A virus counterstained with haematoxylin; bar, 40 µm).
cONcLUSIONS
We show that monitoring of pulmonary lesions of pH1N1 influenza virus-infected ferrets 
under BSL3 conditions by consecutive in vivo imaging with CT-scanning provides valuable 
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data on disease progression and severity that closely coincide with post-mortem data 
obtained at the same time points from euthanised animals. The ground-glass opacities 
observed by CT-scanning in all infected lungs largely corresponded to areas of alveolar 
oedema upon autopsy that were most pronounced on days 3 and 4 and decreased 
towards day 7. As this method involves repeated CT-scans of the same animal instead 
of sacrificing multiple animals at different time points, it results in a refinement of data 
collection and a significant reduction in numbers of laboratory animals. In other words 
the development of respiratory tract lesions of each individual animal can be compared 
with the situation before infection and followed over time. In this way outbred animals 
serve as their own baseline control generating more detailed and relevant data per 
animal. In addition, the assessment of the severity and extent of the lesions over time 
will lead to more adequate and objective criteria for the time point of euthanasia. The 
ability of this CT-scanning methodology will not only allow for a more comprehensive 
study of the pathogenesis of life-threatening infectious diseases, but also of the 
assessment of the efficacy and safety of vaccination and antiviral strategies against 
them. In the present pilot study, CT-scan opacities correspond to alveolar oedema, this 
parameter is among others used as read out in influenza vaccine efficacy studies (390, 
550). Obviously this methodology is not limited to studying the respiratory tract, but 
could also be exploited for new emerging pathogens with their specific target organs in 
other animal models.
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ABSTRAcT
Preclinical vaccine efficacy studies are generally limited to certain read out parameters 
such as assessment of virus titers in swabs and organs, clinical signs, serum antibody 
titers, and pathological changes. These parameters are not always routinely applied and 
not always scheduled in a logical standardised way. We used CT-imaging as additional 
and novel read out parameter in a vaccine efficacy study by quantifying alterations in 
ALVs in ferrets challenged with the 2009 pandemic A/H1N1 influenza virus.
Vaccination protected from marked variations in ALVS compared to naive controls. 
The vaccinated group showed a daily gradual mean reduction with a maximum of 7.8%, 
whereas the controls showed a maximum of 14.3% reduction. The pulmonary opacities 
evident on CT-images were most pronounced in the sham-vaccinated controls, and 
corresponded to significantly increased relative lung weights at autopsy. This study 
shows that consecutive in vivo CT-imaging allows for a day-to-day read out of vaccine 
efficacy by quantification of altered ALVs.
Highlights: We evaluated efficacy of an influenza vaccine by means of CT-scan in the 
ferret. Longitudinal in vivo scanning allows quantification of changes in ALV. Immunisation 
protects from a significant initial severe increase in ALV seen in unprotected controls. 
Immunisation protects from major increase of relative lung weight.
Keywords: Influenza; Preclinical vaccine efficacy; Ferret; In vivo imaging; CT-scan; 
Pathology
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INTRODUcTION
The field of influenza virus research is in particular an area of new emerging viruses 
that requires rapid development of animal models needed for pathogenicity studies 
and assessment of adequate vaccine candidates and antiviral therapies. This was 
recently illustrated by the emergence of the 2009 pandemic H1N1 IAV (395, 506). 
Ferrets are being implemented extensively in human influenza virus research. However, 
influenza virus research is conducted in multiple separate laboratories all with their 
unique approach how to evaluate vaccine candidates within the ferret challenge model. 
Substantial differences can be found in all stages and aspects of challenge protocols, 
study set-ups and read-out parameters. A spectrum of recently published (395, 592-
600) infection/challenge protocols showing this diversity is listed in comparison in 
Table 6.1.1. In addition, obviously, different influenza strains are used as challenge virus 
instigated by the antigenic nature of the vaccine, or alternatively to evaluate efficacy 
to a heterologous influenza virus challenge. The routes of infection being intranasal, 
intratracheal or through virus transmission from experimentally infected and shedding 
ferrets show considerable differences in implementation and outcomes (549). Different 
viral challenge doses are used, whether or not established in preceding dose-finding 
studies. However, the challenge doses are pivotal in the interpretation of a challenge 
outcome. Since, a too robust challenge may prove, false negatively, a poor efficacy of a 
human vaccine candidate in the ferret model, and vice versa. Furthermore, the duration 
of the challenge read out period varies, as well as the types of samples collected and 
frequency of sampling. Often the design of a challenge protocol is based on predefined 
end points and read outs, or may rely on results from historical experiments.
Because of these variations in the assessment of vaccine efficacy, the comparison 
of the outcomes of vaccine studies may be hampered; therefore a certain way of 
standardisation could prove useful by providing clarity.
Recently, we reported that CT-scanning allows quantification and characterisation 
of influenza-induced pulmonary lesions in living animals (599). We showed that the 
pulmonary ground-glass opacities observed by CT-scanning corresponded mainly to 
areas of alveolar oedema, which is a major histological lesion in early influenza-induced 
pneumonia and can be used to quantify the ALV. The present study was performed 
to evaluate the immunogenicity and protective efficacy of an adjuvanted inactivated 
influenza pH1N1 vaccine for intranasal use in the ferret model. A group of six ferrets 
was intranasally immunised with this vaccine candidate and compared to a second 
group of six ferrets that received intranasally administered PBS as sham vaccine. These 
administrations were performed on study days 0, 21 and 42. All animals were subsequently 
intratracheally challenged with 106 TCID50 H1N1 inlfuena A/TheNetherlands/602/2009 
virus on study day 70. The animals were monitored for vaccine induced serological and 
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immunological responses and for infection related clinical and virological responses. 
As novel read out parameter CT-scanning was performed 6 days prior, and daily after, 
virus inoculation on all twelve ferrets to monitor influenza induced lung damage by 
quantifying alterations in the ALVs. The animals were sacrificed at 4 dpi to evaluate 
pathological and virological parameters.
Table 6.1.1 A spectrum of recently published infection/challenge protocols showing divers study 
set-ups
MATERIALS & METHODS
Animals
The ferrets (Mustela putorius furo) were females of 8 months of age, seronegative for 
antibodies against current circulating influenza viruses, and Aleutian disease virus. 
Housing and handling was performed under BSL3 conditions in negatively pressurised 
and HEPA-filtered biocontainment isolator units, approved by an independent 
institutional laboratory animal ethics and welfare committee. General injection 
anaesthesia (ketamine 8 mg/kg and medetomidine-HCl 7.5 μg/kg body weight) was 
applied during handling and scanning.
Immunisation
The animals (n = 6) were immunised three times with a 3-week interval with an 
adjuvanted inactivated vaccine. 200 μl of vaccine was intranasally administered and 
divided equally over both nostrils. The controls (n = 6) were similarly sham-immunised 
with 200 μl PBS intranasally.
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Challenge virus
All animals were challenged, 4 weeks after the last immunisation, intratracheally with 
106 TCID50 of the 2009 pandemic influenza virus A/Netherlands/602/2009 (pH1N1) in 3 
ml PBS, as described previously (506, 585, 600). The virus was routinely propagated in 
MDCK cell cultures and infectious dose determined as described previously (508), and 
titres calculated according to the method of Spearman-Karber (536).
CT-scanning
All animals were scanned on −6, 1, 2, 3, and 4 dpi (see also table 6.1.1). A dual-source 
ultra fast CT-system (Somatom Definition Flash, Siemens Healthcare) was used (temporal 
resolution: 0.075 s, spatial resolution is 0.33 mm, table speed of 458 mm/s: ferret 
thorax acquisition time ≈ 0.22 s; enables accurate scanning of living ferrets without 
the necessity of breath-holding, respiratory gating, or ECG-triggering as previously 
described (599). Briefly, during scanning the ferrets were in dorsal recumbency in a 
purpose-built (Tecnilab-BMI) perspex biosafety container of 8.3 L capacity. The post-
infectious reductions in ALVs were measured from 3-dimensional CT-reconstructs using 
lower and upper thresholds in substance densities of −870 to −430 HU.
Pathology
Following euthanasia by exsanguination all animals were submitted for autopsy. The 
lung lobes were inspected and lesions were assessed while the lung was inflated. The 
trachea was cut at the level of the bifurcation and the lungs were weighed. The relative 
lung weight was calculated as proportion of the body weight on day of death (lung 
weight/body weight × 100).
RESULTS & DIScUSSION
All animals from both groups were scanned 6 days prior to virus inoculation to define 
the uninfected base-line status of their respiratory system. Consecutive in vivo imaging 
with CT-scanning showed that ferrets intranasally immunised with the vaccine candidate 
were largely protected against the appearance of pulmonary ground-glass opacities, as 
is shown by means of transversal CT-images in Figure 6.1.1. The ALVs measured from 
3D CT-reconstructs likewise showed that the immunised ferrets were protected against 
major alterations in ALV (group mean ALV ranging from 0.95 to −7.8%) and did not 
show a temporal increase in ALV on 1 dpi, which was observed in the sham-vaccinated 
group (group mean ALV ranging from 17.3 to −14.3%) (Figure 6.1.2) This sudden and 
short increase of 17.3% (Mann–Whitney test, two-tailed, P = 0.035) in the unprotected 
sham-vaccinated animals may result from a virally induced acute respiratory depression 
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Figure 6.1.1 Consecutive transversal lung CT-images after infection with H1N1 A/Nether-
lands/602/2009. 
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with compensatory hyperinflation. A compensatory increase in respiratory tidal volume 
by means of hyperinflation is a pathophysiological phenomenon known to occur in 
respiratory viral infections (601, 602). However, CT-scanning could not discern possible 
emphysema due to ruptured alveoli as cause of ALV increase. The relative change of 
ALVs on days 2, 3 and especially 4 after infection did not show significant differences 
between the two groups. One possible explanation is that over-expansion of the thorax 
and lungs allows for increased alveolar flooding in excess of base line aeration resulting 
in approximately unaltered ALVs between the two groups. Another explanation is that 
the inflamed and oedematous areas were aerated less than normal, but because the 
unaffected areas of lung were aerated more than normal (hyperinflation or emphysema), 
the overall ALV values remained approximately unaltered.
Figure 6.1.2 Changes in aerated lung volume (ALV) after infection with H1N1 A/Netherlands/602/2009. 
The ALV was calculated using lower and upper thresholds in substance densities of −870 HU for the analysis 
of 3D-reconstructions of the lung. The percentage change of ALV was calculated using the individual base 
line ALVs of day 6 against the ALVs of the different days after infection. These data are expressed as mean ± 
SEM. Animals were intratracheally challenged with 106 TCID50 H1N1 A/The Netherlands/602/2009 on day 0.
← Figure 6.1.1 Consecutive transversal lung CT-images after infection with H1N1 A/Nether-
lands/602/2009. Two columns of consecutive (top to bottom) transversal lung CT-images of one represen-
tative immunised ferret (left) and one representative sham-immunised ferret recorded in vivo compared 
with their gross aspect at autopsy (bottom). At day 6 before infection, the lungs showed the clear aerated 
baseline condition, from 1 dpi with the new pandemic H1N1 influenza virus onwards marked almost diffuse 
ground-glass opacities appear that show a gradual increase with a plateau on 3–4 dpi. The two photo-
graphs taken at autopsy on 4 dpi depict the ventral aspect of the lungs, with the hearts removed. The lungs 
of the sham-immunised animal (bottom right) show diffuse reddish consolidation indicative of acute in-
flammation that essentially match the opacities on the CT-images taken just before autopsy; non-affected 
aerated lung tissue from the immunised animal is light pink in colour (bottom left).
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Figure 6.1.3 Relative lung weights. Mean relative lung weights (RLWs, related to body weight; ± SEM) at 
autopsy (4 dpi) for the immunised group versus the sham-vaccinated control group after infection with 
H1N1 A/Netherlands/602/2009.
Nevertheless, these ALV profiles provide more detailed knowledge about the influenza-
induced respiratory disease development than confined data obtained from a single 
predefined read out. Moreover, survival and recovery from challenge infection can be 
included in this set-up and with the opportunity to still measure the development of 
serum antibody responses upon challenge infection.
Upon autopsy, the relative lung weights (RLWs) of the intranasally immunised ferrets 
was about 2-fold lower (Mann–Whitney, two-tailed, P < 0.0047) as compared to those of 
the sham-vaccinated animals (Figure 6.1.3), which is in agreement with the absence of 
pulmonary ground-glass opacities. Usually, more severely affected and inflamed lungs 
with increased amounts of fluid are heavier compared to normal or less affected lungs. 
This translates within the ferret model in influenza research to RLWs ≤ 1.0 associated 
with non- to minimally affected lungs and RLWs > 1.0 associated with severe pulmonary 
inflammation with oedema (390, 600, 603).
In conclusion, the implementation of consecutive CT-imaging enables repeated 
in vivo measurements of lung aeration as parameter to evaluate vaccine efficacy 
in preclinical protocols. Consecutive day-to-day imaging overcomes the limitations 
entailed by autopsy at a predefined time point after infection, and the lung capacity can 
be repeatedly quantified in real-time.
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ABSTRAcT
The advent of the H1N1 influenza pandemic (pH1N1) in 2009 triggered the rapid 
production of pandemic influenza vaccines, since seasonal influenza vaccines were 
expected and demonstrated not to provide significant cross-protection against the 
newly emerged pandemic virus. To increase vaccine production capacity and further 
evaluate the effectiveness of different candidate pandemic influenza vaccines, 
the World Health Organisation stimulated the evaluation of different vaccination 
concepts including the use of live attenuated influenza vaccines (LAIVs). Therefore, we 
have immunised ferrets intranasally with a single dose of pH1N1-LAIV from different 
manufacturers. They all induced adequate serum HI antibody titers in the ferrets and 
protected them against intratracheal wild-type pH1N1 virus challenge: pH1N1 virus 
replication in the upper respiratory tract and lungs was reduced and no disease signs 
or severe broncho-interstitial pneumonia were observed in any of the vaccinated 
ferrets. These data together with the relatively efficient production process emphasize 
the potential of the LAIV concept for pandemic preparedness.
Highlights: A single intranasal dose of pH1N1-LAIV confers profound protection against 
2009 pandemic H1N1 influenza in intratracheally-inoculated ferrets. pH1N1-LAIVs from 
different manufacturers tested are equally immunogenic and efficacious. This LAIV 
concept has high potential for pandemic preparedness.
Keywords: Influenza virus H1N1; Ferret; Live attenuated influenza vaccine; Vaccine 
efficacy
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INTRODUcTION
The sudden emergence of the H1N1 influenza pandemic (pH1N1) in 2009 triggered 
the rapid production of pandemic influenza vaccines, since seasonal influenza 
vaccines were expected and demonstrated not to provide significant cross-protection 
against the newly emerged pandemic virus (26, 604, 605). Assessment of antibody 
cross-reactivity in sera from humans and/or ferrets vaccinated with recent seasonal 
influenza inactivated vaccines and live attenuated vaccines, did not show significant 
antibody titers to pH1N1 virus, however an adjuvanted inactivated candidate seasonal 
H1N1 vaccine administered 4 weeks before immunisation with adjuvanted inactivated 
candidate pH1N1 vaccine did provide immunological priming in ferrets against pH1N1 
virus (550, 585, 605-607). Also the age distribution of severe and fatal human cases of 
pH1N1 infection indicated priming in humans by exposure to seasonal H1N1 influenza 
viruses having occurred more than 15 years earlier (605, 608). In view of an expected 
pH1N1 vaccine shortage at the global level and the anticipated need for broadly 
protective vaccines, the Strategic Advisory Group of Experts called for the evaluation, 
production and use of both adjuvanted inactivated virus vaccines and live attenuated 
influenza vaccines (LAIVs) (609). LAIV concepts described to date include those using 
cold-adapted (ca) viruses (610-613) and those using viruses with modified NS1, NS2 or 
M2 genes (586, 614-616). Ca-LAIV is the most developed concept with a LAIV having 
been used extensively in Russia from 1954 onward in more than 120,000 children and 
more than 500,000 adults (612, 617-619) and FluMist® being on the market as of 2003 
(619). The former are based upon reassortment of seasonal influenza viruses with 
attenuated ca-strains selected for their ability to replicate at low temperatures, whereas 
the latter is based on the use of ca viruses that are adjusted to circulating seasonal 
influenza viruses by reverse genetics techniques.
The use of LAIVs has major advantages, including less complex downstream 
processing, lower unit cost and higher production yield as compared to inactivated 
vaccines (620). Furthermore, LAIVs are administered via the intranasal route, which is 
less invasive than commonly used parenteral routes. LAIVs have been shown to rapidly 
induce protective systemic antibody and nasal (mucosal) IgA antibody responses as well 
as cell-mediated immune responses (621). LAIVs developed by Maassab and colleagues 
(622) have been shown to be safe, genetically stable and do not convert back to the wild-
type virus even in immunocompromised mice (623). Although registered LAIVs have 
been shown to be safe and effective in certain risk-groups like influenza vaccine-naïve 
children aged 6 to <36 months (624), they are so far not used in immunocompromised 
individuals.
LAIVs that should protect humans against influenza viruses of animals with 
pandemic potential, like the H5N1 HPAIVs, are currently being evaluated. Rudenko and 
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colleagues have tested a live vaccine based on a low pathogenic avian influenza virus of 
the H5N2 subtype in human trials and showed that the vaccine was well tolerated and 
that mucosal- as well as protective levels of systemic antibody responses were induced 
(625). Kobinger and colleagues tested commercially available seasonal 2008–2009 
LAIV FluMist® in ferrets against challenge with pH1N1. As indicated above, antibody 
titers to pH1N1 virus were not detectable, but a specific T cell response was detected 
(607). Remarkably, upon the heterologous challenge with pH1N1, the vaccinated ferrets 
exhibited increase in mortality and greater lung damage associated with early up-
regulation of interleukin-10. Recently, others have described the production of a LAIV 
based on a pH1N1 A/California/07/2009 6:2-reassortant with ca-A/AnnArbor/06/1960 
and the initial hurdles of poor replication in embryonated eggs through large-plaque 
selection, sequence modification (626). One or two doses of this LAIV preparation 
induced a robust antibody response, which correlated with protection from homologous 
challenging mice and ferrets (627).
Recently, we have shown that the swine-origin wild-type influenza A/
California/07/2009 (wt-Cal-pH1N1) virus is a good parental prototype for LAIV-pH1N1 
preparation showing neither temperature resistance nor inhibitor resistance and is 
unable to grow at 25°C (628). A vaccine candidate A/17/California/38/2009, which 
is an influenza A live attenuated vaccine reassortant (LAIV-pH1N1) based on the 
temperature sensitive (ts) and ca A/Leningrad/134/17/57 (H2N2) master donor strain 
(Len/17), was developed as a candidate human vaccine (628). The present study was 
conducted to evaluate the efficacy of this monovalent (A/17/California/38/2009) LAIV-
pH1N1 in a naïve ferret model against challenge with the homologous influenza virus 
A/Netherlands/602/2009 (pH1N1). The intratracheal route of infection as challenge 
has been used because recently we showed that this method allows for a reproducible 
severe influenza pneumonia (506). Three candidate LAIV-pH1N1 preparations tested in 
this study were produced at three different sites in Russia, Thailand and India.
MATERIALS & METHODS
Vaccines
The monovalent live-attenuated influenza vaccine candidate based on the new H1N1 
A/California/2009/38 was prepared through reassortment with temperature sensitive 
and cold-adapted A/Leningrad/134/17/57 (H2N2) master donor strain as described 
previously. In this study three different batches of the A/17/California/38/2009 LAIV 
were used: freeze dried LAIV Russia (series 2.09.11.09; designated as LAIV-Russia-
pH1N1), LAIV Thailand (ready to use formulation; designated as LAIV-Thailand-pH1N1), 
and freeze dried LAIV India (batch number: 143E9003; designated as LAIV-India-pH1N1). 
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The LAIV-Russia-pH1N1, LAIV-Thailand-pH1N1 and LAIV-India-pH1N1 preparations 
had a titer of 108.3, 107.7 and 107.6 egg infectious dose 50% (EID50), respectively. The 
attenuated phenotype of the LAIV-pH1N1 had been demonstrated by completion of the 
standard protocol for testing in ferrets (629).
Animals
Groups of six healthy outbred male ferrets (Mustela putorius furo), approximately 9 
months of age and seronegative for antibodies against circulating influenza viruses B, 
A/H1N1, A/H3N2 and A/pH1N1 by hemagglutination inhibition (HI) assay were used. 
Two weeks prior to the start of the experiment, the animals were anesthetised using a 
cocktail of ketamine (Alfasan, Woerden, The Netherlands) and domitor (Orion Pharma, 
Espoo, Finland), and a temperature logger (DST micro-T ultra small temperature 
logger; Star-Oddi, Reykjavik, Iceland) was placed in their peritoneal cavity. This device 
recorded body temperature of the animals every 10 min. During the whole experiment 
the animals were maintained in negatively pressurised glovebox isolator cages, and 
provided with commercial food pellets and water ad libitum. The experimental protocol 
was approved before the start of the experiments by an independent institutional 
animal ethics committee according to Dutch law.
Intranasal immunization
Three groups of six ferrets each were immunised intranasally with a single human dose 
of 0.5 ml of LAIV-pH1N1 candidate vaccine divided over two nostrils on study day 0 
under anesthesia with ketamin and domitor. To a fourth group of six ferrets, 0.5 ml of 
PBS was administered intranasally. Blood samples for serum preparation were collected 
on study days 0, 20 and 28.
HI and VN antibody assays
Serum samples collected prior to immunisation, on day 20 after immunisation and on 
the day of challenge infection (day 28 after immunisation) were stored at −20 °C. They 
were tested for the presence of anti-HA antibodies reactive against A/California/4/2009 
(rg-Cal-pH1N1) and A/Netherlands/602/2009 (rg-NL-pH1N1) using a HI assay with 1% 
turkey erythrocytes. For this purpose reverse genetics viruses were used with the HA 
and NA of the 2009 wild-type pH1N1 viruses and the remaining 6 gene segments of 
influenza virus A/Puerto Rico/8/34. In addition, the sera were tested for the presence of 
virus neutralizing antibodies against the same viruses using a virus-neutralisation assay 
(VN-assay) as previously described (585).
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Challenge with wild-type influenza virus A/Netherlands/602/2009
Four weeks after immunisation (day 28), all ferrets were challenged with wild-type 
influenza virus A/Netherlands/602/2009 (wt-pH1N1) as previously described (550, 
585). Briefly, 106 TCID50 of wt-pH1N1 was diluted in 3 ml of PBS and administered via 
the intratracheal route under anesthesia with a cocktail of ketamine and domitor.
Virus replication in the upper and lower respiratory tract
On days 0, 1, 2, 3 and 4 after challenge, nose and throat swabs were taken from the 
animals under anesthesia. Four days after challenge, the ferrets were euthanised by 
exsanguination under anesthesia after which full-body gross-pathology was performed 
and lungs were collected. Samples of all lobes of the right lung and the accessory lobe 
were collected and stored at −70 °C until further processing. Lung samples were weighed 
and subsequently homogenised with a FastPrep-24 (MP Biomedicals, Eindhoven, The 
Netherlands) in Hank’s balanced salt solution containing 0.5% lactalbumin, 10% glycerol, 
200 U/ml penicillin, 200 μg/ml streptomycin, 100 U/ml polymyxin B sulfate, 250 μg/ml 
gentamycin, and 50 U/ml nystatin (ICN Pharmaceuticals, Zoetermeer, The Netherlands) 
and centrifuged briefly before dilution.
After collection, nose and throat swabs were stored at −70 °C in the same medium 
as used for the processing of the lung samples. Quadruplicate 10-fold serial dilutions of 
lung and swab supernatants were used to determine the virus titers in confluent layers 
of MDCK cells as described previously (585).
Gross-pathology and Histopathology
The animals were autopsied according to a standard protocol. The trachea was clamped 
off so that the lungs would not deflate upon opening the pleural cavity. This allowed 
an accurate visual quantification of the areas of affected lung parenchyma. Samples 
for histological examination of the left lung and trachea were taken and stored in 10% 
neutral-buffered formalin (lungs after inflation with formalin), embedded in paraffin, 
sectioned at 4 μm, and stained with HE for examination by light microscopy. Samples 
were taken in a standardised way, not guided by changes observed in the gross 
pathology. Semi-quantitative assessment of influenza virus-associated inflammation 
in the lung was performed as described previously (Table 6.2.1) (506). Slides were 
examined without knowledge of the identity of the animals.
Statistical analysis
Differences between the vaccinated groups (group 1, 2 and 3) were analyzed statistically 
using the Kruskal-Wallis test and differences between vaccinated groups (group 1, 2 
and 3) compared with the sham-immunised (PBS-treated) control group (group 4) were 
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analyzed statistically using the Mann–Whitney U test. Differences were considered 
significant at P < 0.05.
RESULTS
Development of HI and VN antibody responses
Twenty days after a single immunisation all ferrets immunised with the respective LAIV-
pH1N1 preparations (LAIV-Russia-pH1N1, LAIV-Thailand-pH1N1 and LAIV-India-pH1N1) 
developed HI antibodies against both the A/California/4/2009 (rg-Cal-pH1N1) and A/
Netherlands/602/2009 (rg-NL-pH1N1) strain (titers 320–960, 640–1280 and 280–1120 
against rg-Cal-pH1N1, respectively, and titers 320–1120, 560–1280 and 240–1280 
against rg-NL-pH1N1, respectively). Eight days later, these HI titers were largely the 
same or showed a slight decrease (Figure 6.2.1A).
Figure 6.2.1 Development of pH1N1-specific serum HI (A) and VN (B) antibody responses (rg-Cal-
pH1N1, solid bars and rg-NL-pH1N1, open bars) in ferrets at 28 days after a single immunisation with differ-
ent batches of A/17/California/38/2009 pH1N1 LAIV: LAIV-Russia-pH1N1, red; LAIV-Thailand-pH1N1, green; 
LAIV-India-pH1N1, blue and sham-immunised (PBS-treated), black. The HI and VN antibody titers are pre-
sented as group geometric means (6 animals per group) with standard deviation. See text for statistical 
analysis of the results.
There were no statistical differences between the data obtained with the three different 
LAIV-pH1N1 preparations or between the HI antibody reactivity against the two rg-
pH1N1 strains, neither on day 20 (P = 0.11 and 0.23, respectively) nor on day 28 (P = 
0.23 and 0.31, respectively).
The single immunisation resulted in high levels of VN antibodies against both the rg-
Cal-pH1N1 and rg-NL-pH1N1 strain as measured twenty days after immunisation (titers 
256–2048, 362–2896 and 181–2048 against rg-Cal-pH1N1, respectively, and 304–2435, 
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431–3444 and 256–1722 against rg-NL-pH1N1, respectively). Eight days later, these VN 
titers were largely the same or showed a slight increase (Figure 6.2.1B). There were no 
statistical differences between the data obtained with the three different LAIV-pH1N1 
preparations or between the VN antibody reactivity against the two rg-pH1N1 strains, 
neither on day 20 (P = 0.13 and 0.18, respectively) nor on day 28 (P = 0.19 and 0.32, 
respectively). The sham-immunised control ferrets (group 4) did not show pH1N1-
specific HI or VN antibodies.
Protection against challenge with wild-type A/Netherlands/602/2009 (WT-
pH1N1); clinical signs
Upon challenge, which was performed four weeks after the single immunisation, all 24 
ferrets survived the 4 days follow up period (Table 6.2.1). The sham-immunised control 
animals (group 4) developed clinical signs such as lethargy, loss of appetite and dyspnea 
from 2 dpi onward. These clinical signs were milder in the vaccinated animals (groups 
1–3): the control animals (group 4) showed mean body weight loss of 14% (range 
10–18%), while mean weight loss in vaccinated animals was significantly lower with 6% 
(range 0–12%), 8% (range 5–12%) and 7% (range 5–8%) for group 1 (LAIV-Russia-pH1N1; 
P = 0.024), group 2 (LAIV-Thailand-pH1N1; P = 0.024) and group 3 (LAIV-India-pH1N1; P 
= 0.004), respectively, while there was no statistical difference between the vaccinated 
groups (P = 0.692; Table 6.2.1). All animals showed an initial temporal rise in body 
temperature within 24 hours post infection (hpi), which may be considered an acute 
phase reaction to the intratracheal inoculation (Figure 6.2.2). The sham-immunised 
control animals (group 4) developed fever about 24 hpi with peak temperatures of 39.2 
± 0.6 °C. Of all vaccinated animals only few developed slightly elevated temperature 
levels and these belonged to group 2 (LAIV-Thailand-pH1N1; one out of six) and group 3 
(LAIV-India-pH1N1; three out of six) with peak temperatures between 39.4 and 39.8 °C. 
Furthermore, the onset of these elevated temperature levels in vaccinated animals was 
delayed when compared to control animals.
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Figure 6.2.2 Body temperature profiles of ferrets following intratracheal challenge with wild-type 
influenza virus A/Netherlands/602/2009 (pH1N1) as measured by a temperature logger (DST micro-T 
ultra small temperature logger; Star-Oddi, Reykjavik, Iceland) placed in the peritoneal cavity. The data are 
presented as group averages (6 animals per group) of 6 h intervals with standard deviation.
Virus replication in the lungs and upper respiratory tract
None of the vaccinated ferrets (groups 1–3) had detectable replication competent virus 
in the lungs (lower limit of detection ≤101.3 TCID50 per gram tissue) when the animals 
were euthanised at 4 dpi and also from none of their nasal swabs virus could be 
isolated. In contrast, at 1 dpi 11 of the 18 vaccinated ferrets had detectable replication 
competent virus in their throats and these belonged to group 1 (LAIV-Russia-pH1N1; 
three out of six), group 2 (LAIV-Thailand-pH1N1; four out of six) and group 3 (LAIV-India-
pH1N1; five out of six) with titers ranging from 101.0 to 103.0 TCID50/ml. On 2, 3 and 4 
dpi none of the vaccinated ferrets had replication competent virus in their throat except 
for one animal of group 1 (LAIV-Russia-pH1N1), which started to be positive on 2 dpi 
up to the end of the experiment with a titer that increased from 101.5 to 103.5 TCID50/
ml. The sham-immunised control animals (group 4) showed average lung viral titers of 
105.3 (range 104.4–106.1) TCID50 per gram tissue. Virus was detected in the nose of 1–2 
animals on 1 and 2 dpi and of five out of six animals on 3 and 4 dpi with titers ranging 
from 101.5 to 105 TCID50/ml. One control animal had no replication competent virus in its 
nose. From throat swabs of all control animals virus could be isolated on 1, 2, 3 and 4 dpi 
with average titers of 103.4, 103.4, 104.5 and 103.9 TCID50/ml, respectively. The difference in 
the frequency of virus recovery from the throat swabs as compared to the nasal swabs 
could be explained by the fact that with swabs different compartments are sampled and 
maybe also by the sampling technique.
The reduced virus replication in vaccinated animals corresponded with a reduction 
in gross pathological changes of the lungs (Table 6.2.1).
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Gross-Pathology and Histopathology
The principal macroscopic post-mortem lesion concerned the lungs and consisted of 
multifocal pulmonary consolidation, characterised by reddening and increased firmness 
of the parenchyme. The extent of consolidation was estimated by visual assessment. In 
the sham-immunised control group the mean percentage of affected lung tissue was 
60% that corresponded to a mean relative lung weight (RLW) of 1.1 (range 0.94–1.32). 
Whereas in much less affected vaccinated groups LAIV-Russia-pH1N1, LAIV-Thailand-
pH1N1, and LAIV-India-pH1N1 the mean percentages of affected lung tissue and 
corresponding mean RLWs were 1.7% and 0.5 (range 0.47–0.55), 2.2% and 0.5 (range 
0.47–0.55), 4.2% and 0.5 (range 0.47–0.55), respectively (Table 6.2.1).
On histology the macroscopic pulmonary consolidation corresponded with an 
acute broncho-interstitial pneumonia. This pneumonia was characterised by the 
presence of neutrophils and macrophages within the lumina and walls of alveoli, and 
exfoliation and loss of alveolar epithelium. In addition protein rich oedema fluid, fibrin 
and extravasated erythrocytes in alveolar spaces and type II pneumocyte hyperplasia 
were observed in the more severe cases of alveolitis. In comparison of the extent and 
severity of alveolitis and/or alveolar damage (score range 0–3), the sham-immunised 
control group was on average the most severely affected scoring 2.4 and 2.8. Vaccinated 
groups LAIV-Russia-pH1N1, LAIV-Thailand-pH1N1, and LAIV-India-pH1N1 scored for 
both parameters equally noticeably less with 0.2, 0.3, and 0.3, respectively. In the 
sham-immunised control group the other parameters related to alveolar damage, such 
as alveolar oedema, alveolar haemorrhage, and type II pneumocyte hyperplasia were 
like-wise most prevalent, and absent in the vaccinated groups. The differences between 
the groups for the averaged scores for bronchi(oli)tis, tracheitis and mononuclear 
peribronchiolar/perivascular cuffing are summarised in Table 6.2.1.
DIScUSSION
Collectively, our data show that vaccination with three different preparations of a 
monovalent A/17/California/38/2009 live attenuated pandemic H1N1 influenza vaccine 
induced high levels of HI and VN serum antibody titers as well as protection against a 
robust pH1N1 challenge in a naïve ferret model. The ferrets were largely protected with 
one single vaccination against body weight loss, virus replication in both the URT and 
LRT, and against development of severe pathological changes in the respiratory tract. 
This indicates that LAIV produced from the parental pandemic virus as described in 
this ferret model lives up to the primary requirements of vaccines against pandemic 
influenza virus including the prevention of spread of the influenza virus and mitigation 
of the severity of disease.
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The LAIV-pH1N1 preparations used in the present study were produced at 
production plants in Russia (group 1), Thailand (group 2) and India (group 3). Although 
there were slight differences in vaccine formulation and vaccine virus titers, all three 
induced equivalent antibody titers and protection against challenge. This indicates that 
indeed pandemic LAIV production capacity can rapidly be expanded taking advantage 
of production facilities in under-resourced countries (630).
LAIVs have major advantages including less complex downstream processing, lower 
unit cost and higher production yield as compared to inactivated vaccines. In general, 
influenza vaccine (inactivated split virus) production from one egg yields a vaccine 
virus titer of 109 EID50 translating to a mere single 15 μg vaccine dose. In comparison, a 
protective dose of LAIV amounts to an approximate increase to 10–100 doses per egg. 
Furthermore, basically the LAIV is ready for use after one-step purification and it can be 
distributed as suspension or in freeze-dried form.
The ferrets used in the present study where all confirmed seronegative against 
circulating influenza A and B viruses before vaccination. The relatively high HI and VN 
serum antibody levels in the pH1N1 LAIV-vaccinated ferrets at the moment of challenge 
(28 days after one single immunisation) are important because they are at least of the 
same order of magnitude as antibody levels found in ferrets vaccinated with MF59-
adjuvanted 2009 A/H1N1 inactivated vaccine that had been primed with seasonal 
vaccine (550, 585). Similar to those ferrets, the pH1N1 LAIV-vaccinated ferrets had no 
detectable virus in their lungs and there was virtually no virus replication in the URT.
The extent and severity of the lung lesions of the sham-immunised control ferrets 
(group 4) was consistent with that described previously for pH1N1 influenza virus 
infection of ferrets and humans (506, 631). Intranasal immunisation with pH1N1 LAIV 
(groups 1–3) resulted in the strong reduction of alveolar damage, alveolitis, alveolar 
oedema and haemorrhage, bronchiolar and bronchial lesions as well as the extent of 
inflammation. Again, this observation is in line with the data found in ferrets immunised 
with MF59-adjuvanted 2009 A/H1N1 inactivated vaccine that had been primed with 
seasonal vaccine (550, 585).
For seasonal LAIVs it has been suggested that their efficacy is at least in part 
associated with the mimicking of a natural infection and thus the induction of a natural 
immune response. In contrast to seasonal H1N1 and LAIV-pH1N1 that are also restricted 
to replication in the URT, pH1N1 virus infection in both humans and ferrets shows a 
deviant severe diffuse alveolar damage caused by replication in epithelia of the LRT 
(395, 506, 631). However, remarkably LAIV-pH1N1 protects ferrets effectively against 
LRT damage following a robust intratracheal challenge with pH1N1. These data together 
with the relatively efficient production process and similar data obtained with pH1N1-
LAIV based on the A/AnnArbor/6/60 ca-strain (627) emphasize the potential of the LAIV 
concept for pandemic preparedness.
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inoculation in the ferret as a model 
of influenza viral pneumonia and 
intervention studies in humans
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INTRODUcTION
This chapter describes the practical applications of the ferret model in four influenza 
intervention studies that assessed novel adjuvant-antigen formulations and 
immunosuppression strategies. The results regarding pathological interpretation and 
evaluation are summarised.
METHODOLOGy
The ferrets were normally healthy outbred females (390, 632) or males (633, 634) of 
8-12 months of age, seronegative for circulating influenza viruses and ADV, and housed 
in standard cages and/or in negatively pressurised glovebox BSL-3 isolator cages in 
groups of six individuals. Commercial food and fresh drinking water were provided ad 
libitum. A body temperature logger (DST micro-T ultra-small temperature logger; Star-
Oddi, Reykjavik, Iceland) was surgically implanted within the peritoneal cavity of each 
ferret. Routinely, ferrets were challenged by intratracheal (IT) inoculation with IAV, but 
in one study by intranasal (IN) inoculation as well (633). All procedures were conducted 
in compliance with European guidelines (EU directive on animal testing 86/609/EEC) 
and Dutch legislation (Experiments on Animals Act, 1997).
The body weights were recorded during the experiments and at autopsy. Post-
mortem examinations were performed and all abnormalities were recorded. The 
lungs were examined and weighed. The percentages of affected lung parenchyma 
were visually estimated. The relative lung weights (RLW) were expressed as the ratio 
between the lung weight and the body weight at autopsy. Sampled organs/tissues were 
fixed in 10% neutral-buffered formalin for histopathology. After fixation, four samples 
from the left cranial and caudal lung lobes were embedded in paraffin and the tissue 
sections were stained with haematoxylin and eosin (H&E) for histological examination. 
The extent of alveolitis/alveolar damage (0%, <25%, 25–50%, >50% of section) and 
the severity of alveolitis/bronchitis/tracheitis/rhinitis (infiltration of no, few, moderate 
number of, or many inflammatory cells) were scored from 0 to 3. In the study from 
Baras and colleagues 2011, the histology score for alveolitis (including both the extent 
and severity of alveolitis) corresponded to the sum of both scores (score 0–6) (390).
STUDIES
In the first study (632), the efficacy of IN EndocineTM-adjuvanted split virion and whole 
virus pH1N1/09 candidate vaccines challenged IT by homologous wildtype H1N1 A/
206
NL/602/2009 (wt-pH1N1) virus was evaluated. EndocineTM is a mucosal anionic lipid-
based adjuvant composed of mono-olein and oleic acid, which are endogenous lipids in 
humans and other animals (635, 636). Known advantages of this novel IN application of 
EndocineTM mixed with inactivated IAV antigens include induction of local and systemic 
immunity protective against homologous IAV challenge in mice (637) and safe needle-
free application. In contrast to live-attenuated influenza vaccines (LAIV), this application 
of inactivated IAV antigens may prove suitable for people < 2 years and > 59 years of 
age as well.
Nasal vaccine drops (0.2 ml) containing EndocineTM (20 mg/ml) and inactivated 
H1N1/California/2009 split virion antigen at 5, 15 or 30 µg HA or whole virus antigen 
H1N1/California/2009 whole virus antigen containing 15 µg HA (Eurocine Vaccines AB, 
Stockholm, Sweden) were given thrice with three-week intervals to ferret groups 3, 4, 
5, and 6, respectively. These treatments induced high levels of serum antibody titres. 
Control group 1 was similarly sham-vaccinated with PBS (150 mM, pH 7.4). Group 2 
was subcutaneously (s.c.) vaccinated twice with a non-adjuvanted inactivated trivalent 
influenza vaccine (TIV) containing 15 µg HA each of H1N1/California/7/2009, H3N2/A/
Victoria/210/2009, and B/Brisbane/60/2008 (Fluarix® 2010/2011, GSK). IN sham-
vaccination and TIV vaccinations induced no neutralising serum antibody titres. All 
animals were homologously IT challenged with 106 TCID50 IAV H1N1/NL/602/2009 four 
weeks after the last vaccinations, and autopsied at 4 dpi.
The IN immunised ferrets were protected from virus replication in the lungs and 
largely protected from virus replication in the URT, and from major body weight loss 
(≤ 4.7%). In comparison, sham-vaccinated and TIV-vaccinated ferrets showed high 
viral titres in lung (mean titres; 5.7 and 5.5 log10TCID50/gram tissue, respectively) and 
nasal turbinates (mean titres: 7.2 and 6.9 log10TCID50/gram tissue, respectively), and 
most pronounced body weight losses (mean body weight loss of 18.0% and 11.5%, 
respectively). Fever was observed throughout all groups, with the highest body 
temperature increase in the sham-vaccinated animals (Table 6.3.1).
Pathological examination revealed lung lesions consisting of focal or multifocal 
pulmonary consolidation, characterised by well delineated reddening of the parenchyma. 
All ferrets in control group 1 (sham-vaccine) and group 2 (TIV) showed affected lung 
tissue with a mean percentage of 50% and 37%, respectively, and corresponded with 
a mean relative lung weight (RLW) of 1.5 and 1.3, respectively (Table 6.3.1). One 
animal from group 2 was found dead on 4 dpi; it suffered from an acute extensive 
viral pneumonia or DAD, which was the likely cause of death as no other lesions were 
evident. In contrast, lungs in groups 3–6 (EndocineTM vaccines) were much less affected 
with mean percentages of affected lung tissue of 7–8% and low RLWs within a close 
range of 0.8 to 0.9.
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The pulmonary consolidation corresponded with an acute broncho-interstitial 
pneumonia. The histological parameters that were scored are summarised in Table 
6.3.2. The most severe alveolar lesions were found in the control groups 1 (sham-
vaccine) and 2 (TIV). All parameters of alveolar lesions scored lowest in group 5, but in 
fact the differences between the groups 3–6 were not significant.
The novel formulation of EndocineTM-adjuvanted IN vaccines has shown to protect 
against significant lesions of the respiratory tract following IT challenge with pH1N1 IAV 
compared to sham-vaccination and TIV-vaccination in the ferret model. Furthermore, 
no significant differences among dosage or type of HA-antigen used as vaccine 
constituent regarding the conferred protection against respiratory lesions resulted from 
EndocineTM-adjuvantad IN vaccinations.
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In the second study (633), the efficacy of two IN Chitosan (CSN)-adjuvanted H5N1 
Influenza vaccines against HPAIV was evaluated. Challenge consisted of IT and IN 
inoculation of IAV H5N1/Vietnam/1194/2004. Chitosan is a co-polymer of D-glucosamine 
and N-acetyl-D-glucosamine. Chitosan is available commercially in water-soluble (< pH 
6) salt forms, such as CSN glutamate and CSN hydrochloride. Methylation of amine 
groups of CSN as in trimethyl-CSN (TM-CSN) provides increased solubility in neutral and 
basic environments (638). The effectiveness of CSN as vaccine adjuvant correlates with 
its degree of solubility. CSN improves the adhesion of vaccine antigens to the mucosa 
of the nasal cavity.
IN vaccines or PBS as sham vaccine were given (0.2 ml) to ferret groups twice with a 
3-week interval as follows, followed by intratracheal (IT) or intranasal (IN) virus challenge: 
group 1, PBS sham (IT); group 2, non-adjuvanted-antigen (IT); group 3, CSN-antigen 
(IT); group 4, TM-CSN-antigen (IT); group 5, PBS sham (IN); group 6, CSN-antigen (IN). 
The inactivated subunit antigen (15 µg HA) was from vaccine seed strain NIBRG-14, a 
reassortant of PR8 IAV and H5N1 AIV A/Vietnam/1194/2004 (Batch#1090/10, Novartis, 
Italy). The CSN-adjuvanted and TM-CSN-adjuvanted vaccinations induced high levels of 
serum antibody titres, while the sham-vaccinations and non-adjuvanted vaccinations 
induced no detectable antibody titres. All animals were challenged with 105 TCID50 IAV 
H5N1/Vietnam/1194/2004 four weeks after the last vaccinations, and autopsied at 5 
dpi.
CSN-adjuvanted vaccinated group 3 and TM-CSN-adjuvanted vaccinated group 4 
showed reduced viral replication of the LRT and reduced disease, and were protected 
from death following IT viral challenge. In comparison, in non-adjuvanted vaccinated IT-
challenged group 2 showed extensive viral replication of the LRT, and two of six animals 
were not protected from death.
IN viral challenge of sham-vaccinated group 5 induced virus replication 
predominantly in the URT and CNS, without causing mortalities. In comparison, IT viral 
challenge of sham-vaccinated group 1 resulted predominantly in a LRT infection, which 
was associated with a high mortality rate, as five of six animals were either found dead 
or had to be euthanised because of severe illness. Interestingly, all mortalities were 
associated with IT viral challenge and not with IN viral challenge regardless of the type 
of vaccination or sham-vaccination.
The viral infection of the LRT in sham-vaccinated group 1 especially, resulted in 
severe tissue damage, which was characterised by multifocal to coalescing well-
delineated intense reddening of consolidated lung parenchyma. The most severely and 
extensively affected lungs had copious amounts of frothy fluid (oedema) oozing from 
the bronchi, and several had peripheral emphysema also. Related to pneumonia were 
enlarged tracheobronchial lymph nodes. Histopathological examination of the H5N1 
IAV affected lungs revealed flooding of alveolar lumina with macrophages, neutrophils, 
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and erythrocytes, mixed with protein strands and fibrin, oedema fluid, and cellular 
debris. The alveolar septa were thickened, and epithelial cells were swollen or sloughed. 
Subsequent type II pneumocyte hyperplasia was generally observed in cases of mild to 
moderate of alveolar damage. The ferrets that died spontaneously or those that had to 
be euthanised prematurely suffered from similar very severe viral interstitial pneumonia 
or DAD. Both CSN-adjuvanted and TM-CSN-adjuvanted vaccinations strongly reduced 
lesions of the LRT compared to sham-vaccination and non-adjuvanted vaccination 
following IT viral challenge.
IN viral challenge in both sham-vaccinated group 5 and CSN-adjuvanted vaccinated 
group 6 equally induced predominantly mild rhinitis (URT), which was characterised by 
infiltration of mostly neutrophils and fewer lymphocytes and occasional eosinophils in 
the epithelium and lamina propria of the respiratory nasal mucosae.
Five animals were diagnosed with an encephalitis, yet remarkably none of these 
died or had to be euthanised prematurely. All but one of these originated from 
IN-challenged animals (one CSN-adjuvanted vaccinated animal from group 6 and 
three sham-vaccinated animals from group 5). The one IT-challenged animal from 
non-adjuvanted vaccinated group 2 had an inflammation of the brainstem, whereas 
all IN-challenged animals had an inflammation of the olfactory bulb, which is in close 
anatomical proximity to the nasal cavity. All these encephalitides were characterised by 
lymphohistiocytic perivascular cuffing, gliosis, and swelling of endothelial cells.
The novel formulation of TM-CSN-adjuvanted IN vaccines has shown to protect 
against significant lesions of the LRT (Figure 6.3.1) and mortality following IT challenge 
with H5N1 IAV in the ferret model. Furthermore, the CSN-adjuvanted IN vaccine showed 
partial protection against alveolitis following IT viral challenge and no protection against 
rhinitis following IN viral challenge.
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Figure 6.3.1 Histopathology in control and vaccinated ferrets post challenge.
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In the third study (390), the efficacy of a pH1N1 A/California/7/09 split vaccine with 
or without the adjuvant AS03, against challenge with pH1N1 IAV A/NL/602/09 was 
evaluated. AS03 is an oil-in-water-based adjuvant system containing α-tocopherol, 
which showed to increase the immunogenicity in a clinical trial involving an H1N1 strain 
(639).
In this study, AS03 was formulated in two concentrations, 11.86 mg/ml tocopherol 
(AS03A) and 5.93 mg/ml tocopherol (AS03B). Intramuscular vaccines (1.0 ml) with and 
without AS03 or PBS as sham vaccine were given to ferret groups once or twice with a 
3-week interval as follows: groups 2, 4 and 6 received two vaccinations with 15, 3.75 
or 1.9 µg HA of AS03A-adjuvanted pH1N1 A/California/7/09 split vaccine, respectively; 
groups 3 and 5 received one vaccination with 3.75 or 1.9 µg HA of AS03A-adjuvanted 
pH1N1 A/California/7/09 split vaccine, respectively; group 7 received two vaccinations 
with 1.9 µg HA of AS03B-adjuvanted pH1N1 A/California/7/09 split vaccine; control 
groups 1 and 8 received two vaccinations with 15 µg HA of the non-adjuvanted pH1N1 
A/California/7/09 split vaccine or two sham-vaccinations, respectively. Two vaccinations 
of AS03-adjuvanted A/pH1N1 induced substantial levels of neutralising serum antibody 
titres with 100% of animals achieving titres ≥40 against the challenge strain (Table 6.3.3). 
Single vaccination with AS03-adjuvanted A/pH1N1 (groups 3 and 5) induced in 60–67% 
of animals neutralising serum antibody responses ≥40, while single non-adjuvanted 
vaccination induced no detectable neutralising antibody titres (≤4). All animals were 
challenged IT with 106 TCID50 pH1N1 influenza virus A/NL/602/2009 four weeks after 
the last vaccinations, and all survived until autopsy at 4 dpi.
In the AS03-adjuvanted vaccinated animals, compared to non-adjuvanted vaccinated 
and sham-vaccinated animals, the RLWs were lower, and the percentages of visually 
affected consolidated lung tissue were much lower (Table 6.3.3). Histopathological 
examination revealed that the pulmonary consolidation corresponded with an 
acute broncho-interstitial pneumonia. The extent of damage and inflammation was 
consistently lowest in the lungs of ferrets that received two vaccinations with 15 µg of 
AS03A-adjuvanted HA (group 2) and consistently highest in ferrets in the control groups 
(groups 1 and 8). With the exception of group 3, histopathologic scores among all ferrets 
immunised with the AS03-adjuvanted vaccine were significantly lower compared to 
those in ferrets immunised with the non-adjuvanted vaccine or sham vaccine with PBS 
(Table 6.3.3).
← Figure 6.3.1 Histopathology in control and vaccinated ferrets post challenge. Histopathology was 
performed on ferrets that were euthanised according to schedule as well as animals euthanised premature-
ly on welfare groups and any decedents. In those ferrets that were not euthanised according to the sched-
ule all had acute severe pneumonia or diffuse alveolar damage, which was considered the likely cause of 
death. The panels represent: (A) extent of alveolitis, (B) severity of alveolitis, (C) relative weight of lung, (D) 
percentage lung affected, and (E) severity of rhinitis.
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These findings suggested a critical role for adjuvantation and two vaccinations with 
the 2009 A/H1N1 pandemic influenza vaccine intended for human use. Especially so, if 
to protect unprimed children who were at high risk of developing severe complications 
from 2009 A/H1N1 infection.
In the fourth study (634), it was evaluated whether immunosuppression with 
prolonged IAV shedding and antiviral resistance of pH1N1 IAV could be modelled in the 
ferret.
Immunosuppression in the ferret was achieved with a multidrug treatment comprised 
of: mycophenolate mofetil (MMF), tacrolimus, and prednisolone. Advantages of this 
treatment are efficacious immunosuppression in ferrets by means of the same cocktail 
of drugs used in humans to suppress immunity. Disadvantages of this treatment include 
disease from facultative pathogens, which may influence results. Hence all animals 
received antibiotic prophylaxis of amoxicillin and clavulanic acid.
Four days before virus inoculation, all 6 groups received oral amoxicillin/clavulanic 
acid (10/2.5 mg/kg, Pharmachemie BV, Haarlem, NL). One day later, groups 2, 3, 5 and 
6 were treated orally with MMF (20 mg/kg, CellCept, Roche, NL), tacrolimus (0.5 mg/
kg, Prograft, Astellas Pharma BV, Leiderdorp, NL), and prednisolone sodium phosphate 
(8 mg/kg, Hospital Pharmacy, UMCN, Nijmegen, NL) during the remainder of the study. 
Prednisolone dosage was halved every 7 days from 8 mg/kg in the first to 1 mg/kg in the 
last week. One day after virus inoculation, groups 3 and 6 were treated with oseltamivir 
phosphate (10 mg/kg, Tamiflu, Hoffman-La Roche, Basel, Switzerland) for the remaining 
20 days of the study.
The animals of groups 1, 2 and 3 were IT inoculated with 104 TCID50 oseltamivir 
sensitive pH1N1 IAV (A/NL/1715b/2009 wild type; H275) and the animals in groups 4, 
5 and 6 were IT inoculated with 104 TCID50 oseltamivir resistant pH1N1 IAV (mutant; 
H275Y) and autopsied on days of spontaneous death or at 21 dpi.
Pathological examination revealed, in all MMF/tacrolimus/prednisolone-treated 
groups 2, 3, 5, and 6, prolonged virus replication (≥ 7 dpi) evidenced by IAV NP positive 
cells by IHC, whilst oseltamivir treatment in groups 3 and 6 reduced IHC positivity and 
favoured reduced body weight loss and survival until 21 dpi. Additionally, opportunistic 
infections became florid in all these treated groups evidenced by several cases 
(n=8) of bacterial bronchopneumonia (Figure 6.3.2) and few cases (n=3) of mycotic 
bronchopneumonia (Figure 6.3.3). The bacterial infections appeared associated 
with reduced survival. None of the untreated animals showed IAV NP positivity in 
IHC nor opportunistic infections of the respiratory tract at 21 dpi. MMF/tacrolimus/
prednisolone-treated animals showed cellular depletion of lymphoid (Figure 6.3.4) and 
hemopoietic tissues (lymph nodes, tonsils, BALT, GALT, spleen, and bone marrow) in 
comparison to untreated animals.
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Indicators of immunosuppression in MMF/tacrolimus/prednisolone-treated ferrets 
according to pathological examination included: (a) reduction of lymphocyte 
proliferation and follicle formation in lymphoid tissues, (b) prolonged virus replication 
in lungs and noses, and (c) disease from facultative pathogens.
Figure 6.3.2 Bacterial bronchopneumonia in a MMF/tacrolimus/prednisolone-treated ferret with pH1N1 
IAV infection, at 10 dpi. On the right is a close-up photomicrograph showing intrabronchial presence of blu-
ish finely granular colonies of bacteria (arrows). H&E stains, original magnifications 25× and 800×.
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Figure 6.3.3 Mycotic bronchopneumonia in a MMF/tacrolimus/prednisolone-treated ferret with pH1N1 
IAV infection, at 21 d dpi. On the right is a close-up photomicrograph showing intrabronchial presence of 
longitudinal sections and cross sections of septate fungal hyphae (arrows) amidst necrosuppurative exu-
dates. H&E stains, original magnifications 200× and 400×.
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Figure 6.3.4 Reduced lymphoid follicle formation in tracheobronchial lymph nodes and lymphode-
pletion in the tonsils of MMF/tacrolimus/prednisolone-treated ferrets (MMF, mycophenolate mofetil) 
compared to untreated ferrets. Representative photomicrographs of tracheobronchial lymph nodes (origi-
nal magnification 25×) and tonsils (original magnification 50×). H&E stains.
In conclusion of this synopsis, pathological examinations revealed the protective 
systemic immunity against intratracheal IAV challenge induced by novel adjuvanted 
influenza vaccines with a novel innovative intranasal administration route such as 
Endocine-pH1N1 and Chitosan-H5N1, or induced by novel adjuvanted influenza 
vaccine formulations as AS03-pH1N1 by reduced lesions of the ferrets’ respiratory 
tract. Additionally the efficacious development of immunosuppression with prolonged 
IAV replication was shown in ferrets’ respiratory tract and lymphoid tissues. These 
assessments were successfully performed in the ferret model, thus expanding its 
possibilities and confirming its suitability to test protective and therapeutic treatments 
against influenza-induced disease.


 cHAPTER 7
Summarising Discussion
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This final chapter begins with a summary part of the main findings of the research 
performed in these studies and described in the previous chapters, which collectively 
expand on and contribute to the current scientific knowledge on the pathogenesis 
and prevention of influenza. Subsequently, knowledge gaps in the pathogenesis of 
influenza-induced ARDS are discussed, together with recommendations for future 
research. Finally, the overall conclusions and perspectives of this thesis are summarised.
SUMMARy OF THE PERFORMED RESEARcH
The findings from chapter 2.1 indicate that in an infectious respiratory disease like 
influenza the alveolar epithelial cell layer is the most important constituent of the 
EEB in the pathogenesis of influenza-induced ARDS and alveolar oedema formation. 
Not only are these epithelial cells the initial target of viral infection and replication; 
they also constitute the strongest layer of the EEB in preventing alveolar oedema to 
develop. Thus alveolar epithelial cells should be the primary research focus regarding 
both pathogenesis and therefore probably also therapeutic approaches for influenza-
induced ARDS and alveolar oedema.
In contrast to most mammals’ (including humans) and wild waterbirds’ epithelial 
cells being the main target of AIV infections, the findings of chapter 2.2 indicated the 
tropism of HPAIVs for endothelial cells in chickens and black swans. Furthermore, enteric 
inoculation of H5N1 HPAIV in domestic cats also led to endothelial cell involvement. The 
mechanisms involved in these species-specific differences in tropism for epithelial cells 
versus endothelial cells of IAV remain unclear. Regardless whether endothelial cells are 
infected by influenza virus, additional findings from chapters 2.1 and 2.2 point to the 
important role of the endothelium of the alveolar EEB in the pathogenesis of influenza-
induced ARDS as significant contributors to the pro-inflammatory response. Reducing 
the synthesis of pro-inflammatory cytokines and chemokines in endothelial cells should 
mitigate the pulmonary inflammatory response significantly.
In chapter 3.1 we showed that many animal species are susceptible to IAV infections. 
The host range of IAVs includes many more animal species, including humans, than the 
host ranges of influenza B, C, and D viruses. The majority of this broad host range of 
IAV is accounted for by sporadic short-lived infections. Yet, the host range of endemic 
infections is gradually expanding as new IAVs from wild birds or via intermediate 
hosts are introduced and become established infections in humans, pigs, horses, and, 
most recently (2005), in dogs. Canine Influenza is caused by equine-origin H3N8 IAV 
predominantly in North America or caused by avian-origin H3N2 IAV predominantly in 
Asia. However, since April 2015 avian-origin H3N2 IAV has been detected as etiology 
of canine influenza in the USA as well (640). There is ongoing concern that zoonotic 
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transmission of IAVs from animals to humans may give rise to new epidemics or even 
pandemics in the human populati on. Conversely, anthroponoti c transmission of 2009 
pH1N1 IAV from people to few individual pet ferrets, cats, and dogs, and several zoo 
animals has been recorded, yet without becoming endemic in these animals.
Ferrets and carnivores in general, have shown to be highly suscepti ble to IAV 
infecti on and to be very sensiti ve to develop subsequent disease. However in many 
other animal species, the suscepti bility to infecti on does not equal or imply a sensiti vity 
to develop disease, as it may induce subclinical infecti ons only.
Risk factors involved in severe infl uenza outbreaks in novel host species such as 
groups of carnivores (and not in infecti ons of individual animals) were: introducti ons of 
a new IAV into cohorts of immunologically naïve carnivores housed in confi ned spaces, 
as kennels, farms, and zoos. Remarkably, such outbreaks are not apparent in catt le 
under similar conditi ons at all.
The sensiti vity to develop disease aft er infecti on seems mostly inherent to att ributes 
of a parti cular order or family of animal species. However, there are virus-specifi c 
att ributes that infl uence the propensity to develop disease, too. For example, H5N1 
HPAIV induces more severe pneumonia in a ferret than a seasonal H3N2 IAV. In fi gure 
7.1.1 the sensiti vity of several mammals to natural H5N1 HPAIV-induced disease is 
plott ed against their reported incidences.
Incidence 
n=150 Pika        Tiger (& Leopard) 
n=100      Raccoon dog 
n=50 Pig        Cat 
n=10 Raccoon 
n=<5 Horse/Rat     Donkey     Civet 
n=1      Dog    Mink/Stone marten 
Subclinical      –  Low  – Moderate – High     –  Very high  
         Sensitivity                                                       
 
 
Figure 7.1: Sensitivity of mammalian animal species to natural HPAIV H5N1 induced disease and 
reported incidence. 
 
 
Figure 7.1.1 Sensitivity of mammalian animal species to natural H5N1 HPAIV infections and induced 
disease with corresponding reported incidences (641).
In chapters 3.2 and chapters 4 to 6, the ferret model was further characterised and 
developed as a model for infl uenza-induced ARDS and alveolar oedema in humans.
In chapters 4 to 6, intratracheal inoculati on of several diff erent IAVs was applied to 
reproducibly induce the required acute and severe pneumonia in the ferret as model 
for ARDS and alveolar oedema. The intratracheal route was essenti al to cause broncho-
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intersti ti al pneumonia, as intranasal inoculati ons of H5N1 HPAIV caused evident 
neurological signs (642), and meningo-encephaliti s (549).
In chapters 4.1 and 4.2, the ferret model was used to characterise the pathogenicity 
of the newly emerged virus 2013 H7N9 LPAIV from humans, and to characterise the 
pathogenicity and transmission of new escape mutants of 2009 pH1N1 IAV. In contrast 
to the low pathogenicity of this H7N9 AIV in poultry, chapter 4.1 illustrated the high 
pathogenicity of this H7N9 IAV in the ferret, similar to natural infecti ons in humans. The 
fi nding that H7N9 LPAIV induced a rhiniti s in these ferrets was corroborated by the virus’ 
att achment to the URT (68), and by a limited airborne transmission between ferrets 
(643). Studies performed in chapter 4.2 indicated that a neuraminidase-resistant mutant 
virus isolate (NL/2631-R223) had slightly lower, albeit not signifi cant, pathogenicity but 
comparable replicati ve ability and transmissibility to reference pH1N1 (NL/602) IAV in 
ferrets, and thus indicated a potenti al spread of this neuraminidase-resistant mutant 
virus in human populati on.
In chapter 5 the technical development and advancement of implementi ng in vivo 
CT-scanning of pH1N1 IAV-inoculated ferrets was successfully performed as ‘proof of 
principle’ and showed its additi onal value in successive monitoring of infl uenza-induced 
ARDS development in this animal model. This methodology revealed reducti ons in 
aerated lung volume that were replaced by pulmonary oedema and infl ammatory cells, 
visible as ground glass opaciti es.
Consecuti ve in vivo CT-scanning yielded several additi onal benefi ts over conventi onal 
(ti me course) studies: (a) the inter-individual variati on in infl ammatory responses was 
reduced as the day-to-day scanned animal served as its own base-line control animal; 
thereby (b) reducing the number of animals needed; and (c) no need to arti fi cially lump 
together pathology results of ferrets that had been euthanised or had died on diff erent 
days aft er inoculati on; (d) establishment of the opti mal ti me point of maximal pulmonary 
consolidati on allowed for performing autopsies in subsequent trials for anti virals and 
vaccines at the ti me point of the biggest possible spread in values between control 
group and treatment group (3 dpi for pH1N1 IAV in the ferret model).
The subsequent practi cal applicati on of measuring altered ALV by CT-scanning as 
read-out parameter in a vaccine effi  cacy study was described in chapter 6.1. These 
fi ndings confi rmed the suitability of the ferret model in evaluati ng the degrees of daily 
altered ALV as correlate of protecti on against infl uenza virus challenge in vaccinated 
ferrets compared to controls and classical virology and pathology. The fi ndings of chapter 
6.2 confi rmed the suitability of the ferret model to study and compare the effi  cacies 
of several intranasally applied live-att enuated-infl uenza-vaccines against intratracheal 
pH1N1 IAV challenge. These vaccine viruses exhibited controlled replicati on limited 
to the nasal epithelium of ferrets, yet thereby inducing a strong systemic protecti ve 
immune response without the need of an adjuvant. The fi ndings of chapter 6.3 indicated 
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the possibilities and limitations of use of ferrets to study novel adjuvant formulations 
with novel administration routes, and to develop an immunosuppression model. The 
intranasal administration of mucosal adjuvants or immunomodulators combined with 
either intranasal or intramuscular immunisation (against IAVs pH1N1 and H5N1) in the 
ferret model had the advantage of successfully inducing strong systemic protective 
immune responses, as is intended for future use in humans. In the immunosuppression 
study, the ferret model had the advantage that the same drugs used to suppress 
immunity in humans worked equivalently in ferrets, and IAV inoculation lead to 
prolonged viral replication compared to placebo. A disadvantage was that opportunistic 
infections became florid in the ferrets.
DISCUSSION OF THE PATHOGENESIS OF INFLUENzA-INDUCED ARDS 
AND OEDEMA FORMATION AccORDING TO INVOLVED cELL TyPES 
wITH REcOMMENDATIONS FOR FUTURE RESEARcH
In this section, the pathogenesis of influenza-induced ARDS and alveolar oedema with 
future perspectives for further research are discussed according to the main structural 
and inflammatory cell types that constitute and influence the alveolar EEB in influenza-
induced ARDS, as described in chapter 2.1.
Historically, the pathogeneses of ARDS and pulmonary oedema have been studied 
mainly as outcomes of bacterial sepsis. Such studies focused on modelling endothelial 
disruption by bacterial LPS as a starting point of the cascade. However, in IAV infections 
in humans and most other mammals, the initial target constitutes the epithelial cell layer 
of the alveolar EEB. Moreover the alveolar epithelial lining, in which tight junctions (TJs) 
interconnect the epithelial cells, is considered more important as fluid barrier than the 
vascular endothelial lining of the alveolar EEB. Therefore, emphasis is put on the epithelial 
cells lining the alveolus as the major target of aerogenous influenza virus infections. 
Influenza virus infection directly and indirectly leads to damage, and ultimately death 
of epithelial cells, permitting alveolar fluid leakage and respiratory insufficiency, which 
are hallmarks of the pathogenesis of influenza-induced ARDS. However, it should not 
be forgotten that, under some conditions, highly pathogenic avian influenza viruses can 
exhibit endotheliotropism as well, as described in chapter 2.2.
Epithelium
Two types of epithelial cells line the pulmonary alveoli: type I and type II pneumocytes. 
Type II pneumocytes outnumber type I pneumocytes (in the order of 60% vs 40%), 
whilst remarkably, type I pneumocytes cover 95% of the alveolar surface by spanning 
multiple alveoli with their flat cytoplasmic projections. This thin lining allows for easy 
227
Ch
ap
te
r 
7
gas diffusion between air and blood. Type II pneumocytes are not flat but cuboidal cells 
that play a role in re-epithelisation of denuded alveoli. The epithelial layer constitutes 
the main fluid barrier in the EEB as it accounts for more than 90% of the resistance to 
protein transport across this barrier. The thus maintained gradient in colloid osmotic 
pressure across the EEB passively prevents water leakage into the alveolar lumen, and 
subsequently prevents pulmonary oedema.
ARDS is a clinical syndrome and term, which corresponds to the pathological term 
of diffuse alveolar damage (DAD). One of the histopathological hallmarks of DAD is 
the presence of alveolar oedema, caused by damage to the alveolar EEB. However, 
the presence of alveolar oedema only is not adequate to make the diagnosis DAD. By 
definition this requires additional detection of hyaline membranes, as visible evidence of 
epithelial necrosis. Disruption of the normally continuous epithelial layer of the EBB and 
presence of consequent alveolar oedema, as important features of DAD, can be detected 
and scored by histopathology. Microscopic identification of damaged pneumocytes 
in direct conjunction with presence of alveolar oedema will ascertain and emphasise 
the essential role of the epithelial lining in the pathogenesis of ARDS. The gradation 
of histological damage to alveolar pneumocytes may range from subtle disruptions in 
the normally continuous epithelial layer to completely denuded alveoli. Recognition 
of such subtle disruptions is aided when stained with an epithelium-specific antibody 
such as pankeratin by IHC. Therefore, as a recommendation for future research in the 
ferret model, the correlation that anticipatedly exists between damaged pneumocytes 
and alveolar oedema should be investigated in sufficient numbers of slides. As practical 
recommendation for a set-up of acutely IAV-inoculated ferrets, 25 alveoli (or 25 
microscopic fields of alveoli at 100x magnification) per lung slide that contain alveolar 
proteinaceous fluid are scored for the presence or absence of damaged pneumocytes. 
If a total of four lung slides per animal in a total of six animals per group are evaluated 
and added it amounts to a percentage of damaged epithelium in alveolar oedema and 
should allow for sufficient statistical power and significance. Other variables that could 
be included and simultaneously assessed are for example: the degree of pneumocyte 
damage in relation to the degree of alveolar oedema and possibly even the protein 
contents of the fluid (according to the intensity of eosinophilia of the fluid in H&E-
stains), and/or the grade of pneumocyte damage in relation to the number and type 
of inflammatory cells present within the epithelium or alveoli. Preferably this set-up 
entails analyses of ferret lungs sampled at different dpi with different strains of IAVs at 
various viral inoculum dosages to complete a comprehensive dataset. Logically, these 
data are to be compared to equally assessed sham-inoculated control ferrets.
Tight junctions (TJs) firmly interconnect alveolar epithelial cells, and are composed 
of various proteins, including claudins, and zona occludens 1, 2, and 3. As shown 
some time before by Wang and colleagues in 2003 in rats, these proteins were stained 
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specifically by IHC to measure differences in TJ proteins expression (644). Reduction 
of expression likely relates to a degree of loosening of epithelial cells (645), and a 
consequent increase in alveolar EEB permeability. As recommendation for future 
research, a presumed correlation between reduced TJ-proteins expression (qualitative 
and/or quantitative alterations in IHC staining) and the degree of alveolar oedema can 
be evaluated in the ferret model, and should reveal the proportional significance of 
alveolar epithelial TJs in the pathogenesis of influenza-induced ARDS. However, the 
poor availability of ferret-specific antibodies for IHC may prove problematic.
Alveolar amiloride-sensitive epithelial sodium channels (ENacs) on both type I and 
type II pneumocytes maintain, in conjunction with endogenous energy consuming 
basolateral Na+/K+ ATPase pumps, an osmotic gradient across the alveolar EEB. Luminal 
alveolar water passively follows the gradient through epithelial aquaporins (AQP) and 
intracellular pathways towards the interstitium and bloodstream, thus preventing 
pulmonary oedema. As the name of this ion channel suggests, it can be blocked directly 
by amiloride. H1N1 IAV PR/8/1934 has shown to posses the ability to inhibit type II 
pneumocytes’ ENaCs in vitro also (103, 104). As recommendation for future research, 
in order to assess the relative importance of these sodium pumps in influenza-induced 
ARDS/lung oedema, suitable animals like the ferret should be experimentally inoculated 
with an IAV, and treated with amiloride and compared to placebo-treated controls. If 
the outcome of this set-up would amount to significantly increased pulmonary oedema 
in the amiloride-treated group in comparison to the placebo-treated group, it implies 
a trivial role of the pump in influenza-induced pulmonary oedema. Or vice versa, if 
the degree of pulmonary oedema were to be similar for both infected animal groups, 
irrespective of amiloride blockade or not it implies an important role of sodium channel 
and pump in influenza-induced pulmonary oedema.
Aquaporin 5 (AQP5) is expressed in the apical plasma membrane of alveolar type I 
pneumocytes (646, 647). Reduced AQP5 expression of mouse type I pneumocytes was 
shown in vitro after exposure to TNF-α (648) and after exposure to NO (649), suggesting 
down-regulation in viral infection and in neutrophil-dominated alveolitis in vivo. 
Reduced apical expression of AQP5 likely impairs passive flow of alveolar water back 
to the interstitial blood stream. However, alveolar water clearance was not decreased 
in AQP5 knock-out mice (650), suggesting alternative ways of passive water transport 
across the EEB. Nonetheless, development of anti-AQP5 antibodies optimised for IHC 
on ferret tissues is recommended for future research, as it should reveal the relative 
importance of epithelial AQP5 in influenza-induced ARDS in the ferret model.
As described previously, ferrets inoculated with H5N1 HPAIV showed extensive alveolar 
epithelial necrosis, yet without abundant type II pneumocyte hyperplasia. In contrast, 
less pathogenic IAVs such as the 2009 pandemic H1N1 IAV induced more abundant type 
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II pneumocyte hyperplasia in ferrets. A possible explanation for this observation may be 
that the most abundantly present type of pneumocyte in the (ferret) lung is the type II 
pneumocyte, which expresses the ‘avian-type’ SA-alpha-2,3-Gal receptor on its apical 
surface and is responsible for regeneration of damaged epithelial cells. Regeneration of 
pneumocytes indicates lung repair and is evidenced by type II pneumocyte hyperplasia. 
The high pathogenicity of H5N1 AIV in many mammals including ferrets may be explained 
by the virus’ tropism for these type II pneumocytes. Because incapacitation of this cell 
type restricts repair and would logically result in more severe alveolar damage than 
infection of readily replenishable type I pneumocytes, which express the ‘human-type’ 
SA-alpha-2,6-Gal receptor targeted by intrinsic less pathogenic seasonal IAVs.
Type II pneumocyte hyperplasia, recognisable by microscopy as alveolar septal-lining 
rows of contiguous cuboidal-to-columnar pneumocytes, is indicative of replenishing 
lost type I (and type II) pneumocytes, and as argued above also indicative of remaining 
viable cells capable of regeneration. Essential steps in the process of alveolar re-
epithelisation involve proliferation and migration of type II pneumocytes, remodelling 
of the basement membrane, and differentiation of type II into type I epithelial cells. In 
order to migrate, the hemi-desmosomes that normally connect pneumocytes to the 
basement membrane (Bm) are degraded by matrix metalloproteinases (MMPs) secreted 
by involved epithelial and mesenchymal cells, and subsequent upregulated expression 
of cell surface integrins then allows the loosened cells to move along the scaffold of 
BMs. A damaged BM hampers re-epithelisation, as it needs to be resynthesised first 
by the proliferating pneumocytes aided by interstitial fibroblasts that secrete growth 
factors and BM matrix constituents (651). If alveolar necrosis is very extensive it may 
be beyond functional repair capacity and replacement fibrosis forming scar tissue will 
ensue. Interstitial fibrosis may develop if fibrinous exudates persist in alveoli, inciting 
proliferation and ingrowth of fibroblasts that deposit collagenous matrix, followed by 
inclusion to the alveolar interstitium by overgrowth of proliferating epithelial cells and 
BM formation (652, 653). An intact alveolar epithelial cell layer suppresses fibroblast 
proliferation and collagenous matrix deposition (654). Thus enhancement of alveolar 
re-epithelisation in ARDS may reduce fibrosis by restoring alveolar fluid clearance 
preventing proteineacous fluid to accumulate, and by suppression of fibroblasts to 
proliferate (655).
As recommendation for future research on subacute to chronic IAV-induced 
pneumonias (e.g., > 7 dpi) and subsequent repair capacity, the ferret model can serve 
to score the degree of re-epithelisation (type II pneumocyte hyperplasia) in relation 
to the degree of scar tissue (fibroblasts and collagenous matrix) by histopathological 
assessment. Damage of the BM, caused by degrading enzymes from neutrophils 
and macrophages, may be detected more easily in histopathology stained by silver-
precipitation stains or specific immuno(fluorescent) stains. By these methods BMs are 
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routinely stained and evaluated in nephropathology for lesions such as disruptions and 
splitting. As additional future recommendation for future research and histological 
assessments, noticeable defects in the alveolar network of BMs or large areas of 
denuded alveolar BM could be additional microscopic parameters to score present lung 
damage and/or future impaired repair.
Substances with therapeutic potential in lung repair by stimulating re-epithelisation of 
type II pneumocytes are growth factors (GF). GFs such as HGF, KGF and granulocyte 
macrophage colony-stimulating factor (GM-CSF) are specific cytokines synthesised by 
various cell types that drive cellular proliferation and differentiation. Biochemically 
synthesised analogues of such GFs are available and have been shown to stimulate 
re-epithelisation of denuded alveolar BMs in influenza-damaged lungs of mice (656). 
HGF induced type II pneumocytes to proliferate and to synthesise BM remodelling 
enzymes such as matrix metalloproteinase-9 (MMP9) and urokinase-type plasminogen 
activator (uPA) in vitro. These enzymes could be inhibited by tissue inhibitor of matrix 
metalloproteinase-1 (TIMP1) and by transforming growth factor-β1 (TGF-β1) (657), 
involved in re-epithelisation in vivo as well.
Although not yet assessed in the ferret model, application of GFs will likely improve 
the re-epithelisation in damaged ferret lungs as well. So as prospective research topic, 
therapeutic treatment of GFs is recommended to be evaluated in experimentally 
influenza-infected ferrets. The potential benefits such as enhanced type II pneumocyte 
hyperplasia and reduced fibrosis can be evaluated by histopathological examination 
compared to placebo-treated controls. A more comprehensive and functional 
prospective approach to monitor potential therapeutic effects of GFs is implementation 
of extra-corporeal membrane oxygenation (EcMO) in ferrets with influenza-induced 
ARDS. Possible improved amelioration from ARDS should be evidenced by normalised 
blood oxygenation, and normalised respiratory rates and heart rates. The feasibility 
of long-term ECMO implementation in respiratory research has been shown before in 
sheep and recently in rabbits (658).
Besides type II pneumocytes, other progenitor cells like distal airway stem cells 
(DASCs) residing in peribronchiolar niches, and bone marrow derived mesenchymal 
stem cells (MSCs) capable of structural pulmonary self-renewal have been identified 
in mice (659-661). The MSCs could be stimulated in vitro and in vivo to differentiate 
into type II pneumocytes by administration of Wnt ligand Wnt5a. In vivo lung repair 
was enhanced by transplantation of cloned DASCs in IAV inoculated syngeneic mice 
(659). Hopefully future availability of ferret-specific bioreagents will expand research 
possibilities on stem cell based re-epithelisation of influenza-induced lung damage in 
the ferret model. More specifically, administration of Wnt ligand Wnt5a may induce 
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MSCs of ferrets as well, in order to study pathogenesis or therapeutic options of 
influenza-induced ARDS.
In addition to light microscopy, histological assessments by electron microscopy (EM) is 
suggested for future research in the ferret model as it may corroborate lesions or reveal 
ultrastructural lesions of the EEB (in particular pneumocytes and constituents: TJs, ENaCs, 
AQPs, and BM) associated with leakage of plasma fluid. However, the infinitesimal tissue 
samples analysed by regular EM may not represent the majority of involved pneumocytes 
and constituents. To overcome this issue, the implementation of complementary 
microscope techniques collectively named ‘correlative light and electron microscopy’ 
(CLEM) that integrates and overlays larger tissue areas, should allow EM suitable for 
representative assessment of lesions of the EEB. Briefly in CLEM, cells, organelles or 
proteins of interest are localised first by fluorescent markers in light microscopy and 
subsequently evaluated in ultra-high resolution by EM (662, 663). Plasma proteins as 
constituents of oedema fluid within alveoli can be labelled and detected by EM also. The 
combined morphologic evaluations of light and electron microscopy, would contribute 
without doubt to insights in the role that the EEB and especially the alveolar epithelial 
layer plays in the pathogenesis of influenza-induced ARDS and oedema formation.
Cytokines (CK) produced by epithelial cells during IAV infections are discussed since 
they can damage the EEB, by targeting epithelial cells and their TJs and ENaCs. As 
recently performed by K.R. Short (personal communication), the amount of cytokines 
induced depended largely on the type of IAV and seemed less correlated to the speed 
of replication. H5N8 HPAIV appeared in vitro a greater proinflammatory CK inducer 
than H5N1 at comparable replication rates. This suggests that this phenomenon 
may be present in vivo as well. pH1N1 IAV showed to be a greater proinflammatory 
CK inducer than seasonal H1N1 IAV in homogenised ferret lung tissues (664). Thus 
as recommendation for future research on influenza-induced ARDS, the role of these 
cytokines should be examined in the ferret model, in which different extents of ALI at 
comparable rates of replication of different viruses should be noticeable. Furthermore, 
molecular techniques can detect and compare the changes of induced cytokines in 
overtly inflamed lungs vs. lungs without lesions. Quantifying increased proinflammatory 
CK mRNA expression in homogenates of IAV-inoculated fresh ferret lung tissue by PCR 
was shown before (664). More recent PCR techniques can be applied also on formalin-
fixed and paraffin-embedded lung tissues to detect upregulated gene expression of 
several cytokines (665). However, a disadvantage of examining lung tissues as a whole is 
the inherent simultaneous gathering of several other cell types, each with an unknown 
contribution to CK expression profiles. A way around this could be implementation of 
laser-capture microdissection (LCM) techniques on paraffin embedded lung tissue slides 
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in which cell types can be isolated specifically followed by quantitative-PCR analysis 
of that specific cell type. If several ferret-specific antibodies for cell sorting by FACS 
analysis would be available these PCR techniques could be applied on fresh lung tissue 
homogenates like commonly performed in mice (666, 667). Future molecular research 
on influenza-induced ARDS would benefit from using LCM and from developing ferret 
cell-specific antibodies. The combined knowledge of which cell types account for which 
type and amount of cytokines will contribute to understanding the role of cytokines in 
the pathogenesis of influenza-induced ARDS.
The following paragraph that describes methods of functional analyses of the integrity 
of the alveolar EEB is included in this section about epithelium. Since failure of the 
essential epithelial layer will overwhelm the weaker components of the EEB such as 
interstitium to allow leakage of fluid too.
As described for the various ferret studies in this thesis, functional analysis of 
the integrity of the pulmonary EEB is performed routinely by measuring RLWs of IAV-
inoculated ferrets compared with non-infected control animals. Influenza-induced 
acute inflamed lungs are heavier from oedema and influx of inflammatory cells like 
macrophages and neutrophils, whereas body weights are relatively stable over the 
course of an acute infection and inflammation. Alternatively proven methods of 
functional analysis of the EEB in IAV-inoculated animal models is measuring the amounts 
of alveolar FITC-labelled albumin leaked from the circulation (668). Although not 
reported yet, this method could be implemented likewise in ferrets. As recommendation 
for future research, FITC-labelled albumin in BAL fluids should be measured in the 
ferret model as alternative to CT-scanning to quantify influenza-induced pulmonary 
oedema and EEB function. Although, BAL fluid sampling during pathogenesis studies 
has several disadvantages also. First, flushing the respiratory tract with fluids will alter 
the amounts of inflammatory cells and oedema present in the distal airways, interfering 
with pathogenesis and obscuring histopathological changes. Secondly, exposure of the 
epithelial cells lining the respiratory tract to excess amounts of exogenous fluids may 
influence their state and morphology, again interfering with pathogenesis and obscuring 
histopathological changes. Lastly, intermittent BAL sampling during the course of an 
infection experiment will spread infectious virus particles more widely in the lungs than 
would have occurred otherwise, which certainly will interfere with the pathogenesis.
Another important question concerning the alveolar epithelium and the pathogenesis 
of influenza-induced ARDS that should be addressed: Is influenza virus replication in 
pneumocytes required to increase the EEB permeability resulting in oedema? Or does 
inactivated replication-deficient IAV exert toxic effects to the EEB permitting oedema 
to develop? Shown before by Imai and colleagues, inactivated H5N1 IAV induced 
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ARDS in mice via toll-like receptor (TLR)-4 signalling on macrophages producing ROS 
(203). To address this question, UV-light or radiation-inactivated IAVs can be evaluated 
on respiratory epithelial cell cultures for CK induction or for altered trans epithelial 
resistance (TER) as measure cell barrier strength (645). In vivo confirmation of potential 
proinflammatory and/or toxic effects of inactivated IAVs on the delicate EEB should well 
suit the ferret model, and is as such recommended for future research. Presumably, 
results will show damaging capacity related to the type of inactivated IAV, as was shown 
for greater pathogenicity of HA from H5N1 HPAIV than from less pathogenic IAVs.
Macrophages
Macrophages are abundantly present inflammatory cells, resident within the normal 
alveolus or recruited to inflamed lungs. They can exert phagocytic and CK producing 
functions, and as such play an important role in ARDS pathogenesis. Recruited 
macrophages can damage the EEB in influenza-induced pneumonia. They can release 
tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL, also known as 
TNFSF10), NO, and produce proinflammatory cytokines. These substances can induce 
epithelial cell damage and cell death. As mentioned previously in the section on 
epithelium, granulocyte-macrophage colony-stimulating factor (GM-CSF) is a growth 
factor that stimulates pulmonary stem cells and type II pneumocytes to increase 
and accelerate re-epithelisation of injured alveoli. Classically, hence the name, GM-
CSF stimulates stem cells to generate differentiated granulocytes and monocytes/
macrophages. Whether GM-CSF leads to increased numbers of recruited macrophages 
in lungs of experimentally influenza-infected ferrets is not known. However, there may 
well be a conceivable equilibrium between beneficial effects of lung repair or deleterious 
effects potentially induced by recruited activated macrophages by GM-CSF which can 
be assessed in prospective research by histological examination of treated ferrets 
compared with placebo-treated controls. Preferably an additional animal group would 
be included treated with monoclonal antibodies that block TRAIL (anti-TRAIL Ab’s), and 
assess if this leads to noticeable differences in re-epithelisation by histopathology.
In experimental IAV inoculations, in vivo depletion of resident alveolar macrophages 
(AM) by means intratracheal instillation of clodronate-liposomes have been performed 
in ferrets (Kim 2013), permitting increased viral replication and more severe lung lesions 
and disease compared to placebo-treated controls. Under normal circumstances, inhaled 
aerosolised infectious IAV particles will reach deep into lungs, to be subjected to innate 
antiviral immune responses from AMs. Depletion of AM in ferrets would lead to a higher 
‘take’ of the virus, i.e., a higher infectivity of the virus, hereby potentially modelling 
seasonal influenza-induced ARDS in immune compromised patients. Previous methods 
to increase ferrets’ susceptibility to seasonal IAVs and respiratory disease required 
either very high infectious titers (669) or required immunosuppressive medication as 
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described in chapter 6.3. Modulation of the innate or adaptive immune system in the 
ferret model, either by macrophage depletion and/or immunosuppressive medication, 
plausibly resembles more naturally immune compromised patients than unnaturally high 
infectious viral doses would. Considering these approaches, pre-infectious depletion 
of resident AMs is recommended to be intensified in future research as it may well 
improve the applicability of this model, without the poorly controllable drawbacks, such 
as the general deleterious catabolic effects of corticosteroids including, but not limited 
to opportunistic secondary infections, of systemic immunosuppressive medication.
Neutrophils
Neutrophils, or more accurately, neutrophilic granulocytes are short-lived inflammatory 
cells rapidly recruited to inflamed lungs. They can exert phagocytic and microbiocidal 
functions by aspecific degranulation of lysozymes and release of ROS, and by CK 
production. These substances are additionally toxic to IAV-infected and non-infected 
cells that constitute and uphold the alveolar EEB. Especially, matrix metalloproteinases 
(MMPs) secreted by neutrophils (and macrophages) can cause proteolytic damage of 
the alveolar BM. Furthermore neutrophils can undergo cell death called netosis in which 
extruded DNA forms extracellular traps (NETs) foremost involved in killing pathogens and 
thus less likely in damaging the EBB. NETs may contribute to ARDS indirectly by vascular 
damage and thrombus formation (155). However, the specific significance of neutrophils 
in the pathogenesis of influenza-induced ARDS in relation to other inflammatory cells and 
inflammatory processes is not known. Shown by van den Brand and colleagues, in the 
acute stages (<24 hpi) of H5N1 AIV induced ARDS in ferrets, alveolar protein-rich oedema 
fluid was already present before evident influx of neutrophils (316). This suggests that 
neutrophils are not essential in initial stages of alveolar oedema formation. However, 
when in the subsequent stages many activated neutrophils are recruited to IAV-infected 
lungs, and undergo burst degranulation, ROS and proteolytic lysozymes (MMPs) are 
released that can cause major bystander damage to the EEB. This may weaken the barrier 
and MMPs especially, may disrupt the BM leading to impaired re-epithelisation.
Therefore as recommendation for prospective research topic, to assess the 
significance and role of the neutrophil and its MMP in the acute inflammatory process 
and subsequent repair process in the ferret model, neutrophils and/or MMPs should be 
extracted from influenza-induced pneumonia and compared with controls. Experimental 
treatments with monoclonal antibodies to selectively deplete neutrophils followed by 
IAV inoculation in mice in different studies resulted, contrastingly, in increased mortality 
and pneumonia (670-672) and in less severe morbidity and mild pneumonia without 
ARDS (155), suggesting both beneficial and disadvantageous roles of neutrophils in 
acute IAV infection and inflammation. Blockade of MMPs may theoretically lead to less 
severe disease by reduced proteolysis and enhanced alveolar re-epithelisation.
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Endothelium
Endothelial cells are flattened mesenchymal cells that line blood vessels, and as such 
form the direct blood border as structural constituent of the alveolar EEB. As elaborated 
on previously, about 10% of the strength in upholding the colloid osmotic pressure across 
the alveolar EBB is provided by the endothelial cells and interstitium. Endothelial cells 
are not as firmly interconnected with TJs as pneumocytes. They are the most abundant 
cell type present in the lung (30%), and have shown to participate in the pathogenesis 
of influenza-induced ARDS.
Mostly in mammals (except for domestic cats intestinally exposed to H5N1 HPAIV), 
IAV infections are primarily epitheliotropic, infecting and replicating in epithelial cells of 
the respiratory tract. However, in several bird species, such as chickens and black swans, 
HPAIV infections have shown to be primarily endotheliotropic, infecting and replicating 
systemically in vascular endothelial cells. This particular cellular tropism of AIVs has 
consequences for the pathogenesis, virulence, viral excretion and transmission in those 
specific animal species.
The role that endothelial cells play in the pathogenesis of ARDS seems foremost 
indirect through production of pro-inflammatory cytokines when activated by adjoining 
IAV-infected epithelial cells, and not caused by direct structural damage of endothelial 
cells of infection of endothelial cells. These cytokines augment and perpetuate 
the inflammatory response, resulting in damage to the alveolar epithelial cells and 
weakening of the EEB. By some researchers, endothelial cells were proposed to act as the 
central orchestrators in cytokine amplification in the pathogenesis of influenza-induced 
ARDS (135). This proposition is likely because of the abundance of endothelial cells in 
lungs as well as their capacity to produce large amounts of many of pro-inflammatory 
cytokines, and likely also because of their strategic location, by which they can trap 
inflammatory cells passing through the blood vessel and direct them towards the site 
of inflammation in the pulmonary alveoli. The major driving forces in the pathogenesis 
of influenza-induced ARDS may be unravelled by selectively blocking pro-inflammatory 
mechanisms orchestrated by endothelial cells such as the coagulation cascade, 
chemotaxis and diapedesis of inflammatory cells, and complement activation. Although 
the alveolar endothelium does not constitute the strongest layer of EBB, further studies 
in cats with endotheliotropic IAVs such as H5N1 HPAIV might provide further insights in 
the pathogenesis of influenza-induced ARDS and oedema formation. Besides infections 
in chickens and swans, H5N1 HPAIV showed a remarkable yet not fully understood 
endotheliotropism and generalisation of infection after intestinal inoculation with 
infected capsules of cats (144). Interestingly, these cats developed neither ARDS nor 
pulmonary oedema, in contrast to intratracheally H5N1 inoculated cats (249). Together, 
these findings suggest that local endothelial activation plays a more important part 
than does direct endothelial cell damage by rare mammalian IAV infections. Gastro-
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intestinal inoculations with H5N1 HPAIV have been performed in ferrets by feeding 
meat from infected chickens (673) and by infected capsules (274), resulting in systemic 
virus spread, yet endothelial cell infections were not reported. Recommended future 
research on the role of endothelial cells in ARDS should focus on blocking their active 
state, including blockade of permissive selectins and integrins. Preferably such studies 
should be performed in the ferret model, although the lack of ferret specific antibodies 
might prove to be a hurdle. Nonetheless, potential results from ferret studies would 
likely provide additional insights in the pathogenesis of influenza-induced ARDS likely 
valuable for influenza-intervention options.
Lymphocytes
Lymphocytes are inflammatory cells mostly involved in adaptive immune responses. 
In immunologically naïve people and animals, both subtypes (B- and T-lymphocytes) 
need specific antigen priming and activation before they infiltrate and proliferate in 
influenza-inflamed lungs. This process takes several days and as such lymphocytes are 
deemed less relevant in the (per)acute stages of influenza-induced ARDS pathogenesis 
in naïve animal models, and were not discussed extensively previously. However, natural 
killer (NK) cells, being of lymphocytic progeny, are discussed in this section about acute 
inflammation since they function as effector cells of the innate immune response. They 
can kill IAV-infected cells by enzymatic degradation (by granzymes and perforins), or by 
inducing apoptosis by expressing Fas ligand or TRAIL on their cell surface, without the 
necessity of prior activation by antigen presentation (674). As such, they can kill infected 
pneumocytes, and likely influence the integrity of the alveolar EEB. However, the role 
of NK cells in the pathogenesis in acute influenza-induced disease is less straightforward 
than this. Early reports by Nogusa and colleagues (675) and Stein-Streilein and colleagues 
(676) showed that IAV infection in NK-depleted mice and hamsters induced increased 
morbidity and mortality. These finding seem to corroborate a protective effect of NK cells 
following IAV infection. In vitro studies showed that even NK cells could be infected by IAV 
and be killed by apoptosis (677). Conversely, more recent work by Zhou and colleagues 
(678) and Abdul-Careem and colleagues (679) showed that NK cells exacerbated the 
severity of inflammation after influenza inoculation of mice, which suggests that NK cells 
may damage the alveolar EEB by killing influenza-infected epithelial cells.
In summary, though NK cells have shown to participate in the anti-influenza innate 
immunity, their relative significance in potentially weakening the EEB by killing IAV-
infected pneumocytes remains unknown. Speculatively, their role is limited as the low 
numbers of NK cells residing in the normal lung could be overwhelmed by the rapid 
viral replication peaking at 2-3 dpi, whilst significant recruitment of NK cells to the lungs 
occurs from 5 dpi onwards (680), which is also about the same time when the very first 
specific T and B cells appear on the scene (680). If not many pneumocytes are infected by 
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initial inoculation, there may be sufficient NK cells to destroy the infected pneumocytes 
before the virus has a chance to complete the infection cycle and cause a second wave of 
infection among pneumocytes. This also may explain the apparently contradicting results 
of above experiments. If inoculation dose is low, NK cells would be protective and be able 
to abrogate infection. If inoculation dose is high, NK cells would be damaging yet not 
be able to abrogate infection. However to assess the relative significance of NK cells in 
influenza-induced ARDS, prospectively ferrets as apt animal model should be depleted of 
NK cells by treatment with specific monoclonal antibodies, as was performed successfully 
before in other animal models such as mice (675, 676, 681, 682) and hamsters (676).
cONcLUSIONS & PERSPEcTIVES
In conclusion, although influenza-induced ARDS is largely preventable by vaccination, 
permissive conditions such as immunosuppression, zoonotic infections with new 
pathogenic IAVs, and IAV mutants escaping anti-viral drugs, dictate the exploration 
into the pathogenesis and novel therapeutic approaches of ARDS. The need for 
such exploration is accentuated by the fact that once people develop ARDS, case 
fatality rate is high. Classically, interventions and therapies against influenza-induced 
ARDS were focused on reducing viral replication. Except for prolonged infections in 
immunosuppressed patients, the duration of the replicative phase of IAVs is limited to 
only five days on avergae, rendering a narrow window of therapeutic opportunity to 
abrogate viral replication. The longer lasting recovery phase from diffusely damaged 
alveolar epithelial-endothelial barrier (EEB), and impaired gas exchange by pulmonary 
oedema will benefit from enhanced convalescence. Therefore future treatments 
of influenza-induced ARDS should shift their focus towards an augmented recovery 
phase of ARDS rather than trying to limit viral replication. Given our considerations 
on the importance of the alveolar epithelium in influenza-induced ARDS and alveolar 
oedema, this should be attempted by actively stimulating re-epithelisation in order to 
expedite repair of the EEB thereby safeguarding the osmotic gradient allowing restored 
imperative gas exchange across the delicate structure of the pulmonary alveolus. 
Additionally, accelerated re-epithelisation may reduce pulmonary fibrosis in survivors 
of ARDS. Overall, recommendations given in this thesis for prospective research topics 
in influenza-induced ARDS include: visualise and understand microscopic lesions in 
the alveolar EEB, deplete and measure levels of pro-inflammatory cytokines and key 
inflammatory cells, and treatment with drugs like growth factors to enhance lung 
repair. These proposed topics can and should be studied in the ferret model, in order 
to appropriately assess each factor and/or mechanism for its relative significance in the 
pathogenesis and intervention of influenza-induced ARDS.
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NEDERLANDSE SAMENVATTING
In dit hoofdstuk wordt het proefschrift samengevat. Hoofdstuk 1 geeft 
achtergrondinformatie om de rest van het proefschrift te kunnen begrijpen. Infectie 
met een influenzavirus kan de ziekte griep (influenza) bij mens en diverse andere 
diersoorten veroorzaken. Vier genera van influenzavirussen worden op basis van 
antigene en structurele verschillen erkend: influenza A, B, C, en D virussen. Deze genera 
verschillen in gastheerspectrum. Influenza A virussen (IAVs) komen endemisch voor 
bij diverse zoogdieren (voor zover bekend bij mensen, varkens, paarden, honden, en 
vleermuizen) en bij vogels. De IAVs die endemisch bij mensen vóórkomen veroorzaken 
elk jaar griepepidemieën; in gematigde klimaatzones vinden deze doorgaans gedurende 
de wintermaanden plaats. Infecties met een nieuw IAV, waartegen mensen of dieren 
geen of geringe immuniteit hebben, kunnen in zeldzame gevallen leiden tot individuele 
infecties, lokale epidemieën en zelfs tot een wereldwijde uitbraak of pandemie. 
Dergelijke infecties met nieuwe IAVs kunnen afkomstig zijn van vogels of van zoogdieren 
zoals varkens. Influenza B virussen (twee soorten) kunnen bij de mens vergelijkbare 
seizoensgebonden griep veroorzaken als IAVs, en kunnen ook zeehonden en varkens 
infecteren. Influenza C virus kan bij de mens een milde bovenste luchtweginfectie 
veroorzaken, en infecteert ook varkens. Influenza D virus is alleen bij varkens en 
runderen aangetoond.
De rest van dit proefschrift beperkt zich tot studies met IAVs. Deze virussen 
hebben een negatief enkelstrengs RNA genoom van acht segmenten, waarvan twee 
coderen voor de oppervlakte-eiwitten haemagglutinine (HA) en neuraminidase (NA). 
Terwijl HA de aanhechting van een IAV partikel aan een gastheercel mogelijk maakt, 
is NA verantwoordelijk voor het losmaken ervan. Subtypering van IAVs geschiedt op 
basis van hun HA en NA eiwitten: tegenwoordig worden 18 HA subtypen (H1-H18) 
en 11 NA subtypen (N1-N11) erkend, die in vrijwel elke combinatie van HA en NA 
kunnen voorkomen. IAVs kunnen gensegmenten uitwisselen en vormen zo nieuwe 
IAVs. Bij watervogels, die beschouwd worden als het natuurlijke reservoir van IAVs, 
komen IAVs, bestaande uit combinaties van de subtypes H1-H16 en N1-N9, in het 
darmkanaal voor, doorgaans zonder duidelijke klinische verschijnselen te veroorzaken 
(laagpathogene aviaire influenzavirussen; LPAIVs). In pluimvee kunnen de subtypen 
H5 en H7 echter muteren tot hoog pathogene vogelgriepvirussen (hoogpathogene 
aviaire influenzavirussen; HPAIVs), die systemische infecties met een aanzienlijke 
sterfte (mortaliteit) kunnen induceren. H17N10 en H18N11 zijn de meest recente 
IAVs geïsoleerd uit gezonde fruitetende vleermuizen (Sturnira sp. en Artibeus sp.) uit 
Midden- en Zuid-Amerika.
Bij mensen circuleren tegenwoordig de seizoensgriepvirussen (H3N2 en H1N1). 
Deze virussen kunnen jaarlijks aan de bestaande immuniteit van de wereldbevolking 
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ontsnappen door continu optredende kleine mutaties in de HA en/of NA gensegmenten 
(“antigenic drift”), en kunnen zo tot nieuwe infecties en jaarlijkse epidemieën leiden. 
Wereldwijd overlijden per jaar naar schatting 250.000 tot 500.000 mensen aan griep 
tijdens griepepidemieën.
In zeldzame gevallen kan een mens geïnfecteerd worden met een IAV, waarvan 
sommige of alle gensegmenten anders zijn dan die van de seizoensgriepvirussen 
(“antigenic shift”). Deze nieuwe gensegmenten zijn afkomstig van een andere 
diersoort. Een dergelijk nieuw IAV kan een pandemie veroorzaken door ontwikkeling 
van een efficiënte overdraagbaarheid (transmissibiliteit) van mens naar mens in een 
relatief immunologisch naïeve populatie, wat leidt tot een hoge infectiegraad, een 
hoog ziektecijfer (morbiditeit) en soms hoge mortaliteit. Gedurende de laatste eeuw 
zijn er vier belangrijke pandemieën voorgekomen: de Spaanse griep (H1N1) met piek 
in 1918, de Aziatische griep (H2N2) in 1957, de Hong Kong griep (H3N2) in 1968, en de 
Mexicaanse griep (H1N1) in 2009. De Spaanse griep was zeer ernstig vanwege, naar 
schatting, ernstige ziekte bij een kwart van de wereldbevolking, en zo’n 50 miljoen 
sterfgevallen.
Vogelgriepvirussen zoals H5N1 en H7N9 kunnen tot infecties bij mensen leiden door 
nauw contact met pluimvee of met hun producten en hun excreta. Vooral in Zuidoost-
Azië en Egypte hebben dergelijke infecties in de afgelopen jaren geleid tot ernstige en 
soms dodelijke griepgevallen met longontsteking. Deze vogelgriepvirussen worden 
praktisch niet van mens op mens overgedragen. Echter, mocht een vogelgriepvirus zich 
zodanig ontwikkelen dat dergelijke overdracht wel efficiënt plaatsvindt, dan kan dit tot 
een pandemie leiden.
Ongecompliceerde influenza is een ziekte ten gevolge van infectie met een 
influenzavirus, meestal een seizoensgriepvirus, en wordt gekenmerkt door ontsteking 
van slijmvliezen van de bovenste luchtwegen zoals neus- en bijholten en keel, maar 
ook van de luchtpijp (trachea) en grotere vertakkende luchtwegen (bronchiën), en 
voorts algemene malaise en koorts. Seizoensgebonden IAVs kunnen zich hechten aan 
epitheelcellen met humane type IAV-receptoren (zogenaamde α-2,6 siaalzuurgebonden 
receptoren), welke vooral in de bovenste luchtwegen voorkomen. Na virusaanhechting 
kunnen deze epitheelcellen worden geïnfecteerd gevolgd door virusreplicatie welke 
piekt op zo’n twee dagen na infectie om in de daaropvolgende dagen geleidelijk af 
te nemen. Virusreplicatie resulteert gewoonlijk in het verlies van de geïnfecteerde 
epitheelcellen en inductie van een ontstekingsreactie met lokale en gegeneraliseerde 
ziekteverschijnselen. De ontstekingsreactie van ongecompliceerde influenza is 
doorgaans mild en van vlot voorbijgaande aard en wordt histologisch gekenmerkt 
door epitheliale degeneratie en loslating (desquamatie). Voorts kan er sprake zijn 
van bloedrijkdom (hyperaemie), vochtophoping (oedeem), en lymphohistiocytaire 
ontstekingsinfiltraten in de direct onderliggende slijmvlieslagen.
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IAV infectie kan zich onder bepaalde omstandigheden uitbreiden naar de longen, 
waardoor er dan sprake is van een gecompliceerde influenza, die wordt gekenmerkt door 
een ernstiger ziektebeeld met longontsteking (pneumonie). Belangrijke risicofactoren 
voor het ontwikkelen van ernstige griep met longontsteking zijn: onderliggende hart- 
en vaatziekten, andere longaandoeningen, verminderde weerstand, stofwisselings- en 
tumorziekten, vetzucht en zwangerschap. De diep gelegen longblaasjes (alveoli) zijn 
bekleed met epitheelcellen bestaande uit type I longcellen (pneumocyten) die de 
wanden van de alveoli bekleden met een flinterdunne doch waterdichte laag, en uit 
type II pneumocyten die o.a. een rol spelen in herstel na beschadiging. Rondom de 
alveoli circuleert bloed door een netwerk van haarvaten (capillairen), die bekleed 
worden door endotheelcellen. Gezamenlijk vormen deze epitheel- en endotheelcellen 
de begrenzing (epithelio-endotheliale barrière; EEB) tussen de luchthoudende alveoli en 
de bloedstroom, waarin de epitheelcellen de sterkste laag vormen. Een ontsteking van 
de alveoli tijdens IAV infectie beschadigt het epitheel en belemmert de levensbelangrijke 
gasuitwisseling van zuurstof en koolzuurgas tussen lucht en bloed, door zwelling van 
de EEB en door lekkage van vocht (alveolair oedeem) uit de bloedstroom naar de 
alveoli. Dit kan aanleiding geven tot het ontstaan van acuut longfalen, en het daarop 
volgende “acute respiratory distress syndrome” (ARDS). De ziekteverschijnselen 
en symptomen van een door influenza geïnduceerde virale pneumonie en ARDS 
worden gekenmerkt door hoge koorts, algehele malaise, benauwdheid (dyspneu), 
zuurstoftekort (hypoxie), blauwzucht van o.a. slijmvliezen en vingertoppen (cyanose) en 
ophoesten van bloed (haemoptysis). Tekenen van multi-orgaan falen en sterfte kunnen 
optreden reeds 48 uur na de eerste symptomen. Veelal worden virale pneumonieën 
verergerd door secundaire opportunistische bacteriële infecties. Een door influenza 
geïnduceerde pneumonie wordt macroscopisch gekenmerkt door gezwollen, zware, 
en vochtrijke paars-rode longen met ribafdrukken, en een histologisch beeld van een 
uitgebreide alveolaire celdood (necrose) en ontsteking, zogenaamde “diffuse alveolar 
damage” (DAD) met bloedingen (haemorrhagie), oedeem, hyaliene membranen en 
acute ontstekingsinfiltraten. Een laag van zich vermeerderende type II pneumocyten 
(hyperplasie), die zich kunnen differentiëren in type I pneumocyten om zo de EEB te 
herstellen, kan aanwezig zijn.
In tegenstelling tot menselijke seizoensgriepvirussen, hecht het H5N1 vogelgriepvirus 
zich bij de mens bij voorkeur aan de zogenaamde α-2,3 siaalzuurgebonden receptoren, 
die vooral bij vogels voorkomen en bij de mens vooral op de epitheelcellen in de diepere 
delen van het ademhalingsstelsel (respiratietractus), zoals de kleinste vertakkende 
luchtwegen (bronchioli) en alveoli. Het H7N9 vogelgriepvirus en het Mexicaanse 
H1N1 griepvirus van de pandemie in 2009 kunnen zich zowel aan humane α-2,6 
siaalzuurgebonden receptoren, als aan aviaire type α-2,3 receptoren hechten in de 
bovenste delen en in de diepe delen van de respiratietractus. De aanhechtingspatronen 
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van deze virussen worden weerspiegeld door de presentatievormen van influenza die ze 
veroorzaken, waarbij veelal sprake is van gecompliceerde virale pneumonieën.
Manieren om influenza te voorkomen (profylaxe) zijn vaccinatie en behandeling 
met antivirale middelen die zowel profylactisch als genezend (therapie) kunnen 
worden toegepast. Jaarlijks moet het seizoensgriepvaccin worden aangepast aan 
de circulerende virussen. Voorbeelden van antivirale middelen zijn de bestaande 
neuraminidaseremmers, waaronder oseltamivir (Tamiflu®) en zanamivir (Relenza®) 
en de in ontwikkeling zijnde specifieke antilichaampreparaten. Diermodellen zijn 
nodig om vaccins en antivirale middelen op hun werkzaamheid te toetsen. Voor de 
evaluatie van de gecompliceerde processen van de ziekteontwikkeling (pathogenese) 
of het juist het veelal beoogde voorkómen van ziekte, en transmissibiliteit van een IAV 
volgende op een infectie bestaan geen proefdiervrije (in vitro) alternatieven. Diverse 
proefdiersoorten (o.a. muis, cavia, fret) worden gebruikt in dergelijke evaluaties. De 
fret is als proefdiersoort voor veel experimenten het meest geschikt gebleken om als 
model te dienen om influenza bij de mens na te bootsen.
Hoewel influenza, in zowel de ongecompliceerde als de gecompliceerde vorm, een 
bekend ziektebeeld is, is de pathogenese ervan slechts ten dele bekend. Het doel 
van dit proefschrift was, middels onderzoek naar de pathogenese van influenza in 
het frettenmodel, opheldering van de belangrijkste pathogenetische factor(en) in het 
ontstaan van door influenza geïnduceerd ARDS en het optredend longoedeem. Inzicht 
in de pathogenese is van het grootste belang om deze acute aandoening gericht en 
adequaat te kunnen bestrijden of wellicht zelfs te voorkomen.
Hoofdstuk 2 van dit proefschrift is een literatuurstudie naar de kennis over de 
pathogenese van door influenza geïnduceerd ARDS op het moment dat de studies in 
het kader van dit proefschrift werden aangevangen. De diverse betrokken structurele 
elementen van de EEB, ontstekingscellen en ontstekingsfactoren (cytokinen en 
chemokinen) werden betrokken in de analyse. Met name de bevindingen uit hoofdstuk 
2.1 hebben geleid tot het inzicht dat bij door influenza geïnduceerd ARDS in het bijzonder 
de alveolaire epitheelcellen van groot belang zijn. Niet alleen worden deze cellen direct 
geïnfecteerd via de inademingslucht en vindt de virusvermeerdering er plaats, maar 
ook vormen deze alveolaire epitheelcellen onder normale omstandigheden de meest 
waterdichte cellaag van de EEB. Eerdere onderzoeken naar de pathogenese van ARDS 
hebben zich veelal primair gericht op alveolaire endotheelschade door toxinen via de 
bloedcirculatie als startpunt van dit proces. Derhalve moest de focus van het onderzoek 
en behandeling van door influenza geïnduceerd ARDS en longoedeem juist gericht 
worden op het alveolaire epitheel.
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Onder bepaalde omstandigheden bij diverse diersoorten vertoont IAV ook een 
systemisch tropisme voor endotheelcellen. Zo wordt in hoofdstuk 2.2 beschreven dat 
HPAIVs in bepaalde vogelsoorten (o.a. de kip en de zwarte zwaan) juist de endotheelcellen 
primair infecteren en niet de epitheelcellen zoals bij de meeste zoogdieren en andere 
vogelsoorten. Een uitzondering binnen de zoogdieren is een experimentele inoculatie 
van H5N1 HPAIV in het darmkanaal van katten, die leidt tot systemische endotheliale 
infecties en ziekte zonder ARDS. Dit is een tegenstelling tot intratracheale inoculatie van 
katten met hetzelfde virus, hetgeen wel leidt tot infectie van respiratoir epitheel. Hoewel 
IAV de endotheelcellen van de EEB van zoogdieren meestal niet infecteert, spelen deze 
endotheelcellen wel degelijk een rol in de pathogenese van door influenza geïnduceerd 
ARDS en longoedeem. Dit komt doordat geactiveerde endotheelcellen middels hun 
kwalitatieve en kwantitatieve cytokineproductie beschouwd worden als belangrijke 
stuwers van een pro-inflammatoire ontstekingsreactie. Medicamenteuze remming van 
endotheelactivatie en cytokineproductie bij influenza zou een ontstekingsremmend 
effect moeten hebben in de pathogenese van ARDS.
In hoofdstuk 3.1 wordt beschreven dat vele diersoorten gevoelig zijn voor IAV infecties. 
De meeste infecties zijn kortdurend en voorbijgaand echter het gastheerspectrum 
van endemische infecties breidt zich uit. Onderzoek dat leidt tot beter begrip van de 
omstandigheden waaronder en de wijze waarop nieuwe IAVs naar een andere diersoort 
worden overgedragen, en hoe het virus zich vervolgens efficiënt kan verspreiden in de 
populatie van de nieuwe gastheersoort, is van groot belang. Met dit wetenschappelijk 
inzicht zouden mogelijk griepepidemieën of zelfs pandemieën beter kunnen worden 
bestreden. Waarom in de ene diersoort een IAV endemisch kan worden en ziekte kan 
veroorzaken en in de andere diersoort niet is grotendeels onbekend. Groepshuisvesting 
met hoge bezettingsgraad van immunologisch naïeve individuen zijn wel als risicofactoren 
aangemerkt voor ernstige influenzauitbraken na introductie van nieuwe IAVs. In het 
algemeen zijn van zoogdieren de carnivoren en omnivoren gevoeliger voor IAV infecties 
en ziekte dan herbivoren onder vergelijkbare omstandigheden. Opmerkelijk genoeg 
zijn paarden en kamelen een uitzondering en juist wel gevoelig voor endemische en 
epidemische IAV infecties en ziekte. De geschiktheid van fretten (ook carnivoren), zoals 
beschreven in hoofdstuk 3.2, voor onderzoek naar influenzapathogenese wordt deels 
toegeschreven aan het met de mens vergelijkbare, aanhechtingspatroon van IAVs in de 
respiratietractus. De fret is ook zeer gevoelig voor natuurlijke en experimentele infecties 
met onveranderde humane en aviaire IAVs. Deze induceren na intratracheale inoculatie 
in de fret een vergelijkbaar ziektebeeld en vergelijkbare longlaesies als bij de mens 
met dezelfde infecties. In dit proefschrift worden intratracheale inoculatie van IAVs in 
fretten als model voor influenza bij de mens verkort aangeduid met “het frettenmodel”. 
Diverse andere proefdiersoorten gebruikt voor influenzaonderzoek hebben allen hun 
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diersoortspecifieke voor- en nadelen, die zorgvuldig dienen te worden afgewogen vóór 
het opzetten van studies, met een gerichte wetenschappelijke vraagstelling.
In hoofdstuk 4 wordt het frettenmodel gebruikt om het ziekteverwekkende 
vermogen (pathogeniciteit) en transmissibiliteit van nieuwe IAVs te evalueren. Zo wordt 
in hoofdstuk 4.1 beschreven hoe de fret wordt ingezet voor modelontwikkeling om 
pathogenese- en interventiestudies te kunnen verrichten naar het H7N9 vogelgriepvirus, 
dat bij mensen in China vanaf 2013 een nieuwe influenzauitbraak met hoge morbiditeit 
en mortaliteit induceerde. De resultaten van deze studie bevestigen de geschiktheid 
van het frettenmodel, en ook toonden zij aan dat dit laagpathogene vogelgriepvirus 
juist een hoge pathogeniciteit in de fret vertoonde, wat overeenkwam met de hoge 
morbiditeit en mortaliteit bij de mens. Tijdens de pandemie van 2009 werden bij 
immuungecompromitteerde, persistent geïnfecteerde en met neuraminidaseremmers 
behandelde patiënten gemuteerde resistente virusstammen van het nieuwe Mexicaanse 
H1N1 griepvirus in een hoog percentage aangetroffen. Omdat het risico voor introductie 
en verspreiding van deze therapieresistente virusstammen te evalueren werden de 
pathogeniciteit en potentiële transmissibiliteit in het frettenmodel bestudeerd. In 
hoofdstuk 4.2 wordt beschreven dat deze therapieresistente virusmutant in vergelijking 
met het wildtype pandemische Mexicaanse griepvirus een vergelijkbare transmissibiliteit 
en pathogeniciteit in het frettenmodel vertoonde.
In hoofdstuk 5 is beschreven hoe voor het eerst “computed tomography”(CT)-
scanning succesvol en herhaaldelijk toegepast op levende fretten, om de pathogenese 
van ARDS door het destijds pandemische Mexicaanse H1N1 griepvirus in het 
frettenmodel in beeld te brengen. Het was mogelijk om de mate van verandering van 
luchthoudendheid van de frettenlong in procenten te kwantificeren en tevens bleek 
op 3 dagen na virusinoculatie de piek van witte longversluiering aanwezig die reeds 
vanaf de volgende dag herstellende was. Middels histologische identificatie bleek 
deze versluiering te bestaan uit longoedeem en ontstekingsinfiltraten ter plaatse van 
virusgeïnfecteerde epitheelcellen van alveoli en bronchioli. Voordelen van deze nieuwe 
analysemethode t.o.v. conventionele studies met meerdaagse sectiemomenten zijn: (a) 
vermindering van het aantal benodigde proefdieren, daar (b) het gescande dier ook 
fungeert als zijn eigen controledier, (c) geen noodzaak om pathologiedata verkregen 
van verschillende sectiemomenten van verschillende proefdieren met elkaar te 
moeten vergelijken, (d) vaststelling van het optimale sectiemoment met maximale 
longversluiering zodat in volgende influenza-interventiestudies optimaal gebruik 
gemaakt kan worden van de maximale spreiding in longlaesies tussen behandelde 
dieren en onbehandelde controledieren. Op dit sectiemoment zal namelijk de mate van 
werkzaamheid van het te toetsen vaccin of antivirale middel het meest evident zijn.
In hoofdstuk 6 worden diverse influenza-interventiestudies beschreven waarbij het 
frettenmodel veelal voor het eerst wordt toegepast. In hoofdstuk 6.1 werden middels 
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dagelijkse in vivo CT-scanning veranderingen in luchthoudendheid van de frettenlong 
na experimentele influenza-inoculatie gekwantificeerd om de werkzaamheid van 
een influenzavaccin uit te lezen. De bevindingen van deze studie bevestigden de 
geschiktheid van het frettenmodel om een vaccinwerkzaamheid te toetsen aan 
de hand van de mate van luchthoudendheid van de longen, naast de traditionele 
virologische en pathologische uitleesparameters. In hoofdstuk 6.2 wordt beschreven 
hoe het frettenmodel werd toegepast om de werkzaamheid van verschillende nieuwe 
zogenaamde levend-geattenueerde vaccins tegen het Mexicaanse H1N1 griepvirus te 
evalueren. Deze vaccins worden intranasaal toegediend, alwaar het vaccinvirus beperkt 
kan repliceren om zodoende toch een adequate immuniteit tegen Mexicaanse griep 
te induceren, zonder noodzaak van een additioneel immuunstimulerend bestanddeel 
(adjuvans).
Hoofdstuk 6.3 vat de praktische inzetbaarheid van het frettenmodel aan de hand 
van de pathologische bevindingen in een viertal van influenza-interventiestudies samen. 
Telkens werden verminderingen van laesies van de respiratietractus in gevaccineerde 
dieren t.o.v. schijngevaccineerde (sham-vaccinated) controledieren aangetroffen. 
Tevens werd beschreven hoe met pathologische evaluatie de geslaagde opzet van een 
medicamenteuze immuunsuppressie in het frettenmodel is beoordeeld. Aanwijzingen 
hiervoor waren een histologische afname van het aantal immuuncellen in lymfoide 
en bloedvormende (haemopoietische) organen, zoals lymfknopen, tonsillen, milt, en 
beenmerg, en verder ook het optreden van een verlengde virusexcretie en het opkomen 
van opportunistische bacteriële en mycotische infecties van de longen. Dit model is 
van belang bij het bestuderen van influenza bij immuungecompromitteerde individuen, 
zoals geriatrische patiënten en mensen na orgaantransplantatie.
Hoofdstuk 7 bevat de samenvattende discussie van de belangrijkste bevindingen 
van dit proefschrift. Ondanks dat seizoensinfluenza grotendeels voorkomen kan 
worden door vaccinatie, is pathogeneseonderzoek relevant vanwege het voortdurend 
optreden van factoren die predisponeren voor een ernstig beloop van influenza zoals 
bij patiënten met een verhoogd risico op complicaties zoals genoemd in hoofdstukken 
1 en 6.3, zoönotische infecties met nieuwe pathogene IAVs, en het ontstaan van 
therapieresistente virusmutanten. Voorts bestaan er nog steeds hiaten in de kennis over 
specifieke eigenschappen van de EEB (zie tabel 7.2.1) die een rol spelen bij het ontstaan 
van ARDS, dat ondanks de beste geneeskundige zorg nog altijd tot hoge mortaliteit 
leidt. Pathogeneseonderzoek geeft kennis en inzicht die van groot belang kunnen zijn 
voor de ontwikkeling van nieuwe behandelmethoden van ARDS. De belangrijke rol die 
het frettenmodel in het influenzaonderzoek kan spelen wordt bevestigd bij nieuwe 
toepassingen zoals CT-scannen, bij de bestudering van nieuwe IAVs, maar ook bij het 
testen van nieuwe geadjuveerde influenzavaccins, antivirale therapieën en de effecten 
van medicamenteuze immuunsuppressie. De belangrijkste celtypen betrokken bij de 
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pathogenese van influenza werden besproken in de discussie. Concluderend kan de 
alveolaire epitheelcel in de EEB niet alleen als een zeer belangrijk celtype beschouwd 
worden in de pathogenese van door influenza geïnduceerd ARDS en longoedeem, 
maar dit zeker ook als doelwit voor het ontwikkelen van interventiesstrategieën. Waar 
conventionele interventies zich richten op afremming van influenzavirusreplicatie, wordt 
in dit proefschrift de aandacht tevens gevestigd op de mogelijke rol van medicamenteuze 
toepassing van lichaamseigen groeifactoren, zoals HGF*, KGF en GM-CSF (CSF2). Deze 
zouden het herstel van ARDS kunnen bespoedigen door het bevorderen van reparatie 
van het alveolaire epitheel, hetgeen zou kunnen leiden tot versneld functioneel herstel 
van de EEB, resorptie van longoedeem, en op de lange termijn een vermindering van 
het ontstaan van longfibrose.
*HGF, hepatocyte growth factor; KGF, keratinocyte growth factor; GM-CSF, granulocyte-
macrophage colony stimulating factor, syn. CSF2, colony stimulating factor 2.
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ABBREVIATIONS
ADV - Aleutian Disease Virus
AEC - 1Alveolar Epithelial Cell, 23-Amino-9-Ethylcarbazole
AGID - Agar Gel Immunodiffusion (assay)
AIV - Avian Influenza Virus
ALI - Acute Lung Injury
ALV - Aerated Lung Volume
ARDS - Acute Respiratory Distress Syndrome
AUC - Area Under Curve
BAL - Bronchoalveolar Lavage
BALB/c - ‘Bagg’s Albinos’ inbred mouse strain
BALT - Bronchus-associated Lymphoid Tissue
BM - Basement Membrane
BSA - Bovine Serum Albumin
BSL - Biosafety Level
ca - Cold Adapted
CCL -  CC motif (two adjacent cysteines) Chemokine Ligand (several subtypes 
are recognised)
CDC - Centers for Disease Control and Prevention
CFSE - Carboxyfluorescein Diacetate Succinimidyl Ester
CIV - Canine Influenzavirus
CNS - Central Nervous System
CO - Corticosteroid
CSF - Colony stimulating factor (several subtypes are recognised)
CT - Computed Tomography
CXCL - CXC motif (two N-terminal Cysteines separated by one amino acid X)
  Chemokine Ligand (several subtypes are recognised)
CXCR - CXC motif (two N-terminal Cysteines separated by one amino acid X)
  Chemokine Ligand Receptor (several subtypes are recognised)
C57BL/6 - ‘C57-Black 6’ inbred mouse strain
DAB - 2,3-diaminobenzidine
DID - Double agar Immunodiffusion
DIC - Disseminated Intravascular Coagulation
DLG1 -  Disks large homolog 1, also known as synapse-associated protein 97 
or SAP97
dpe - Days Post Exposure
dpi - Days Post Infection
DR5 - Death Receptor 5
300
ECMO - Extra Corporeal Membrane Oxygenation
EMEM - Eagle’s Minimal Essential Medium
ENaCs - amiloride-sensitive Epithelial Sodium Channels
ESEV -  ligand sequence Glu-Ser-Glu-Val, at C-terminal of NS1 proteins of 
most AIVs
ECG - Electrocardiogram
EDTA - Ethylenediaminetetraacetic Acid
EID50 - Median Egg Infective Dose
ELISA - Enzyme-Linked Immunosorbent Assay
FITC - Fluorescein Isothiocyanate
HA - Haemagglutinin, receptor-binding glycoprotein
HI - Hemagglutination Inhibition
ENaC - Amiloride-sensitive Epithelial Sodium Channel
FCS - Fetal Calf Serum
Gal - Galactose
HEPA - High Efficiency Particulate Air (filter)
HMPV - Human Metapneumovirus
HPAIV - Highly Pathogenic(ity) Avian Influenza Virus
hpi - Hours Post Infection
HU - Hounsfield Units
HGF - Hepatocyte Growth Factor
H&E - Haematoxylin & Eosin
GALT - Gut-associated Lymphoid Tissue
GGO - Ground Glass Opacity
GM-CSF - Granulocyte Macrophage Colony Stimulating Factor
IAV - Influenza A virus
IBV - Influenza B virus
ICAM - Intercellular Adhesion Molecule (several subtypes are recognised)
ICV - Influenza C virus
IFN - Interferon (several subtypes are recognised)
Ig - Immunoglobulin (several subtypes are recognised)
IHC - Immunohistochemistry
IL - Interleukin (several subtypes are recognised)
ILI - Influenza-Like Illness
i.m. - Intramuscular
IN - Intranasal
ISH - In Situ Hybridisation
IT - Intratracheal
IVPI - Intravenous Pathogenicity Index
301
Ad
de
nd
a 
KGF - Keratinocyte Growth Factor
LAIV - Live Attenuated Influenza Vaccine
LLF - Lung Lavage Fluid
LPAIV - Low Pathogenic(ity) Avian Influenza Virus
LPS - Lipopolysaccharide
LRT - Lower Respiratory Tract
MDCK cells - Madin-Darby Canine Kidney cells
MEM - Minimal Esential Medium
MK cells - Monkey Kidney cells
MMF - Mycophenolate Mofetil (CellCept®)
MMP - Matrix metalloproteinase (several subtypes are recognised)
MODS - Multi-Organ Dysfunction Syndrome
MPO - Myeloperoxidase
MRI - Magnetic Resonance Imaging
M1 - Matrix 1, ribonucleoprotein-interacting matrix protein
M2 - Matrix 2, ion channel protein
NA - Neuraminidase, sialic acid (SA)-destroying enzyme
NADPH - Nicotinamide adenine dinucleotide phosphate
NAI - Neuraminidase inhibitor
Na+/K+ -  ATPase-Sodium-Potassium Adenosine Triphosphatase, also known as 
the Na+/K+ pump or Sodium-Potassium pump
NAL - NA-like (protein)
NET - Neutrophil Extracellular Trap
NHP - Non-Human Primate
NO - Nitric Oxide
NOS2 - Nitric Oxide Synthase 2
NP - Nucleoprotein, RNA-binding protein
NS - 1Non-Structural (protein), 2Nose Swab
NS1 - Non-Structural 1 (protein), interferon (IFN)-antagonising protein
NS2 - Non-Structural 2 (protein) nuclear export protein
OS - 1Oseltamivir (Tamiflu®), 2Oropharyngeal Swab
PA - Polymerase Acidic
PB1 - Polymerase Basic 1
PB1-F2 - Polymerase Basic 1-F2, pro-apoptotic protein
PB2 - Polymerase Basic 2
PBM - PDZ-ligand Binding Motif
PBMC - Peripheral Blood Mononuclear Cell
PBS - Phosphate-Buffered Saline
PCR - Polymerase Chain Reaction
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Pdm09 - 2009 pandemic
PDZ -  Acronym of three proteins, Post synaptic density protein (PSD95), 
Drosophila disc large tumor suppressor (Dlg1), and Zonula occludens-1 
protein (ZO1). A common structural domain anchoring receptors.
PFU - Plague Forming Unit
pH1N1 - 2009 pandemic H1N1 IAV
PIP - Pandemic Influenza Preparedness
PIV - Parainfluenza Virus
RBC - Red Blood Cell (=erythrocyte)
rg - Reverse Genetic
RLW - Relative Lung Weight (=lung weight / body weight * 100)
ROS - Reactive Oxygen Species
RPMI - Roswell Park Memorial Institute (medium)
RSV - Respiratory Syncytial Virus
SA - Sialic Acid
SARI - Severe Acute Respiratory Infection
SARS - Severe Acute Respiratory Syndrome
s.c. - Subcutaneous
SD - Standard Deviation
SEM - Standard Error of Mean
SPF - Specified Pathogens-Free
TCID50 - Median Tissue Culture Infective Dose
TGF β - Transforming Growth Factor β
TIMP -  Tissue Inhibitor of Metalloproteinases (several subtypes are 
recognised)
TIV - Trivalent Influenza Vaccine
TJ - Tight Junction
TNF - Tumour Necrosis Factor (several subtypes are recognised, α β γ)
TRAIL -  Tumour-necrosis-factor-Related Apoptosis-Inducing Ligand, also 
known as TNFSF10
URT - Upper Respiratory Tract
VCAM - Vascular Cell Adhesion Molecule
VN - Virus Neutralisation
vWF (F8) - von Willebrand Factor (=Factor 8)
WT - Wild Type
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DANKwOORD
Na lang wachten en veel ‘gezwoeg’, is het nu dan eindelijk zover! De afronding van dit 
proefschrift middels het schrijven van mijn dankwoord aan al die personen welke een 
rol hebben gespeeld in de totstandkoming van dit proefschrift. Bedankt aan alle leden 
van de lees- en promotiecommissie.
Beste Ab, mijn promotor en ‘silverback’ van de afdeling waar je mij het vertrouwen en de 
mogelijkheid gaf te promoveren naast een reguliere aanstelling als veterinair patholoog 
bij Viroclinics (VC), hartelijk dank hiervoor! Altijd (vaak) had je tijd en gelegenheid voor 
overleg en reflectie. Ondanks het niet altijd volbrengen van studies met vernieuwende 
experimentele onderzoeksideeën die opborrelden tijdens brainstormsessies, was het 
voor mij niet alleen een voorrecht maar vooral een groot plezier om jou, vanwege je 
immer constructieve en motiverende instelling, als promotor te mogen hebben.
Beste Thijs, mijn promotor, bedankt dat je altijd oprecht, objectief en wetenschappelijk 
kritisch bent. Jouw insteek als promotor is om de promovendus te onderrichten als 
wetenschappelijk onderzoeker in brede zin. Zodoende heb ik veel van je geleerd, zelfs 
meer dan van pathologie en onderzoek alleen. Zo wil ik je bij dezen roemen om je 
brede scoop, je visie, en ook je vogelgeluidenimitaties zijn legendarisch. Altijd (meestal) 
maakte je tijd voor overleg, zij het direct probleemoplossend of breder meer holistisch 
middels enige wetenschapsfilosofie. Het is een privilege van je te hebben mogen leren 
en met je samen te werken, hopelijk ook nog in de toekomst. En wie had ooit gedacht, 
ik zeker niet, dat wij jarenlang dezelfde slaapkamer, al zij het niet gelijktijdig, zouden 
delen!
Hartelijk dank ook aan de directie van VC, met name Hans en Bob (en eerder James), 
voor de mij geboden mogelijkheid om te promoveren naast mijn reguliere aanstelling 
bij VC, al ging het niet altijd even vlot als verwacht. Echter het uitgangspunt van het 
promotietraject was dat het mes aan twee kanten zou snijden, mijn promoveren 
enerzijds en het proefschrift als uithangbord voor de preklinische capaciteiten met 
specialistische mogelijkheden van VC anderzijds, en dat is uiteindelijk prima gelukt.
De preklinische groep van VC, Koert ik wil je bedanken voor je nimmer aflatende 
vasthoudendheid maar vooral voor de plezierige samenwerking tijdens de imagingstudies 
aan het begin van dit promotieonderzoek, Geert (‘zonder Geert geen dierproeven’) 
bedankt voor je professionaliteit, tomeloze inzet en gezelligheid en tijdens het verrichten 
van de vele secties, ik denk dat ik met niemand meer gelachen heb tijdens het seceren. 
Beste Leon, Willem, Rob, Cindy, Vera, Ronald, preklinikers van het eerste uur, maar 
316
ook die van meer recente samenstelling, Ikrame, Willem H., Rosalie, Marla, Saskia SB, 
Saskia SCB, Patricia, Jonneke, Marie, Stephane, Simone, en Susan welke allen direct en 
indirect hun bijdrage hebben gehad aan dit proefschrift, bedankt. Natuurlijk bedankt 
ook aan alle andere collega’s van VC met wie ik in de afgelopen jaren zeer plezierig heb 
samengewerkt, al dan niet direct gerelateerd aan de totstandkoming dit proefschrift. 
Voorts wil ik in deze context ook nog noemen de mensen uit het Bilthoventijdperk, Nico, 
Hans ook nog bedankt voor de muziek, Jan (†), Wim, en Stephane (thans dus ook ‘echte’ 
VC collega), en ook dank aan de medeauteurs van mijn wetenschappelijke publicaties 
m.n. die van de Afdeling Radiologie van het EMC, Marcel Dijkshoorn, Ieneke Hartmann 
en Prof Krestin.
Dan de befaamde wildlifegroep alias de comparative-pathologygroep, bedankt voor 
de gezelligheid en de extra-curriculaire bezigheden zoals etentjes bij collega’s thuis en 
andere uitjes, en ook wil ik een ieder prijzen om het altijd warme welkom dat jullie als 
groep heten aan nieuwe langdurige of kortere tijdelijke gastkamerbewoners (zoals o.a. 
Tony, Victor, Ursula, Caroline, Marianna, Rebecca (thans VC collega) en Janneke). Verder 
specifiek dank aan, Peter altijd vriendelijk, punctueel en perfectionistisch, bedankt 
voor al je histologische werk met strakke planning (coupes zeker weer z.s.m. klaar…?), 
Marco bedankt voor de gezellige gesprekken vooral die met autosport-updates, Niels 
bedankt voor je regelmatige onregelmatige maar altijd opwekkende aanwezigheid op 
de kamer en ook voor het delen van je werkplek, Lonneke bedankt omdat je altijd zo 
aardig en behulpzaam bent in nog even snel wat immuno’s of in situ’s, Debby bedankt 
voor je wetenschappelijke ambitie dat het naast mijzelf voor velen tot inspiratie 
mag zijn, jammer dat na af en toe wat ‘sparren’ het (nog) nooit tot een vruchtbare 
wetenschappelijke samenwerking of publicatie is gekomen maar wie weet, Leslie 
bedankt voor je specialistische kennis van kansberekeningsmodellen en enthousiaste 
uitleg daarover, jammer dat je plots geen kamergenoot meer was, Kirsty bedankt voor 
onze plezierige en efficiënte samenwerking aan jouw papers met co-auteurschap, en ik 
waardeer je harde en doelgerichte werken en ook je talenknobbel, Lineke bedankt dat 
je, nadat je vanuit Utrecht naar elke maandelijkse ‘Comparative Pathology Meeting’ 
kwam, na enige tijd gelukkig ook in Rotterdam bleef hangen als, door iedereen en zeker 
door mij, zeer gewaardeerde aanwinst in de groep (alleen al voor de lekkere koffie), 
Lidewij bedankt voor ons fijne contact gedurende de laatste jaren zowel in Utrecht als 
Rotterdam, het lijkt nog maar zo kort geleden dat wij onderweg naar een walvis een 
gesprek voerden over je komende promotieonderzoek, om daarna als tussenstopje naar 
Rome in sneltreinvaart even je promotie af te ronden, chapeau! Jurre, je maakt mij altijd 
aan het lachen, bedankt voor je vrolijkheid op de kamer en het lab, en we gaan hierna 
echt een biertje doen, beloofd. En natuurlijk mijn paranimf Judith, bedankt voor onze 
hechte band zowel professioneel als persoonlijk gedurende onze parallel verlopende 
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loopbaan, bedankt voor de regelmatige gesprekken en gezamenlijke vakinhoudelijke 
interesse en kennisuitwisseling met als voorbeeld van weleer onze (samen met Jaco) 
memorabele ‘Ten Bells’ die onze boards verzekerde.
Verder nog van de afdeling, beste Rogier altijd (hoorbaar) goedlachs en opgewekt, 
bedankt voor je kunde en tijd die je er voor over had om mij wegwijs te maken met 
viruskweken, virustitraties en inoculeren van muizen en meer, maar ook voor de goede 
en amusante gesprekken die we veelal voerden tijdens onze gezamenlijke terugreis naar 
Utrecht. Voorts, Joost bedankt voor je plezierige en professionele samenwerking met 
de muizenproeven en later met de frettenstudie, Stella bedankt voor o.a. je spoedhulp 
bij de H7N9 immunokleuringen, Erhard bedankt voor de prima samenwerking tijdens 
de vele frettenstudies, Pieter jammer dat ons ECMO initiatief nooit van de grond is 
gekomen en ook jammer dat de pred-studie dat ook bleek en bleef, echter bedankt voor 
de goede samenwerking met brainstormen en je gezelligheid en behulpzaamheid, David 
bedankt voor je onmisbare ondersteuning op statistisch gebied en je opgewektheid in 
gedagzeggen op de gang.
Verder dank aan de dames van het secretariaat, Simone, Loubna, Maria, en Anouk, 
bedankt voor de uiteenlopende, tot manuscriptsubmissies aan toe, administratieve 
ondersteuning. Verder wil ik aan ieder van de afdeling mijn algemene dank uitspreken 
voor mijn welkom voelen, en wil daarbij, zonder niet genoemden tekort te doen, 
met naam noemen: Ron, Guus, Jan, Theo, Sander H, Monique, Mathilde, Sander v B, 
Miranda, Patrick, Rob, Stalin, Petra, Byron, Nella, Sarah, Penelope, Josanne, Rik, Arno, 
en Marion, en in het bijzonder ook dank aan diegenen van de afdeling die op mijn 
verzoek een voordracht gaven op een van de ‘Comparative Pathology Meetings’: Bart, 
Georges, Rory, Tien, Werner, Cox, Marco G., Corine, en nogmaals Debby/Rogier en ook 
weer Kirsty.
Frank en Joris van de MolMed PGS bedankt voor de vlekkeloze organisatie en plezierige 
samenwerking tijdens deze ‘Comparative Pathology Meetings’ op elke tweede dinsdag 
van de maand en later tijdens de ‘Advances in Comparative Pathology’ in voor- en najaar, 
en in deze context ook hartelijk dank aan Rob Verdijk voor zijn onmisbare ‘humane’ 
bijdrage aan de vergelijkende pathologie.
Verder wil ik graag een aantal mensen, allen bevlogen veterinair pathologen, bij naam 
noemen welke door hun kennis en kunde in de veterinaire pathologie, en dus indirect 
voor dit proefschrift, van groot belang zijn geweest (en de meesten nog steeds zijn): 
Ingrid van der Gaag bedankt dat je zo’n enorme motiverende uitwerking op mij hebt 
gemaakt tijdens de co-schappen in de sectiezaal, voorts heel veel dank aan mijn 
hoofdopleider Ted van den Ingh, en verder natuurlijk aan Jaap van Dijk, Erik Gruys en 
Peer Zwart. Beste Erik en beste Peer bedankt voor onze goede en warme contacten, 
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ook met vakinhoudelijke uitwisseling, die wij tot op de dag vandaag onderhouden. 
In het bijzonder bedankt Peer voor de vele interessante casuïstieken van exoten die 
wij gezamenlijk onder de microscoop bestudeerden in mijn tijd in Utrecht, waarbij wij 
beiden telkens weer bijna kinderlijk zo blij verwonderd waren over de schoonheid van 
ons vak, zo zal ik nooit de simpele maar functionele perfectie van de bouw van het 
‘camera obscura-oog’ van een nautilus vergeten die je mij onder de microscoop schoof. 
Verder veel dank aan Guy en Jaco voor jullie bijdrage in mijn vorming als patholoog en 
ook voor de fijne tijd als directe collega’s en voor jullie vriendschap.
Mijn lieve moeder en vader, veel dank voor de steun en ook zeker voor de vrijheid die 
ik van jullie kreeg tijdens mijn jeugd en later tijdens mijn studie diergeneeskunde te 
Utrecht. Bedankt voor het stimuleren van mijn interesses in dieren en hun natuur door 
mij nooit een strobreed in de weg te leggen om deze verder te kunnen ontdekken en 
te ontwikkelen. Als een voorbeeld van mijn onbezorgde en prima gefaciliteerde jeugd; 
bedankt mam dat je altijd zo stoïcijns mijn ontsnapte slangen vanuit de wasmand of 
vanachter verwarmingsradiatoren in een van de vele terraria, waar mijn kinderkamer 
volledig mee volgebouwd was, terugstopte, of de vanzelfsprekendheid waarmee je 
jonge slangen uit hun ei hielp uitkomen wanneer ik op pad was, en dat jullie er ook 
nooit een punt van maakten wanneer je in het vriesvak weer eens misgreep naar 
een zak vol met eigen gekweekte knaagdieren i.p.v. de beoogde diepvrieszakjes met 
mensenvoedsel, en ook dat waterteilen vol levende vissen, soms met ook allerhande 
kikkers en/of salamanders en/of schildpadden het balkon mochten bevolken. Kortom, 
lieve pap en mam, en ook aan mijn lieve zuster Peggy, bedankt voor mijn warme nest, 
bedankt voor het beantwoorden van al mijn vragen en bedankt voor de mogelijkheid 
mij onbezorgd te laten opgroeien en studeren.
Als laatste wil ik mijn lieve vrouw Marcelle bedanken voor alle geduld die ze afgelopen 
jaren met mij heeft gehad, dank voor je steun en motivatie, dank voor je liefde, dank 
voor onze zoon Ocke, die ondanks dat hij ons drukke schema wat drukker maakte, het 
mooiste en grootste geluk in ons leven is.
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